Printed Abstracts Only

PAO-1

Two cases of Fanconi-Bickel syndrome - first report from China
Zhao Su; Hua-mei Ma; Pi-mei Zheng
The First Affiliated Hospital of Sun Yat-Sen University, Pediatric Department, Guangzhou, China

Background: Fanconi-Bickel syndrome (FBS) is a rare autosomal recessive disorder of carbohydrate metabolism caused by mutations in Glut2. To date there is no case has been reported from China.

Objective and hypotheses: To summarize the clinical characteristics of FBS by reviewing the 2 cases and published literature.

Methods: We reported the first two cases of FBS in China. We summarized the clinical characteristics of FBS by reviewing the 2 cases and published literature.

Results: The both cases presented similar manifestations as reported, including severe short stature, hypoglycemia, hepatomegaly secondary to glycogen accumulation, severe glycuoremia secondary to proximal renal tubular dysfunction. And more points may help to differentiate FBS and type I glycogen storage disease(GSD I) including glucose intolerance with normal lactic acid and uric acid, possible and slightly glucose response to glucagon stimulation without accumulation of lactic acid, severe symptoms of hypophosphatemia and rickets, and metabolic acidosis caused by type II renal tubular acidosis. After receiving symptomatic treatment both children presented catch-up growth.

Conclusions: FBS is a rare inherited disease caused by mutations in Glut2. It should be carefully differentiated from GSD I and diabetes mellitus in clinical practice. Symptomatic treatment can be helpful.

PAO-2

Final height outcome of boys with central precocious puberty treated with gonadotropin-releasing hormone analogue
P. Mei Zheng; Hua-mei Ma; Qu-b Chen; Zhe Su
First Affiliated Hospital of Sun Yat-Sen University, Pediatric Department, Guangzhou, China

Background: Data on the final height outcome of boys with central precocious puberty treated with gonadotropin-releasing hormone analogues (Gn-RHa) are far less than those in girls.

Objective and hypotheses: To report the final adult height of 20 boys with central precocious puberty treated with gonadotropin-releasing hormone analogue (Gn-RHa).

Methods: Twenty boys with central precocious puberty treated with GnRHa at a dose of 60–80 µg/kg every 4 weeks for (20.5 +/- 6.7) months. At the beginning of therapy, mean chronological age and bone age was (11.2 +/- 1.0) y and (13.0 +/- 0.4) y, respectively. GnRHa was discontinued when the boys reached the chronological age and bone age of (13.2 +/- 1.1) y and (13.7 +/- 0.6) y, respectively. At the conclusion of the study, all the boys had been followed up for (3.3 +/- 1.5) y and had achieved adult height. Comparisons were made among their final adult height (FAH), target height (TH), predicted adult height (PAH) at the start and the end of GnRHa treatment (PAH and PAHe).

Results: Final height was similar to the target height [(168.6 +/- 5.6)cm versus (167.8 +/- 4.6)cm] with no significant difference from the predicted adult height [PAH] [(169.8 +/- 5.6)cm versus (169.8 +/- 6.0)cm] based on the Bayley-Pinneau method, using a table for average bone age at the beginning of GnRHa analogue therapy. Predicted adult height (PAHe) at discontinuation of GnRHa therapy was significantly higher than predicted adult height at the beginning of GnRHa analogue therapy [(172.5 +/- 7.6)cm versus(166.8 +/- 5.6)cm, P<0.05]. Ninety percent (90.0%) of the boys reached target height range (FAH>/=THt-1SD). The height gain in comparison with predicted adult height before the start of treatment was (-1.2 +/- 3.3) cm, with the residual growth capacity of (10.6 +/- 4.3)cm.

Conclusions: GnRHa treatment can improve final height into the range of target height in boys with central precocious puberty.

PAO-3

Prevalence of impaired glucose tolerance and insulin resistance among obese children and adolescents
Robabeh Ghergherehchi; Nazanin Hazhir; Ali Tabrizi
Tabriz University of Medical Sciences, Pediatric Endocrin, Tabriz, Islamic Republic of Iran

Background: Obesity is one of the most important nutritional disorders in the world which has an obvious relationship with the incidence of metabolic diseases. Obesity prevalence has increased among children and adolescents during recent decades, leading to a rise in Type 2 diabetes mellitus (DM II) prevalence in these two age brackets. Hence, the aim of this study was to assess impaired glucose tolerance and insulin resistance, and gather metabolic findings in obese children and adolescents.

Methods: We studied 110 obese children and adolescents (body mass index, 95th percentile for age and gender) 4–18 years of age referred to the endocrine clinic of the Children’s Hospital at Tabriz University in a descriptive cross-sectional study. Fasting glucose, insulin, and lipid profile in all subjects were determined. Oral glucose tolerance test after eating 1.75 g/kg glucose was performed. Homeostatic model assessment was used to estimate insulin resistance.

Results: Impaired glucose tolerance and insulin resistance prevalence in 68 obese adolescents was 14.7% and 31.8%, respectively. Impaired glucose tolerance and insulin resistance was not seen in 23.8% of 42 obese children. No case of DM II was seen. There was a significant statistical difference in glucose (P = 0.003) and insulin (P , 0.001) level at minute 120 in individuals with impaired glucose tolerance compared to obese children and adolescents without impaired glucose tolerance. Rate of insulin resistance in patients with impaired glucose tolerance was greater and had a significant statistical difference (P = 0.03).

Conclusions: Obesity has a close relationship with increased risk of impaired glucose tolerance and insulin resistance in children and adolescents. Oral glucose tolerance test, unlike fasting glucose test, is a benefit test to predict impaired glucose tolerance. With prompt identification and treatment of obese children with impaired glucose tolerance, we can prevent it from progression towards DM II.
Introduction: In this study, we investigated the changes of serum levels of Free T4 and T3, T3 resin uptake (T3RU) and TSH in epileptic children during chronic treatment with anti-epileptic drugs (carbamazepine, Primidone, phenobarbital and valproate) and 3 months later than prescription.

Material and method: This study consisted of four case-series comparisons, was accomplished on 115 (in 4 same groups) epileptic children who were involved 37 girls and 78 boys with ages between 2 months up to 15 years (mean: 62.06 ± 44.97 months), who were taking either phenobarbital (n=29), PRM(n=28), CBZ (n=29), or VPA (n=29) at least for 3 months were evaluated, T3, T3 resin uptake (T3RU), T4 and thyroid-stimulating hormone (TSH) levels in start and end of study.

Results: All patients were in euthyroid state, there were no clinical findings or laboratory results of hypothyroidism. In collation with thyroid hormones be- fore of prescription in all bundles (Phenobarbital, CBZ, VPA and primidone), there was no significant distinctions in serum FT4, FT3, T3RU and TSH levels. No statistically meaningful relation were found between thyroid function and thyroid hormones levels variants and among AEDs receiving time and thyroid function and hormones levels, in any of 4 groups (P > 0.05).

Conclusions: Thyroid function should be evaluated intermittently in epileptic children using AEDs specially in long term prescriptions.

PAO-5

Influence of birth brain size on newborn serum insulin-like growth factor-I: role of birth size beyond the presence of intrauterine growth retardation and of preterm birth

Cesare Terzi1; Raffaele Viridi1; Werner F. Blum2; Sergio Zani3; Marco Riani4; Gabriele Tridoni5; Andrea Cerioli5; Elena Chess5; Sergio Bernasconi6; Giacomo Banchini6

1University of Parma, Department of Pediatrics, Parma, Italy; 2University of Giessen, Department of Pediatrics, Giessen, Germany; 3University of Parma, Department of Economics, Parma, Italy; 4S. Maria Nuova Hospital, Department of Obstetrics, Reggio Emilia, Italy; 5University of Parma, Department of Pediatrics, Parma, Italy

Background: The deviation from the proportionality between brain size and body size at birth has been related to fetal-neonatal stress.

Objective and hypotheses: We evaluated the possibility that preterm birth (PT) and intrauterine growth retardation (SGA) do not completely explain the birth size - related predictor role of birth brain weight (BRW) on serum Insulin-like Growth Factor-I (IGI) in the human newborn (NWB).

Methods: 78 NWBs 1) free of diabetes mellitus (DM)/life-threatening disease, 2) free of mother with DM and 3) with all of the following variables available were included in the study: gender (SEX), birth gestational age in completed weeks (GA), birth head circumference in cm and birth body weight in gr (resp. HC and BW), IB2 and chronologically corresponding IB3 measured in ug/dL at one of the first 5 postnatal days (x), 5 days after x (y) and 10 days after x (z) by radioimmunoassay, as well as postnatal age in completed days at x (PNA) and birth brain weight (BRW) respectively.

Results: a) BRW was calculated according to the formula “ BRW = 0.037 x HC - 2.506 ” (McLennan JE, 1983; Lindley AA, 2000). An estimate of birth body size not represented by brain was obtained by subtracting BRW from BW (BW - BRW). b) Binding Protein-2 and -3 (resp. IB2 and IB3) in the human newborn (NWB) were measured in ug/dL at one of the first 5 postnatal days (x), 5 days after x (y) and 10 days after x (z) by radioimmunoassay and postnatal age in completed days at x (PNA) and birth brain weight (BRW) respectively.

Conclusions: A direct BRW relation to IG1 was observed in studied NWBs after controls including PT and SGA, which could be in part explained by preterm birth (PT) and intrauterine growth retardation (SGA).

PAO-6

Influences of birth brain size on the ratios between newborn serum insulin-like growth factor binding protein-2 and -3: role of birth size after controlling for the presence of intrauterine growth retardation and of preterm birth

Cesare Terzi1; Raffaele Viridi1; Werner F. Blum2; Sergio Zani3; Marco Riani4; Gabriele Tridoni5; Andrea Cerioli5; Elena Chess5; Sergio Bernasconi6; Giacomo Banchini6

1University of Parma, Department of Pediatrics, Parma, Italy; 2University of Giessen, Department of Pediatrics, Giessen, Germany; 3University of Parma, Department of Economics, Parma, Italy; 4S. Maria Nuova Hospital, Department of Obstetrics, Reggio Emilia, Italy; 5University of Parma, Department of Pediatrics, Reggio Emilia, Italy

Background: The birth brain size - body size ratio has been related to fetal-neonatal stress.

Objective and hypotheses: The birth size - related predictor role of birth brain weight (BRW) on the ratio between serum Insulin-like Growth Factor Binding Protein-2 and -3 (resp. IB2 and IB3) in the human newborn (NWB) could not be completely explained by preterm birth (PT) and intrauterine growth retardation (SGA).

Methods: 78 NWBs 1) free of diabetes mellitus (DM)/life-threatening disease, 2) free of mother with DM and 3) with all of the following variables available were included in the study: gender (SEX), birth gestational age in completed weeks (GA), birth head circumference in cm and birth body weight in gr (resp. HC and BW), IB2 and chronologically corresponding IB3 measured in ug/dL at one of the first 5 postnatal days (x), 5 days after x (y) and 10 days after x (z) by radioimmunoassay and postnatal age in completed days at x (PNA).

Conclusions: A direct BRW relation to IG1 was observed in studied NWBs after controls including PT and SGA, which could be in part explained by preterm birth (PT) and intrauterine growth retardation (SGA).
Edema has been accepted as an uncommon complication occurring after initiating of insulin therapy in the absence of heart, liver or renal disease. In newly diagnosed type 1 diabetic children and adolescents insulin-induced edema should be considered after the initiation of insulin therapy.

Case report: A 13 year old boy was admitted with a one month history of polyuria, polydipsia, enuresis nocturna and also weight loss developed within last fifteen days. On admission, physical examination was normal except the last fifteen days. On admission, physical examination was normal except the lower leg arteries and veins were normal. After four days, the edema subsided spontaneously in parallel with a decrease in daily insulin doses, at a dose of 0.9 units/kg/day.

Discussion: Insulin edema is a poorly understood phenomenon, which is a rare complication of insulin therapy. Probably it is an underestimated complication, since most of the cases are mild. Here we reported a newly diagnosed type 1 diabetes case who developed insulin edema, in order to make physicians be aware of that rare complication. In most of the cases no therapy is needed and spontaneous resolution of the edema has been mentioned, as was the case in our patients.

Background: Steroid 21-hydroxylase deficiency (21-OHD) is an autosomal recessive disorder that is traditionally divided into three forms, salt-wasting (SW), simple virilizing (SV), and a milder non-classical (NC) form. Genotype-phenotype correlation is found in most 21-OHD. In Japan, very rare cases of the NC form have been detected at neonatal mass screening, and the P30L mutation appears to be associated with Japanese NC patients. However, the P30L mutation in NC 21-OHD was found to have poor genotype-phenotype correlation in prior studies.

Objective and hypotheses: In this report, we describe a patient with the SV form of 21-OHD in compound heterozygous mutations for P30L and deletion in the CYP21A2.

Methods: The patient was a Japanese girl with 21-OHD detected by newborn screening. She showed ambiguous genitalia (Prader stage 3) and skin pigmentation at birth. Her serum 17-OHP level was elevated (78 ng/ml at 13 days of age). Serum Na, K and plasma renin activity were 140 mEq/l, 5.0 mEq/l, and 71.8 ng/ml/hr, respectively. Based on these findings, she was diagnosed as having the SV form of 21-OHD.

Results: Molecular analysis for CYP21A2 revealed a compound heterozygous mutation (P30L, del or conv) that was predicted to become the NC form of 21-OHD. Further molecular analysis of CYP21A2 for discrepancy between genotype and phenotype revealed promoter conversions on the same allele as the P30L mutation.

Conclusions: We concluded that promoter conversion of CYP21A2 can partly cause discordance between genotype and phenotype in 21-OHD with the P30L mutation.

Background: Nowadays CGMS is used for the control optimization and medical treatment of the type 1 diabetes mellitus in children.

Objective and hypotheses: The aim of the research is to study the glycemic control readings (of mean glycemia and HbA1C) while using self-control and CGMS.

Methods: 20 children (11 boys and 9 girls) with type 1 diabetes mellitus were included in the study. The mean age of the patients was 10.13±3.85 years; the mean diabetes duration was 3.85±3.56 years. All patients wore 72 hrs CGMS sensor (Medtronic, MiniMed, System Gold.) The medical history studying revealed 6 cases of acute complications (hypoglycemia and hyperkalemia) and 13 cases of chronic complications. During the study patients were measuring the glucose level with the help of glucometer six times per day. The analysis was made by Statistica 6.0.
Result: The study revealed that according to the glucometer’s readings the minimum glycemia level was 6,72±1,31 mmol/L; CGMS displayed 3,46±0,44 mmol/L (p < 0,001).The maximum glycemia level was 14,93±1,15 mmol/L (glucometer) and 18,18±1,48 mmol/L (CGMS) (p < 0,01). The mean glycemia level was 9,76 mmol/L (glucometer) and 10,88 mmol/L (CGMS). According to the CGMS results the patients were in the normoglycemia conditions during the 73% of the whole research period, hyperglycemia was registered at 24,68%; and hypoglycemia was registered at 3,47%. The readings of the regular glucometer showed normoglycemia at the 52% of the whole period, hyperglycemia at the 48%; hypoglycemia wasn’t revealed. The initial HbA1C level was 7,95%; after the three months it decreased to 7,41%(p < 0,05). The lack of accuracy may be caused by the limited sampling.

Conclusion: CGMS is able to reflect the adequate ratio of the hyper- hypo and normoglycemia and helps to reveal the most serious latent hypoglycemies which are difficult to detect with the glucometer. CGMS helps to detect the actual glycemia variability in patients. CGMS shows more accurate results in the mean glycemia measuring and improves glycemic control quality.

Methods: Group 1 included 121 healthy children born in Italy or living in Italy since at least 1 year (78 females and 43 females, mean age 9.5±4.1 years). Group 2 included 168 adopted or migrant children living in Italy since less than 1 year (62 females, 106 males, mean age 5.45±3.3 years); the geographical area of origin were Sub-Saharan Africa (n=29), Latin America (n=36), Eastern Europe (n=37), Russia (n=24), Southeast Asia (n=25), Indian subcontinent (n=17).

Results: In group 1 mean serum level of 25(OH)D was 25.3±11.1 ng/mL; 34.7% of children was vitamin-D deficient and 39.6% was insufficient. In group 2 mean serum level of 25(OH)D was 29.0±17.9 ng/mL (significantly higher compared to 1, p=0.04); 29.8% of children was vitamin-D deficient and 29.8% was insufficient. The subgroup from Southeast Asia had better levels of 25(OH)D (40.2±24.3 ng/mL) compared to the other subgroups. Comparing group 1 versus group 2 without subgroup from Southeast Asia (n=143), mean 25(OH)D 27.0±15.9 ng/mL, we found no significant differences (p=0.05).

Conclusion: Hypovitaminosis D is highly prevalent in both Italian (74.3%) and adopted or migrant children (59.6%); if we exclude subgroup from Southeast Asia the prevalence in group 2 raises to 65.7%. We have no explanation for the higher levels of 25(OH)D found in this subgroup (Philippines, Cambodia and Vietnam).

Background: Variants in the FTO (fat mass and obesity associated) gene are associated with early onset and severe obesity.

Objective and hypotheses: To investigate the impact of variants of the FTO gene (rs1421085, rs17811749, rs9939609) in obese children before and after lifestyle intervention.

Methods: 75 overweight children (40 male, mean BMI 30.4 ± 5.5 kg/m²; mean age 12.6 ± 2.6 years). Measurements: Genotyping by means of a TaqMan SNP genotyping assay. Lean and fat mass were determined by means of DXA. The lifestyle intervention program consisted of an increase in physical activity from one to two hours per day including all daily life activities and fitness training; nutritional recommendations based on the ‘Optimized Mixed Diet for German Children and Adolescents’ of the Research Institute of Child Nutrition, Dortmund, Germany.

Results: For the whole study population, the 6-month lifestyle intervention resulted in a significant improvement (before intervention minus time point 6 months; mean ± SD) in BMI-SDS (0.10 ± 0.17, p < 0.001), HOMA (1.41 ± 3.19, p<0.001) and relative fat-mass-SDS (0.09 ± 0.23, p=0.005). Before and after lifestyle intervention, there was no significant difference between heterozygote (n=52) and homozygote (n=21) carriers of the FTO gene in terms of BMI, body composition, and the metabolic profile (Insulin, HOMA, lipids, liver function tests).

Conclusion: Variants in the FTO gene are common in obese children. However, they seem to have no impact on body composition and metabolism before and after lifestyle intervention.
Objective and hypotheses: The aim of the study is to assess the effect of physical activity on BMD, BMC and bone area (BA) in healthy Danish children. The study also aims to evaluate the relationship between fracture risk and BMD.

Method: The study is a three year controlled intervention study from August 2008- August 2011 in 10 public schools in the municipality of Svendborg, DK. Children aged 8 to 11 years were invited, 740 children accepted. Six schools were selected as intervention schools, where the children receive 6 lessons of physical education (PE) per week versus 2 lessons of PE at the four control schools. Blood samples were collected during September 2008 and September 2010. Biomarkers of bone health are measured. Whole-body DXA scans, (Lunar Prodigy) were performed at 718 children at baseline and BMD, BMC, and BA were measured. The DXA scans were repeated during the fall 2010 to February 2011. 684 children participated. Anthropometrics was registered every four month. X-ray of the left hand- wrist was taken at baseline and after the intervention for assessment of bone age. The children’s level of physical activity was recorded by accelerometers. Information about fractures was received through questionnaires and SMS-track.

Results and perspectives: Preliminary analysis has revealed that, the children in the two groups were similar regarding to anthropometrics, motor performance and aerobic fitness at baseline. Results from the DXA scans will be correlated to fracture risk and the two groups will be compared regarding BMD, BMC and BA values.

Conclusions: The data collection has just been completed and the results will be processed through the following months.

PAO-14

Serum leptin and adiponectin in relation to appetite grade, gender and puberty in children with obesity

Anzhalka Solntsova1; Ludivina Vazquez2; Elena Dashkevich2
1Belarusian State Medical University, Children Disease Department number 1, Minsk, Belarus; 2City Children's Clinical Hospital, Out-patient Endocrinological Department, Minsk, Belarus; *10-th City Clinical Hospital, Hormonal Laboratory, Minsk, Belarus

Background: Leptin and adiponectin suspected to be potential markers of obesity, but the importance as metabolic risk factors is still discussed.

Objective and hypotheses: Our aim was to investigate gender differences of leptin and adiponectin concentrations in relation to appetite grade in obese children.

Methods: Children (n=300) with obesity (4,8 -17,8 years old) from Belarus were assessed for anthropometric parameters, pubertal stage, serum lipids, insulin, sex-binding globulin (SBG), leptin and adiponectin, appetite (A) grade (4-point assessment). Statistical analysis were performed by using SPSS 16.0 (p<0.05).

Results: Leptin levels were significantly different during puberty and increased especially in late pubertal girls (prepubertal - 27.7 ng/ml, p=0.002, early pubertal - 37.8, p=0.001, late - 54.7) versus adiponectin decreasing (prepubertal - 22.3, mg/ml, p=0.001, early pubertal - 14.2, p=0.001, late - 12.1).

Peak leptin and adiponectin concentrations were shown in early pubertal boys - 47.6 ng/ml, p=0.021 and 26.8 ng/ml, p=0.02 with further decreasing in late puberty - 24.7, p=0.024 and 21.8, p=0.048 respectively that was connected with negative influence of high testicular androgen to leptin and adiponectin production. There were positive correlations between serum leptin and body mass index (BMI) (p=0.0001), waist circumflex (WC) (p=0.01) triglycerides (p=0.05), insulin (p=0.0001), low-density lipoproteins (LDL) (p=0.02) and negative with SBG (p=0.002) in children with obesity. Adiponectin had negative correlation with the same parameters: BMI (p=0.02), WC (p=0.03) triglycerides (p=0.03), insulin (p=0.02), LDL (p=0.03) and positive with SBG (p=0.01). The highest leptinemia was shown in children with risen afternoon and evening A (118,3 ng/ml p=0.05). Conversely adiponectinemia were independent from rising A time (p>0.05).

Conclusions: Serum leptin increases with obesity grade, whereas adiponectin decreases, both are influenced by gender and puberty and correlate with metabolic dysfunction markers. Appetite grade has influence on leptinemia.

PAO-15

A peculiar cognitive and behavioural phenotype as the first clue to suspect Klinefelter syndrome in prepubertal males

Maria Francesca Messina; Fortunato Lombardo; Valentina Comito; Tommaso Aversa; Danila Pecoraro; Mariella Valenzise; Filippo De Luca University of Messina, Department of Pediatrics, Messina, Italy

Background: Klinefelter syndrome (KS) with the classic 47 XXY karyotype is the most frequent chromosomal aneuploidy with a prevalence of 1 in 700 males and, although the classical clinical picture is well-known and easily recognizable, most patients remain undiagnosed. The rate of diagnosis is extremely low in childhood and only 10% of cases are identified before puberty because the classical signs and symptoms of androgen deficiency appear only in late adolescence. A common element, often underappreciated, in these young boys is the peculiar cognitive and behavioural pattern.

Case report: We describe two patients who were diagnosed in prepubertal age, respectively at 7.1 and 10 years, due to a peculiar neurocognitive profile. Both of them showed on WISC III low-normal scores, i.e. FSIQ, PIQ and VIQ ranging between 80 and 85 and a behavioural profile characterized by immaturity, insecurity, shyness and low-self esteem, learning disabilities and academic difficulties. On clinical examination both of them showed a height taller than target height and a progressive growth acceleration between 5 and 7 years, and from the puberal point of view they had prepuberal testicular volume (< 2 cc) and one of them had hypoplastic scrotum with monolateral cryptorchidism. Hormonal pattern confirmed normal prepuberal basal levels of gonadotropins.

Conclusions: We believe that to achieve the goal of an early diagnosis in KS, it is necessary to increase medical awareness of the disease and in particular to augment paediatricians’ knowledge that in prepubertal age pathognomonic endocrinological features of KS are often lacking but a peculiar cognitive and behavioural pattern is always present, especially when accurately searched.

PAO-16

Effect of a large ventricular defect (VSD) on linear growth: a lesson from an affected baby who is one of triplets

Ashtaf Soliman1; Amal Sabt2; Ahmed Elawwa1; Haytham Yassin3
1Hamad Medical Center and University of Alexandria, Pediatrics, Doha, Qatar; 2Hamad Medical Center, Pediatrics, Doha, Qatar; 3Hamad Medical Center, Cardiology, Doha, Qatar

Background: Large VSD may delay growth and compromise adult height.

Objectives: Study the effect of large VSD on linear growth in a girl with large VSD, who was a part of triplet and compare it with her siblings’ growth.

Methods: This girl (C) was born as a part of triplet at 38 weeks of gestation. The other parts of triplet were a male (A) and female (B). The girl (C) birth weight = 1.82 kg, length = 41 cm. We compared girl C anthropology, bone maturation and IGF-I level data with her normal siblings’ data.

Results: Clinical examination, CXR and echocardiography revealed a large-size VSD with cardiomegaly and lung congestion. There was no cyanosis, pallor, jaundice or dysmorphic features. The girl was treated with lasix and nutritional support. At the age of 3.5 years a complete corrective surgery was performed. At the age of 6.5 years the bone age of girl C = 5 years, girl B and boy A = 6 years. Their IGF-I were 85, 125 and 185 ug/L respectively. Analysis of growth data of girl C before and after surgery in comparison to the other parts of the triplet reflected the effect of VSD on linear growth as followings:

a) The VSD prevented catch-up growth in girl C which occurred in her 2 siblings (3SDS) during the first 3 years,

b) Correction of VSD accelerated growth for 2 years with a significant (2.2 SDS) but incomplete catch-up growth (still 1 SDS below mid-parental HBS-DS),

c) catch-up growth stopped during the 3rd year after surgery,

d) in girl C, VSD was associated with delayed bone age (a year) and lower IGF-I versus her siblings.

Conclusion: In girl C, VSD prevented catch-up growth during the first 3 years of life with significant but incomplete catch-up growth for 2 years following surgical correction and lower IGF-I secretion. However, VSD was associated with a delay in bone age with a better potential for final adult height.
PAO-17

Thrombocytopenia in a girl with idiopathic central precocious puberty treated with long-term gonadotropin hormone agonists (GnRHa)

Marina Krsteva-Konstantinova; Aleksandra Janchevska; Zoran Gucev
University Children’s Hospital Skopje, Endocrinology and Genetics, Skopje, Macedonia, FYrom

Background: Central precocious puberty (CPP) is a frequent endocrine problem in childhood. The idiopathic and organic etiology of CPP are most commonly treated with GnRH agonists. They have been considered in many studies to be safe and effective.

Case report: We present a 7 year old girl with idiopathic CPP diagnosed by standard GnRH testing. She developed severe thrombocytopenia during GnRH treatment. The familial history showed that the mother has been treated 8 years for infertility. The pregnancy was controlled and uneventful. At the time of diagnosis her weight was at the 75th percentile and she was 130.5 cm tall on the 97th percentile. The Tanner stage was B3, A1, P1. The bone age was advanced to 8.5 years. Before the treatment she was otherwise healthy. All laboratory evaluations were normal from blood count to thyroid function and brain imaging techniques. After receiving her 9th month depot therapy of GnRH agonist, tripotrenol acetate, 3.75 mg i.m., she developed bleeding from the injection site, bruises and rash on the skin all over her body. Her platelets were 27 x 10³/µl (150-300 x 10³/µl). The coagulation factors and myoglobinemia were normal. She was hospitalized at the hematology department in our hospital for 5 days and treated with corticosteroids. Recovery was after one week and treatment with GnRH agonists was discontinued.

Conclusions: To our knowledge, thrombocytopenia has not been yet reported in children receiving GnRH agonist treatment. This may represent a possible serious adverse effect which needs further investigation.

PAO-18

Peripheral blood karyotype poorly represents tissue mosaicism determined by FISH and QF-PCR - a case report

Dóra Török1; Irén Halbach1; Bálint Nagy1; Zsuzsa Tóth1; Zsolt Jórász1; Andrea Luczay1
1Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary; 2Semmelweis University, 1st Department of Obstetrics and Gynecology, Budapest, Hungary; 3Bethesda Children’s Hospital, Department of Surgery, Budapest, Hungary

Background: Cytogenetic analysis in disorders of sexual differentiation is routinely performed on peripheral blood lymphocytes. The presence of Y chromosome material in the gonads is of major interest because of the risk of gonadoblastoma development. However, there is a lack of evidence whether the gonadal karyotype is congruent with lymphocyte karyotype.

Patient and methods: A three-week-old boy with normal male genitals presented with left inguinal hernia and cryptorchidism. The inguinal hernia surgery revealed an unusual anatomic situation. His free testosterone was normal (23.21 pg/ml). Peripheral blood karyotype was mos 45,X[25]/46,X,i(Y)[p10], id(1)(p11)(DXZ1++)(DXZ1+)(SRY-)[20]/(DXZ1+)(SRY+)[88]/(DXZ1+)(SRY++)[52]/(DXZ1+)(SRY++)[12]

Results: The X:Y ratio was normal in the testis and nearly 2:1 in the blood, fibroblast and a dysgenetic gonad samples by QF-PCR. However, FISH analysis in the testis have found one X centromere in 60% and presence of different mosaic SRY+ cell lines (with single or double SRY signals) in 40% of cells (inc. idic(DXZ1+)(SRY+)1)1(DXZ1+)(SRY+)[88](DXZ1+)(SRY++)[52]/(DXZ1+)(SRY++)[12].

Conclusions: Our case underlines that peripheral blood lymphocyte karyotype might not provide a reliable representation of specific tissue karyotypes. Further studies may prove whether Y chromosome material present in the gonads would be completely absent or undetected in lymphocytes. Peripheral blood is an easy and reliable source of material for cytogenetic analysis, however, the interpretation of test results might require caution.

PAO-19

Complete catch-up growth in a neglected case of hypoaldosteronism a year after starting therapy

Noura Alhemaidi1; Ashraf Soliman1; Amal Sabt1; Ahmed Elawwa1
Hamad Hospital, Pediatric, Doha, Qatar

Background: Early growth impairment may be a Sequel to untreated hypoaldosteronism in infants.

Objective and hypotheses: To study the growth pattern of an infant with neglected hypoaldosteronism after treatment for 3 years.

Methods: This boy presented at the age of one year, with recurrent vomiting and poor growth. He was a product of full-term pregnancy and normal vaginal delivery. Birth weight = 3.1Kg, length = 50 cm. His parents were first-degree cousins. He had five sisters and one brother, all were healthy. He was on formula feeds and started weaning at six months of age, with good appetite and normal bowel motion. He showed delayed gross motor milestones (can sit but can not stand at 1 y) with normal other developmental parameters. Examination revealed an unusual anatomic situation. His free testosterone was normal, aldosterone = 10 mmol/L (N 1-4.5), creatinine = 20umol/L (N 25-65), Cl = 90mmol/L (N 87-120), sodium = 137mmol/L (N 135-145), aciddes (HCO3 = 17mmol/L) (N 24-30), BUN = 10 mmol/L (N 4-8.4), potassium = 4.8mmol/L (N 4-5.5). Hormonal analysis showed: Aldosterone = 10 mmol/L (N 8-35), and normal blood glucose. Hormonal analysis showed: Aldostereo-

Horm Res 2011;76(suppl 2) Printed Abstracts Only
58 children with DMT1 were included into this research and divided depending on gender and pubertal stage.

Objective and hypotheses: The study aim was to assess nutritional stereotypy’s influence on emotional status and life quality in children with DMT1.

Conclusions: Hypoparathyroidism may present with severe growth retardation during the first year of life. Complete catch-up of growth was achieved during the first year of treatment.

PAO-20

Abstract withdrawn.

PAO-21

Do we need to change the policy of hydrocortisone administration by emergency personnel?

Rebekah Pryce
Abertawe Bro Morgannwg Healthboard, Department of Paediatrics, Swansea, United Kingdom

Background: A 8 year old male with congenital hypopituitarism requiring hydrocortisone, growth hormone and thyroxine replacement had an episode of unresponsiveness whilst at school. There was a health care plan in place with appropriate advice suggesting an oral dose of hydrocortisone and if the patient remained unwell to call an ambulance so that intramuscular hydrocortisone could be administered. The patient was brought to hospital where it was evident that the ambulance team were unable to administer intramuscular hydrocortisone as the diagnosis was not that of Addison’s disease.

Objective and hypotheses: To review the pre hospital management of adrenal crisis.

Methods: The paediatric population of Swansea with conditions that require long term steroid dependence.

Results: There are currently 13 paediatric patients in Swansea requiring hydrocortisone in their emergency equipment. However current guidelines (1) state this can only be administered in an Addisonian crisis. This is interpreted to mean that if the underlying diagnosis. This risk currently applies across Wales and the rest of the UK as all ambulance crew carry hydrocortisone in their emergency equipment.

Conclusions: Do we need to change the policy of hydrocortisone administration by emergency personnel.

PAO-22

Diabetes influence on nutritional stereotype and children’s quality of life

Ekaterina Lepetilo; Angelika Solnceva; Liudmila Viazava
Belarusian State Medical University, Pediatrics, Minsk, Belarus

Background: Diabetes mellitus type 1 (DMT1) can influence on life quality and emotional stability in children.

Objective and hypotheses: The study aim was to assess nutritional stereotype’s influence on emotional status and life quality in children with DMT1 depending on gender and pubertal stage.

Methods: 58 children with DMT1 were included into this research and divided to 4 groups depending on gender and pubertal stage. Group A (n=14) and B (n=15) included early pubertal boys at age 10,1±2,1 years and girls (10,1±2,1 years) respectively. Group C (n=14) and D (n=15) ~ late pubertal boys at age 15,1±2,2 years and girls (15,1±2,2 years) equally. Patients were interviewed by self-report questionnaires (Diagnostic Interview for psychological disturbances in childhood and adolescence (DIPS-K)) with point estimation.

Results: Fast-food consumption frequency in late pubertal boys higher than in other groups. Intensity of life quality’s dissatisfaction and anxiety about the future relate from the disease duration.

Conclusions: The anxiety about DMT1 influence on the future life increased with the age (with maximum in group D: 48 from 100).

PAO-23

Values of levels of IGF-1, IGFBP-3 and urinary GH to diagnose of short stature

Said Ismailov¹; Barno Nazanova¹
¹Center of Endocrinology, Sugery, Tashkent, Uzbekistan; ²Center of Endocrinology, Pediatric Endocrinology, Tashkent, Uzbekistan

Background: Levels of IGF-1, IGFBP-3 and also urinary GH (uGH) are recognized by markers of GH deficiency and have diagnostic value in various variants of short stature.

Objective and hypotheses: To define differences of IGF-1, IGFBP-3 and uGH values in various variants of short stature.

Methods: We have examined 147 subjects (85 boys and 62 girls), aged 3-18 yrs (mean age 11±3,9yr.) with short stature and 20 healthy children (10 boys and 10 girl). Serum levels of IGF-1, IGFBP-3 and uGH were measured by IRMA (Immuno tech, Beckmann Coulter).

Results: The obtained data of laboratory researches of levels of IGF-1, IGFBP-3 and uGH are given in the table. GH excretion and basal levels of IGF-1 and IGFBP-3 were lower in growth hormone deficiency, hypothyroidism and raised in case of familial short stature in compare with healthy children.

Conclusions: Estimates of disturbances in childhood and adolescence (DIPS-K) with point estimation.
**PAO-24**

**Descriptive study on growth of small for gestational age (SGA) babies in a multi-ethnic population**

**Sharon Lim**

Broomfield Hospital, Paediatric, Chelmsford, United Kingdom

**Background:** The childhood population under study is approximately 200,000 with an annual birth rate of approximately 11,000.

**Objective:** In this prospective observational study, the aim was to collect data on parental ethnicity, educational attainments, social habits, medical history and auxology of SGA babies till the first birthday.

**Methods:** SGA babies were defined as birth weight or length less than the third percentile for gestation. Measurements were converted to SD scores. Mothers of SGA babies were interviewed by one of the authors using a standardised questionnaire. Babies were measured using a stadiometer and weighed using digital weighing scales.

**Results:** 24 mothers were interviewed. Growth data was available for all babies except 1 final measurement. Only 5 out of 24 mothers were Caucasian, 14 were Asian, 3 were mixed and 1 was African. Mean maternal age was 31 (range 21 - 40yrs). 2 admitted to smoking before and during pregnancy. 10 admitted to alcohol intake prior to getting pregnant, with 3 continuing to drink in pregnancy. Birth weight SDS ranged between -2.7 to -1.3, mean -1.8, weight SDS at 1 year ranged between -2.2 to 1.1, mean -0.7 (see chart).

**Conclusions:** It was possible but difficult to study this largely multiethnic group of families (hence the small numbers). Data obtained can be used in future to compare with other populations and with the comparisons, possible factors may be identified to be more strongly linked to having a SGA baby.

**PAO-25**

**Serum IGF-1 and IGFBP-3 levels in central precocious puberty girls with gonadotropin releasing hormone agonist (GnRHa) treatment**

**Kyung Hee Yi**; **Eun Young Kim**

Wonkwang University Sanbon Medical Center, Pediatrics, Gunpo, Gyeonggi province, Republic of Korea; *Chosun University School of Medicine, Pediatrics, Gwangju, Republic of Korea*

**Purpose:** To investigate changes of serum IGF-1 and IGFBP-3 levels during one year gonadotropin releasing hormone agonist (GnRHa) treatment in central precocious puberty (CPP) girls.

**Methods:** From 2007 through 2009, twenty six girls were enrolled in this study. They were diagnosed as central precocious puberty and were treated with GnrHa (Leuprolide acetate) for one year. Height, bone age, IGF-1, IGFBP-3 were evaluated every terhonths.

**Results:** At the time on diagnosis, their mean serum IGF-1 and IGFBP-3 were 302.90 ± 102.54 ng/mL and 3103.58 ± 705.08 ng/mL. At 6month after treatment, IGF-1 secretion was slightly decreased and IGFBP-3 production was slightly increased. One year later, IGF-1 concentrations were more increased than before treatment and IGFBP-3 levels were decreased. Gonadal suppression with gonadotropin releasing hormone inversely influences circulating IGF-1 and IGFBP-3 levels. But IGF-1/IGFBP-3 were maintained relatively steady levels with normal height velocity (mean ± SD, 6.10 ± 1.36 cm/yr HV SDS 0.02 ± 1.63).

**PAO-26**

**First-year response to growth hormone in children with brain tumours: analysis of data from KIGS Turkey**

**Ece Bobet**; **Feyza Darendeli**; **Firdves Bas**; **Korcın Demir**; **Pınar Işıgurev**; **Erdal Adal**; **Oya Ercan**; **Merih Berberoglu**; **Sukran Darcan**; **Omer Faruk Tarim**; **Banu Cakucumre Aydini**; **Zeynep Siki**; **Dania Gokseri**; **Olcay Evliyagolu**; **Suie Cari**; **Zehra Aycar**

**1Dokuy Ezul University, Department of Pediatric Endocrinology, Izmir, Turkey; 2Istanbul University, Istanbul Faculty of Medicine, Department of Pediatric Endocrinology, Istanbul, Turkey; 3Goztepe Education and Investigation Hospital, Department of Pediatric Endocrinology, Istanbul, Turkey; 4Bakirkoy Maternity and Children Education Hospital, Department of Pediatric Endocrinology, Istanbul, Turkey; 5Istanbul University, Cerrahpaşa Faculty of Medicine, Department of Pediatric Endocrinology, Istanbul, Turkey; 6Ankara University, Department of Pediatric Endocrinology, Ankara, Turkey; 7Ege University, Department of Pediatric Endocrinology, Izmir, Turkey; 8Uludag University, Department of Pediatric Endocrinology, Bursa, Turkey; 9Istanbul University, School of Medicine, Istanbul, Turkey; 10Children’s Education and Research Hospital, Department of Pediatric Endocrinology, Ankara, Turkey**

**Background:** Determinants of first-year response to growth hormone (GH) are not well established in children with brain tumor.

**Objective and hypotheses:** To retrospectively analyze first-year response to GH in children with brain tumor registered in KIGS (Pfizer International Growth Database) Turkey.

**Methods:** Among 53 eligible patients, 9 were excluded due to a follow-up period of under 9 months and 7 due to lack of relevant data. Remaining patients were divided into two as Group 1 (change in height SD score >0.5, n=15) and Group 2 (change in height SD <0.5, n=22), which were compared regarding clinical and laboratory variables. Correlation analysis, receiver operating characteristic (ROC) curve, and logistic regression analysis were used to further assess the association of follow-up variables with the degree of height gain.

**Results:** Thirty seven cases [M/F: 17/20, median (interquartile range) age 11.8 (8.9-13.7); ratio of pubertal patients, 28%] were included in the study. Majority of the patients were suffering from craniopharyngioma (n=15, 41%) or medulloblastoma (n=12, 32%). Median (interquartile range) value for height SD score at the start of treatment was 2.83 (-4.01 – -1.93) and duration of follow-up 2.7 years (1.35-4.93). Higher age and height SD scores and greater number of cranial tumors distant from pituitary/hypothalamic area were found in Group 2. Age (r=-0.462, p=0.004) and height SD scores (r=-0.419, p=0.01) at the start of GH were moderately negatively correlated with first-year response. ROC curve analyses provided cut-off levels for age (>9.75 years) and height (>3 SD score) for prediction of poor first-year response. Risk of poor first-year response increased 2.9 times per 1 SD score increase in height and 1.6 times per 1 year increase in age.

**Conclusions:** Poor response to GH treatment in children with brain tumor is associated with some clinical variables, which might serve to make treatment modifications.
Diabetic ketoacidosis as initial presentation in children with type 1 diabetes mellitus in South Region of Saudi Arabia

Mohammed A. Fawaz Alkahtani
MOH, Pediatric, Abha, Saudi Arabia

Background: Type 1 Diabetes Mellitus (DM) represents about 5-10% of total diabetes with more susceptibility to develop Diabetic Ketoacidosis (DKA) than Type 2 DM as the underlying cause is insulinopen.

Objective: To study the percentage of patients with Type 1 DM that presents initially with DKA as this is a good indicator of public health knowledge about diabetes in the pediatric age group.

Method: A retrospective study to evaluate charts of patients seen regularly in Aseer Diabetes Center (ADC) over a period of 10 years from 1st Jan 2000 till 31 Dec 2009 whether they present initially in DKA or not.

Result: A total of 614 patients with Type 1 DM were registered. Among them 487 patients with completed data, 228 patients were seen in DKA as initial presentation (47%), whereas 259 patients were discovered before reaching DKA (53%). This percentage is higher than what have been published from the United States (25%) and in between if compared to the International figures (16-80%). In relation to age we found that 83% of patients who are less than 1 year of age had DKA as initial presentation. Beyond that age there was no much difference.

Conclusions: A relatively high percentage of DKA as initial presentation necessitates a follow up study to evaluate what can be the cause of this relatively high percentage, with suggestion to have more public health programs in the media and training courses for primary health care physicians in order to reaches developed countries percentages.

Hypoglycaemia in a Nigerian paediatric emergency ward

Jerome Ellusiyan
Ebudoluwa Adejugbe; Oluwagbenba Adeodu
Obafemi Awolowo University, Paediatrics and Child Health, Ile-Ife, Nigeria

Background: Hypoglycaemia is a common problem in paediatric emergency admissions. It has not received enough attention in Nigeria. It has been shown to complicate many childhood illnesses.

Objective: This study aimed to determine the prevalence of hypoglycaemia in paediatric emergency admissions, describe clinical factors that commonly predispose to it and investigate its effect on outcome of management.

Method: Three hundred and ninety-two consecutively admitted patients were studied. Two milliliters of blood was obtained from each patient for plasma glucose determination. Hypoglycaemia was defined as plasma glucose 52.5 mmol/l (95 mg/dl).

Results: Out of these 392, twenty-five (25) of them were hypoglycaemic giving a prevalence of hypoglycaemia to be 6.4 per cent in our emergency ward. Hypoglycaemia was found to be associated commonly with severe malaria, septicaemia, pneumonia, and protein energy malnutrition. Interval of last meal and unconsciousness were the only two significant associated factors to hypoglycaemia. However, the likelihood of hypoglycaemia is increased with night admissions and prolonged duration of illness before admissions. Presence of hypoglycaemia at admission was also found to be significantly associated with death and dying within 24 hours of admission.

Conclusions: The prevalence of hypoglycaemia was found to be 6.4 per cent. It was found to complicate many childhood illnesses and it is associated with a higher mortality. It should be suspected in all very ill children, particularly when they are unconscious and have not eaten for over 12 hours.
PAO-32

Growth and weight-regulation disorders in children are not commonly associated with mutations of the ghrelin and GH secretagenous receptor (GHSR) genes

Ora Hess1; Gadir Elia2; Tal Almagor1; Osnat Admoni1; Morad Khayat2; Stavit Salev-Alon1; Yevdiena Tenenbaum-Rakovets1

1Ha’Emek Medical Center, Pediatric Endocrine Unit, Afula, Israel; 2Ha’Emek Medical Center, Genetic Institute, Afula, Israel

Background: Ghrelin and its receptor, growth hormone secretagenous receptor, GHSR, play a major role in appetite control and growth regulation. To date, only four confirmed mutations in the GHSR gene have been identified in children with obesity and short stature, while no such mutations have been found in the ghrelin gene.

Objective and hypotheses: In the current study, we tested the hypothesis that mutations in ghrelin or GHSR will result in subjects being either overweight or underweight, and exhibiting abnormal growth.

Methods: Ninety-five subjects (37F-58M) were enrolled with FTTh (10 pts), GHD (45 pts), ISS (18 pts) or obesity (22 pts). Both ghrelin and GHSR genes were sequenced.

Results: Seven different sequence changes were identified (66.3%) in GHSR, two of them novel and five described previously. None of the sequence changes identified in the GHSR gene changed the sequence of the encoded protein. The prevalence of these sequence changes did not differ between the subgroups. One previously described sequence change, Leu72Met, within the preproghrelin/ghrelin gene was identified in two patients (2%), one with FTTh and the other with obesity and partial GHD. This sequence change, which had been identified previously in obese women, is located in exon 2 outside the coding region of the mature ghrelin.

Conclusions: Our results suggest that mutations of the ghrelin and GHSR genes are not commonly associated with growth and weight-regulation disorders in children.

PAO-33

The relationship between initial BMI and BMI change during 1-year of GnRH agonist therapy in girls with idiopathic central precocious puberty

Juoyang Yoon; Sei Won Yang; Young Ah Lee; Min Jae Kang; Sinni Kim; Jeun Lee; Choong Ho Shin

Seoul National University Children’s Hospital, Department of Pediatrics, Seoul, Republic of Korea

Background: Childhood obesity is associated with early pubertal development, and early sexual maturation is associated with increased prevalence of obesity. Above-average BMI is frequent at diagnosis of central precocious puberty (CPP). The relationship between initial BMI and BMI after 1-year of GnRH agonist therapy in girls with CPP is not well described.

Objective and hypotheses: The purpose of this study is to evaluate the relationship between initial BMI and BMI after 1-year of GnRH agonist therapy in girls with CPP. We also compared the group in which BMI-standard deviation score (BMI-SDS) increased after treatment with the group in which BMI-SDS remained the same or decreased.

Methods: The subjects were ninety-nine CPP girls treated with GnRH agonist (GnRHa) for more than 1 year. We investigated chronologic age (CA), bone age (BA), BA advance (BA-CA), height, HT-standard deviation score (Ht-SDS), BMI, BMI-SDS, predicted adult height (PAH), PAH-SDS before initiation of GnRHa treatment and 1 yr later.

Results: There was no difference in initial CA, BA, BA-CA, HT-SDS, target height between normal BMI group and overweight/obesity group. BMI-SDS increased more in normal BMI group than in overweight/obesity group (0.2 vs -0.1, P<0.004), and initial BMI and delta BMI-SDS showed negative relationship (R2=0.251, P<0.001). PAH-SDS increased less in normal BMI group than in overweight/obesity group (0.3 vs 0.7, P<0.02), but there was no linear relationship between initial BMI and PAH-SDS. Delta BA-CA, delta HT-SDS also was not different between normal BMI group and overweight/obesity group. Comparing pts. in whom BMI-SDS increased or remained the same after treatment with those whose BMI-SDS decreased, there was no difference in delta BA, delta HT-SDS, delta PAH-SDS. Delta BMI-SDS was related only with initial BMI SD and showed no relationship with CA, BA, BA

Conclusions: In CPP girls treated with GnRHa for 1 year, BMI SDS increased in those with normal BMI. Delta BMI-SDS had negative relationship with initial BMI-SDS, but weight loss was not influenced by other factors such as initial CA, initial BA, initial BA-CA, initial HT-SDS, initial PAH-SDS, target height, drug dose.

PAO-34

A case of salt-wasting and virilizing form of congenital adrenal hyperplasia in a patient with male phenotype and 46,XX karyotype

Maia Rkhivashvili1; Mariam Balakhadze1; Revaz Morgoshia1; Rolf Peter Willig2

1JSC “Vere XXI”, Department of Physical and Sexual Development of Children and Adolescents, Tbilisi, Georgia; 2Endocrinologikum Hamburg, Pediatrics, Hamburg, Germany

Background: In congenital adrenal hyperplasia (CAH) with 21-hydroxylase or 11β- hydroxylase deficiency, futile trophic hormone stimulation results in excess sex hormone precursors. Androgen predominance in these forms of CAH leads to virilization of affected females in utero.

Objective and hypotheses: We describe a patient with virilizing and salt-wasting form of CAH.

Methods: A case report.

Results: Patient 7.2 years old boy. The complaints were: Delay of physical and sexual development (unchoria), pubic hair since the age of 2 years. Anamnesis over the postnatal period the child was frequently hospitalized due to intensive vomiting, diarrhea and weight loss. The patient was on symptomatic treatment. Auxology: HSDS 1.22. Sexual development stage P3 A1 G2; Testes not palpable. Bone age by Greulich and Pyle 10.5 years. Genetical research: karyotype - 46;XX; Laboratory research: 17OH Prog 50 µg/l, Potassium 4.1 mmol/l, Sodium 136 mmol/l, LH <0.1 IU/l, FSH 2.8 IU/l, Estradiol 10 ng/l, Androstendion 0.7 µg/l, ACTH 133 ng/l, Renin 241 ng/l. Abdominal MRI: In the pelvic cavity on both sides ovary like structur, with the size: 0.8X1.33 cm. At the posterior side of the urinary blade tubular mass with the size 2.7X7 mm (apparently vagina). The conclusion of children’s psychologist: The psychologic development of the child coresponds to male. Therapy: Hydrocortisone 15mg/day, Fludrocortisone 1 mg/day, Cyproterone 10 mg/day. By substitutional therapy hormone concentration in the blood came down to the normal range and puberty stopped. The condition of the patient was explained to the parents and to an ethical committee for the decision, to raise the patient as a girl or as a boy by gender reasignment surgery (extirpation of uterus and ovaries).

Conclusions: Continued excessive adrenal sex steroids in untreated CAH patient causes several problems which reveal not only physical, but also psychological deviations.

PAO-35

A case of a 1 year 9 months old girl with a hypothyroidic hormatoma associated with precocious puberty

Mariam Balakhadze1; Maia Rkhivashvili1; Revaz Morgoshia1; Rolf Peter Willig2

1JSC “Vere XXI”, Department of Physical and Sexual Development of Children and Adolescents, Tbilisi, Georgia; 2Endocrinologikum Hamburg, Pediatrics, Hamburg, Germany

Background: Gonadotropin-releasing hormone (GnRH) dependent, or central precocious puberty (CPP) results from early onset of pubertal hypothyroidism-pituitary-gonadal activity. This occurs as a consequence of physiologic gonadotropin stimulation emanating from the GnRH secretion of hypothalamic origin. Both boys and girls with an organic etiology of CPP are more likely to present at a younger age, than those with idiopathic etiology.

Objective and hypotheses: We describe a child with hypothyroidic hormatoma associated with precocious puberty on Triptorelin treatment.

Methods: A prismatic case report.

Results: We report 1 year 9 months old girl. Complaints: premature puberty. Sexual development stage: Tanner 3 (B3, P3, A2, A2. At the age of 8 months) Anamnesis: from the age of 2 weeks till today vaginal discharge (white), at the age of 3 months pubic hair appeared, at the age of 6 months breast de-
Background: Disorder of sexual differentiation can produce phenotype alterations. Some of them are imperceptible at birth. We present the case of a girl with a karyotype and internal/external phenotype never described before. We present a large iconography of this peculiar case.

Clinical case: 14 years old patient with not sign of thelarche and important hirsutism (Ferriman 12 points) Tanner A5P5B1. Clitoromegaly (Prader 2Txagorritxu Hospital, Urologic Unit, Vitoria, Spain).

Evolution: Quick estrogenization (etinilestradiol VO and combined progesterone). Some of them are imperceptible at birth. We present the case of a girl with hypothyroidism, the average age in the 6 patients was 13.36 years (11-18 years) 6 months after quirurgery, there was a reduction of basal testosterone, partial reduction of body hair, telarche development grade III and a substantial improvement of patient’s self-esteem. Clitoromegaly is lower too.

Methods: Complementary tests TSH 1.98 uI/mL FSH 51.6 U/L LH 33.2 U/L Estradiol 13.3 ng/mL Testosterone total 10.41 ng/mL SHBG 52.92 nmol/L DHEA-S 174 ng/dl Free Testosterone 19.3 17 OHP 1.64 ng/mL Karyotype: (400 bands): 47,XY,Y[28]/45,X[2]

Conclusions: Gynecologic exploration through laparoscopy: Uterus and Fallopian tubes were normal. Left ovary compatible with testicle; with a similar form between fimbriaes in right side. Tissues biopsy: Compatabile with testicular tissue. Karyotype of gonadal biopsy 47 XY Evolution: Quick estrogenization (estradiol VO and combined progesterone). 6 months after quirurgery, there was a reduction of basal testosterone, partial reduction of body hair, telarche development grade III and a substantial improvement of patient’s self-esteem. Clitoromegaly is lower too.

Conclusion: Despite therapy with deoxofrin, treatment should be evaluated in the 6 patients was in Tanner 1 to Tanner 2. 6 patients were all short stature, 4 cases of ketoacidosis were detected insulin level <2 μu/L, C peptide mean 24pmol/L, suggesting lack of insulin secretion. Pancreas MRI showed the signal to reduce, which was related with iron deposition. The puberty stage of 6 patients was in Tanner 1 to Tanner 2. 6 patients were all short stature, 4 cases of hypothyroidism, 2 cases of GHD. Mild liver function abnormalities (2 cases) and abnormal heart function (1 case) were detected. All patients treated with transfusion, deoxofrin, exercise, diet control, Glucobay and insulin. Comprehensive therapy was good.

Conclusions: Despite therapy with deoxofrin, treatment should be evaluated in the 6 patients was in Tanner 1 to Tanner 2. 6 patients were all short stature, 4 cases of hypothyroidism, 2 cases of GHD. Mild liver function abnormalities (2 cases) and abnormal heart function (1 case) were detected. All patients treated with transfusion, deoxofrin, exercise, diet control, Glucobay and insulin. Comprehensive therapy was good.

Conclusions: Despite therapy with deoxofrin, treatment should be evaluated in the 6 patients was in Tanner 1 to Tanner 2. 6 patients were all short stature, 4 cases of hypothyroidism, 2 cases of GHD. Mild liver function abnormalities (2 cases) and abnormal heart function (1 case) were detected. All patients treated with transfusion, deoxofrin, exercise, diet control, Glucobay and insulin. Comprehensive therapy was good.

Conclusions: Despite therapy with deoxofrin, treatment should be evaluated in the 6 patients was in Tanner 1 to Tanner 2. 6 patients were all short stature, 4 cases of hypothyroidism, 2 cases of GHD. Mild liver function abnormalities (2 cases) and abnormal heart function (1 case) were detected. All patients treated with transfusion, deoxofrin, exercise, diet control, Glucobay and insulin. Comprehensive therapy was good.

Conclusions: Despite therapy with deoxofrin, treatment should be evaluated in the 6 patients was in Tanner 1 to Tanner 2. 6 patients were all short stature, 4 cases of hypothyroidism, 2 cases of GHD. Mild liver function abnormalities (2 cases) and abnormal heart function (1 case) were detected. All patients treated with transfusion, deoxofrin, exercise, diet control, Glucobay and insulin. Comprehensive therapy was good.
in 39% of patients shows impairment of 3-axis pituitary in 28% of 2 or more axes in 11% of 1 or more and 22% no axis compromise. [5]. The most frequent response is that of a GH deficiency present in more than 75% of cases, followed by a gonadotropine deficiency in 40% of cases and a ACTH and TSH deficiency in 25%. Despite craniopharyngiomas are usually of significant size already at diagnosis, the pituitary stalk is rarely interrupted, for which only 20% of patients presents hyperprolactinemia resulting from the compression pedicle.

Our experience: In 25 children (16 males and 9 females) whose age at diagnosis was between 0.35 and 13.30 years with an average of 6.6 years (SD 3.04). Location of craniopharyngioma. Suprasellar 8 Sellar suprasellar 8 Saddle 3rd ventricle 1 Suprasellar diencéfalic 1 Suprasellar 3rd ventricle 1 Chiasmatic 2 3rd ventricle 1 Retrochiasmatic 1 Rétrosellar 1 Suprasellar retrochiasmatic 1 Total 25 Aduo-encephalic abnormalities at diagnosis. Growth retardation 4 / 25 (16%) Precocious puberty, 1 / 25 (4%) Delayed puberty 1 / 25 (4%) PU / PD 1 / 25 (4%) Overweight / obesity 5 / 25 (20%) Gignatism 1 / 25 (4%) Endocrine abnormalities detected after treatment. Diabetes insipidus 20 (80%) Precocious puberty 2 (8%) Hypopituitarism 18 (72%)

Conclusion:
- High incidence of short stature and / or = 2
- High incidence of obesity hyperphagia
- Marked hyperphagia (binge eating) with difficulty in controlling appetite.
- Increased behavioral and psycho-social.

PAO-40

Prevalence of subclinical hypothyroidism in child cancer survivors and efficacy of levothyroxine treatment

Shinichiro Sato; Yuichi Nakagawa; Toshiki Nakashima; Rie Matsuhashi; Eiichiro Takeyoshi; Yoko Fujisawa; Eiko Nagata; Takehiko Ohzeki
Hamamatsu University School of Medicine, Pediatrics, Hamamatsu, Japan

Background and objective: Child cancer survivors (CCS) have some complications. Although hypothyroidism in CCS has been well reported, little is known about subclinical hypothyroidism (SCH). The aim of this study was to investigate the prevalence of SCH and efficacy of levothyroxine (LT4) supplementation in CCS with SCH.

Methods: Twenty CCS were divided into two groups. The chemo group (n=8) was treated with chemotherapy alone and the chemo group (n=12) received chemotherapy plus radiotherapy. Control group was healthy children who showed short stature but normal hypothalamic-pituitary and thyroid function. TSH, FT3, and FT4 were measured in all patients. TRH stimulating test was performed only in the patients who were diagnosed with SCH. The definition of SCH is TSH > 5 µIU/ml while FT3 and FT4 are within normal range. Lipid profile and QOL were evaluated after 2 or 3 month of LT4 supplementation in these patients.

Results: No patients in the chemo group showed SCH. Four patients in the radiation group (33%) were diagnosed with SCH. They received radiotherapy both in spine and brain. Their TRH stimulating test showed hyperresponse and persistence of high levels of TSH. Their cholesterol levels were significantly higher than those of the chemo group. Mild dose of LT4 administration improved their lipid profile and QOL.

Conclusions: High prevalence of SCH was seen in CCS with radiotherapy. Our findings suggest that irradiation of spine plus brain is high risk of SCH. Mild dose of LT4 can improve the lipid profile and QOL in SCH patients.

PAO-41

Adenohypophysitis in a boy with pan-sinusitis and meningitis

Mariella Valenzise1; Malgorzata Wasniewska1; Francesca Granata1; Sabrina Cardile1; Maria Rosaria Velletri1; Filippo De Luca1
1University of Messina, Department of Pediatrics, Messina, Italy; 2University of Messina, Department of Neurosciences, Psychiatry and Anaesthesiology, Messina, Italy

Background: Although hypophysitis is usually thought as a primary process, it may occur secondarily in relation to infections or other processes such as Langerhans cell histiocytosis, Crohn disease.

Case report: We report the case of a 15-year-old boy who was admitted to our Clinic due to headache, fever, visual disturbances and rigor nucalis. A 3D-CT showed pansinusitis whereas CSF showed a pleiocytosis (500 cell/mm3); therefore, broad spectrum antibiotics therapy were administered. After 5 days headache, fever, rigor nucalis were resolved, but diplopia persisted. MRI examination could be performed after pansinusitis in order to detect early involvement of pituitary gland that, after gadolinium, presented asymmetrical enlargement in size. Basal concentrations of plasma ACTH, cortisoll, PRL, FSH, LH, testosterone were very low; also TSH appeared very low but thyroid hormones were still within the normal limits. Anti-pituitary antibody was also negative. Corticosteroid treatment (1mg/kg/ die) was administrated for six months and after two months of discontinuation endocrinological investigations were repeated. There were normal responses of FSH and LH to appropriate stimuli, normal levels of T, ACTH, cortisoll, TSH, T4. Only GH secretion after stimulation tests appeared subnormal (Peak 3.71 ng/ml). Follow-up MRI showed that the pituitary had reduced in size.

Conclusion: On the basis of our case we may conclude that: a) pansinusitis can have devastating intracranial sequelae, as involvement of the adjacent pituitary gland and cavernous sinuses; b) endocrinological and radiological examination could be performed after pansinusitis in order to detect early involvement of pituitary gland; c) corticosteroid therapy can be effective in reducing the pituitary size, attenuating inflammation and restoring pituitary function; d) a pattern of pituitary hormone deficiency with early loss of ACTH and TSH and sequential loss of GH could be observed. Long term follow-up is mandatory to monitor other possible hormonal deficits.
PAO-42
Adrenal agenesis secondary to DAX 1 mutation in a newborn
Ignacio Díez-Lopez1; Jinhoa Sarasua Miranda1; Enrique Gonzalez Molina2; Mercedes Martinez Aycaar3; Amaia Rodriguez Estevéz4; Luis Castaño Gonzalez5; 1Txagorritxu Hospital, Paediatric Endocrinology Unit, Vitoria, Spain; 2Txagorritxu Hospital, Newborn Unit, Vitoria, Spain; 3Cruces Hospital, Paediatic Endocrinology Unit, Bilbao, Spain; 4Cruces Hospital, Paediatric Research Laboratory, Bilbao, Spain

Background: Agenesis or hypoplasia of adrenal glands associated to alterations of Gen DAX-1 (crom X) are a very unusual clinical subject, and could be accompanied by other hormonal and genetic alterations. We present a clinical case, supported with images.


Methods: Weight 3880 G (>2 SD) Height 56,5 cm (>2 SD) CP 37 cm Hypotonic, with labial sub cyanosis and general hyper pigmentation, Silverman score 3-4/10. Normo configured genitalia, except hyper-pigmentation. Aggar 2/6/8. Requires RCP type II

Results: Laboratory: pH 7,26, CO3H 19,4; EB -6. Sodium 119 mEq/L, potassium 7,3 mEq/L, PCR 23,8 mg/dL after 24 hours/life Cultivates: Negative. Cortisol 2,86 mcg/dL. DHEA-S 8,32 mcg/dL (32-431), 170HP 3,73 ng/ml (0,4-3,3). ACTH 1,129,1 pg/mL (5-77), cholesterol 177 mg/dl (50-170), Noraphinefrine: 5 mcg/24 horas (12 mcg/L) Epinefrine: < 1 mcg/24 horas (<2 mcg/L) Dopamine: 65 mcg/dl (163 mcg/L).

Abdominal ultrasound and MRI: There is no sign of adrenal glands. Genetic study: 46 XY (DAX-1 +) at index case, father not affected, mother 46 XX*, (null/DAX-1 –).

Conclusions: After Hydro-electrolytic correction and treatment with hydrocortisone; the values of Na,K were normal. We use supplementary dose of sodium too. After 3 months, the levels of ACTH were normal. Up to date (18 months age), patient is asymptomatic. His psychomotor and somatometric development is according to his age. Bone-age equivalent and the hyper-pigmentation has disappeared.

PAO-43
Bone mineral density and turnover in patients with idiopathic hypogonadotropic hypogonadism
Eva-Maria Laitinen1; Johanna Tommiska2; Kirsti Vuoralahti2; Tanelli Raivo3
Helsinki University Central Hospital, Hospital for Children and Adolescents, and, University of Helsinki, Institute of Biomedicine/Physiology, Helsinki, Finland

Background: Patients with idiopathic hypogonadotropic hypogonadism (IHH) may have reduced peak bone mass in early adulthood, and increased risk for osteoporosis despite long-term hormonal replacement therapy (HRT). Objective and hypotheses: We investigated markers of short bone turnover, and the relationship between HRT history and bone mineral density (BMD) in patients with IHH.

Methods: 33 subjects (24 men, 9 women; mean age 39.8 yrs, range 24.0—69.1) with IHH (Kallmann Syndrome or normosmic IHH), were physically examined and measured for circulating PINP, ICTP, and sex hormone levels. 26 subjects underwentDEXA for BMD of lumbar spine, hip, femoral neck, and whole body.

Results: In men, serum PINP correlated with ICTP (R=0.61; p=0.002), but these markers correlated neither with circulating T, nor with serum E levels in women.

Treatement history had a clear impact on bone health in men: lumbar spine (BMD, mean Z-score -2.0 SD, range -4.1—1.4) was reduced in subjects with inadequate HRT (n=7, including those with long (>25 yrs) treatment pauses) as compared to those with a history of adequate HRT (n=11); LBMD: -0.5 SD, -2.4—0.7) (p=0.037).

The overall duration of treatment pause (range 0.15—30 yrs) correlated negatively with lumbar and femoral neck Z-scores (R=0.64 and 0.53, p=0.014 and 0.041, respectively), and the overall duration of HRT (range 2.6—37.3 yrs) had positive correlations with hip and femoral neck Z-scores (R=0.42 and 0.61; p=0.039 and 0.001, respectively). Age, BMI, or age at onset of HRT did not correlate with BMDs. In addition, BMDs did not differ between subjects with KAL1 (n=3), FGFR1 (n=5), or GNRRH (n=4) mutations (data not shown).

Conclusions: In patients with IHH, the prevailing sex steroid milieu does not affect short-term bone turnover. Our data suggest that both the quality and quantity of HRT influence BMD in IHH patients irrespective of age.

PAO-44
Two cases with HDR syndrome (hypoparathyroidism, sensorineural deafness and renal disease)
Mehmet Keskin1; Yılmaz Kor1; Ali Yalçın1; Hatice Uygu1; Ozlem Keskin2; Deniz Kor2
1Gaziantep University, Faculty of Medicine, Pediatric Endocrinology and Metabolism, Gaziantep, Turkey; 2Gaziantep University, Faculty of Medicine, Pediatrics, Gaziantep, Turkey

Background: HDR syndrome (hypoparathyroidism, sensorineural deafness and renal disease) was first reported by Barakat et al. described two brothers with steroid-resistant nephrosis with progressive renal failure, sensorineural deafness and hypoparathyroidism in 1977. Autosomal dominant disorder that is caused by mutations of the GATA3 gene, which is located on chromosome 10p15, has been identified recently. GATA3 is expressed in the developing parathyroid glands, inner ears and kidneys, together with thyamus and central nervous system.

Objective and hypotheses: The patients with symptoms of hypocalcemia must be evaluated carefully.

Results: Hypoparathyroidism, sensorineural deafness and renal anomaly were diagnosed in our two patients with symptoms of hypocalcemia.

Conclusion: These cases are reported because of HDR syndrome is a very rare condition and the history of deafness in patients with hypocalcaemia for understanding of this syndrome.

PAO-45
Effects of growth hormone on muscle strength, tone and mobility of children with Prader-Willi syndrome
Shabab Salehpour1; Omid Aryani2; Farzaneh Rohani3
1Shaheed Beheshti University of Medical Sciences, Pediatric Surgery Research Center, Pediatric Endocrinology, Tehran, Islamic Republic of Iran; 2Special Medical Center, Molecular Genetics, Tehran, Islamic Republic of Iran; 3Tehran University of Medical Sciences, Pediatric Endocrinology, Tehran, Islamic Republic of Iran

Background: Prader-Willi syndrome (PWS) is a genetic syndrome presenting with severe hypotonia and decreased agility. Growth hormone (GH) which is often used in these cases to treat short stature and obesity, seems to have some improvement in hypotonia, physical strength, activity, and locomotor developmental ability.

Objective: The aim of this study is to find the growth hormone effect on the agility and strength of these patients.

Material and methods: In a prospective, randomized controlled clinical trial, at an out-patient pediatric endocrine clinic in Tehran, 21 PWS children (12 boys and 9 girls, 4 to 9 years old) were divided either in GH-treated or control groups and followed for two years. Agility run, sit ups, weight lifting, and loco-motor developmental ability.

Results: All the outcome measures of the GH treated group showed a significant improvement compared to those of the control (p<0.01).

Conclusions: GH causes a significant improvement in agility and strength of PWS children.
An unusually early diagnosis of 17-alpha-hydroxylase deficiency

Nicolin Datz1; Jens Siegel2; Felix Riepe3; Michaela Hartmann1; Stefan A. Wudy4; Sabine Heger1
1Children’s Hospital Bult Hannover, Department of Pediatric Diabetology and Endocrinology, Germany; 2Children’s Hospital Bult Hannover, Department of Neonatology, Hannover, Germany; 3Christian-Albrechts University, Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Kiel, Germany; 4Justus-Liebig-University, Steroid Research Unit, Center of Child and Adolescent Medicine, Giessen, Germany

Background: Mutations of the CYP17A1 gene result in 46,XY disorder of sex development, hypertension, hypokalemia and absent pubertal development. It is a rare, autosomal recessive form of congenital adrenal hyperplasia (CAH).

Objective and hypotheses: Usually, most patients are detected rather late as adolescents due to lack of puberty or hypertension.

Methods: We report about a neonate born to a 40 year old woman, 1st para, 1st gravida. Amniocentesis revealed a fetus with a 46,XY karyotype. At 20 weeks of gestation the development of male external genitalia was missing. Further molecular testing excluded an androgen receptor and SRY gene mutation. A phaenotypically female child was born at 41st week of gestation. Gonads were palpable in the labia majora.

Results: Postpartal ultrasound revealed testes in both labia majora, absence of uterus and normal adrenal glands. Screening for 21-hydroxylase-deficiency was normal. Multisteroid analysis in serum showed reduced basal glucocorticoid, testosterone and androsterone levels at the age of two weeks. The urinary steroid metabolome – assessed by GC-MS - showed excessive excretion of 17-desoxy-steroids, decreased glucocorticoid metabolites and absent C19-steroids. Such a metabolic constellation proves 17-alpha-hydroxylase-deficiency. Molecular analysis identified a novel mutation of the CYP17A1 gene: c.896T>A (p.I299N) in exon 5. Substitution with hydrocortisone was started at a moderate dose to prevent hypertension. The child is growing well so far.

Conclusion: Herein we report the unusually early diagnosis of a newborn with the rare CAH form of 17-alpha-hydroxylase-deficiency allowing installment of early treatment.

The effect of gonadotropin-releasing hormone agonists in Korean boys with idiopathic central precocious puberty and early puberty

Hae Sang Lee; Hong Kyu Park; Jin Soon Hwang
Ajou University School of Medicine, Pediatrics, Suwon, Republic of Korea

Background: Central precocious puberty (CPP) is less common in boys than in girls. There is little data available on the long-term safety and efficacy of GnRHa treatment in boys with CPP. The effects of GnRHsa, with and without growth hormone, on the predicted adult height in boys with CPP and early puberty were evaluated after two years of treatment.

Methods: This study included nine boys with CPP and 13 boys with early puberty that were treated with depot leuprolide acetate. Anthropometry, bone age, sexual maturity rating and predicted adult height (PAH) were assessed at baseline, and after 6, 12, 18, and 24 months.

Results: The PAH standard deviation score (SDS) in the GnRHa group of boys with CPP (n=9) was significantly increased (+0.23 ± 1.60 vs 0.49 ± 0.71; P=0.0014). The PAH SDS of the GnRHa group with early puberty (n=9) was significantly decreased to the pretreatment PAH SDS (0.57 ± 1.06 vs 0.36 ± 0.68; P=0.05). Multiple regression analysis revealed that height gain was influenced significantly by age at the start of treatment.

Conclusions: GnRHa treatment significantly improved the growth potential in boys with idiopathic CPP. However, GnRHa treatment alone did not affect the growth prognosis in boys with early puberty.
Introduction: All carriers of a point mutations in the RET proto-oncogene with multiple endocrine neoplasia type 2A (MEN2A) develop medullary thyroid carcinoma (MTC), while 50% and 30% of patients develop phaeochromocytoma and hyperparathyroidism. MTC tends to disseminate early. It is chemo- and radio-resistant and remains the cause of death in 15-20% of MEN2A patients. Consequently, early prophylactic total thyroidectomy is performed in all MEN2A patients.

Case report: A 32-yr-old father presented with bilateral phaeochromocytoma, MTC and parathyroid adenoma. Genetic analysis revealed a point mutation in codon 634 of exon 11 of the RET proto-oncogene. Genetic testing confirmed that both siblings were carriers of the same mutation. In a 10-yr-old son ultrasound of the neck disclosed nodules in both thyroid lobes and enlarged paratracheal and left jugular lymph nodes. Laboratory examination revealed high calcitonin concentrations (437 pg/ml), while serum calcium and PTH levels were on the upper limit of normal values. In a 7-yr-old son serum calcium level was slightly elevated (20.7 pg/ml), and plasma calcium and PTH levels were normal. On ultrasonography, a nodule in a right thyroid lobe, enlargement of the left jugular and right submandibular lymph nodes were observed. Both children underwent total thyroidectomy with neck dissection. Pathological examination showed bilateral MTC in a boy and MTC of the right thyroid lobe in a girl, with no lymph node metastatic disease. Laboratory examination showed no phaeochromocytoma in siblings. After surgery both children began with thyroid replacement therapy. Due to the permanent hypocalcaemia in a boy, treatment with calcium-carbonate and calcitriol was initiated. Eighteen months after thyroidectomy, the children are doing well.

Conclusions: At present, genetic testing and prophylactic total thyroidectomy prevents the development of an invasive MTC in MEN2A patients. However, the risk of permanent hypoparathyroidism and the issue of thyroid replacement therapy remain a concern.

Conclusion: DAX1 mutation analysis should be considered in males with adrenal dystrophy, mental retardation-IL1RAPL1, glycerol kinase and ornithine -transaminase deficiency sex reversal-Adrenal hypoplasia congenita critical region on the X chromosome (DAX1)-syndrome caused by DAX1 deletion.

A case of adrenal hypoplasia congenita caused by DAX1 deletion

Eun Young Kim-Kook1; Yang Ji Kang1; Hyun Wook Shin1;

Han-Wook Yoo2

1Kwangju Christian Hospital, Pediatrics, Gwangju, Republic of Korea; 2Asan Medical Center, Pediatrics, Seoul, Republic of Korea

Background: Adrenal hypoplasia congenita caused by DAX1 (Dosage sensitive sex reversal-Adrenal hypoplasia congenita critical region on the X chromosome gene-1) mutation, is a rare disorder and presents usually acute severe adrenal insufficiency in the neonatal period and hypergonadotrophic hypogonadism. Because DAX1 is located on Xq21, the mutation affects primarily boys (X-linked). Associated with deletion of DAX1, the Duchenne muscular dystrophy, mental retardation-IL1RAPL1, glycerol kinase and ornithine transcarbamylase genes may also be deleted as part of a contiguous gene syndrome.

Case: We report an 1 month old male patient presenting with weight loss, dehydration, lethargy, poor feeding, and hyperpigmentation. The first laboratory investigation showed hypoadrenalinemia (121 ng/dL), hyperkalemia (7.8 mEq/L), high ACTH (342 pg/ml), and high renin (24.6 ng/ml/hr), so he was diagnosed with primary adrenal insufficiency (PAI). To reveal the cause of PAI, further investigations were performed and showed normal 17-OH, VLCFA, and negative adrenal Ab. On abdominal CT, adrenal hypoplasia was detected. DAX1 gene analysis using PCR presented complete deletion and contiguous genes (glycerol kinase and IL1RAPL1) were also deleted. He showed clinical improvement after glucocorticoid and mineralocorticoid treatment, but at present (12months of age), shows mild motor developmental delay.

Conclusion: DAX1 mutation analysis should be considered in males with adrenal hypoplasia congenita.

Comparison of the efficacy of multiple daily insulin injection therapy and flexible intensive insulin therapy in children with type 1 diabetes mellitus

Guro Gulacak1; Ozlem Sangun2; Bumin Dundar2

1Suleyman Demirel University, Department of Pediatrics, Sparta, Turkey; 2Suleyman Demirel University, Department of Pediatric Endocrinology, Sparta, Turkey

Objective: To compare the effects of multiple daily insulin injection therapy (MDI) and flexible intensive insulin therapy (FIIT) on metabolic parameters and quality of life in children with type 1 Diabetes Mellitus (DM).

Method: Twenty eight patients who were followed regularly at least 1 year in our Pediatric Endocrinology outpatient clinic and being treated with MDI (three doses of pre-meal insulin aspart and a single daily dose of basal detemir/glargine insulin) were included in the study. All the patients were evaluated for HbA1c, BMI-SDS, hypoglycaemia, mean fasting plasma glucose (FPG) levels, lipid profile, total daily insulin requirement and quality of life (QOL) before and after the 6 months of FIIT. Treatment periods of MDI and FIIT were compared. The Medical Outcomes Survey Short Form-36 (SF-36) was performed in order to assess QOL.

Results: Mean age of the patients was 12.9 ± 2.59 years old. The mean HbA1c and FPG levels of the patients during MDI treatment were found significantly decreased after switched to FIIT (p=0.001 and p=0.024). Insulin requirement, frequency of hypoglycaemia, total cholesterol, low density lipoprotein (LDL), triglyceride levels, HDL levels and BMI-SDS of the patients was not significantly decreased with FIIT (p>0.05).

Conclusion: HbA1c and mean FPG levels significantly decrease with FIIT without causing significant difference in insulin requirement, frequency of hypoglycaemia and lipid profiles. FIIT also improves mental health and is a reasonable choice in treatment of pediatric Type 1 DM patients.

Suspicious reflections and a solitary nodule in Hashimoto thyroiditis: finally carcinoma

D Mull1; J Kivel1

1Haga teaching Hospital / Juliana Children’s Hospital, Pediatric Endocrinology, The Hague, Netherlands; 2Leiden University Medical Center, Surgery (section Endocrine/Head & Neck), Leiden, Netherlands

Background: There is controversial literature on the association between Hashimoto thyroiditis (HT) and the incidence and course of papillary thyroid carcinoma (PTC) in children.

Case report: Our patient was first seen as a young girl at age 14 with a clinical picture of HT with positive antiTPO antibodies. Ultrasound revealed an inhomogeneous pattern in the left lobe with many reflections, mimicking microcalcifications, and Tc-99m-pertechnetate scan was inconclusive. Fine needle aspiration (FNA) suggested a benign etiology with lymphocytic thyroiditis as in HT. Levothyroxin supplementation was initiated. At age 16.5, our patient complained of a swollen neck and the thyroid gland was found to have increased in size. Ultrasound showed a 2 cm hypervascular solitary nodule in the left lobe near the isthmus. FNA again showed an HT picture. The risk for malignancy, given these repeated negative biopsies, was low and no surgical intervention was performed. Three months later the patient returned. On holiday abroad she had fallen ill and was seen at a hospital outpatient department. Complaints of further diameter increase of the thyroid led to another FNA, which this time suggested PTC. After her return from holiday, a total thyroidectomy was performed, showing a 3.5 cm diameter differentiated PTC (T2N0M0). No KRAS of BRAF mutations were detected in DNA analysis as markers of a malignant clinical course.

Conclusions: This case shows the co-occurrence of HT and PTC and the difficulties in diagnosis. In children it is not well defined whether HT increases risk for PTC incidence or prognosis. Ultrasound findings should aid in risk assessment, but its sensitivity in HT is poorly established. In this case, microcalcifications and hypervascularity of the nodule suggested further analysis, but FNA did not support clinical suspicion. Evidence-based medical decision making could guide clinical decisions in children with HT presenting with nodular abnormalities.
PAO-53

Abstract withdrawn.

PAO-54

Influence of body mass index on peak GH level in provocation test: children without growth hormone deficiency

Jaeun Lee; Juyeong Yoon; Min Jae Kang; Shin Mi Kim; Young Ah Lee; Choongho Shin; Sei Won Yang

Seoul National University Children's Hospital, Pediatrics, Seoul, Republic of Korea

Background: Obesity and other related factors are known to suppress the secretion of growth hormone. But the influence of obesity on the peak GH level of provocation test is still controversial in children without growth hormone deficiency (GHD).

Objective and hypotheses: This study aims to evaluate the influence of obesity on the peak GH level of provocation test in children without GHD.

Methods: The subjects were children who were admitted to Seoul National University Children's Hospital and got provocation tests done due to short stature from January 2000 to July 2010. Their medical records were retrospectively reviewed, and patients with obvious growth hormone deficiency were excluded. The main outcome measure was peak GH level of provocation test, and the height, weight, and serum IGF-1 levels were also recorded.

Results: Simple linear regression analysis showed that body mass index (BMI) had a positive correlation with peak GH level (P<0.004), but gender, age, pubertal status, and IGF-1 had no correlation, respectively. In multiple logistic regression analysis, BMI SDS (P<0.042) and age (P<0.017) were suggested to be significant predictors of peak GH level.

Conclusions: In children without overt GHD, a higher BMI SDS may have negative correlation with the peak GH level. Therefore, we can take BMI SDS into consideration when analyzing the results of growth hormone provocation test.

PAO-55

Paediatric nephrology; chronic kidney disease (CKD) & coping – psychology vs. immunology & neuroendocrinology; discussion paper

Shahid Muhammad1; David Jessop2; Pauline Banks1; Colin Martin1

1University of the West of Scotland, School of Health Nursing and Midwifery, Hamilton, United Kingdom; 2University of Bristol, Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, Bristol, United Kingdom

Background: The study of coping with Chronic Kidney Disease (CKD) in young people is a unique and challenging task because their circumstances are quite divergent from their adult counterparts. The aim of this article is to use a combination of retrospective and present literature to inform discussion linking psychology, immune and neuroendocrine systems to recognize a deeper perspective on coping in young people facing CKD.

Ckd in children and young people: CKD is a chronic illness and it is irreversible. Coupled with its devastating effects, CKD is associated with cardiovascular dysfunction, anaemia, malnutrition, muscle wasting, muscle weakness, glucose intolerance, reduced bone density; all leading to reduced coping, well-being and overall quality of life.

Coping strategies (psychological and physiological): The majority of young people with CKD would be expected to cope adequately with daily events and stresses under normal circumstances. Anxiety is a common psychological pattern of children/young people with CKD. Physiologically, due to the influence of internal conditioning factors, what might generally be called ‘a normally well-tolerated degree of stress’ can become chronic for individuals with vulnerable body systems, thus leading to long-term adapting/ coping in young people with CKD.

Central mechanisms: The hypothalamic-pituitary-adrenal (HPA) axis is a major part of the neuroenocrine system, involving the interactions of the hypothalamus, the pituitary gland and the adrenal glands; thus how well a young individual with CKD copes may be related to stress hormone levels and cell types in the blood.

Conclusions: Overall, an integrated PNI approach is desirable to better understand coping. The immune system has a ‘means’ to signal and ready the body to respond to stressful challenges enabling it to cope. Understanding coping in children/young people with CKD should not be restricted to psychological/psychosocial research.

PAO-56

Breasts condition in adolescent girls with autoimmune thyroiditis

Olga Gumenyuk1; Yury Chernenko2

1Saratov Medical University, University Hospital 5, Pediatric Endocrinology and Gynecology, Saratov, Russian Federation; 2Saratov Medical University, Department of the Hospital, Polyclinic Pediatrics and Neonatology, Saratov, Russian Federation

Background: The reproductive health is frequently associated with thyroid disorders.

Objective: To study of mammary glands (breasts) condition in adolescent girls with autoimmune thyroiditis (AT).

Population and methods: The study included 30 girls (aged 15-18 yrs) with AT (group I) and 30 girls without thyroid diseases (control group). AT was diagnosed on the basis of thyroid peroxidase antibodies level and typical picture of thyroid ultrasound. Mammary glands (MG) disease (mastopathy or dysplasia) was diagnosed on the basis of signs and typical picture of MG ultrasound.

Statistical analysis was performed using Mann-Whitney Test.

Results: Thyroid function was normal in all these girls. TSH levels in girls of group I and control group were 2.9±0.9 and 1.7±0.5 mIU/l, respectively. The investigation shows that only 2 girls without AT and all girls (100%) with AT had MG diseases. Among the patients with MG disease the diffuse fibrous dysplasia was found in 26 (87%) in group I and 2 girls – in control group. The cistic diffuse dysplasia was diagnosed only in girls with AT (in 2 patients). The study demonstrated that all adolescents with AT and MG disease had cyclic (premenstrual) mastalgia, 27% girls – persistent mastalgia and 45% girls – cyclic and persistent mastalgia. The investigation shows that only 2 girls with MG disease of in control group had premenstrual mastalgia.

Conclusions: This study has shown a high frequency of mastopathy (38%) among the examined adolescent girls with AT. The AT is risk factor for the mastopathy and the indication for observation and examination of MG.

PAO-57

Computer diagnostics of diabetic cardiac autonomous neuropathy in children

Elena Novikova; Nina Bobolova; Elena Peresypkina

Saratov Medical University, Pediatric endocrinology and diabetology, Saratov, Russian Federation

Diabetic cardiac autonomous neuropathy (DCAN) – is one of chronic complications of diabetes mellitus (DM) which indicates the unfavorable prognosis of disease.

Objective: To study the possibilities of apparatus programmed test in diagnostics of DCAN in children. Population and methods. There were examined 40 children with DM1, at the age from 7 to 16 yrs. 12 children have the deforming form of diabetes (I group), 16 children have suffered the disease from 1 to 5 yrs (II group) and 12 children have had the disease more than 5 yrs (III group). To diagnose DCAN there was used cardiac vegetative test by means of apparatus programmed complex «VNS - spectrum» (Neurosoft), with program analysis «Poly-spectrum». The evaluation of cardiac rhythm variability (5 cardiac vascular tests on Ewing) was used as the basis of investigation. Each one is estimated from 0 to 2 points.

Results: In all patients of I group there was revealed compensation of carbohydrate metabolism; subcompensation in 6 patients of II group and in 5 patients of III group; uncompensation in 10 patients of II group and in 7 patients of III group. DCAN of I degree (5-7 points) was revealed in 20 children with DM: 4 patients of I group; 8 – of II group, 8 – III group. DCAN of 2 degree (8 – 10 points) was revealed in 5 children with DM: 1 from I group; 4 from III group. There was detected the correlation of DCAN with the age of children at the debut of the disease, duration of the disease, degree of compensation.

Conclusions: Cardiac vegetative test allows to diagnose DCAN in children and administer the treatment at early stage, when there is no irreversible death of the nerve fibres.
Background: Diencephalic syndrome is a rare condition which typically presents with severe failure to thrive despite preservation of normal linear growth. This is associated with tumours involving the hypothalamus and/or optic chiasma, with the majority being astrocytoma.

Objective and hypotheses/method: We describe 3 patients seen at our centre who were diagnosed with diencephalic syndrome over the past 20 years.

Results: Initial differential diagnoses for failure to thrive included celiac disease, generalized lipodystrophy and Russell Silver syndrome in one patient who was short. Only one patient presented with nystagmus, which suggested an intracranial pathology. After extensive workup for failure to thrive, Computed Tomography of the brain eventually revealed the presence of a suprasellar tumour in all 3 patients, which were subsequently confirmed to be inoperable hypothalamic astrocytomas. The age of diagnosis ranged from 9 to 18 months old. There was one death, with the other two patients demonstrating a more protracted course. The child who died presented at the earliest age and had the largest tumour which recurred within 1 month of surgery, suggesting a more aggressive course. Of the other two patients who have survived into adulthood, one underwent cranial irradiation before the age of 5 years, and suffered the consequences of late onset endocrinopathies and mental retardation. Both surviving patients have reached adulthood, with minimal increase in tumour size, suggesting a more indolent course. In diencephalic syndrome, the overall mortality rate is 55% with death ranging from 8 months to 13 years.

Conclusions: Diencephalic syndrome must always be considered in any child with failure to thrive from no other apparent reason. This peculiar syndrome provides a unique model of partial growth hormone resistance (elevated growth hormone levels) with normal linear growth, and suggests that there are hypothalamic-pituitary factors in the feedback mechanisms of appetite regulation and metabolism.

Introduction: Iron deficiency is a significant public health problem in terms of epidemiology and potential comorbidities. Its prevalence and easy diagnosis and treatment, put into question the relevance of performing screening programs or targeted screening in high risk populations or suspected cases.

Objectives: To study the potential impact of IBD in mineral metabolism in pediatric patients, evaluating clinical, biochemical, densitometric and radiographic parameters.

Material and methods: Cross-sectional study in children with IBD. We collected anthropometric and clinical data (cumulative dose of corticosteroids, index of IBD activity, nutrition survey and lifestyles). It was carried out a blood analysis. It included CBC and serum biochemical study on the levels of glucose, urea, creatinine, sodium, potassium, calcium, phosphorus, orosomucoid, transferrin, ferritin, total protein, albumin, HDL-cholesterol, triglycerides, iron, ferritin, transferrin, orosomucoid and C-telopeptide. The urine analysis included: glucose, urea, creatinine, ions, calcium, inorganic phosphate, total protein, microalbuminuria and urate. We performed bone densitometry (DEXA) of spine and hand-wrist radiograph. Multiple linear regression was performed in successive steps, using as dependent variable bone mineral density (BMD) quantified by the z score value obtained from the DEXA.

Results: About 30% of patients with IBD had a low BMD. Among the known factors leading to this comorbidity are: corticosteroid therapy, the activity of IBD and duration of symptoms and lifestyle.

Objectives: To study the potential impact of IBD in mineral metabolism in pediatric patients, evaluating clinical, biochemical, densitometric and radiographic parameters.

Material and methods: Cross-sectional study in children with IBD. We collected anthropometric and clinical data (cumulative dose of corticosteroids, index of IBD activity, nutrition survey and lifestyles). It was carried out a blood analysis. It included CBC and serum biochemical study on the levels of glucose, urea, creatinine, sodium, potassium, calcium, phosphorus, orosomucoid, transferrin, ferritin, total protein, albumin, HDL-cholesterol, triglycerides, iron, ferritin, transferrin, orosomucoid and C-telopeptide. The urine analysis included: glucose, urea, creatinine, ions, calcium, inorganic phosphate, total protein, microalbuminuria and urate. We performed bone densitometry (DEXA) of spine and hand-wrist radiograph. Multiple linear regression was performed in successive steps, using as dependent variable bone mineral density (BMD) quantified by the z score value obtained from the DEXA.

Results: About 30% of patients with IBD had a low BMD. Among the known factors leading to this comorbidity are: corticosteroid therapy, the activity of IBD and duration of symptoms and lifestyle.

Objectives: To study the potential impact of IBD in mineral metabolism in pediatric patients, evaluating clinical, biochemical, densitometric and radiographic parameters.

Material and methods: Cross-sectional study in children with IBD. We collected anthropometric and clinical data (cumulative dose of corticosteroids, index of IBD activity, nutrition survey and lifestyles). It was carried out a blood analysis. It included CBC and serum biochemical study on the levels of glucose, urea, creatinine, sodium, potassium, calcium, phosphorus, orosomucoid, transferrin, ferritin, total protein, albumin, HDL-cholesterol, triglycerides, iron, ferritin, transferrin, orosomucoid and C-telopeptide. The urine analysis included: glucose, urea, creatinine, ions, calcium, inorganic phosphate, total protein, microalbuminuria and urate. We performed bone densitometry (DEXA) of spine and hand-wrist radiograph. Multiple linear regression was performed in successive steps, using as dependent variable bone mineral density (BMD) quantified by the z score value obtained from the DEXA.

Results: About 30% of patients with IBD had a low BMD. Among the known factors leading to this comorbidity are: corticosteroid therapy, the activity of IBD and duration of symptoms and lifestyle.

Objectives: To study the potential impact of IBD in mineral metabolism in pediatric patients, evaluating clinical, biochemical, densitometric and radiographic parameters.

Material and methods: Cross-sectional study in children with IBD. We collected anthropometric and clinical data (cumulative dose of corticosteroids, index of IBD activity, nutrition survey and lifestyles). It was carried out a blood analysis. It included CBC and serum biochemical study on the levels of glucose, urea, creatinine, sodium, potassium, calcium, phosphorus, orosomucoid, transferrin, ferritin, total protein, albumin, HDL-cholesterol, triglycerides, iron, ferritin, transferrin, orosomucoid and C-telopeptide. The urine analysis included: glucose, urea, creatinine, ions, calcium, inorganic phosphate, total protein, microalbuminuria and urate. We performed bone densitometry (DEXA) of spine and hand-wrist radiograph. Multiple linear regression was performed in successive steps, using as dependent variable bone mineral density (BMD) quantified by the z score value obtained from the DEXA.

Results: About 30% of patients with IBD had a low BMD. Among the known factors leading to this comorbidity are: corticosteroid therapy, the activity of IBD and duration of symptoms and lifestyle.
pelvic ultrasound revealed the presence of an uterus. At laparotomy a uterus, fallopian tubes and small gonad-like tissue masses in the region of the Fallopian fimbria were found. Histological analysis revealed no organized testicular or ovarian morphology, fallopian tubes on the right side and epididymis on the left side. The second case is a 10 year old girl presenting with features of Turner syndrome (broad chest, mouth abnormalities, cubitus valgus), short stature, and primary gonadal failure. The pelvic ultrasound reveals the presence of an uterus; no gonads were visualized. The laparoscopy confirms the presence of an uterus and fallopian tubes with streak gonads.

Results: In the first case G-banding analysis of blood lymphocytes confirmed a 46XY karyotype while in the second there was a mosaicism 45XO/46XY. FISH analysis for the eventual presence of isodisomy Y chromosome, as well as gene sequencing for SRY, SONX, AMH and AR are in progress.

Conclusions: Comprehensive cytogenetic, endocrine, histological and molecular studies on the gonads are further needed in order to explain the causality between the genetic profile and the phenotype in these two particular cases.

---

**PAO-62**

The experience of recombinant growth hormone treatment in a secondary endocrine referral centre in Saudi Arabia

Suzanne Elkholy; Sulaiman AlMuhaimad

King Fahad Medical Complex, Paediatrics, Dhhran, Saudi Arabia

Background: King Fahad Medical Complex is a secondary referral centre for paediatric endocrinology for the eastern province in Saudi Arabia. Recombinant Growth Hormone has been used for many years as a treatment option for children and young adults with many endocrine disorders mainly short stature resulting from growth hormone deficiency or insufficiency.

Objective and hypotheses: The aim of the present study is to evaluate the use of R-GH treatment use, indication, dose, effect on height as well as effect of discontinuation of treatment due to compliance or lack of supply issues.

Methods: We have identified over 50 patients who are receiving R-GH and performed a retrospective chart review to assess the effect of treatment of GH.

Conclusions: Most patients were diagnosed with growth hormone deficiency followed by children with Turner syndrome, then other genetic disorders, and ideopathic short stature. Doses used were generally less than recommended and periods of treatment interruption were noted. The study results will help guide the newly published growth curves for children from Saudi Arabia.

---

**PAO-65**

Side effect profile of diazoxide in children with congenital hyperinsulinism. A retrospective study

Jan Marquard; Laura Huberman; Thomas Meissner

University Hospital Duesseldorf, Department of General Pediatrics, Duesseldorf, Germany

Background: Diazoxide is the first-line drug for long-term treatment of congenital hyperinsulinism (CHI). However, the use of diazoxide is often limited by side effects, e.g. hypokalemia, fluid retention and feeding problems. Up to now the frequency of these side effects is based on estimation.

Objective: To precisely determine the frequency of major side effects of diazoxide in children with CHI.

Patients and methods: Interviews on side effects were performed with the parents of CHI patients who received diazoxide. In addition, patients’ records were retrospectively searched for side effects of diazoxide.

Results: So far we identified 24 patients (13 female, 11 male) with CHI who are or had been treated with diazoxide. Preliminary data shows that 92% of them developed hyperinsulinism. The treatment of 16 patients is still ongoing, for 25% of these patients hyperinsulinism has been regressive in the course of the treatment. In 8 cases the diazoxide treatment has ended because of remission of the disease. In all of these patients hyperinsulinism regressed completely. Hypokalemia was most distinctive along the spine (48%) followed by now the frequency of these side effects is based on estimation.
Ambiguous genitalia – a 15 years overview

Abiola Odunola; Rolli Nwodo; Elizabeth Ebechiri Ogwensi; Chris Bode; James Rennier
Lagos University Teaching Hospital, Paediatrics, Surulere, Lagos, Nigeria

Background: The term ambiguous genitalia or indeterminate sex is a terminology that parents fear to hear. This is most devastating within the African continent where being in the 21st century the sex of a child is of utmost importance. Fortunately this disorder is uncommon. Classifying the cases into different groups is formidable especially when investigative support is minimal.

Objective: To determine the prevalence of ambiguous genitalia, categorizes patients, the mean length of time for completion of investigation and therapy outcome.

Methodology: This is a review of all patients referred with ambiguous genitalia to the clinic over 13 years. Assessment criteria were based on clinical presentation, hormonal and biochemical estimations, sonogram of the abdomen, genitogram and karyotype / baccal smear. Stimulation with human chorionic gonadotropin (hCG) and ACTH (adrenocortical hormone) stimulation tests were performed as required.

Results: Reviewed were 44 out of 245 patients with endocrine disorders (1997 to 2010) who had ambiguous genitalia. They were categorized as genetic females with virilisation or FPH (15, 34 %) all were due to congenital adrenal hyperplasia (CAH), Genetic males over virilized (4, 9%) Genetic males under virilized or MPH (11, 25%), Microgenitalis with severe choordee 3, 6.8%, micropenis with hypospadias (3, 6.8%), micropenis with cryptorchidism (5, 11%), true hermaphrodism (2, 4.5%) and the syndromic form of ambiguous genitalia (1, 2.2%). Age at presentation ranged from 48hrs to 10 years. Mean length of time for investigation 9 months while 75% had appropriate therapy.

Conclusions: Ambiguous genitalia appear very rare when compared to similar collections for the length of time of review. This may be an invalid conclusion due to the inadequate health delivery service, referral system and or older age presentation. Finance seems to be a big constraint to management. The obvious indeterminate external genitalia in females with CAH may account for higher percentage amongst cohorts.

Characteristics and prevalence of non-classical congenital adrenal hyperplasia with a v281l mutation in patients with premature pubarche

Senay Savas Erdeve1; Merih Berberoglu1; Nuket Yurur Kutlay2; Zeynep Sikkar1; Bulent Hachimidoglu1; Aljam Tukun1; Gonul Ocal1
1Ankara University School of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology, Ankara, Turkey; 2Ankara University School of Medicine, Department of Medical Genetics, Ankara, Turkey

Background: The frequency of NCCAH with V281L among children presenting with premature pubarche (PP) is variable.

Objective and hypotheses: To determine the prevalence, clinical and laboratory characteristics of NCCAH with the V281L mutation in patients with PP.

Methods: The study group was composed of 159 unrelated patients with PP. ACTH stimulation test was performed in 14 of the 159 patients with PP who had basal 17-OHP levels >2 ng/ml. Patients whose stimulated 17-OHP level on the ACTH test was ≥10 ng/ml underwent a mutational analysis of the CYP21 gene, and those with the mutation were considered to have NCCAH.

Results: NCCAH was defined in nine (5.7%) among 159 patients with PP and all of them had the V281L mutation. The gender distribution showed a similarity between NCCAH and patients with idiopathic PP (IPP). When compared with the IPP group, the NCCAH group had higher bone age and BA-chronological age ratio. However, chronological age, age at pubic hair onset, height, height standard deviation score, parental adjusted deficit in height, weight, and body mass index (BMI) were similar in both groups. All nine patients whose peak 17-OHP levels in the ACTH stimulation test were >10 ng/ml had the CYP21P2 gene mutation. Four of them were homozygote and four of them were heterozygote. Other one patient was compound heterozygote for the V281L mutation and the 12 splice mutation . The one of the patients with V281L heterozygous mutation developed true precocious puberty and the other one patient had rapid progressive early puberty and developed polycystic ovary syndrome.

Conclusions: ACTH stimulated > 17-OHP 10 ng/ml in PP patients is load star to mutation analysis and heterozygote patients should be followed for clinical and biological hyperandrogenism up to completion of the whole gen sequence.

Continuous subcutaneous insulin infusion (CSI): a successful mode of therapy for neonatal diabetes (experience in Qatar)

Fahmya Alkhraisat; Maryam Al Ali; Ashraf Tawfeq; Mohamoud Zyyoud; Noura Alheimeria; Amal Satt; Ahmed Alawa
Hamad Medical Corporation, Pediatric, Doha, Qatar

Background: Neonatal diabetes is defined as persistent hyperglycemia occurring in the first months of life that lasts more than two weeks and requires insulin for management.

Objective and hypotheses: Although pediatricians face numerous difficulties in managing insulin therapy at this age, very few data are available on possible methods of insulin delivery in neonatal diabetes.

Methods: We report our experience over 3 years of continuous subcutaneous insulin infusion (CSI) in cases of neonatal diabetes requiring insulin therapy (n = 5). Two neonates were negative for ABCCR,-ve KCNJ11, two had pancreatic agenesis and one has Wolcott-Rallison syndrome. CSI therapy in neonatal diabetes allows easy adaptation of insulin delivery, closely following the current feeding regimen (a basal infusion needed with very minimal dose; preprandial boluses being started with intermittent bottle feeding).

Results: Management using very small insulin doses (e.g. bolus = 0.20 U and basal rate = 0.02 U/h) was required and was only possible after insulin dilution (5-10 U/ml) and is more accurate with CSI than with using syringes. CSI allows easy delivery of such small doses without dilution errors. CSI achieved good glycemic control for all neonates (mean HbA1c = 8 %) with few hypoglycemic events; which are particularly frequent and dangerous at this age. Neonates tolerated the subcutaneous infusion lines well without any local side effects.

Conclusions: During the neonatal period, and under the supervision of an experienced team, CSI is safe, more physiological, accurate and easy to manage than using syringes or pens.
growth hormone (GH), L-thyroxine and hydrocortisone replacement. Marked improvement of linear growth occurred with complete catch-up to his mid-paternal height SDS occurred in 2 years. He maintained normal linear growth during the following 3 years.

Conclusions: Our case represents the first report of complete catch-up growth in a case of Johansen blizzard syndrome after severe postnatal growth retardation during infancy.

Linear Growth JBS on Therapy

Conclusions: TSH Receptor antibody levels were higher in patients with ophthalmopathy (33.3 %) were compared with 40 patients without ophthalmopathy (66.7 %). Among them, 20 patients associated with Graves ophthalmopathy

Results: The subjects were 60 patients under the age of 18 years diagnosed with Graves disease from January 2000 to December 2010 at the Catholic University Saint Vincent Hospital. We reviewed the medical records retrospectively.

Methods: Among them, 20 patients associated with Graves ophthalmopathy (33.3 %) were compared with 40 patients without ophthalmopathy (66.7 %). TSH Receptor antibody levels were higher in patients with ophthalmopathy than in patients without it (111.25±140.50 U/L vs 57.52±103.08 U/L, p = 0.024), and the percentage of elevated anti-microsomal antibody level was also higher in patients with ophthalmopathy (80 % vs 45 %, p=0.013).

Objective and hypotheses: To show how celiac disease can mimic hyperthyroidism followed by rheumatic complaints.

Patient: A 12-year old Gambian girl living in north Europe was developing abdominal and joint pain. Serum analysis revealed low serum-calcium, significantly elevated parathormone and decreased vitamin D. Immigrant rickets was assumed. Because of abdominal pain and iron deficiency, lamination was ruled out. Celiac disease was demonstrated by gladiin- and tissue transglutaminase-antibodies as well as by intestinal mucosa biopsy. Despite of a gluten-free diet the joint pains persisted. They were declared by rheumatologists to be caused by a chronic juvenile arthritis (sister disease of celiac disease). However, there were no positive inflammation signals and no clear elevated rheuma-immunology.

Follow up: Gluten-free diet and additional treatment with calcium and active vitamin D did not stop increasing parathormone levels, did not stop abdominal and joint pain, and did not stop increment of positive celiac disease antibodies. Assuming compliance problems the patient was then treated with vitamin D injections, which caused decreasing parathormone levels and vanishing joint pain.

Conclusion: Celiac disease can cause intestinal rickets with elevated parathormone levels mimicking chronic juvenile arthritis, if gluten-free diet is not strictly performed by compliance problems. Parenteral supply of depot-vitamin D is the therapy of choice in these patients exhibiting normalization of parathormone and vitamin D25 levels with disappearance of rheumatoid joint pain.

Background: As pediatric Graves disease is an uncommon condition, Graves ophthalmopathy should be more unusual. Graves ophthalmopathy has been reported to be associated with high titers of thyroid autoantibodies. Nevertheless, studies on children are not abundant.

Objective and hypotheses: We aimed to compare the thyroid autoantibody levels in Graves disease patients with ophthalmopathy to those in patients without ophthalmopathy.

Methods: The subjects were 60 patients under the age of 18 years diagnosed with Graves disease from January 2000 to December 2010 at the Catholic University Saint Vincent Hospital. We reviewed the medical records retrospectively.

Results: Among them, 20 patients associated with Graves ophthalmopathy (33.3 %) were compared with 40 patients without ophthalmopathy (66.7 %). TSH Receptor antibody levels were higher in patients with ophthalmopathy than in patients without it (111.25±140.50 U/L vs 57.52±103.08 U/L, p = 0.024), and the percentage of elevated anti-microsomal antibody level was also higher in patients with ophthalmopathy (80 % vs 45 %, p=0.013).

Conclusions: Pediatric Graves ophthalmopathy was associated with high titers of thyroid autoantibodies in our study. Nevertheless, large-scale studies with more patients are required.

Background: Hyperparathyroidism is a rare finding in children. It is a typical sign of vitamin D-deficiency caused by different reasons. It may also be due to calcium wasting syndromes, and it can rarely be induced by adenomas of the parathyroid glands and in parathormone receptor mutations (pseudohypoparathyroidism).

Objective and hypotheses: To show how celiac disease can mimic hyperthyroidism followed by rheumatic complaints.

Patient: A 12-year old Gambian girl living in north Europe was developing abdominal and joint pain. Serum analysis revealed low serum-calcium, significantly elevated parathormone and decreased vitamin D. Immigrant rickets was assumed. Because of abdominal pain and iron deficiency, lamblasia was ruled out. Celiac disease was demonstrated by gladiin- and tissue transglutaminase-antibodies as well as by intestinal mucosa biopsy. Despite of a gluten-free diet the joint pains persisted. They were declared by rheumatologists to be caused by a chronic juvenile arthritis (sister disease of celiac disease). However, there were no positive inflammation signals and no clear elevated rheuma-immunology.

Follow up: Gluten-free diet and additional treatment with calcium and active vitamin D did not stop increasing parathormone levels, did not stop abdominal and joint pain, and did not stop increment of positive celiac disease antibodies. Assuming compliance problems the patient was then treated with vitamin D injections, which caused decreasing parathormone levels and vanishing joint pain.

Conclusion: Celiac disease can cause intestinal rickets with elevated parathormone levels mimicking chronic juvenile arthritis, if gluten-free diet is not strictly performed by compliance problems. Parenteral supply of depot-vitamin D is the therapy of choice in these patients exhibiting normalization of parathormone and vitamin D25 levels with disappearance of rheumatoid joint pain.

Background: Despite recent progress in imaging techniques, it is not possible to distinguish between TSH-producing macroadenoma and hyperplasia of pituitary thyrotroph cells on CT and MR scans. In such cases, repeat MRI after therapy with thyroxine may provide a definitive diagnosis and eliminate unnecessary surgery.

Objective and hypotheses: We describe an example of reactive pituitary hyperplasia from primary hypothyroidism that mimicked a pituitary macroadenoma in a child.

Case report: A 10 year old boy presented with occipital headache over the last three months and height growth arrest. Cranial Magnetic Resonance Imaging (MRI) detected an intrasellar and suprasellar pituitary mass. Endocrine evaluation revealed a severe primary hypothyroidism (TSH 589 mU/L, free T4 1.5 pmol/L, mild hyperprolactinemia (1.23 mmol/L) and low IGF-1 (8.6 mmol/L). Thyroid ultrasound showed normal thyroid size with markedly heterogeneous echo texture and hypo-echoic areas. Thyroid peroxidase and thyroglobulin antibodies were high. The patient was started on levothyroxine at 100 mcg/day. Three months later IGF-1 and thyroid function had returned to the normal range and height growth velocity had increased. MRI study documented resolution of the mass effect.

Conclusions: Primary hypothyroidism should be considered in the differential diagnosis of solid mass lesions of the pituitary gland. Examination of thyroid function in patients with sellar and suprasellar masses revealed by MRI may avoid unnecessary operations which can cause irreversible complications.
Methods: Case 1: Eleven -year-old male patient was admitted to our clinic with complaints of a neck swelling, weight loss, irritability, sweating. In his physical examination his weight and height were in the normal range, cardiac rate was 100/min above the upper limit. Thyroid examination revealed grade 2 goiter. The patient’s laboratory examination: TSH:0.199IU/ml (0.5-4.8), free T4: 1.23ng/ml(0.8-2.3), free T3:4.92pg/ml(2-4), anti-TPO:175IU/ml, anti-TG:21.6IU/ml(0-134), anti-TSH receptor was negative. Imaging of the thyroid gland both thyroid glands and isthmus thickness increased, 3mm colloid nodule was seen in right lobe. The patient’s mother also had goiter with hyperthyroidism which was resistant to treatment so radioactive iodine treatment was applied. Also autoantibody and anti-TSH receptor were found negative in mother.

Case 2: Ten-year-old female patient was admitted because of goiter with his (case1) older brother. Beside intolerance the heat, she had no symptom. In her physical examination her weight and height were in the normal range, cardiac rate was 104/min above the upper limit. The patient had grade 2 goiter whose laboratory examination: TSH:9.3IU/ml (0.5-4.8), free T4:1.43ng/dl (0.8-2.3), free T3: 4.66pg/ml (2-4), anti-TPO:12.8 IU/ml(0-134), anti-TG:19.7 IU/ml (0-134) and anti-TSH receptor was negative. Imaging of both thyroid glands and isthmus thickness increased TSHR gene mutations were sent for genetic analysis because of known two-generation family affected and hyperthyroidism no autoimmune.

Result: TSHR activating mutations as the cause of subclinical hyperthyroidism may be more common and should be considered in the differential diagnosis especially if familial.

Background: Hypothalamic obesity is one of the most important effects of central nervous system damage. Generally lifestyle modification and diet are ineffective to treat the hypothalamic obesity. Sandostatin has been trying in children even in younger ages, strongly associated with insulin resistance. Their -Elevated transaminases is a common finding among obese children and adolescents (BMI >95th centile) who attended our Department between January 2000 and January 2010. A total of 114 obese subjects were found with elevated (>40U/L) serum alanine (ALT) and/or aspartate (AST) amino transferases, considered as surrogate marker of NAFLD, since other causes of hepatitis and alcohol consumption were excluded. Variables studied included BMI, pubertal status, and fasting levels of glucose, insulin and lipids. Insulin resistance was evaluated by means of HOMA-IR and Quicki.

Methods: Sandostatin treatment was safe but not as effective to treat the hypothalamic obesity. Sandostatin has been trying in a child with hypothalamic obesity.

Results: The TNF-α levels were higher in overweight children [15.4(13.2-24.0) vs. 12.7(11.2-14.8) pg/ml; p= 0.03]. Also the levels of fibrinogen (Fg), plasma insulin, HOMA index, uCRP and triglycerides were statistically higher than in the control group. The TNF-α was positively correlated with the waist circumference.

Conclusions: The high TNF-α, uCRP and fibrinogen levels confirm a proinflammatory state associated with abdominal obesity in the studied population.
Background: Wolcott-Rallison syndrome (WRS) is a rare autosomal recessive disease. Its main characteristic is permanent neonatal diabetes mellitus (PNDM) associated with skeletal epiphyseal dysplasia.

Clinical report: The female infant was born from unrelated parents. Pregnancy was uneventful and delivery was at term. Birth weight was 2100 g (below 5th centile) and length was 48 cm. At 3 months of age, the diagnosis of NDM was established and insulin treatment was introduced. From the very beginning, diabetes was difficult to control. At the age of 1.5 years she was admitted to the hospital for vomiting, edema and hepatomegaly. Laboratory workup showed extremely high levels of liver enzymes. This episode of hepatitis resolved spontaneously within 4 weeks. By that time, she was also diagnosed a hypothyroidism and was started on L-thyroxine. Eight months later, when investigated for steatorrhoea, pancreatic hypotrophy was found on abdominal ultrasound.

After exocrine pancreatic insufficiency has been confirmed, therapy with pancreatic enzymes was initiated. At the age of 2.6 years an episode of liver failure (requiring hospitalization) reappeared. She had seizures soon after and was put on Phenobarbital. The etiology of seizures was unrevealed. Mutation analysis of the EIF2AK3 gene showed that the child is homozygous for a nonsense mutation, R902X, in exon 13.

This result confirmed the diagnosis of WRS. After the diagnosis had been established skeletal X-ray was performed. It revealed multiple epiphyseal-methaphyseal dysplasia affecting long bones, vertebrae and pelvis.

Conclusions: WRS is a very rare disease. However, it should be considered in any child with NMD and associated disorders, especially if skeletal changes are detected. The diagnosis of WRS in our patient delayed since genetic testing had not been performed at the time of making the diagnosis of NDM and hypothyroidism.

Although genetic diagnosis of WRS does not alter therapeutic approach, it might help in predicting the outcome, as well as offering informed genetic counseling.

Background: Obesity in Greek children: a meta-analysis of available data from the last decade

Eleni Kotanidou1; Maria Grammatikopoulou1; Bessie E. Spiliotis4; Christina Kanaka-Gantenbein1; Maria Tsigga2; Assimina Galli-Tsinopoulou1
1Faculty of Medicine, Aristotle University of Thessaloniki, 4th Department of Pediatrics, Thessaloniki, Greece; 2Alexander Technological Educational Institute, Department of Human Nutrition and Dietetics, Thessaloniki, Greece; 3University of Patras School of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology and Diabeties, Patras, Greece; 4University of Athens, First Department of Pediatrics, Division of Endocrinology, Diabeties and Metabolism, Athens, Greece

Objective and hypotheses: The aim of this study presents the prevalence of childhood overweight, obesity and their relationship with factors which focused on watching TV, using the computer or playing video games, fast foods consumption, breast feeding and birth weight.

Methods: In this cross sectional study 960 (480 male and 480 female) primary school children aged 6-12 years old were selected by a two stage cluster sampling method. Height and weight were measured by the standard methods. Additionally BMI was calculated based on the weight, height and obesity; overweight were defined based on the BMI scores using CDC chart. Obesity, overweight and normal weight were defined: BMI≥97th percentile and BMI=85-95th 15≥BMI≤85th respectively. The other data were collected by questionnaire that completed by parents. Data were analyzed by using chi square and fisher exact test(ANOVA).

Results: According to our findings 11.9% of the subjects were overweight and 6% were obese. The results have shown a positive significant relationship between BMI and the mean time of watching TV, using computer or playing video games and fast food consumption during childhood (p<0.0001). There was no relationship between BMI and gender, birth weight and breast feeding.

Conclusions: In this study the prevalence of overweight and obesity was compared to the same study in the last seven years which show increasing in this community. Several studies have shown breast feeding is a protective factor for obesity, but this study has shown fast foods consumption, the mean time of watching TV and using computer or playing video games during childhood in spite of breast feeding in infancy period can be more effective on obesity.
Results: In group 1, the average height was -3.1 SD +/- 1SD (between -6.1 and -1.5 SD). In the first year, the height gain was of 0.8 SD with an average GV of 3.9 SD (0.6 cm/year). In the second and third years of treatment the height gain and GV were 0.9 SD and 3.3 SD (8.5 cm/year) respectively. 0.4 SD and 2.3 SD (7.4 cm/year). In group 2 the initial growth deficit was -2.7 SD +/- 1.2 SD (between -5.0 and -1.1 SD), with a gain of 0.5 SD in one year. The GV was 2.5 SD – 3.6 cm/year (p=0.02 compared with the 1st group) but dropped to 1.2 SD (6.9 cm/year) in the second year (p=0.05), with a further gain of 0.5 SD in height. Group 3 had a -3.3 +/- 0.7 SD height deficit with a gain of 0.5 SD in the first year and of another 0.4 in the second year. The GV was 2.7 SD – 9.1 cm/year (compared with the group 1 p= 0.15) respectively 1.2 SD – 6.8 cm/year (p=0.1). In the 4th group, the initial growth deficit was -3.3 +/- 0.5 SD, with a growth of 0.6 SD in the first year of treatment. The GV was 1.4 SD, (8.5 cm/year) significantly lower than in the first group (p=0.01). There was an increase of blood glucose levels (p=0.03), but the values remained normal.

Conclusions: GH therapy in short children is effective, especially in children with GH deficiency. The maximum of catch-up growth is obtained in the first year of treatment. The therapy is safe, but clinical and biochemical follow-up is necessary.

PAO-81
Congenital adrenal hyperplasia – still an undiagnosed condition with serious consequences
Corina Chirita1; Cristina Dumitrescu2; Margarita Matei2; Andra Caragheorgheopol3; Carmen Corpocu4; 1Anima Specialty Medical Services, Endocrinology, Bucharest, Romania; 2National Institute of Endocrinology, Pediatric Endocrinology, Bucharest, Romania; 3National Institute of Endocrinology, Endocrinology, Bucharest, Romania

Introduction: Classic congenital adrenal hyperplasia is one of the causes of virilisation of the female fetus and can have dramatic implications if it is not diagnosed in time.

Case presentation: We present the case of a 4 yrs 8 month old boy, who was diagnosed in time.

Case presentation: We present the case of a 4 yrs 8 month old boy, who was diagnosed in time.

Patient Age

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Clinical signs</th>
<th>TSH(TAG)</th>
<th>GH (mg/L)</th>
<th>FSH (mg/L)</th>
<th>LH (mg/L)</th>
<th>Pregnanate (mg/L)</th>
<th>Other</th>
<th>Time to the normalization of the pituitary size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>11</td>
<td>Menstrual bleeding</td>
<td>48 / 1.8</td>
<td>1254</td>
<td></td>
<td></td>
<td></td>
<td>GH deficiency Hyperprolactinemia</td>
<td>6 weeks</td>
</tr>
<tr>
<td>2.</td>
<td>8</td>
<td>Anemia, Interruption of growth, Headache</td>
<td>48 / 0.9</td>
<td>&gt;2000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 months</td>
</tr>
<tr>
<td>3.</td>
<td>9.3</td>
<td>Growth retardation</td>
<td>71.9 / 1.5</td>
<td>&gt;1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6 months</td>
</tr>
<tr>
<td>4.</td>
<td>13</td>
<td>Obesity, Anemia, Interruption of growth and puberty</td>
<td>&gt;75 / &lt;1</td>
<td>&gt;1000</td>
<td></td>
<td></td>
<td></td>
<td>FSH, LH deficiency</td>
<td>13 months</td>
</tr>
<tr>
<td>5.</td>
<td>13</td>
<td>Migraine, Anemia, Interruption of growth and puberty</td>
<td>72 / &lt;1</td>
<td>&gt;1000</td>
<td></td>
<td></td>
<td></td>
<td>GH, FSH, LH deficiency</td>
<td>4 months</td>
</tr>
</tbody>
</table>

Results: In group 1, the average height was -3.1 SD +/- 1SD (between -6.1 and -1.5 SD). In the first year, the height gain was of 0.8 SD with an average GV of 3.9 SD (0.6 cm/year). In the second and third years of treatment the height gain and GV were 0.9 SD and 3.3 SD (8.5 cm/year) respectively. 0.4 SD and 2.3 SD (7.4 cm/year). In group 2 the initial growth deficit was -2.7 SD +/- 1.2 SD (between -5.0 and -1.1 SD), with a gain of 0.5 SD in one year. The GV was 2.5 SD – 3.6 cm/year (p=0.02 compared with the 1st group) but dropped to 1.2 SD (6.9 cm/year) in the second year (p=0.05), with a further gain of 0.5 SD in height. Group 3 had a -3.3 +/- 0.7 SD height deficit with a gain of 0.5 SD in the first year and of another 0.4 in the second year. The GV was 2.7 SD – 9.1 cm/year (compared with the group 1 p= 0.15) respectively 1.2 SD – 6.8 cm/year (p=0.1). In the 4th group, the initial growth deficit was -3.3 +/- 0.5 SD, with a growth of 0.6 SD in the first year of treatment. The GV was 1.4 SD, (8.5 cm/year) significantly lower than in the first group (p=0.01). There was an increase of blood glucose levels (p=0.03), but the values remained normal.

Conclusions: GH therapy in short children is effective, especially in children with GH deficiency. The maximum of catch-up growth is obtained in the first year of treatment. The therapy is safe, but clinical and biochemical follow-up is necessary.
and metabolic syndrome are also associated with low testosterone levels in potential late effects of therapy in adult survivors treated with SCT. Obesity

**Background:**

Obesity

---

- **Objective and hypotheses:** To evaluate the clinical characteristics of vitamin D deficiency and its association with IDA.

- **Methods:** A total of 261 children aged ≤2 years underwent 25-hydroxyvitamin D3 tests between January 2007 and July 2009. The study cohort was classified into two groups: normal and vitamin D deficient, by their 25-hydroxyvitamin D3 levels.

- **Results:** In total, 171 children were in the normal group (mean age, body weight and height 12.5± 7.0 months; 9.3±0.9 kg and 76.8±1.1 cm), and 51 children in the vitamin D deficient group (9.9±5.4 months, 9.0±0.9 kg and 75.1±0.9 cm). Vitamin D deficiency was most commonly diagnosed in the spring (44%). The proportion of complete breast-feeding was higher in the deficient group (92%), and 25.5% of the children in the deficient group also experienced iron deficiency anemia compared that 12% of normal group. Wrist radiographs showed findings suggestive of rickets in 7 children in the normal group. Nine children in the deficient group experienced persistent bony changes. Six children received calcitriol medication in the normal group, by their 25-hydroxyvitamin D3 levels.

- **Conclusions:** This study demonstrated that approximately 30% of children aged ≤2 years experienced vitamin D deficiency associated with subclinical rickets. Many children also experienced concurrent iron deficiency anemia. Guidelines for vitamin D supplement in such children must therefore be established.

---

**PAO-85**

**Decreased serum testosterone levels in long-term adult survivors with fatty liver after childhood stem cell transplant**

**Background:** Fatty liver and gonadal dysfunction have been identified as potential late effects of therapy in adult survivors treated with SCT. Obesity and metabolic syndrome are also associated with low testosterone levels in general population.

**Objectives:** The objective was to determine the relationship between degree of fatty liver and testosterone levels in adult survivors.

**Methods:** We reviewed the clinical records of 34 patients who received allogeneic SCT at Tokai University Hospital. The median age of the 34 patients at SCT was 10.0 years, the median age at the last evaluation was 25.5 years, and the median follow-up duration after SCT was 15.9 years. The study population was categorized into 4 groups: CRT (cranial radiotherapy) + TBI (total body irradiation) group, TBI group, TAI (thoraco-abdominal irradiation) group, and Chemo groups.

**Results:** Among the 34 patients, 1 patient treated with only chemotherapy had a greater than 25 kg/m2 BMI. On the other hand, 11 patients had a BMI less than 18.5 kg/m2. No patient satisfied the criteria for metabolic syndrome. Fatty liver was diagnosed in 15 patients during the follow-up period. Concerning the mode of irradiation, a greater number of patients who received CRT+TBI developed fatty liver compared among other groups. Patients in CRT+TBI group were statistically associated with decreased testosterone levels increased LH and FSH levels compared among other groups (p<0.001, respectively), although testosterone levels in all patients were within normal range during follow-up period. Moreover, severe fatty liver was statistically associated with decreased testosterone levels compared among moderate, mild and non-fatty liver (p<0.001, median 273ng/dL, 335ng/dL 345ng/dL, and 530ng/dL, respectively).

**Conclusion:** Even patients who are not overweight/obese may develop fatty liver, and degree of fatty liver was associated with decreased testosterone levels in adult survivors.
**PAO-88**

**Phenotypic and metabolic characteristics in non-obese adolescents with PCOS**

Hae Soon Kim1; Hye Jin Lee2; Ji Young Chi3; Young Sun Hong4; Yeon-Ah Sung5

1Ewha Womans University School of Medicine, Pediatrics, Seoul, Republic of Korea; 2Ewha Womans University Mokdong Hospital, Internal Medicine, Seoul, Republic of Korea

**Purpose:** Polycystic ovary syndrome is characterized by hyperandrogenemia, insulin resistance, and dyslipidemia. We evaluated the clinical characteristics and metabolic components of non-obese adolescent girls with PCOS.

**Subjects and methods:** Thirty six non-obese (BMI-25kg/m2) adolescent girls (16-18years) with PCOS were compared to thirty two control group girls in similar age and BMI with regular menstrual cycles and were evaluated for anthropometric data and blood pressure. Fasting glucose, triglyceride, HDL-cholesterol, LDL-cholesterol, GGT, GPT were measured.

**Results:** BMI and waist circumference of the PCOS group were not different to the control. Frequency of menstruation and FG score of the PCOS group were significantly lower than the control. Blood pressures of the PCOS group were not different compared to the control. Fat mass and fat percentes were higher in the PCOS group but were not significantly different to that of the control. AST ALT, triglyceride, total cholesterol, HDL-cholesterol, fasting glucose were not significantly different between the two groups. LDL-cholesterol was significantly higher in the PCOS group compared to the control. Frequency of abnormal components in metabolic syndrome was not different between the two groups.

**Conclusion:** In non-obese adolescents with PCOS, metabolic derangements were not remarkable.

**PAO-89**

**Does gonadotrophin-releasing hormone analogue affect the body mass index of the girls with idiopathic precocious puberty?**

Ayla Guven

Goztepe Educational and Training Hospital, Pediatric Endocrine Clinic, Istanbul, Turkey

**Background:** To assess whether Gonadotrophin-releasing hormone analogue (GnRHa) affects body mass index in children with idiopathic central precocious puberty (ICPP).

**Patients and methods:** At least 12 months followed up 41 girls (mean age 8.6±3.1years) with CPP were included in the study: 34 girls with ICPP were followed up 18 months. Complaints had been begun before 8 years old. 28 girls underwent GnRH stimulation test. All children were treated with Leuprolide acetat (LA) 3.75 mg/4 wk and the dose was increased only if there is inadequate suppression of LH. The dose had to be increased 7.5 mg/q4 wk in non-obese adolescents with PCOS and the dose was increased only if there is inadequate suppression of LH. The dose had to be increased 7.5 mg/q4 wk in non-obese adolescents with PCOS.

**Results:** Pelvic ultrasound findings and basal hormone levels were given in Table 1. At the admission thelarche was a major complaint (32/41) and 5 girls had menarche. PRE-BMI was significantly positive correlated with BMI at 3rd, 6th, 12th and 18th months of therapy (r: 0.879; r: 0.909; r: 0.909; r: 0.909; respectively). PRE-BMI significantly differed from BMI at at 3rd, 6th, 12th and 18th months of therapy (F: 69.808, p<0.0001). BMI gradually increased after 6 months of therapy (Figure1). LA dose was significantly correlated with all body mass indexes during therapy. Bone age was correlated with volume of right (r:0.404; p:0.015) and left (r:0.360; p:0.034) ovary

**PAO-90**

**Age of puberty in a sample of Iranian girls**

Fatemeh Saffari1; Maryam Rostamian2; Toktam Karimzadeh3; Neda Esmailzadeh4; Stef Van Buuren5

1Qazvin university of medical sciences, Pediatric Endocrinology, Qazvin, Islamic Republic of Iran; 2Qazvin university of medical sciences, pediatrics, Qazvin, Islamic Republic of Iran; 3Qazvin university of medical sciences, Metabolic diseases research center, Qazvin, Islamic Republic of Iran; 4Qazvin university of medical sciences, Children hospital clinical research center, Qazvin, Islamic Republic of Iran; 5TNO Quality of life, Statistics, Leiden, Netherlands

**Introduction:** Entering puberty is an important milestone in reproductive life. Many physiological and psychological processes are influenced by puberty and hormone secretion. Based on data from late 1800s to present, pubertal entry and menarche is occurring earlier than in the past. National data on these milestones can serve as a baseline for assessing secular trends in pubertal development for the population.

**Objective:** To obtain normal values of pubertal stages in 6-16 years old girls of Qazvin province, Iran.

**Methods:** This cross-sectional study was conducted during 2009-2010 in 2759 elementary and middle school girls in Qazvin. Healthy girls (6.0 to 16.0 years old) were selected by clustered random sampling. In all subjects height and weight were measured and pubertal stages were evaluated by trained general practitioners. Breast Stages 1-5 were determined by both inspection and palpation, using the criteria and definitions described by marshall and Tanner. The self-reported date of menarche was recorded as well. Pubic hair stages were not evaluated because of cultural difficulties and most subjects disagreeement.

**Results:** The mean age of Tanner stage2 breast development (B2) was 9.67 years. The 3rd and 90th percentile for B2 was 6.5 and 12.5 years old, respectively. The mean age of menarche between 548 (24.5%) girls was 12.55 years (9.5 -14.75). The mean BMI was significantly higher in pubertal females (at the stage B2 and menarche) comparing to prepubertal girls (at stage B1). In comparison with percentile value proposed by tanner, the 50th percentile age of stage B2 is decreased by 1.7 years in our subjects.

**Conclusions:** The mean age of pubertal onset in girls living in Qazvin (9.67 year) is lower than internationally accepted. Mean age of menarche was 12.55 years old and the onset of puberty less than 6.5 years is considered precocious in the study area.
Comparison of antithyroid antibodies in type 1 diabetic children and control group in 2010
Fatemeh Safar1; Ali Asgari2; Tahereh Sadeghi3; Neda Esmaeilzadeh4
Qazvin university of medical sciences, pediatrics, Qazvin, Islamic Republic of Iran; 2Qazvin university of medical sciences, Pediatrics Department - Paediatric Endocrinology Unit, Oporto, Portugal

Background: Type 1 diabetes is the most common metabolic disease worldwide. thyroid autoimmune diseases accompany with type 1 diabetes is the most common endocrinopathy. Therefore, thyroid function tests and antithyroid antibodies in patients suffering from Type 1 diabetes is essential to diagnosis of thyroid autoimmune disorders.

Objective: To compare the anti-thyroid antibodies in patients with Type 1 diabetes and healthy individuals.

Methods: In this descriptive-analytic study, 65 children with Type 1 diabetes and 65 healthy children were selected using simple sampling. Anti-TG, Anti-Tpo, TSH and T4 hormones were measured. The amount of antibodies in both groups compared by using Chi-square statistical analysis, t-independent, Kruskal Wallis.

Results: There was not significant difference between two group of samples (case and witness group) in case of sex and age but BMI percentile of two group was significantly different. Positive Anti-TG in patients was 10.8% and in controls was 1.5% and the difference was statistically significant (p=0.029). 16.9% of patients and 3.1% of controls had positive Anti-Tpo that was significantly different between two groups (p=0.024). 10.8% of patients had overt hypothyroidism and 4.6% of controls had subclinical hypothyroidism. The difference was not significant statistically.

Conclusions: According to the results of research, it seems that the prevalence of Hashimoto thyroiditis in patients with type 1 diabetes is more than healthy people. Hence, thyroid function tests (TFT) and antithyroid antibodies (Anti-Tpo) in patients with Type 1 diabetes is necessary in order to early diagnosis of autoimmune thyroid disorders, prevention of their complications and timely treatment.

Maturity onset diabetes of the young (MODY) 2: clinical and genetic spectrum in five children
Maria Joao Oliveira; Cristina Couto; Manuel Oliveira; Joana Freitas; Helena Cardoso; Teresa Borges
Centro Hospitalar do Porto, Paediatrics Department - Paediatric Endocrinology Unit, Oporto, Portugal

5 cases of MODY2 diagnosed in paediatric age.

Case report:

<table>
<thead>
<tr>
<th>Case</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of detection of diabetes (years)</td>
<td>5</td>
<td>5</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Family history of type 2 diabetes mellitus and/or hyperglycaemia</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Body mass index (Kg/m2) at 1st exam (percentile)</td>
<td>12.6 (3)</td>
<td>19.4 (85)</td>
<td>15.8 (40)</td>
<td>24.1 (90.5)</td>
<td>14.2 (11)</td>
</tr>
<tr>
<td>Fasting glucose &gt;126 mg/dl</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Initial HbA1c (%)</td>
<td>7.3</td>
<td>6.5</td>
<td>5.3</td>
<td>6.1</td>
<td>5.9</td>
</tr>
<tr>
<td>Serum insulin (mU/ml)</td>
<td>&lt;2</td>
<td>9.4</td>
<td>&lt;2</td>
<td>8</td>
<td>6.6</td>
</tr>
<tr>
<td>Serum C peptide (ng/ml)</td>
<td>0.9</td>
<td>0.0</td>
<td>1.2</td>
<td>1.1</td>
<td>1.2</td>
</tr>
<tr>
<td>Antibodies: anti-ICA, anti-GAD</td>
<td>negative, negative, negative, negative, positive, negative, negative</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Glucose at 0h and 2h in oral glucose tolerance test (mg/dl)</td>
<td>0</td>
<td>116, 157</td>
<td>130, 189</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Genetic testing (GCK)</td>
<td>mutation c.579+1_579+33del53 in exon 5</td>
<td>mutation c.579+1_579+33del53 in exon 5</td>
<td>mutation c.616A&gt;C in exon 10 (not previously described)</td>
<td>mutation c.1268T&gt;A in exon 10 (not previously described)</td>
<td>mutation c.616A&gt;C in intron 5</td>
</tr>
<tr>
<td>Age at genetic diagnosis (years)</td>
<td>7</td>
<td>11</td>
<td>12</td>
<td>14</td>
<td>8</td>
</tr>
<tr>
<td>Treatment</td>
<td>diet</td>
<td>measures</td>
<td>diet</td>
<td>measures</td>
<td>diet</td>
</tr>
<tr>
<td>Complications</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
</tbody>
</table>

Case 1. 5-year-old boy with random hyperglycaemia detected during hospitalization due to gastroenteritis. Hba1c was 7.3% and spot urine analysis was normal. The initial diagnosis was the early presentation of type 1 DM.

Case 2. 11-year-old asymptomatic boy with fasting and random hyperglycaemia since 5 years.

Case 3. 9-year-old asymptomatic boy with fasting hyperglycaemia during the previous year.

Case 4. 8-year-old girl, obese, with fasting hyperglycaemia detected during co-morbidity study. Clinical insulin resistance signs were absent. The initial diagnosis was type 2 DM.

Case 5. 8-year-old asymptomatic girl with fasting hyperglycaemia during the previous 7 months.

Evolution Patient 4 was treated with metformin and the other patients didn’t start pharmacological treatment. During follow-up, patients 1, 2 and 3 maintained occasional fasting hyperglycaemia; mean Hba1c was 6%. In case 4, despite treatment with metformin, evolution was similar and Hba1c didn’t improve. Genetic testing for MODY2 was performed after few months to several years of follow-up. Any of the patients started or maintained pharmacological treatment.

Conclusions: GCK-MODY is characterized by non-progressive mild hyperglycaemia, rare microvascular complications and unnecessary pharmacological treatment. The authors describe 5 patients with mild asymptomatic hyperglycaemia and mildly elevated Hba1c. All presented family history of DM or untreated hyperglycaemia. Genetic testing detected heterozygosity for mutations in GCK gene, 2 previously described and 3 apparently novel variants. This is a vital clinical tool in selected cases since it confirms a diagnosis, predicts clinical course, defines family risk and determines treatment.
PAO-93
Persistent pubertal gynecomastia: an unusual presentation of a steroid 17-alpha-hydroxylase deficiency
Francoise Paris1; Marianne Ribotton1; Yves Morel2; Charles Sultan1
1CHU and UMI, Hormonologie and Unité d’Endocrinologie Pédiatrique, Montpellier, France; 2Centre de Biologie et pathologie Est, Service d’Endocrinologie Moléculaire et Maladies Rares, Bron, France

Background: Pubertal gynecomastia is a frequent reason for consultation in pediatric endocrinology. Although it is usually idiopathic, hypogonadism, hyperprolactinemia, hyperthyroidism and rare testicular or adrenal tumors must be considered. Most often, idiopathic pubertal gynecomastia regresses at the end of puberty when the testosterone (T) level increases.

Objective and hypotheses: We report a case of persistent pubertal gynecomastia revealing a mutation of steroid 17-alpha-hydroxylase (CYP17).

Methods: This 15-year-old boy was referred to our pediatric endocrinology clinic because of bilateral gynecomastia, stage III with pigmented and developed areolae. Pubertal development was P3,G3 with a normal penis (length=7 cm). Basal LH and FSH were 7.5 mIU/ml (N=1.5-8.5 and 3.8, respectively). Plasma T=5.5 nmol/l (N=12-38), DHEA=1.8 nmol/l (N=10-19) and 17OHP=11 nmol/l (N=15). E2 level was 175 pmol/l (N=1-80). Basal PRL level was 230 µIU/ml (N=500). Plasma TSH and T4L levels confirmed euthyroid status. Plasma βCG and αFP were negative. Testicular sonography found normal pubertal testis structure. The low plasma T led us to evaluate other steroid precursors. Plasma progesterone (P) level was 10.9 nmol/l (N=0.7-2) with low and non-ACTH-stimulated plasma cortisol deficiency (154.4-212.3 µmol/l).

Results: The discordance between the high P level and the low values of other 17OH steroid precursors suggested 17OH deficiency. Sequencing of the CYP17a gene identified an heterozygote composite mutation: p.Pro35Thr and p.Arg239X. Substitution by testosterone enanthate was introduced.

Conclusions: This report points out the usefulness of investigating adolescents with persistent pubertal gynecomastia to identify a specific cause and thus propose adequate management.

PAO-94
Congenital hypothyroidism in a neonate born to a mother with autoimmune thyroid disease
Malgorzata Kumorowicz-Czoch1; Dorota Tylek-Lemanska2
1Polish-American Institute of Pediatrics, Collegium Medicum, Jagiellonian University, Department of Pediatric and Adolescent Endocrinology, Krakow, Poland; 2University Children’s Hospital in Krakow, Division of Screening and Inborn Errors of Metabolism, Krakow, Poland

Background: Congenital hypothyroidism (CH) induced by maternal TSH receptor-blocking antibodies is responsible for approximately 2% of all CH cases.

Objective: A case report of a newborn with CH born to mother with autoimmune disease.

Methods: TSH in blood on filter paper, serum TSH, FT4 and TSH receptor antibodies (TRAb) tests, imaging pictures.

Results: A female newborn is presented pregnancy 1, delivery 1, terminated by a cesarean section at 40 weeks of gestation, birth weight 3150g, length 54cm, Apgar score 8 and 10 at 1 and 5 minutes, respectively). Maternal medical history indicated hyperthyroidism treated with thiamazol for 5 years, followed by hypothyroidism supplemented with L-thyroxin (LT4) for 3 years prior to conception and during pregnancy. Available data suggested LT4 substitution during pregnancy to be insufficient, resulting in periodic hypothyroxinemia. Suspected fetal arrhythmia led to echocardiography at 31 weeks of gestation, showing regular, but rather slow heart action (112-120/min). In mass screening for CH, TSH concentration in blood on filter paper was 130.5 mIU/L [N=15]. Serum levels of TSH >60 mIU/L [N:0-4.9] and FT4 9.6 pmol/l [N:10-26] determined in the 4th hour of life confirmed the diagnosis of CH. A high neonatal TRAb value [67.8 IU/L, N<1] was correlated with maternal TRAb [68.5 IU/L]. Ultrasound showed the thyroid situated normally and normal in size, yet no marker uptake by the gland was demonstrated by Tc99m scintiscan. On day 7 of life, the neonate received LT4 substitution at the dose of 12 µg/kg/d, the dosage being modified based on serum FT4 and TSH levels. A decrease of demand for LT4 was seen along with normalization of TRAb concentration; at 4 month of life, TRAb was 0.7 IU/L. At 13 month of life serum FT4 and TSH levels during LT4 substitution (1 µg/kg/d) were normal.

Conclusions: The presented case confirms the diagnostic importance of TRAb determinations in newborns with CH born to mothers with autoimmune disease, additionally pointing to maternal hypothyroxinemia in pregnancy as a significant CH risk factor in newborns.

PAO-95
Central precocious puberty in a female child of very young age
Kim Jong-Duck1; Choi See-Seung2
1Wonkwang University Hospital, Pediatrics, Iksan, Republic of Korea; 2Wonkwang University Hospital, Radiology, Iksan, Republic of Korea

Background: Central precocious puberty under age of 6 years old is rarely related to morphological abnormality of hypothalamus and pituitary gland, and the type of abnormality was variable.

Objective and hypotheses: We report a case that a two year and 10 month aged female child was diagnosed central precocious puberty with pituitary intermediate cyst.

Methods: This child was visited the pediatric out-patient clinic due to breast budding and progressively increased size of breast for three months. Physical examination with laboratory and radiological study for precocious puberty of this patient was done.

Results: On visiting day, breast size was 3 x 3 cm and pubic hair was not noticed. Height and weight of this patient were 99.6 cm (95-97 percentile) and 16 kg (90-95 percentile). Head circumference of this patient was 49 cm (50-75 p). This patient was born by the full term normal spontaneous vaginal type delivery and birth weight was 3,200 gm, and height 49 cm. Bone age was 5 years old but chronological age was two year and 10 months old. The basal serum level of E2 and LH was 25.58 pg/mL and 7.8 mIU/mL respectively, but the maximum serum level of LH was 43.8 pg/mL after GnRH stimulation. Brain MRI shows pituitary cyst between anterior and posterior pituitary lob. Breast size of this patient regresses to 2 x 2 cm and sustained after GnRH agonist therapy.

Conclusions: We report a case of central precocious puberty that is very young age with intermediate cyst of the pituitary gland and respond well to GnRH agonist therapy. However, careful follow-up will be needed in this patient.
PAO-97

Pattern of presentation and management when neonatal screening for congenital adrenal hyperplasia is not available
Suzanne Elkholy
King Fahad Military Medical Complex, Paediatrics, Dhahran, Saudi Arabia

Background: We present the present findings and management of sixteen cases of congenital adrenal hyperplasia following up in the paediatric endocrine clinic at King Fahd Military Medical Complex Dhahran, Saudi Arabia. Cases were diagnosed at our centre or referred from other hospitals.

Objective and hypotheses: The aim of the study is to highlight the different presentations and on rare occasions delay of management even when family history exists. The different treatment regimens and follow up plans were also evaluated and compared with current guidelines.

Methods: Retrospective chart reviews of sixteen patients diagnosed with congenital adrenal hyperplasia.

Results: Family history was positive but was denied or concealed by some families which delayed diagnosis for some cases. Salt loss and ambiguous genitalia was the main presenting feature in neonatal period. Genetic diagnosis was performed for some cases and new mutations were identified. Doses of steroids were adequate according to current guidelines but follow up was hindered by lack of local laboratory evaluation of urinary and serum steroid precursors.

Conclusions: We conclude that laboratory support needs to improve as well as parents’ education about need to disclose important medical information.

PAO-98

Endocrine disorders in 62 children with Turner syndrome
Ruimin Chen; Xiaohong Yang; Ying Zhang; Xiangquan Lin
Fuzhou Children’s Hospital of Fujian, Endocrinology, Fuzhou, China

Background: Turner syndrome (TS) is a common genetic disorder, is associated with reduced adult height and with ovarian failure. However, it is becoming increasingly evident that patients with TS are also susceptible to a range disorders.

Objective and hypotheses: Explore the endocrine disorders in Chinese children with TS.

Methods: 62 patients with TS diagnosed in our clinic from 1999–2010 by karyotyping, FSH, LH, growth hormone stimulation, IGF1, TSH, FT3, FT4, fasting glucose (GS), A1c (if GS high), ultrasound (varian, uterus and thyroid), bone age, laboratory MRI (if Growth hormone deficiency."

Results: Chronicol mean age: 10.9(0.2–18 years), mean height z score (HSDS): -3.96 (+0.9–7.3)SD, >1.3 years no puberty signs (15/17, 88.2%), Distribution of karyotype: X monosomy-45,X; (27/62, 43.6%); mosaicism (22/62, 35.5%); including 45,X/46,XX, 45,X/46,X-marker, 45,X/47,XXX, 45,X/46,x(aQq), 45,X/46,XY, 45,X/46,X dup(X(q24), 45,X/46,X dic(X)(q24), 45,X/46,XX,47,XXX, 45,X/46,X add(Xp22.1), 45,46,X,a(Xq)/47,XY (8q)q+, aberration of X structure: 46,X(aq)(q10/16, 16.1%); 46,X,del(X)(q22)(3/62,4.8%), Hashimoto thyroiditis (15/40, 37.5%), Hyperthyroidism (3.60, 5%), Hypothyroidism (8/60, 13.3%), growth hormone deficiency (31/55, 56.4%), Diabetes (2/62, 4.8%), LH (11.7±1.2) IU/L, FSH (66.5±5.8)IU/L, IGF1 (201±416)ng/ml Pituitary MRI: small (4/29, 13.8%), empty sella turcica (2/29, 6.9%); pituitary tumor or pituitary hyperplasia (2/29, 6.9%); Arachnoid cyst (1/29, 3.4%).

Conclusions: Endocrine disorders are common in Chinese children with TS. Children with TS are at risk for growth hormone deficiency, Hashimoto thyroiditis, thyroid dysfunction, diabetes, which require treat early.

PAO-99

A case of myasthenia gravis with graves disease
Order Aasan; Aycan Zehra; Sema Cetinkaya; Havva Nur Peltek
Kendirci; Sebahat Yilmaz Agaladoglu; Veyssel Nijat Bas
Ankara, Pediatric Endocrinology, Ankara, Turkey

Background: Thyrotoxicosis due to autoimmune thyroid disease (AITD) occurs in % 5-10 of patients with Myasthenia Gravis (MG) whereas MG has a frequency of % 0.2 among the patients with AITD. MG and AITD can also be seen together in Autoimmune Polyglandular Syndrome (APS) type 2 and type 3.

Objective and hypotheses: Hereby, we report a patient with MG and Graves diseases.

Methods: A 15 years old male patient was referred to our clinic for hyperthyroidism. He had diplopa since 8 months and pitiosis since 3 months. His height was 169.5 cm, weight was 64 kg, blood pressure was 130/80 mmHg and he had a heart rate of 132/minute. He had unilateral pitosis and diffuse enlarged thyroid gland. Laboratory findings were as follows: TSH: <0.004 mIU/ml, free T4: 4.4 ng/dl, free T3: 13.7 pg/ml, anti thyroglobulin antibody: 2175 IU/ml, anti microsomal antibody: >1000 IU/ml, TSH receptor antibody: 36.9 U/. He had a positive response when we performed prostigmine test.

Results: Our case was diagnosed with MG and Graves diseases. He started to receive methimazole, propanolol, predostigmine. We found that plasma cortisol was 10 μg/dl, ACTH was 23 pg/ml, c ANCA, p ANCA, anti dsDNA, ANA, anti Ro, anti La and anti tissue transglutaminase antibodies, anti GAD, anti insulin antibody, islet cell antibody were negative. Vitamin B12 was 175 pg/ml and parietal cell antibody was positive. So, we started to give B12 vitamin replacement. We regulated methimazole dosages, beta-blocker therapy was terminated and there was a decline in TSH receptor antibody levels. His diplopa was recovered on the second month of predostigmine treatment.

Conclusions: Autoimmune thyroid diseases should be investigated in the presence of Myasthenia Gravis. Further exploration about Autoimmune Polyglandular Syndrome type 2 and type 3 is needed in the association of Myasthenia Gravis and Graves diseases.

PAO-100

Abstract withdrawn.

PAO-101

Recombinant GH treatment in a female patient with Seckel-like syndrome and a novel homozygous mutation 7055 – 7056insC in the PCNT gene
Natalya Voletodz1; Elena Hennessy2; Louise Bicknell3; Andrew Jackson4
1Endocrinology Research Centre, Institute of Paediatric Endocrinology, Moscow, Russian Federation; 2Western General Hospital, MRC Human Genetics Unit, Edinburgh, United Kingdom

Background: Seckel syndrome is a rare autosomal recessive disorder, characterized by pre- and postnatal growth deficiency, microcephaly, mental retardation, and characteristic facial appearance beaklike protrusion of the midface (bird-headed). This disorder is associated with defective ATR-dependent DNA damage signaling. Mutations in ATR gene and also gene encoding pericentrin (PCNT) cause Seckel syndrome.

Objective and hypotheses: We describe rGH treated patient with confirmed Seckel-like syndrome.

Methods: We report a female patient, 1.5 years old, who has classic features of the syndrome Seckel: height at birth -3.3SD, postnatal growth retardation -10.5SD, OFC -9.9SD, bird-head phenotype, mental retardation. She also has...
micronathia, face asymmetry, low-fitting ears, disproportionately large eyes, clinodactyly of fifth finger. The patient’s tooth system is at the initial stage of eruption. She does not have haematological and bone abnormalities.

Results: The girl had treatment of recombinant growth hormone “Saizen” 0.05 mg/kg/day. After six months of treatment height was -9.52SD, height velocity 5.5 cm/6 months (+0.53SD), the level of IGF-1 increased to 80.2 ng/ml (before growth hormone treatment IGF-1 was 46.9 ng/ml). Molecular genetic researches confirmed Beckel-like syndrome in our patient: a novel homozygous mutation in the PCNT gene 7055 – 7056insC. Her unaffected parents and two brothers are heterozygous for this mutation.

Conclusions: We described a positive effect of GH treatment in patient with Beckel-like syndrome with a novel homozygous mutation (7055 – 7056insC) in the PCNT gene.

PAO-102
Precocious puberty caused by granulosa cell tumors
Liliana Maria Mejía1; Audrey Matalana2
1Clinica Valle del Lili, Valle del Cauca, Cali, Colombia; 2Hospital Universitario del Valle, Valle del Cauca, Cali, Colombia

Background: Juvenile granulose cell tumors a rare tumor wich originates from the sex stromal cord, occurs in the first two decades of life and represents less than 5% of ovarian tumors in girls. It contains granulose and theca cells and is associated with endocrine manifestations of excess estrogen production. Treatment is surgical. The tumors markers are estrogens and inhibin. Objective and hypotheses: Describe two patients with granulose cell tumors presenting with precocious puberty. Methods: Describe two cases: case1: Five year old girl with thelarche, pubic hair, axillary odor and menarche. Physical examination breast Tanner 3, hyperpigmentation of the nipple and pubic hair T Tanner 2. LH 0.1 ng/dl, FSH 4.1ng/dl, estradiol 38.8 pg/ml, pelvic ultrasound: walled cystic image of right ovary. Inhibit post quirurgical 10 ng/dl Case 2: Seven years old girl with seven months history of mammary growth, Tanner 3 nipple pigmentation, pubic hair tanner 2, LH 0.3 ng/dl FSH 0.3 ng/dl pelvic ultrasound Heterogenous isodense mass of right ovary. Bone age 10 years 6 months. Inhibit post quirurgical 45ng/dl. Two cases were diagnosed precocious puberty. Treatment was surgical and pathological. Two cases were diagnosed precocious puberty. Treatment was surgical and pathological report was JUVENIL GRANULO-SA CELL TUMORS. CEA and alpha fetoprotein negative. Conclusions: Patients with granulose cell tumors presented with precocious puberty, increased estrogen production and decreased gonadotropins. Pelvic Ultrasound reveals an ovarian mass. Treatment was surgical and supervision of inhibin of less than 10ng/ml.

PAO-103
Polycystic ovary disease and its fearsome consequences
Maria Cristina Bazán1; Alejandro Medina Ardissone2; Teresa Ana Ardissone3; Zulema Chaita3
1Facultad de Medicina - UNT, Carrera de Especializacion en Endocrinologia, San Miguel de Tucuman, Argentina; 2Facultad de Medicina - UNT, Carrera de Especializacion en Tocoginecologia, San Miguel de Tucuman, Argentina; 3Facultad de Medicina, Carrera de Especializacion en Endocrinologia, San Miguel de Tucuman, Argentina

Background: Polycystic ovary is a common endocrine disease, 70% of cases present insulin resistance, determining infertility, and in the long-term, endometrial and breast cancer and metabolic syndrome. Objective: Determine the consequences of polycystic ovary syndrome in young women. Method: Descriptive, cross sectional study, targeting women between 13 and 21 years old, who were assisted in the Instituto de Maternidad, Tucuman, Argentina. The analysis was performed using descriptive statistics, the association of variables with SPSS V7.5. Results: N: 293. The main complaints were secondary infertility and hypertrichosis. 65% of patients were obese and 80% showed insulin resistance. 77% of the patients were dyslipidemic and the remaining 23% had values within the limits of normal. 48% had fertility desires without success after a year of sexual active life. 32% were diabetic type II and 26% were hypertensive. Conclusions: The fearsome consequences of polycystic ovary disease in the short term are present in most of the young patients, which is a personal, familiar and social tragedy, considering the low age of the affected. We propose educational and preventive measures to avoid the potential rapid progress of polycystic ovary syndrome in short, medium and long term.

PAO-104
Final height in patients with type 1 diabetes mellitus (DM1)
Maria Claudia Schmitt-Lobe; Raiza Rodrigues Weber; Thaisa Silva Gios
FURB-Faculty of Medicine, Pediatric Department, Blumenau, Brazil

Background: Final Height (FH) could be compromised in DM1 pediatric patients. Poor control, growth retardation secondary to celiac disease, chronic acidosis and hypothyroidism are possible causes that could compromise FH in these patients. A retrospective study with 130 patients was performed between 1993-2010. Objectives: To evaluate FH in patients who have DM1 at childhood or adolescence and to compare with their target height (TH). To identify factors that could compromise FH. Material and methods: FH was considered when growth velocity were < 1cm/year at last year and/or Bone age (Greulich-Pyle atlas) >15y for girls, and, >16y for boys. The FH was compared with their TH; mother and father height were obtained from each patient. We analysed: chronological age (CA) at diagnosis; time of disease(TD) is the time since diagnosis until FH; numbers of hospitalization due to ketoadicosis and hypoglycemia since the diagnosis and, glycosylated hemoglobin (HbA1c) mean during follow up. In addition autoimmune disease: Hashimoto Tiroiritis was considered with positives antibodies TPO and/or TG and elevated TSH; Graves Disease was considered with positive antibody anti-TRAB, low TSH and elevated T4free; Celiac Disease was considered with positive antibody antiendomysium IgA and intestinal biopsy confirmed. Presence of microalbuminuria during the follow up were analysed. The HSDS was used for statistical analysis. A p value less than 0.05 was considered statistically significant. Results: 55 patients (34 girls reached FH.

<table>
<thead>
<tr>
<th></th>
<th>Median</th>
<th>Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSDS-FH</td>
<td>-0.14 (-2.08 - +2.02)*</td>
<td>-0.16 (±0.81)</td>
</tr>
<tr>
<td>HSDS-TH</td>
<td>-0.27 (-2.28 - +0.96)*</td>
<td>-0.34 (±0.78)</td>
</tr>
<tr>
<td>HSDS-FH minus HSDS-TH</td>
<td>0.22 (-1.9 + +1.95)</td>
<td>0.16 (±0.76)</td>
</tr>
</tbody>
</table>

*p=0.059 (Wilcoxon)

In Table 02 are show the findings of overall and the comparison of two groups of patients. We separated and compared two groups of patients; Group A: HSDS-FH minus HSDS-TH >0.37 [-1.9 – 0.01]; and; Group B: HSDS-FH minus HSDS-TH ≥ zero (0.54 [0.05 - 1.95]), p<0.01 (Mann-Whitney).

Conclusion: The patients reached FH according their TH. None of the factors evaluated compromised FH in these patients.

50th Annual Meeting of the ESPE
Horm Res 2011;76(suppl 2)
PAO-105

Growth hormone excess in two children with neurofibromatosis type 1 and optic pathway glioma
Patrizia Bruzzi; Assunta Albanese
Royal Marsden Foundation Trust, Paediatric Endocrine Unit, Sutton, United Kingdom

Background: In children with neurofibromatosis type 1 (NF1) growth hormone excess (GHE) is extremely rare, but reported in the presence of optic pathway glioma (OPG). GHE can be the result of hypothalamic regulatory defect due to OPG infiltration of somatostatinergic pathways reducing somatostatin tone and leading to GHRH-mediated overproduction of GH.

Objective and hypotheses: We present 2 cases of children with NF1, OPG and GHE.

Methods: It is a case-report.

Results: First case: A pre-pubertal 5 years old girl with NF1 and a diffuse suprasellar low grade glioma involving the optic pathway was referred for tall stature. After completion of chemotherapy, GHE was documented by failure of GH levels to suppress during a standard OGTT and elevated age-adjusted plasma IGF1 levels. She was started on long acting somatostatin analogue (SSa) therapy which normalized her growth velocity and plasma IGF1 levels. Six months after starting SSa she developed central precocious puberty (CPP) and from the age of 7.5 years she also received LHRHa therapy. However following an episode of acute pancreatitis at the age of 10.2 years SSa was stopped. IGF1 levels and growth velocity remained normal while off SSa and subsequently when at the age of 13.5 years LHRHa was also discontinued. This is the first reported case in the literature documenting spontaneous resolution of GHE after treatment with SSa in a child with NF1-1 and OPG.

Second case: A tall 7.3 years old girl with NF1 and OPG treated with chemotherapy was referred for precocious puberty. CPP was confirmed and treated with LHRHa. Despite documented biochemical and clinical suppression of puberty, growth velocity remained accelerated with raised IGF1 age-adjusted plasma levels. GHE was suspected and then confirmed by a failure of GH levels to suppress in response to an OGTT. Treatment with SSa was started with a normalization of both auxological and biochemical data.

Conclusions: Tall stature and growth acceleration in children with NF1 and OPG require investigation for both precocious puberty and GHE.

PAO-106

Screening results for vascular complications and associated autoimmune diseases in children and adolescents with type 1 diabetes
Fatima Demirel; Derya Tepe; Ozlem Kara; Ihsan Esen
Ankara Child Diseases Hematology and Oncology Education and Research Hospital, Pediatric Endocrinology Department, Ankara, Turkey

Background: Diabetes-related microvascular complications, as retinopathy, nephropathy and neuropathy are life-threatening complications in children and adolescents with type 1 diabetes mellitus (T1DM). Longer duration of diabetes, older age and puberty are the risk factors for the development of complications. Further risk factors include smoking, hypertension, higher body mass index and dyslipidemia. Therefore prevention and screening for complications is an important part in the care of children and adolescents with T1DM.

Objective and hypotheses: Our aim was to investigate diabetic complications and associated autoimmune diseases in children and adolescents with T1DM of more than 5 years duration.

Methods: The study included 46 children and adolescents with T1DM (18 male, 28 female), mean aged 14.1±2.8 years, with a T1DM duration of 8.4±2.9 years. Forty-two (91.3%) cases were adolescent and 4 (8.7%) cases were in prepubertal age.

Results: Insulin treatment consisted of four daily injections in all of the patients and mean HBA1c level was 8.3% (range 5.9%-12.4%). The prevalence of microalbuminuria was 32.6%, dyslipidemia was 21.7%, hypertension was 17.4%, and peripheral neuropathy was 2.2%. None of the patient had diabetic retinopathy. Prevalence of autoimmune thyroiditis and celiac disease were found to be 21.7% and 6.5% respectively. Despite intensive insulin treatment, 47.8% (n=22) of patients with T1DM developed at least one detectable diabetes complication after approximately 8 years of diabetes. Microalbuminuria was the most common complication and the strongest risk marker was high blood pressure.

Conclusions: Annual complication screening should be done after diabetes duration of 5 years in patients with T1DM. Additionally screening at an onset and repeated measurements for autoimmune thyroiditis and celiac disease are recommended.

PAO-107

Cushing’s disease in a 14-year old female: difficulties of diagnosis
Violetta Csakvary1; Zoltan Locsei2; Gyorgy Oroszlan3; Zita Halasz4; Miklos Toft5; Sandor Czitjak5; Karoly Racz1
1Markusovsky Teaching Hospital, Department of Pediatrics, Szombathely, Hungary; 2Markusovsky Teaching Hospital, 1st Department of Internal Medicine, Szombathely, Hungary; 3University of West Hungary - Savaria Campus, Institute for Health Promotion, Szombathely, Hungary; 4Szeimelweis University, 1st Department of Pediatrics, Budapest, Hungary; 5Semmelweis University, 2nd Department of Internal Medicine, Budapest, Hungary

Background: Cushing’s disease (CD) is rare in childhood and remains a difficult condition to diagnose and treat. Although the diagnosis of CD is of crucial importance in effective diagnosis and treatment. Sometimes it is difficult to confirm the location of microadenoma in CD.

Objective and hypotheses: We report the case of 14-year old girl, who was referred to our hospital because of growth retardation with muscle weakness and rapid onset weight gain. On admission, she had typical Cushingoid appearance with Tanner pubic hair stage 3. Endocrinological examinations showed elevated levels of serum cortisol, and 24-h urinary free cortisol (UFC), and plasma ACTH. Lack of diurnal variation of ACTH and cortisol was observed. Serum cortisol levels were not suppressed by low and high dose dexamethasone as well. We established ACTH dependent CD. Perforning the corticotrophin-releasing hormone (CRH) test, increased cortisol response confirmed the diagnosis of CD. Gonadotropin levels were subnormal suggesting a suppressive effect of chronic hypercortisolism. Although, on 3.0 Tesla brain MRI, no microadenoma was detected in the pituitary gland. Considering the patient’s age, hormonal findings compatible with pituitary ACTH production and the possible complications the bilateral inferior petrosal sinus sampling for ACTH was not performed.

Results: Despite of the lack of positive radiomorphological MRI signs, the patient underwent successful and curative transphenoidal pituitary surgery and a 2 mm microadenoma was removed. The histopathological features- ACTH secreting microadenoma was consistent with the diagnosis.

Conclusions: Hypercortisolism was resolved after pituitary surgery. Possessing the typical clinical presentation and endocrinological investigation of CD in special cases –lack of detected microadenoma- the transphenoidal surgery is henceforward a safe and effective procedure in children.

PAO-108

Noonan syndrome: clinical phenotype and response to GH treatment
Yulia Makarava; Julia Boiko
State Center of Medical Rehabilitation, Pediatric Department, Endocrinology Group, Minsk, Belarus

Background: Noonan syndrome (NS) is a disorder characterized by congenital heart defects, facial dysmorphism, skeletal malformation and short stature. Objective and hypotheses: The aim of the study was to describe a cohort of patients with NS in Belarus, evaluate the effect of rGH treatment for 24 months on metabolic, clinical and cardiac status in patients with NS.

Methods: Since 2008 at the State Endocrinology Center 8 NS patients (5m, 3f) were observed. Median age was 13.7yr (11.0-17.8). All but one were in puberty Tanner stage 2-3 at the first observation. One boy had early puberty, a gonadal atrophy was found in one boy also. Two patients had a mild growth retardation (mean height SDS -2.9 (from -4.8 to -2.0SDS)) according to population standards. Means birth weight and length were normal. Typical face dysmorphism were found in all patients. 3/8 were diagnosed with pulmonary valve pathology (mean height SDS -2.9 (from -4.8 to -2.0SDS)) according to population standards. Means birth weight and length were normal. Typical face dysmorphism were found in all patients. 3/8 were diagnosed with pulmonary valve
stentosis, 3- with atrial septum defect, one at a time - with hypertrophic cardiomyopathy, tetralogy of Fallot and ventricular septal defect. Only 1/8 had mental retardation. 6/8 patients with severe growth retardation were undergone rhGH treatment. Basal serum IGF-1 levels according to age and puberty stage were -1.9 SDS. rhGH dose ranged from 47 to 67 µg/kg/d. Anthropometry, bone age, serum IGF-1 level, lipids, fasting glycemia and insulin, cardiac evaluations were performed at baseline, at 12 and 24 months of treatment.

Results: At 12 and 24 months of treatment mean height SDS elevation was found (A1 height SDS = -0.43 and A2 height SDS = 0.64, respectively). Basal serum IGF-1 levels normalized after 1st yr of rhGH therapy: -0.48 SDS. No significant difference was observed in lipids profiles, fast glycemia, fast insulin levels and clinical cardiac status during two years of rhGH treatment.

Conclusions: Cohort of patients with NS in Belarus showed the typical clinical phenotype as well as in other researches. Effect of rhGH treatment starting at the age of puberty in NS is minimal. Early genetic analysis is required to be helpful in selecting the appropriate patients for rhGH therapy.

Case report: A 5.5 year-old girl admitted to our clinic with mutation caused by deepening of voice. Her previous history revealed that pubic and axillary hair appeared at the age of 1 year and she was admitted to another hospital. However, the parents could not have brought the child to the regular follow up because of economic deprivation. During subsequent years, clinical progression of virilization have resulted in deepening of voice and ultimately a vocal mutism have occurred which was chief complaint for admission to our clinic. At the time of presentation, in physical examination there were signs of virilization(deepening of voice, hyperpigmentation in genitalia and areola, acne, cliteromegaly, axillary and pubic hair). Laboratory examination revealed virilization(deepening of voice, hyperpigmentation in genitalia and areola, acne, cliteromegaly, axillary and pubic hair). Laboratory examination revealed virilization(deepening of voice, hyperpigmentation in genitalia and areola, acne, cliteromegaly, axillary and pubic hair). Laboratory examination revealed virilization(deepening of voice, hyperpigmentation in genitalia and areola, acne, cliteromegaly, axillary and pubic hair).

Conclusions: The patient is interesting in her major presenting symptom, mutism, caused by coarsening of the voice and unwillingness to speak.

Background: Albeit growth disorders occur in 1 of 33 children, only in 1 of 6,000 children a growth hormone deficiency (GHD) results to be the cause, being early discovered and treated successfully. Seldom genetic disorders require complex diagnosis, like the LS, termed after Dr. Eric Legius since 2009 (Messiaen et al 2009), which belongs to the group of neuro-facial-cutaneous syndrome related to NF1. Children with short stature and macrocephaly, axillary freckling cafe-au-lait spots, signs of Noonan syndrome and learning disability funnel diagnosis towards NF1. If no punctmutation of NF1 gene is present, LS is to be considered as a less severe and predictable prognosis. A mutation in the SPRED1 gene confirms LS. 155 patients have been reported so far.

Objective and hypotheses: Investigation of heredity transmission of LS. Population and methods: We report a 6-year-old patient with typical NF1 symptoms. With no NF1 mutation, the analysis of SPRED1 gene showed the mutation c.293dupA in Exon 4, which was decided to also investigate in other family members.

Results: The same mutation was found in the father; a family tree provides more evidence on the heredity transmission. The inter-disciplinary treatment concept is shown.

Conclusions: The exact clinical description, confirmation of SPRED1 gene mutation and the assessment of heredity allow for an individual treatment and reduction of psychological strain.

Background: Adrenocortical carcinoma (ACC) is an unusual, and highly malignant childhood tumor. In children, the incidence is reported 0.3 cases per million per year. We describe a giant virilizing ACC in a girl presenting with mutation.

Case report: A 5.5 year-old girl admitted to our clinic with mutation caused by deepening of voice. Her previous history revealed that pubic and axillary hair appeared at the age of 1 year and she was admitted to another hospital. However, the parents could not have brought the child to the regular follow up because of economic deprivation. During subsequent years, clinical progression of virilization have resulted in deepening of voice and ultimately a vocal mutism have occurred which was chief complaint for admission to our clinic. At the time of presentation, in physical examination there were signs of virilization(deepening of voice, hyperpigmentation in genitalia and areola, acne, cliteromegaly, axillary and pubic hair). Laboratory examination revealed virilization(deepening of voice, hyperpigmentation in genitalia and areola, acne, cliteromegaly, axillary and pubic hair). Laboratory examination revealed virilization(deepening of voice, hyperpigmentation in genitalia and areola, acne, cliteromegaly, axillary and pubic hair). Laboratory examination revealed virilization(deepening of voice, hyperpigmentation in genitalia and areola, acne, cliteromegaly, axillary and pubic hair).

Conclusions: The patient is interesting in her major presenting symptom, mutism, caused by coarsening of the voice and unwillingness to speak.

Background: Albeit growth disorders occur in 1 of 33 children, only in 1 of 6,000 children a growth hormone deficiency (GHD) results to be the cause, being early discovered and treated successfully. Seldom genetic disorders require complex diagnosis, like the LS, termed after Dr. Eric Legius since 2009 (Messiaen et al 2009), which belongs to the group of neuro-facial-cutaneous syndrome related to NF1. Children with short stature and macrocephaly, axillary freckling cafe-au-lait spots, signs of Noonan syndrome and learning disability funnel diagnosis towards NF1. If no punctmutation of NF1 gene is present, LS is to be considered as a less severe and predictable prognosis. A mutation in the SPRED1 gene confirms LS. 155 patients have been reported so far.

Objective and hypotheses: Investigation of heredity transmission of LS. Population and methods: We report a 6-year-old patient with typical NF1 symptoms. With no NF1 mutation, the analysis of SPRED1 gene showed the mutation c.293dupA in Exon 4, which was decided to also investigate in other family members.

Results: The same mutation was found in the father; a family tree provides more evidence on the heredity transmission. The inter-disciplinary treatment concept is shown.

Conclusions: The exact clinical description, confirmation of SPRED1 gene mutation and the assessment of heredity allow for an individual treatment and reduction of psychological strain.
BS measurement at school. The classmates and teachers of the patient knew that they were diabetic in %95 and %94 respectively. 30% of the children were avoiding injections at school, 33% were injecting at classroom, 15% at infirmary, 11% at cantina and 11% at restrooms. There was no school nurse in 80% of the schools. 18% of the children reported severe hypoglycemia in the last year. Glukagon was present at 19% of the schools and 72% of the homes of diabetic children.

**Conclusions:** This survey demonstrated a need for more vigorous education and organisation for diabetes-care (especially for blood sugar measurement, insulin injections and glucagon) at school environment in Istanbul. It also demonstrates importance of a specialist (pediatric endocrinologist) in care of children with T1DM.

**Introduction:** WRS is the most common genetic cause of Permanent Neonatal Diabetes Mellitus in consanguineous families. Much information can be gained by the identification of a susceptible gene in a particular disorder. WRS is a rare autosomal recessive disorder resulting from mutations in EI-F2AK3 (or PEK), the gene encoding the eukaryotic translation initiation factor 2 α kinase 3 (eIF2α kinase).

**Description:** We report a case of 35 days old female, who presented with seizures, hepatic dysfunction and diabetes mellitus and diagnosed as WRS on the basis of genetic studies with identification of mutations in the gene EI-F2AK3. The baby was born an uneventful 36 weeks pregnancy from healthy consanguineous parents with birth weight of 1700 grams. Initial glucose level was 1020mg/dl, insulin needs dropped gradually from 4u/kg to 0.5u/kg until adequate glycemic control was achieved.

**Result:** Sequencing analysis has shown that she is homozygous for the nonsense mutation, L425X, in exon 7 of the EIF2AK3 gene. This mutation is a T>A substitution at nucleotide 1274 (c.1274T>A) resulting in a premature termination codon (p.Leu425X). This result confirms a diagnosis of Wolcott Rallison syndrome. Her mother is heterozygous for the EIF2AK3 nonsense mutation L425X and her father, heterozygous for a nonsense mutation in exon 7 of the EIF2AK3 gene.

**Discussion:** WRS results from the lack of trans-membrane enzyme activity which leads to the cell death by apoptosis in a number of different tissues. The development of early onset diabetes mellitus and skeletal dysplasia in almost all patients of WRS explains the high level of expression of EIF2AK3 in both pancreatic β cells and bone tissues. However the gene is expressed at a lower level in several other tissues, which explains the variability of the clinical manifestations observed in this syndrome. The clinical features of variable intensity found in different tissues include mental retardation, hepatic and renal dysfunction, cardiac abnormalities, exocrine pancreatic dysfunction and neutropenia.

**Introduction:** Permanent neonatal diabetes mellitus (PNDM) is a rare autosomal recessive disorder characterized by hyperglycemia that starts within the first 6 months of life without the presence of other features of congenital anomalies (CAAs). It is the most common cause of permanent neonatal diabetes mellitus.

**Conclusions:** We studied 87 patients with 21-OHD from Republic Bashkortostan with salt wasting (SW) (n=42) and simple virilizing (SV) (n=45) forms. Mutations of the CYP21A2 gene were revealed in 71.82% of cases. Objective and hypotheses. To evaluate age of patients with 21-hydroxylase deficiency, at which the disease was diagnosed, during performance of the neonatal screening.

**Introduction:** Neonatal Diabetes Mellitus in consanguineous families. Much information can be gained by the identification of a susceptible gene in a particular disorder. WRS is a rare autosomal recessive disorder resulting from mutations in EI-F2AK3 (or PEK), the gene encoding the eukaryotic translation initiation factor 2 α kinase 3 (eIF2α kinase).

**Description:** We report a case of 35 days old female, who presented with seizures, hepatic dysfunction and diabetes mellitus and diagnosed as WRS on the basis of genetic studies with identification of mutations in the gene EI-F2AK3. The baby was born an uneventful 36 weeks pregnancy from healthy consanguineous parents with birth weight of 1700 grams. Initial glucose level was 1020mg/dl, insulin needs dropped gradually from 4u/kg to 0.5u/kg until adequate glycemic control was achieved.

**Result:** Sequencing analysis has shown that she is homozygous for the nonsense mutation, L425X, in exon 7 of the EIF2AK3 gene. This mutation is a T>A substitution at nucleotide 1274 (c.1274T>A) resulting in a premature termination codon (p.Leu425X). This result confirms a diagnosis of Wolcott Rallison syndrome. Her mother is heterozygous for the EIF2AK3 nonsense mutation L425X and her father, heterozygous for a nonsense mutation in exon 7 of the EIF2AK3 gene.

**Discussion:** WRS results from the lack of trans-membrane enzyme activity which leads to the cell death by apoptosis in a number of different tissues. The development of early onset diabetes mellitus and skeletal dysplasia in almost all patients of WRS explains the high level of expression of EIF2AK3 in both pancreatic β cells and bone tissues. However the gene is expressed at a lower level in several other tissues, which explains the variability of the clinical manifestations observed in this syndrome. The clinical features of variable intensity found in different tissues include mental retardation, hepatic and renal dysfunction, cardiac abnormalities, exocrine pancreatic dysfunction and neutropenia.

**Introduction:** WRS is the most common genetic cause of Permanent Neonatal Diabetes Mellitus in consanguineous families. Much information can be gained by the identification of a susceptible gene in a particular disorder. WRS is a rare autosomal recessive disorder resulting from mutations in EI-F2AK3 (or PEK), the gene encoding the eukaryotic translation initiation factor 2 α kinase 3 (eIF2α kinase).

**Description:** We report a case of 35 days old female, who presented with seizures, hepatic dysfunction and diabetes mellitus and diagnosed as WRS on the basis of genetic studies with identification of mutations in the gene EI-F2AK3. The baby was born an uneventful 36 weeks pregnancy from healthy consanguineous parents with birth weight of 1700 grams. Initial glucose level was 1020mg/dl, insulin needs dropped gradually from 4u/kg to 0.5u/kg until adequate glycemic control was achieved.

**Result:** Sequencing analysis has shown that she is homozygous for the nonsense mutation, L425X, in exon 7 of the EIF2AK3 gene. This mutation is a T>A substitution at nucleotide 1274 (c.1274T>A) resulting in a premature termination codon (p.Leu425X). This result confirms a diagnosis of Wolcott Rallison syndrome. Her mother is heterozygous for the EIF2AK3 nonsense mutation L425X and her father, heterozygous for a nonsense mutation in exon 7 of the EIF2AK3 gene.

**Discussion:** WRS results from the lack of trans-membrane enzyme activity which leads to the cell death by apoptosis in a number of different tissues. The development of early onset diabetes mellitus and skeletal dysplasia in almost all patients of WRS explains the high level of expression of EIF2AK3 in both pancreatic β cells and bone tissues. However the gene is expressed at a lower level in several other tissues, which explains the variability of the clinical manifestations observed in this syndrome. The clinical features of variable intensity found in different tissues include mental retardation, hepatic and renal dysfunction, cardiac abnormalities, exocrine pancreatic dysfunction and neutropenia.
the studied CAH-chromosomes with the following frequencies: delA2orL- GC (27.62%), R536W (16.02%), I2splice (11.6%), I172N (7.18%), P453S (4.97%), V281L (2.76%), F30L (1.1%) and P435S (0.55%).

Results: The mutations frequency distribution in the CYP21A2 gene in 2 groups of patients with classical disease forms showed statistically significant differences. SW 21-OHD patients demonstrated delA2orLGC of the gene CYP21A2 twice more often than patients with SV (37.65% and 19.32%, respectively, p<0.012), mutation R536W - 2.6 times higher (23.53% and 9.09% respectively), p=0.018, mutation I2splice - 2.9 (16.47% and 5.68%, respectively, p=0.043), and mutation Q318X - 8.3 (4.41% and 1.14% respectively, p=0.044).

The mutation I172N, on the contrary, was more typical for SV patients than SW patients (13.64% and 1.18%, respectively, χ²=7.95, p=0.005). Mutations P30L and V281L were detected only in SW patients. Thus, we have been able to detect the spectrum of diagnostic significant CYP21A2 gene mutations typical for SW and for SV forms in CAH patients.

We found 621-OHD patients who carried 3 mutations, two of which formed a cluster: Q318X+R536W (2.87%), I72N+Q318X (0.57%, 1/74). Precise conclusion: The studying of molecular-genetic nature of 21-OHD represents the doubtless scientific and practical importance in respect of use of the received data for differential diagnostics of its various forms, medical and genetic consultation and prenatal diagnostics.

PAO-116

A rare case of adiposegenital puberal obesity
Suzanne Fricke-Ott1; Reinhardt Mühlenberg2; Katrin Held4
1Helios Clinic Krefeld, Department of Endocrinology, Krefeld, Germany; 2Helios Clinic Krefeld, Children's Department, Department of Endocrinology, Krefeld, Germany

Background: We present a girl with the diagnosis of a growth hormone producing tumour of the pituary gland.

Objective: We would like to present the case of a 1411/12-year-old girl who was referred to our outpatient clinic for endocrine evaluation of obesity. The auxology findings showed a body weight of 97.6 kg, a BMI of 32.8 (= 99.8 Perc.) and a body height of 172.6 cm (= 90. Perc.) with familiar aim size of 156 cm. X-ray of the left hand showed a retardation of the bone age of 1.6 J, the prospective final size was calculated at 177 cm. 2-3 years ago, at the beginning of the first puberty signs remarkable changes of the physical development and the appearance were noted for the first time.

The patient increased extremely in weight and showed a persistent growth push by shoe size at last 45. Clinically she suffered from occasional episodes of headaches, strong sweating and a primary amenorrhoe.

Because of the clear discrepancy between informal aim size and prospective final size, the external appearance of the patient and her distinct obesity we performed detailed endocrinology analysis incl. chromosome analysis, cerebro MRI and ophthalmologic investigation and could diagnose a growth hormone producing tumour of the pituary gland. The patient was transferred to a specified neurosurgery for transphenoida tumor extirpation.

Methods: Clinical history and clinical findings, measuring of height, familiar auxology findings, subcutaneous insulin. The therapy protocol was analyzed in terms of amount of fluid and insulin therapy while patients with DK were treated with intravenous fluid and insulin therapy.

Result: After diagnosis of a growth hormone producing tumour of the pituary gland, the patient was transferred to a specified neurosurgery for transphenoidal tumor extirpation.

Conclusion: If you see a clear discrepancy between informal aim size and prospective final size in a patient you have to search after a tumor in the pituary gland.

PAO-117

Delirium in diabetic ketoacidosis
Ayse Nurcan Cebeci1; Ayla Guven1
1Goztepe Educational and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey

Background: Neurologic changes during the course of diabetic ketoacidosis (DKA) should be considered as early signs of cerebral edema and should be treated immediately. Yet, delirium is not a usual neurological complication of DKA and has not been reported in pediatric DKA so far. We report our case here.

Case report: A 15-year-old female patient with known type 1 diabetes mellitus of two years duration was referred because of fatigue and symptomatic hyperglycemia. She had abdominal pain for the last 24 hours, could not eat her meals appropriately and had hypoglycemia in the morning of admission. Due to appetite loss and hypoglycemia, she emitted the insulin dose at lunch time. On physical examination she was alert, had dehydration, deep sighing respiration and a smell of ketones. Her height was 168 cm (+1.02 SDS), weight 68 kg (+1.66 SDS), respiratory rate was 38/min, pulse 80/min. She had normal body temperature and blood pressure. Blood glucose was 414 mg/dl (23 mmol/l), capillary pH: 6.99 and bicarbonate: 5.0 mmol/l. Base excess was -25.2 mmol/l and anion gap was 29.8 mmol/l. Blood urea, liver enzymes and electrolytes were within normal limits. At the sixth hour of treatment the acidosis with administration of fluid and insulin, the patient became delirious.

Delirium persisted despite the normalization of acidosis and was difficult to manage. Brain imaging studies revealed neither brain edema nor other intracranial pathologies. No evidence of intoxication could be found. The patient gradually regained consciousness and “merely” suffered from massive DKA associated with infection.

Conclusion: We did not find any similar case in childhood period in the literature thus we thought that clinicians should be aware that delirium can be seen in DKA due to severe acidosis.

PAO-118

Differences in clinical features and responses to treatment in different age groups of children with diabetic ketoacidosis and ketosis
Ayse Nurcan Cebeci1; Ayla Guven1; Heves Kirmizibekmez2; Metin Yildiz1; Fatma Dursun2
Goztepe Educational and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey

Objective and hypotheses: To compare clinical features and responses to a certain treatment protocol in different age groups.

Material and methods: Hospital records of patients with diabetic ketoacidosis (DKA) and ketosis (DK) who admitted to our hospital between January 2007 and December 2009 were reviewed. Symptoms, clinical and laboratory findings of all patients were recorded. Patients were divided into subgroups regarding to age [Group 1 (<5.0 years), Group 2 (5.1-10.0 years), Group 3 (>10.1 years)]. All patients with DKA were treated with a standardized intravenous fluid and insulin therapy while patients with DK were treated with subcutaneous insulin. The therapy protocol was analyzed in terms of amount and duration of fluid therapy, dose of insulin infusion and complications of therapy.

Result: 132 episodes in 107 patients with DKA (101 episodes) and DK (31 episodes) were studied. 64 patients (%60) were female, 43 (%40) were male, 81 (%60) were in new onset, 51 (%40) were in established diabetes. There were 22 episodes in group 1 (16.7%), 30 episodes in group 2 (22.7%) and 80 episodes in group 3 (60.6%). Patients in group 1 and 2 reported more polyuria and polydipsia than patients in group 3 involving patients mostly with established diabetes. Blood glucose and corrected Na levels, as well as pH and osmolality did not differ between groups. HbA1c was found significantly higher with age. Children in group1 had significantly lower HCO3 levels compared to group 2 (p=0.047) and group 3 (p=0.014). Duration and amount of fluid therapy did not differ between groups. Patients in group 3 received significantly higher doses of insulin and patients in group 1 received significantly more bicarbonate therapy. Only one patient experienced cerebral edema which recovered without any sequel owing to appropriate therapy.

Conclusion: Children less than five years of age are at higher risk of acidosis and require more attention and closer monitoring during treatment.
Background: Cranial radio-prophylaxis (CR) and total body irradiation (TBI) for hematopoietic stem cell transplantation are risk factors for obesity and insulin resistance (IR) in long term childhood cancer survivors.

Objective hypotheses: To evaluate overweight and IR in a group of childhood acute lymphoblastic leukaemia (ALL) survivors regardless BMI SD, in particular in pts who underwent TBI.

Methods: On 74 patients (pts) treated for ALL at our Centre, at age 5.2±3.1 yrs (yrs), follow-up 7.8±3.4 yrs. They were subdivided in 3 groups according to RT: group 1 (CR 1800 cGy) 17/74 pts, group 2 (TBI 800-1800 cGy) 16/74, group 3 41/74 pts not irradiated. In each group BMI SD and HOMA were evaluated yearly. HOMA was normal if < 2.5 in adults and children, <4 in adolescents.

Results: The prevalence of obesity was 9% in group 1 (after the 5th year), 7% in group 2 (in the first 5 years), 0% in group 2. 18% of pts in group 1, 14% in group 2 and 20% in group 3 were overweight. In the first 3 yrs, group 2 pts showed lower mean BMI SD (p=0.03) than the others. HOMA was abnormal in 9.5% of all pts and in 39% of overweight and obese pts. HOMA improved during follow-up in group 1 and 3. In group 2 IR was found in 47% of pts, increasing after the 4th year of follow-up. HOMA was abnormal also in some lean pts (8.3% from group 1, 27% from group 2 and 18.5% from group 3).

Conclusions: Obesity is rare in our pts. CR seems to be a risk factor for late obesity onset. TBI showed some protective effect on BMI SD while it negatively affected insulin sensitivity. HOMA should be evaluated in ALL survivors regardless BMI SD, in particular in pts who underwent TBI.

PAO-119

Long term longitudinal evaluation of overweight and insulin-resistance in patients treated for acute lymphoblastic leukaemia during childhood

Federico Baronio; Martina Zanotti; Alessandra Rolo; Arcangelo Prete; Riccardo Masetti; Alessandro Cicognani

University of Bologna, Pediatrics, Bologna, Italy

Objective hypotheses: To evaluate overweight and IR in a group of childhood acute lymphoblastic leukaemia (ALL) survivors who received or not radiotherapy (RT).

Methods: We evaluated 74 patients (pts) treated for ALL at our Centre, at mean age 5.2±3.1 yrs (yrs), follow-up 7.8±3.4 yrs. They were subdivided in 3 groups according to RT: group 1 (CR 1800 cGy) 17/74 pts, group 2 (TBI 800-1800 cGy) 16/74, group 3 41/74 pts not irradiated. In each group BMI SD and HOMA were evaluated yearly. HOMA was normal if < 2.5 in adults and children, <4 in adolescents.

Results: The prevalence of obesity was 9% in group 1 (after the 5th year), 7% in group 2 (in the first 5 years), 0% in group 2. 18% of pts in group 1, 14% in group 2 and 20% in group 3 were overweight. In the first 3 yrs, group 2 pts showed lower mean BMI SD (p=0.03) than the others. HOMA was abnormal in 9.5% of all pts and in 39% of overweight and obese pts. HOMA improved during follow-up in group 1 and 3. In group 2 IR was found in 47% of pts, increasing after the 4th year of follow-up. HOMA was abnormal also in some lean pts (8.3% from group 1, 27% from group 2 and 18.5% from group 3).

Conclusions: Obesity is rare in our pts. CR seems to be a risk factor for late obesity onset. TBI showed some protective effect on BMI SD while it negatively affected insulin sensitivity. HOMA should be evaluated in ALL survivors regardless BMI SD, in particular in pts who underwent TBI.

PAO-120

Comparison of efficacy of growth hormone (GH) treatment in short children with neurosecretory dysfunction (NSD) and partial GH deficiency - 3 years of observation

Marek Hilczer1; Joanna Smyczynska1; Renata Stawerska1; Andrzej Lewinski1

1Medical University of Lodz, Department of Pediatric Endocrinology, Lodz, Poland; 2Medical University of Lodz, Department of Endocrinology and Metabolic Diseases, Lodz, Poland

Background: Improvement of height velocity (HV), related to an increase of insulin-like growth factor-I (IGF-I) secretion, is the most important index of growth hormone (GH) therapy effectiveness.

Objective hypotheses: The aim of the study was an assessment of the efficacy of 3 years GH treatment by estimation of HV, IGF-I secretion and IGF-I to IGF binding protein-3 (IGFBP-3) molar ratio.

Methods: The analysis comprised 54 children (40 boys) with short stature and: partial GHD (pGHD – GH peak in 2 stimulating tests 5-10 ng/ml), and neurosecretory dysfunction (NSD – GH peak in stimulating tests >10 ng/ml) but after falling asleep <10 ng/ml, decreased IGF-I secretion. All the patients were treated with GH in a dose of 0.18±0.02 mg/kg/week for – at least – 3 years. Before GH administration and after following years of therapy HV, IGF-I secretion and the IGF-I/IGFBP-3 molar ratio were compared.

Results: There were no significant differences in any of the analysed parameters between the groups either before the therapy or at any time of treatment, except for the significantly lower (p<0.01) IGF-I/IGFBP-3 molar ratio in NSD group before treatment. For detailed data see the Table.

Conclusions: The effectiveness of treatment presented similar in NSD and pGHD groups. It seems that normal GH results of stimulating tests should not be a reason for disqualifying short children with disorders of spontaneous GH secretion from GH therapy.

PAO-121

A case of osteopetrosis tarda in childhood presenting with polyarthralgia and rickets

Gonul Cattı, Korcan Demir, Ayça Altıncık, Ayhan Abacı, Ece Bober

Dokuz Eylül University, Department of Pediatric Endocrinology, Izmir, Turkey

Background: Osteopetrosis refers to a clinically and genetically heterogeneous group of rare, heritable disorders of the skeleton characterized by increased bone density resulting from abnormalities in osteoclast differentiation or function. Based on clinical features, mode of inheritance and pathogenetic mechanisms osteopetrosis is classified into several distinct entities ranging in severity from asymptomatic to fatal in infancy. Osteopetrosis tarda (autosomal dominant osteopetrosis) typically has onset in adolescence and adulthood and the main complications are confined to the skeleton, including fractures, scoliosis, hip osteoarthritis and osteomyelitis.

Objective hypotheses: To present the clinical features of a child presenting with osteopetrosis tarda.

Methods: An 8-year old girl was admitted suffering from back, neck and ankle pain for six months. She was born to nonconsanguineous parents with a birth weight of 3600 grams. At the age of 4 she was referred for pain in thumb, wrist and knees and was diagnosed as having reactive arthritis. She had broken her finger in an accident 1 year ago. Family history was unremarkable except her fathers’ broken fingers and metacarpals after a minor trauma.

Physical examination revealed no pathological sign with a height of 138 cm (SDS 1.46) and weight 34 kg (SDS 1.24).

Results: Laboratory studies showed mild anemia and normal biochemistry with mildly elevated values of PTH (78.4 pg/ml, normal range 12-72) and osteocalcin (30.2 ng/ml, normal range 3.2-13.7) and a low 25-hydroxy vitamin D level of 58 nmol/L (normal range 80-250 nmol/L). Radiographic examination revealed findings of generalized osteosclerosis, sandwich vertebra and teocalcin (30.2 ng/ml, normal range 3.2-13.7) and a low 25-hydroxy vitamin D level of 58 nmol/L (normal range 80-250 nmol/L). Radiographic examination revealed findings of generalized osteosclerosis, sandwich vertebra and thus diagnosis of osteopetrosis tarda and rickets was made. After stoss therapy her complaints have diminished and PTH level was normalized (51 pg/ml).

Conclusions: Osteopetrosis tarda is generally diagnosed incidentally in adolescence and adulthood but it may also present in childhood with mild anemia, fractures, polyarthralgia and rickets as in our case.
Multiple endocrine complications of allogeneic hematopoietic stem cell transplantation

Anna Wędrychowicz; Agata Zygmunt-Górska; Joanna Wojtyła; Marta Ciechanowska; Aleksandra Krassowska-Kwiecien; Jerzy Starzyk
1Polish-American Children’s Hospital, Medical College, Jagiellonian University, Department of Pediatric and Adolescent Endocrinology, Department of Transplantation, Cracow, Poland; 2University Children’s Hospital, Pediatric and Adolescent Endocrinology, Cracow, Poland; 3Polish-American Children’s Hospital, Medical College, Jagiellonian University, Department of Pediatric and Adolescent Endocrinology, Cracow, Poland

Background: Since the 1980s, hematopoietic stem cell transplantation (HSCT) has been performed for malignant and non-malignant disorders leading to increasing numbers of long-term survivors. Some of them have endocrine complications that arise many years after the end of the initial disorder treatment.

Objective and hypotheses: We present the 16.5 year-old girl with endocrine complications after treatment of acute lymphoblastic leukemia diagnosed at the age of 10.

Method: First chemotherapy was complicated with an acute pancreatitis after L-asparaginase. Eight months after diagnosis an allogeneic HSCT from HLA-matched sibling donor was performed. In the conditioning regimen fractionated total body irradiation and high-dose etoposide were used. After HSCT several early and late complications occurred: bacterial and mycotic infections, engraftment syndrome with renal and respiratory failure, graft versus host diseases (GVHD) and pancreatitis.

Results: We observed multiple endocrine complications successively appearing after HSCT: i) transient carbohydrate metabolism disorders in first days, followed by regular diabetes requiring insulin therapy, ii) euthyroid sick syndrome in first months, then an overt primary hypothyroidism treated with L-thyroxin, iii) transient hyponatremia due to SIADH syndrome, iv) growth hormone deficiency supplemented with recombinant human growth hormone, v) low bone mineral density detected in repeated densitometry examination, in spite of calcium and vitamin D supplementation, vi) some elements of metabolic syndrome in spite of diabetes with insulin resistance, as high blood pressure, and dyslipidemia.

Conclusions: The significant endocrine complications of HSCT in the presented patient were associated with radiation exposure, but were also related to some chemotherapeutic agents, GVHD, and prolonged corticosteroid exposure.

Central hypothyroidism following chemotherapy for acute lymphoblastic leukemia

Federico Baronic; Laura Battiati; Giorgio Radetti
Regional Hospital of Bolzano, Pediatrics, Bolzano, Italy

Background: Thyroid dysfunction is frequently reported in patients treated with radiotherapy for childhood cancer. However, it has been suggested that chemotherapy per se might also impair the hypothalamus-pituitary-thyroid axis.

Objective and hypotheses: We examined 8 patients, out of a cohort of 31 subjects treated for acute lymphoblastic leukemia (ALL) with chemotherapy alone, who showed, during the follow-up, thyroid findings consistent with central hypothyroidism (CHI).

Methods: The patients were diagnosed with ALL at a mean age (range) of 3.8 (0.3-6) years and were, at the time of the study, for 6 years (range 6-13) off therapy. Auxological data were recorded and TSH, FT4, thyroid peroxidase and thyroglobulin antibodies, cortisol and IGF-I were evaluated and a thyroid ultrasound was performed. Four subjects, who gave their consent, underwent a TRH test and a MRI scan of the hypothalamic-pituitary region.

Results: All subjects showed basal TSH above the normal range, while FT4 was normally low in two patients only. FT3 was always in the normal range. After TRH infusion, an increase in TSH serum level was observed; however, 2 patients showed an exaggerated TSH increase while 3 patients showed a slow TSH decline. Two patients showed an impaired FT3 net increase.

Conclusions: Our study shows that central hypothyroidism could arise at any time after childhood leukemia following only chemotherapy treatment. Although overt hypothyroidism was detected in only two patients, a careful follow-up of the thyroid function is recommended also for not irradiated ALL survivors.

Hyponatremia, hypothyroidism and metabolic acidosis

Ozlem Korkmaz; Damla Goksener; Gulgun Yenen; Afg Berdeli; Sukran Dercan
1Ege University, Faculty of Medicine, Pediatric Endocrinology, Izmir, Turkey; 2Ege University, Department of Pediatrics, Izmir, Turkey

Background: Severe hyponatremia with hyperkalemia and dehydration is an uncommon but life-threatening occurrence in infancy.

Objective and hypothesis: To highlight the importance of diagnosis and treatment of hypothyroidism in infancy.

Method and results: A two month old female patient with a history of first degree parental consanguinity admitted to hospital with failure to thrive. At initial examination her weight was 2990 gr. height was 53 cm and she was hypotonic. Laboratory evaluation revealed serum sodium concentration 108 mEq/l, potassium 5.3 mEq/l, chloride 71 mEq/l. She received saline solution, hydrocortisone and fludrocortisone with an initial diagnosis of adrenal failure. Additional evaluation was not remarkable with adrenal failure since ACTH was 18.8 pg/ml (10-70 pg/ml), 17-OH Progesteron, 7.7 ng/ml (1.7-17 ng/ml), cortisol, 14 mcg/dl (3-23 mcg/dl), DHEA-S: 35 mcg/dl (45-150 mcg/dl) and aldosteron was 408 pg/ml(20-1300 pg/ml). Urinary sodium excretion was 27 mEq/l and serum osmolarity was normal. Thyroid replacement therapy was initiated because her TSH and FT4 levels were 100 mIU/l and 0.47 mg/dl respectively. With the initiation of L thyroxin therapy and with the exclusion of adrenal failure fludrocortison was tapered. An immediate decrease in serum Na levels was seen and fludrocortisone was restarted. Metabolic diseases that can because hyponatremia was excluded with normal lactic acid, pyruvic acid, tandem mass and quantitative urinary amino acid levels. She was noted to have increasing values of urea, creatinine and uric acid and intermittent metabolic acidosis on the second week of her hospitalization. She died with metabolic acidosis and septic shock on the 6th week of admission. The patient was negative forNR3C2, SCN11B,SCNN1G and a heterozygous genetic variant in SCN1A gene (p.Thr6363Ala) was found. Glycolisation deficiency disorder, systinosis and membrane transport defects (Pendrin mutation) was thought in the differential diagnosis of these two siblings.

Intractable hypercalcemia following transplantation for osteopetrosis

Sung Yoon Cho; Sohn Young Bae; Jin Dong-Kyu
Samsung Medical Center, Pediatric, Seoul, Republic of Korea

Background: Autosomal recessive osteopetrosis is characterized by insufficient osteoclast activity resulting in defective bone resorption and marked increase in skeletal mass and density. Osteopetrosis results in generalized sclerotic bones and bone marrow failure. Allogeneic bone marrow transplantation (BMT) is the only treatment for cure, secondary to engraftment of donor-derived functioning osteoclasts resulting in remodeling of bone and establishment of normal hematopoiesis. One of the complications following a successful BMT is hypercalcemia that is a unique complication in this group of patients.

Methods and results: We report a three-yr-old girl with osteopetrosis who developed hypercalcemia following the successful bone marrow transplantation. These findings indicated an active donor-derived osteoclastic function and thus bone resorption following the successful donor engraftment in the patient. Her calcium level was 14.8 mg/dl at postBMT 10 days, therefore calcitonin (4 IU/kg sc every 12hr) as well as hyperhydration and furosemide were started. However, the calcium level increased to 16.8 mg/dl at post-BMT 13 days, and then intravenous pamidronate (15mg/BSA) and steroid (methylprednisolone 1mg/kg every 12hrs) was started. At that evening, she...
was very irritable with more increased calcium level of 18.2 mg/dL. Her status was considered malignant hypercalcaemia, therefore we started continuous renal replacement therapy. After two days, the calcium level decreased to 13 mg/dL without any adverse events, and CRRT had been maintained for six days. At present (postBMT 45 days), her calcium level below 11 mg/dL with weekly pamidronate, daily calcitonin and daily methylprednisolone with tapering dose.

Conclusions: In conclusion, hypercalcaemia is common in patients with osteopetrosis after BMT. If the conventional therapeutic strategies including isotonic saline, furosemide and calcitonin would not be successful, continuous renal replacement therapy should be considered seriously to prevent severe adverse events of hypercalcaemia.

PAO-126
Vitamin D status in pediatric patients with malignancy
Dallit Moden-Moise1; Ori Pinhas-Hamiel1; Vered Temam2; Dafna Munitz- Sheinkara3; Toren Amos1
1The Edmond and Lily Safra Children’s Hospital, Pediatric Endocrinology, Ramat-Gan, Israel; 2The Edmond and Lily Safra Children’s Hospital, Pediatric Hemato-Oncology, Ramat-Gan, Israel; 3The Edmond and Lily Safra Children’s Hospital, Pediatric Hematology-Oncology and BMT, Ramat-Gan, Israel

Background: Multiple studies demonstrated an inverse association between vitamin D and its metabolites and cancer morbidity and mortality. Despite this impressive body of evidence, only a handful of studies estimated vitamin D status in pediatric patients with malignancy.

Objective and hypotheses: Our aim was to assess vitamin D status in a large cohort of pediatric cancer patients and survivors, and to define risk factors to vitamin D deficiency. We hypothesized that 25OHD levels will be low in this population, particularly among actively treated patients.

Methods: 25OHD levels were obtained in 154 consecutive patients (aged 12.1±5.9y, M=76) during their routine visits to the hemato-oncology department (mean time from diagnosis 4.4±3.9y). Patients or their parents were asked to answer a questionnaire regarding calcium intake and sun exposure habits.

Results: Average daily calcium intake was 742.1±415.5mg/day. Mean 25OHD levels were 21.8±8.2ng/ml. Eighty patients (11.8%) were vitamin D deficient (<11ng/ml), and another 87 (80.3%) were vitamin D insufficient (11-32ng/ml). Only 12 patients (7.9%) were vitamin D sufficient. Younger age and the amount of sun exposure were associated with higher serum 25OHD levels (r=−0.24, p=0.003; r=0.21, p=0.008, respectively). No association was found with sun protection habits, calcium intake, disease type, gender, years since diagnosis, or undergoing stem cell transplantation.

Conclusions: The prevalence of vitamin D deficiency and insufficient in pediatric haematology-oncology patients is high, while daily calcium intake is significantly lower than the RDA. While these values may be similar to those of pediatric hemato-oncology patients is high, while daily calcium intake is significantly lower than the RDA. Conversely, values may be similar to those of pediatric hemato-oncology patients. Patients or their parents were asked to answer a questionnaire regarding calcium intake and sun exposure habits.

PAO-127
Quantitative ultrasound evaluation of bone status in obese children with or without metabolic syndrome
Valeria Calcaterra1; Tiziana Muratori1; Paola Brambilla1; Alexandre Diouf1; Rossana Toglia1; Claudia Caramagna1; Daniela Larizza1; Valeria Calcaterra1; Tiziana Muratori1; Paola Brambilla1; Alexandre Diouf1; Rossana Toglia1; Claudia Caramagna1; Daniela Larizza1; Valeria Calcaterra1; Tiziana Muratori1; Paola Brambilla1; Alexandre Diouf1; Rossana Toglia1; Claudia Caramagna1; Daniela Larizza1
University of Pavia and IRCCS Policlinico San Matteo Foundation, Department of Pediatrics, Pavia, Italy

Background: The relation between metabolic syndrome (MS) and bone metabolism is not clear, because MS has both conflicting factors of osteoporosis: one with a protective property, obesity, and another one which can activate bone resorption, inflammation. We evaluated bone status with quantitative ultrasound (QUS) technique in pediatric obese subjects with or without MS.

Methods: Phalangeal QUS measures for amplitude-dependent speed of sound (ADSoS) and bone transmission time (BTT) were obtained in 56 obese patients (30M/26F; mean age 12.9±1.63 years) with BMI≥97th percentile for their age and sex. Bone parameters were expressed as Z-score based on age-sex-matched normal controls. Patients were classified as having MS according to Pediatric International Diabetes Federation. Insulin sensitivity was calculated by the homeostasis model assessment (HOMA) and impaired insulin sensitivity (IIS) was defined as a HOMA-IR of 4 or higher. In all pts complete blood count and CRP were performed.

Results: MS was present in 25 patients (10M/15F, 17.8%); 7 of these pts had IIS (p=0.02). Mean ADSoS Z-score was -1.07±1.1 (males -1.19±1.25 vs females -0.92±0.9, p=0.36) and mean BTT Z-score -0.18±1.3 (M. –0.41±1.25 vs F. 0.07±1.35, p=0.18), without significant difference in subjects with or without MS (ADSoS Z-score -1.16±0.82 vs -1.05±1.16, p=0.89; BTT Z-score -0.06±1.11 vs -0.21±1.35, p=0.74). ADSoS and BTT Z-scores were reduced in 10 (2 with MS, p=1) and 4 subjects respectively (none with MS, p=0.17); bone event was not found. None subject presented signs of inflammation.

Conclusions: In our patients normal bone parameters were found, without significant difference in pts with or without MS. Probably, in obese children the inflammation is low and protective role of obesity is predominant on the bone status.

PAO-128
Osteoporosis-pseudoglioma syndrome: clinical outcome after treatment with growth hormone and bisphosphonates
Gloria Bueno1; Feliciano Ramos1; Jesus Fleta1; Inés Bueno1; Jesus Maria Garargorn2; Nizar Smaoui2; Jose Luis Olivares2
1Lozano Blesa University Clinical Hospital, Department of Pediatrics, Zaragoza, Spain; 2GeneDx, DNA Diagnostic Experts, Gaithersburg, United States

Background: Osteoporosis-Pseudoglioma Syndrome (OPPG, MIM 259770) is a very rare genetic autosomal recessive condition characterized by early blindness and bone fragility with fractures. The affected gene is called LRPS, located at the chromosomal region 11q13.4. Recently, the combined growth hormone (GH) and bisphosphonates treatment in OPPG patients was proposed.

Objective: To present the case and the clinical evolution of a 10-year-old rumanian girl with OPPG, confirmed by the identification of a mutation in exon 11 of the LRPS gene (c.2409, 2503+79del174), who was treated for one year with GH and intravenous bisphosphonates.

Case report: She was the third child of healthy non-consanguineous parents. Sibs were apparently normal but she has two maternal cousins, living in Rumania, who are blind. She was first seen in our Hospital at the age of 10 years. She weighted 23.5 kg (-3%), measured 110 cm (-3%), and had a head circumference of 48.5 cm (-10%). She was disproportionate with shortening of the upper segment secondary to a severe kyphoscoliosis. She could not walk. Extremities were not deformed neither had visible fracture calluses. She had hypotonia and hyperextensible joints. She had bilateral microphtalmia, cataracts and entropion. Bilateral horizontal nystagmus was also present. She was blind.

Laboratory analyses included: Calcrema: 10.3 mg/dL, phosphatemia: 5 mg/dL, alkaline phosphatase: 221 U/L. PTH 43.4 pg/mL, 25(OH)D3: 28 ng/mL, osteocalcine: 17 ng/mL, all in normal ranges. Skeletal survey: Generalized osteopenia, thin long bones, flattened dorsal vertebrae, pectus carinatum and deformed chest. Epyphyses were normal. No anomalies were found in the skull. Bone densitometry (L1-L4): 0.378 g/cm2 (-4 SD for age). She was treated with Pamidronate , calcium, vitamin D and GH.

Conclusion: After 1 year of treatment, the intravenous pamidronate therapy was safe, bone mineralization increased (-2.5 SD for age) and fracture rate and pain decreased. Further follow-up is needed in order to confirm the long term efficacy of this treatment.
Background: Classical Congenital Adrenal Hyperplasia (CAH) may present some traits of the metabolic syndrome.

Objective: Aim of this study was to investigate cardiovascular and metabolic risk profiles in children and adolescents with classical CAH.

Methods: We compared 20 classical CAH patients (10 males and 10 females, age range 9-19 years) with 20 age- and sex-matched controls. Anthropometry, lipids, blood pressure, fasting glucose concentrations, serum insulin levels and insulin sensitivity were studied. Adiposity was expressed as BMI SDS. Waist Circumference (WC) and Waist-to-Hip Ratio (WHR) were used to evaluate visceral adiposity.

Results: BMI SDS was significantly higher in patients than controls (0.9±0.9 vs -0.13±1.53; p=0.000). Five patients (25%) and two controls (10%) had a BMI SDS of >2.0. WC, but not WHR, resulted significantly higher in patients than in controls (82.9±13.7 vs 72.77±13.6; p=0.01). No differences were found for lipid parameters and mean systolic and diastolic blood pressures between the two groups. Fasting insulin levels (12.0±7.6 vs 5.1±5.08; p=0.01) and HOMA index (2±1.34 vs 0.98±1.03; p=0.01) were significantly higher in CAH patients, compared to controls. A significant correlation was observed between WC and BMI SDS (r=0.78, P<0.0001), fasting insulin levels (r=0.4525, p=0.04) and HOMA (r=0.45, p=0.04).

Conclusions: Children with classical CAH are at risk for increased BMI, obesity, hyperinsulinism and reduced insulin sensitivity. WC is an accurate predictor of these metabolic abnormalities and thus it should be monitored during follow-up in patients with classical CAH.

Successful switching from insulin to oral sulfonylureas in neonatal diabetes mellitus patients

Ngoc Can1; Chi Dung Vu2; Phuong Thao Bui1; Ngoc Khanh Nguyen1; Maria Craig3; Sian Ellard2; Hoan Nguyen1
1National Hospital of Pediatrics, Endocrinology, Metabolism and Genetics, Hanoi, Vietnam; 2St George Hospital and The Children's Hospital, Endocrinology, Westmead, Australia; 3Human Molecular Genetics, Peninsula Medical School, Department of Molecular Genetics, Exeter, United Kingdom

Background: Neonatal diabetes mellitus (NDM) may be defined as hyperglycemia diagnosed within the first 6 months of life and can result from mutations in the Kir6.2 or sulfonylurea receptor 1 (SUR1) subunits of the ATP-sensitive K+ channel. Transfer from insulin to oral sulfonylureas in patients with NDM due to Kir6.2 or SUR1 mutations is well described.

Objective and hypotheses: Determine gene mutation of KCNJ11 and ABCC8 in NDM patients; assess the results of oral sulfonylurea therapy replacing insulin injection.

Methods: Case study: 5 patients suffer NDM at 45, 35, 47, 36, 44 days of age, respectively with ABC8 or KCNJ11 mutations are treated in National Hospital of Pediatrics, Hanoi, Vietnam.

Results: 2 patients have heterozygous for a missense mutation on KCNJ11: R201H (p.Arg201His) & R201C (p.Arg201Cys); 3 patients with ABCC8 mutations: missense R1183W (p.Arg1147Trp), nonsense E747X and compound heterozygote for E747X & E128K. All 5 patients switched from insulin to sulfonylurea therapy at 5 years, 2.5 years, 7 years, 5 years and 8 months of age, respectively. Before of switching, HbAIC levels were 9.9; 6; 6; 8; 3.5; 5.8 percent with insulin dose of 1; 5; 5; 0.5; 0.5; 0.67 IU/kg/d, respectively. After 15; 10; 5; and 5 days, they successfully discontinued insulin, respectively. HbAIC levels improved in 3 first patients to 6.3; 6.2; 6.1 percent after 12 weeks of treatment) other patients has received sulfonylureas for 5 days. Improved glyemic control was sustained at one year.

Conclusions: KCNJ11 & ABCC8 mutations for NDM has been determined in Vietnam and treatment with sulfonylureas.

A child with concomitant precocious puberty secondary to factor V leiden mutation and type II diabetes mellitus

Ayla Guven; Fatma Duran; Hewes Kirmizibekmez; Nurcan Cebeci
Goztepe Educational and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey

Background: In children, the prevalence of type 2 diabetes (T2D) is increasing worldwide. At diagnosis, most patients have a positive family history of T2D. Heterozygosity for Factor V Leiden mutation (FVLMA) leads to a 3-fold increase in relative risk of venous thrombosis. The most common causes of precocious puberty are organic cranial lesion such as tumors, trauma, cerebral anomalies, anoxic encephalopathy, in males.

Case: An eight year-old-boy was presented with polyuria. He was diagnosed as cerebral venous thrombosis secondary to FVLMA two years ago. The patient’s father also was diagnosed as T2D and FVLMA. Due to cerebral stroke the patient was on artificial ventilation with BIPAP, has spastic paraplegia and no verbal response. His weight was 40 kg (97th p), height couldn’t measured because of spasticity. Testes volume was Tanner stage 2, pubic hair Tanner stage 3. Basal LH (2.8 IU/L), FSH (2.38 IU/L) and testosterone (0.55 ng/ml) levels of the patient were found pubertal. The other hormonal evaluation was normal. He was diagnosed as central precocious puberty with basal hormonal overgrowth. Cranial and pituitary Magnetic Resonans was revealed encephalomalasic changes secondary to cerebral thrombosis. We considered that his central precocious puberty was secondary to cerebral thrombosis and anoxic encephalopathy. His blood glucose was measured 350 mg/dl with ketone in urinary analysis and no acidosis, he was diagnosed as diabetes mellitus and treated with insulin. All antibodies for type 1 diabetes were negative. HbA1c was high for his age (%10.4). Because of high C-peptide (14.7 ng/ml) the patient was diagnosed as type 2 diabetes. He was discharged with metformin and basal insulin glargine treatment.

Conclusions: In this report we presented an eight-year-old boy with concomitant precocious puberty, T2D and positive family history for these diseases.
Isolated 17,20-lyase deficiency with testicular regression

Ayla Guven1; Heves Kirmizibekmez2; Fatma Dursun2; Berin Guculer1; Hamit Okur1
1Goztepe Educational and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey; 2Goztepe Educational and Research Hospital, Pathology, Istanbul, Turkey; 3Goztepe Educational and Research Hospital, Pediatric Surgery, Istanbul, Turkey

Background: The CYP17A1 gene encodes P450c17 and is expressed in adrenal and gonads. Mutations of this gene is the cause of combined 17-hydroxylase/17,20-lyase deficiency or in very rare cases isolated 17,20-lyase deficiency. Disturbance of sex steroid production leads to disorder of sex development in 46 XY individual and failure of pubertal development in 46 XX individual.

Case report: A 2 years old male patient referred as bilateral undescended testis. He has been investigated for disorders of sex development. Physical examination revealed bilateral non-palpable gonads and hypoplastic scrotum, penile size was 3.2 x 1.5 cm (lower limit for age). In baseline hormonal analysis; total testosterone and androstenedione levels were low, while FSH and LH were elevated. ACTH (250 µg) and hCG stimulation tests were performed in order to evaluate adrenal and gonadal steroidogenesis. There was not meaningful increase in testosterone, androstenedione. DHEAS was low (0.54 µg/dL; N: 5.57 -7.0 µg/dL). Cortisol production was normal. Normal dehydroepiandrosterone level and absence of water retention, hypertension or hypokalemia dissuaded us from thought of 17-hydroxylase deficiency. The caryotype was 46 XY, testes could not be detected by ultrasonography. In laparoscopic examination gonads could not be found, but some remnant structures had been excised. Histopathologic investigation of these remnants revealed immature testes tissue with focal dystrophic calcifications and significant hyalinization which adjust to testicular regression syndrome.

Conclusion: Isolated 17,20-lyase deficiency is a rare cause of deficiency in sex steroid production. Normal penile formation and absence of Müllerian structures are proofs of normal testicular functions in critical time (12th-14th gestational weeks). This patient who had been presented with two different clinical entities made us think either a coincidental condition or evoked testicular regression syndrome by impaired steroidogenesis.

Bilateral adrenal hemorrhage in a neonate

Nicola Impropia1; Manuela Carbone1; Iolanda Di Donato1; Lucia De Martino1; Antonia Coppola1; Mariacarolina Salerno1
1Federico II University, Department of Pediatrics, Naples, Italy; 2Federico II University, Regional Reference Centre for Coagulation Disorders, Department of Clinical and Experimental Medicine, Naples, Italy

Background: Adrenal hemorrhage is a rare yet potentially life-threatening event that occurs both in traumatic and in a variety of nontraumatic conditions. The incidence of acute adrenal hemorrhage in infancy range from 0.2 to 3%. Only 5% to 15% of cases reported have bilateral hemorrhage. We report on a neonate with bilateral adrenal hemorrhage associated with thrombophilia.

Case report: On day 3 of life the child, a female, presented signs of neonatal sepsis. On day 7, an occasional abdominal ultrasound revealed bilateral adrenal hemorrhage. However, the adrenal function was still normal. On day 36, the child appeared pale and lethargic. Subsequent hormonal and biochemical assessment showed adrenal insufficiency and she, therefore, started therapy of Addisonian crisis with improvement of clinical condition and biochemical parameters.

Discussion: The adrenal gland of the newborn is particularly vulnerable to hemorrhage. In this condition of vulnerability, it seems likely that sepsis and combined thromboembolic risk may have interact in causing bilateral adrenal hemorrhage. Moreover, accumulating evidences suggest that the association of multiple haemostatic defects increases the risk of thrombosis. Thus, thrombosis might be considered as a cause of neonatal adrenal hemorrhage and pro-thrombotic risk factors should be investigated in case of familiar history of thrombophilia.

RegISTRY OF CONGENITAL ADRENAL HYPERPLASIA IN VIETNAM

Chi Dung Vu1; Phuong Thao Bui1; Ngoc Khanh Nguyen1; Thi Bich Ngoc Can1; Thi Hoan Nguyen2; Thanh Liem Nguyen2; Kate Armstrong1; Maria Craig1; Garry Warne1
1National Hospital of Pediatrics in Hanoi, Endocrinology, Metabolism and Genetics, Hanoi, Vietnam; 2National Hospital of Pediatrics in Hanoi, Surgery, Hanoi, Vietnam; 3CLAN, CLAN (Caring & Living As Neighbours), Sydney, Australia; 4The Children’s Hospital at Westmead, Endocrinology and Diabetes, Sydney, Australia; 5Royal Children’s Hospital, Endocrinology and Diabetes, Melbourne, Australia

Aims: The National Hospital of Pediatrics (NHP) in Hanoi is an 900 bed tertiary referral centre servicing approximately 40 million people from northern provinces of Vietnam. This audit was undertaken to analyze anecdotal reports of increasing patient numbers.

Methods: Retrospective review of all CAH patients registered at NHP from 1999-2010. Ethical clearance was granted by the NHP Directorate.

Results: At the start of 1999 there were 90 children with CAH managed at NHP. By December 2010 this increased to 551 (47% male and 53% female; 72% salt wasting CAH), representing a more than five fold increase over 11 years. Number of new cases doubled from 30 to 60 in 2009. Most children (72%) were diagnosed at less than 12 months of age (39% at less than 1 month of age); 70% of all children were younger than 10 years. Formal mortality figures were low (6 known deaths), although loss to follow-up unknown. There are data to suggest persisting mortality from undiagnosed CAH (evidenced by low ethnic minority group representation; few children from remote provinces; higher average income of CAH families; gender ratio shift; reports of sibling deaths). Patient to paediatric endocrinologist (551:6) ratios at NHP are very high compared with higher income countries.

Conclusions: The caseload of CAH at NHP has increased since 1999 and additional capacity is needed for patient care given high patient to staff ratios. Introduction of NBS would enable more accurate estimation of CAH incidence, reduce infant mortality and minimize trauma to affected infants and their families.

Ethnic background influences the distribution of body fat in obese children and adolescents

Gabriel Angel Martino-Moreno1; Saar Sirvent2; Guillermo Martinez3; Federico Hawkins3; Jesus Argente1
1Hospital Infantil Universitario Niño Jesús, Universidad Autónoma, ISCIII, II La Princesa, Endocrinology, Department of Pediatrics, CIBERobin, Madrid, Spain; 2Hospital Infantil Universitario Niño Jesús, Radiology, Madrid, Spain; 3Hospital Universitario 12 de Octubre, Universidade Complutense de Madrid, Endocrinology, Madrid, Spain

Background: The ethnic background, sex and pubertal progression determine body fat in growing children. These factors could also influence the deposition of excess adipose tissue in obese children and adolescents, with potential metabolic impact.

Objective and hypotheses: Our aim was to compare the amount and distribution of body fat between obese Latino and Caucasian children and adolescents and their eventual metabolic repercussions.

Methods: One-hundred obese children [11.5 ±2.9 years; 4.1 ±1.4 BMI-SDS; 53 females/47 males; 57 Caucasian (C); 43 Latino (L)] were studied. Glucose, insulin, uric acid, cholesterol and triglyceride levels were measured. Body composition (DXA) and abdominal MRI and ultrasonography were performed in all patients.

Results: Both ethnic groups showed similar ratios of visceral and subcutaneous (SQ) abdominal fat in the MRI. DXA scans showed that Latinos had higher trunk to whole body T/WB;
Results: Based on UPDR the number of children 0-17 y.o. with DM1 in 2007 was 6650, in 2008 – 6762, in 2009 - 6974, therefore prevalence in children without complications (CWC), type and dose of insulin, the level of HbA1c.

Background: The aim of this study was to determine the frequency of acute and chronic complications of diabetes mellitus type 1 (DM 1) at children 0-17 y.o. during the last 3 years based on the Ukraine Pediatric Diabetes Register (UPDR).

Methods: UPDR was established in 2004, it contains information about children with diabetes, 0-17 y.o.: their age, duration of DM1, frequency of acute complications (DKA 2-3, DKA 4), presence of chronic complications (diabetic retinopathy (DR), nephropathy (DN), peripheral neuropathy (DNp), angiopathy of legs (DA), steatohapatosi (DS), lymphoedema (DL), hypothyroaidism (D), etc), frequency of children without complications (CWC), type and dose of insulin, the level of HbA1c.

Results: Based on the UPDR the number of children 0-17 y.o. with DM1 in 2007 was 6650, in 2008 – 6762, in 2009 - 6974, therefore prevalence increased over 3 years by 4.7% (especially in group of children 0-6 y.o. during the last 3 years based on the Ukraine Pediatric Diabetes Register)

<table>
<thead>
<tr>
<th>Years</th>
<th>Age</th>
<th>DKA 2-3</th>
<th>Hypo</th>
<th>CWC</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>6,04</td>
<td>0,45</td>
<td>8,9±1,52</td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td>9,23</td>
<td>0,43</td>
<td>8,8±1,45</td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>11,39</td>
<td>0,57</td>
<td>8,9±1,44</td>
<td></td>
</tr>
</tbody>
</table>

Table 1. The frequency of acute complications (%) and HbA1c level (%).

<table>
<thead>
<tr>
<th>Years</th>
<th>DKA 2-3</th>
<th>Hypo</th>
<th>CWC</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>6,04</td>
<td>0,45</td>
<td>8,9±1,52</td>
</tr>
<tr>
<td>2008</td>
<td>9,23</td>
<td>0,43</td>
<td>8,8±1,45</td>
</tr>
<tr>
<td>2009</td>
<td>11,39</td>
<td>0,57</td>
<td>8,9±1,44</td>
</tr>
</tbody>
</table>

Table 2. The frequency of acute complications (%) in children with different age.

Conclusions: The main reason of increasing the frequency of chronic diabetic complications in Ukraine for the last 3 years is the using of the unified methods of diagnostics.

Background: Turner syndrome is a relatively common chromosomal disorder. The disease affects only females, causing hypogonadism and short stature. Early treatment can improve short stature and hypogonadism.

Objective and hypotheses: Describe chromosomal abnormalities, clinical characteristics and its relationship with chromosomal abnormalities in patients with Turner syndrome.

Methods: 116 patients with Turner syndrome diagnosed in National Hospital of Pediatrics, Hanoi. A retrospective study was used.

Results: Mean age on diagnosis was 12.2 ± 4.9 years. Monosomy 45, XO occupied 54.31%, 45, X/46, XX was seen in 14.66%; 27.59% had structural disorders of chromosome X. Short stature was found in all patients aged more than 15 years. Severity of short stature and percentage of patients with short stature went up with age. There was no difference in term of height between karyotype groups. In group aged ≥ 12 years, 95.2% of cases had hypogonadism. Other symptoms frequently seen were nail hypoplasia (77.4%), cubitus valgus (74.7%), broad chest (69.2%) and Abnormalities in face and neck were found more frequently in 45, XO group.

Conclusions: Based on the UPDR the number of children 0-17 y.o with DM1 in 2007 was 6650, in 2008 – 6762, in 2009 - 6974, therefore prevalence increased over 3 years by 4.7% (especially in group of children 0-6 y.o. by 15.7%).

Table 3. The frequency of chronic complications (%).

<table>
<thead>
<tr>
<th>Years</th>
<th>DK</th>
<th>DR</th>
<th>DN</th>
<th>DA</th>
<th>DNp</th>
<th>DL</th>
<th>DS</th>
<th>CWC</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>0,94</td>
<td>7,56</td>
<td>10,69</td>
<td>15,42</td>
<td>18,67</td>
<td>3,01</td>
<td>7,59</td>
<td>11,49</td>
</tr>
<tr>
<td>2008</td>
<td>1,92</td>
<td>8,52</td>
<td>11,43</td>
<td>19,14</td>
<td>19,31</td>
<td>7,29</td>
<td>8,55</td>
<td>16,12</td>
</tr>
<tr>
<td>2009</td>
<td>2,01</td>
<td>8,92</td>
<td>12,95</td>
<td>19,04</td>
<td>20,46</td>
<td>8,26</td>
<td>8,30</td>
<td>14,75</td>
</tr>
</tbody>
</table>

Background: The incidence of Type 1 diabetes mellitus (T1DM) has dramatically increased worldwide and it is estimated that it may reach the status of an epidemic in the 21st century.

Objective and hypotheses: To calculate the incidence of T1DM in Greek-Cypriot children aged less than 15 years between 1990 and 2009 and to examine any changes in the incidence between the two decades, to analyse gender differences in the age of onset and any seasonal variation at the manifestation of the disease.

Methods: All newly diagnosed cases of T1DM in children less than 15 year old were registered with the capture – recapture method from 1990 until 2009 and relevant information was obtained. The data were statistically processed in relation to the population data provided by the Department of Statistics and Research of the Ministry of Finance.

Results: The overall mean annual incidence of T1DM during this 20 year period is 12, 46/100000. By using the Wilcoxon two-sample test the mean incidence rate in the second decade 2000-2009 was significantly increased when compared to the first one (14.4 vs 10.46/100000). There was an overall male predominance (M/F: 1.03) but not in the group who manifested T1DM at ages 10-15 years, where females prevailed. The percentage of children who...
developed T1DM at ages 0 – 5 years increased in the second decade (24.5 vs 17.4 %). The seasonal distribution at the time of diagnosis (higher incidence during winter and autumn months) disappeared in the second decade.

**Conclusion:** The incidence of T1DM in Cyprus is rising. The identification of environmental factors, which increase the risk of T1DM development in genetically susceptible individuals, will theoretically explain this phenomenon. New preventive strategies will therefore be developed if such factors that are implicated in the etiopathogenesis of T1DM will be recognized.

**PAO-140**

**A rare cause of primary ovarian failure in a 16 years old patient: 48,XXXX karyotype**

**Marie-Béatrice Saarde**, David Briand; Laurent Pasquier; Livie Chatelais; Marc de Kerdatel; Sylvie Nivot; Patrick Playda

CHU Rennes, Paediatric department, Rennes, France

**Background:** 48,XXXX is a rare karyotype. Since first described in 1961, fewer than 60 patients have been described in literature as suffering from this condition. The main feature described is mental retardation. Some women have tall stature, as in other extra X chromosome karyotype (47,XXX, 47,XXXX). Only three patients have been reported so far with primary ovarian failure. Irregular or normal menses are more often described.

**Case report:** Our patient was first seen in the paediatric endocrine ward at 16 years old for primary amenorrhea. She had a mild mental retardation and attended a special school. She had hyperphagic access and obesity, her parents also had obesity. Her pubertal status was A2PS1 with important adipomastia giving a “false” stage 3 breast development. She had a tall stature (183 cm) above her target height (168.5 cm) and had little finger insertion anomaly.

Her bone age was 15 years as determined by the Greulich and Pyle method. Blood analysis showed high levels of gonadotrophins: luteinizing hormone: 25.6 mL/ml and follicle-stimulating hormone: 33.3 mL/L and low level of estradiol 10 pg/ml, consistent with primary ovarian failure. Neither pelvic ultrasound nor MRI showed any ovaries. She had prepuberatal uterus. She had chromosome analysis regarding to the amenorrhea associated with the mental retardation and it showed a 48,XXXX karyotype. Estrogen therapy was started to develop sexual secondary characters, close epiphyseal growth plates and prevent osteoporosis.

**Conclusion:** Theses features add data on height and ovarian function in 48,XXXX women. Mental retardation is often described in women with 48,XXXX but tall stature and primary ovarian failure are described in a few cases. This patient had obesity which is not, to our knowledge, described in literature. Not only small patients (Turner syndrome) but also tall women with 48,XXXX karyotype. Not only small patients (Turner syndrome) but also tall women with 48,XXXX karyotype. This patient had obesity which is not, to our knowledge, described in literature. Not only small patients (Turner syndrome) but also tall women with 48,XXXX karyotype.

**Objective and hypotheses:** This report compares dose force and dose accuracy of three growth hormone injection devices: Norditropin® NordiFlex® (N), Norditropin® FlexPro® (FP) (both Nordo Nordisk A/S, Denmark) and Genotropin® GoQuick® (GQ) (Pfizer Inc, NY, USA).

**Methods:** Mean of maximum dose force was determined for a 1.5 mg dose at speeds of 4, 6, and 8 mm/s for NF and GQ pens and the dose activation force was measured for FP in 25 pens of each type. Dose accuracy was assessed at 0.1, 0.75 and 1.5 mg doses (60 measurements at each level) in 30 pens of each type. All pens were fitted with a NovoFine 32 G x 6 mm needle. Testing was done at 20°C, 45°C relative humidity. Dose force was measured with a tensile testing machine in compression mode (within specifications) Lloyd, LRx plus (ID: 24K-04-115) and transducer (measuring cell) of max 100 N (ID: 24K-04-116). Dose accuracy was assessed using an analytical balance (ID: MST813) and METDose data system (ID: LP3812). Results: Estimated relative dose force (N/N) for FP was significantly lower than for GQ (3.6, 4.4, 5.2; p<0.0001) and NF (2.5, 2.9, 3.5; p<0.0001) at all speeds (4, 6, 8 mm/s). Dose force for NF was reduced compared with GQ (1.4, 1.5, 1.5; p<0.0001). Dose accuracy at 0.10, 0.75 and 1.50 mg doses was 97, 99 and 99% for FP, 100, 95 and 97% for GQ, and 101, 99 and 99% for NF. Dose precision (CV, %) was 2.5, 0.8 and 0.8 for FP, 11.1, 2.6 and 1.6 for GQ and 3.8, 0.7 and 0.7 for NF.

**Conclusions:** Dose force was significantly lower for FP and NF than for GQ. Dose accuracy was not dissimilar between devices but dosing precision was improved with FP and NF vs. GQ.

**PAO-143**

**Virilization of a toddler girl by paternal use of testosterone cream**

**Sophie Stoppa-Vaucher**,1 Timothy Hirter;1 Franziska Phan-Hug;1 Claire-Lise Fawer;2 Michael Hauschild2

1University of Lausanne, Pediatric Endocrinology and Diabetology Unit, Lausanne, Switzerland; 2University of Lausanne, Pediatrics, Lausanne, Switzerland

**Background:** A 15-month-old healthy female was referred because of rapid growth of dark pubic hair and a high testosterone (T) level (9 nmol/L, normal range 0.6 – 0.7 nmol/L). Ultrasound nor MRI showed any ovaries. She had prepubertal uterus. She was prescribed testosterone cream for the IGF-I (consistently around +5.4SDS). MRI performed when she was 15 years-old showed an enlarged pituitary gland (1.2x1.1x0.8 cm) with small suprasellar extension. Final height was 1.58m (-0.7SDS), below middle parental height.

**Conclusion:** After 10 years of follow up we believe that the lack of IGF negative feedback due to a partial IGF-I insensitivity could explain the high concentrations of GH and IGF-I with normal height and the pituitary image. Height velocity analysis was mislead by puberty during the investigation.

**PAO-145**

**Pituitary enlargement due to partial IGF-I insensitivity**

**Soraya Milan1; Mariana Sarti de Paula1; Ligia Bataglin de Carvalho1; Rodrigo Custodio;1 Marcelo do Amaral Ruiz1; Ayrton Moreira1; Sonir R. Antonini1; Carlos Eduardo Martinelli Jr1**

1School of Medicine of Ribeirão Preto, Paediatrics, Ribeirão Preto, Brazil; 2School of Medicine of Ribeirão Preto, Medicine, Ribeirão Preto, Brazil

**Background:** Until recently patients bearing partial GH or IGF-I insensitivity have been diagnosed as idiopathic short stature.

**Objective and hypotheses:** Few data are available regarding pituitary image in these patients.

**Methods:** We describe a 5.5 year-old girl that was seen at the emergency room with nausea, vomiting, headache and unilateral eye lid ptosis. Cranial MRI was normal and ophthalmoplegic migraine was diagnosed.

**Results:** Five years later a second MRI showed a 0.7x0.4cm pituitary lesion with suprasellar extension. Furthermore, a severe protanopia was observed. On the other hand, teeth gapping were normal, her hands and feet were delicate and there were no other signs of possible GH/IGF-I excess or hypopituitarism. Puberal stage was B3P3. Serum IGF-I was 1490ng/dl (+6.1SDS). Daytime GH profile was suggestive of increased GH secretion as only 4 determinations were below the detection limit of the assay (0.1ng/ml). GH suppression (-0.1mg/l) was confirmed by OGTT. Due to the severe protanopia, pituitary image and maintained elevated IGF-I levels, the diagnosis of acroagrandism was considered and a surgical procedure was proposed. However, facing the slow size increase of the pituitary lesion an option for a regular follow-up was taken with laboratory and image control. Nowadays she is 16 years-old, bone age is 18yr and puberty is complete with regular menses. Laboratory determinations regarding pituitary function remain normal except for the IGF-I (consistently around +5.4SDS). MRI performed when she was 15 years-old showed an enlarged pituitary gland (1.2x1.1x0.8cm) with small suprasellar extension. Final height was 1.58m (-0.7SDS), below middle parental height.

**Conclusions:** After 10 years of follow up we believe that the lack of IGF negative feedback due to a partial IGF-I insensitivity could explain the high concentrations of GH and IGF-I with normal height and the pituitary image. Height velocity analysis was mislead by puberty during the investigation.
mal, no growth acceleration was observed. Tanner stage II pubic hair and an enlarged clitoris (12 mm) were found. She had no palpable breast tissue or posterior labial fusion, axillary hair, or acne. Pelvic ultrasound showed prepubertal uterus but no adrenal or ovarian mass were visualized. Adrenal hyperandrogenism was ruled out based on normal values of 17-OHP (0.7 nmol/L; N<3), Androstenedione (<0.5 nmol/L; N 0.38 ± 0.20) and DHEAS (<0.5 µmol/L; N 0.06 ± 0.04). Prolactine, thyroid function test and tumoral markers (β-hCG (< 2 U/L; N<5), αFP (5.5 kU/l; N<10)) were normal. Her father, a former elite athlete, reported that he was using a T-cream (10% in PCCA Lipoderm-Base®) for muscle problems the last 2-3 months. Four weeks after the father had ceased the treatment, T level decreased to 1.7 nmol/L. The child’s clinical virilization signs regressed. We observed no sign of hyperandrogenism in her brother.

Conclusions: We describe a virilized toddler girl with isolated high T level due to transdermal intoxication. The differential diagnosis of virilization in childhood includes both endogenous and exogenous causes. Increased utilization of easily available curative androgen applications should prompt clinicians to inquire about exogenous androgen exposure in the medical history of virilized children.

PAO-144
Silent corticotrope adenoma – report of two cases
Liliana Maria Mejía1; Ernest Senz2; William Jübab2
1Clinica Valle del Lili, Centro de Endocrinología, Universidad Libre Fundación Clínica Infantil Club Noel, Valle Del Cauca, Cali, Colombia;
2Clinica Valle del Lili, Valle Del Cauca, Cali, Colombia; Centro de Endocrinología, Valle Del Cauca, Cali, Colombia

Background: Some Pituitary adenomas exhibit immunoreactivity to hypothalamic hormones but because of the absence of clinical syndromes. They are known as silent adenomas. In 1979 Hassouny and collaborators describe the silent pituitary adenomas. In reference to corticotrope adenomas 43% are silent because they produced a biologically inactive hormone. They can be large and have a tendency to invade and recur.

Objective and hypotheses: We describe two cases of silent corticotrope adenomas in children.

Methods and results: CASE 1: Nine years old boy presented with frontoparietal headaches, loss of vision, no hypertension, no obesity or evidence of Cushing syndrome Laboratory: 8 am cortisol 4.2 µg/dl, TSH 2mUI/ml prolactin 25.9 ng/ml MRI revealed Intrassellar mass of 3.7x2.4x2.4 mm. Treatment surgery, pathology revealed an ACTH producing adenoma Pituitary. KI67 1%. Post surgery ACTH 13.4 pg/ml cortisol 7µg/dl prolactina 20.4ng/ml

Conclusions: Silent corticotrope adenoma are not associated with a clinical picture of hormone excess but they can cause pituitary damage and they have a tendency to recur. Clinical diagnostic is difficult.

PAO-145
Karyotype-phenotype presentation and interim results of growth hormone (GH) treatment of girls with Turner syndrome (TS) in Belarus
Natalia Akulievich; Julia Bosia; Yuliya Makarava; Irina Kunawitch
State Center of Medical Rehabilitation, Department of Pediatrics, Pediatric Endocrinology Group, Minsk, Belarus

Background: TS is a genetic condition associated with different developmental anomalies including short stature.

Objective and hypotheses: This work aimed to verify clinical details and response to GH treatment of TS girls in Belarus with relation to karyotype.

Methods: Retrospective study of 81 TS patients in our Center.

Results: The mean age of TS diagnosis was 9.3±4.9 yrs; 7/81 (8.6%) girls, all 45,X, were diagnosed perinatally. Karyotypes distribution: 45,X – 45/81 (55.5%), mosaicism 45,X/46,XX – 22/81 (27.2%), abnormalities of an X chromosome -1/81 (1.2%), mosaicism with Y chromosome - 3/81 (3.7%).

Conclusions: TS in Belarus are manifested with high genetic variability and somatic abnormalities rates. Due to rather late diagnosis, GH therapy of TS in Belarus is often belated. Nevertheless, TS girls have good growth response.

PAO-146
Late development of celiac disease in type 1 diabetes mellitus
Gucio Maiton1; Stefano Zucchini; Mirella Scipione; Angela Rizzello; Silvana Salardi; Alessandro Cicognani
S.Orsola-Malpighi Hospital, Pediatrics, Bologna, Italy

Background: Patients with type 1 diabetes mellitus (T1DM) are at a high risk for developing autoimmune diseases such as coeliac disease (CD). Although CD mainly occurs at T1DM onset, it can also develop in the following years, but in our experience never after 6 years from T1DM onset (Salardi et al, J Pediatr Gastroenterol Nutr 2008). There is no consensus as to the duration of follow-up for autoimmune diseases in T1DM. We report a case of a male who developed CD 15 years after the diagnosis of T1DM.

Case report: A 19 yr-old male diagnosed with T1DM at 4 years of age. HLA phenotype was DR 3, 4 and DQ 2, 3. His siblings were also tested for autoimmune diseases and the older sister developed CD and few years after autoimmune thyroiditis. Lab examinations for associated autoimmune diseases were performed annually. 13 years after T1DM onset Hashimoto’s thyroiditis was diagnosed, not leading to clinical hypothyroidism. Unexpectedly, after 15 years from T1DM onset, he showed a marked positivity for CD autoantibodies (antiendomysial antibodies 128 u/ml, normal value <10). During the previous year he was completely asymptomatic: he did not refer gastrointestinal symptoms or an increased frequency of hypoglycaemic episodes. There were no biochemical signs of CD (ferropenic anemia, hypertransam- inase, hypocalcaemia). Antibody positivity was also confirmed in another laboratory. Bowel biopsy showed a total villous atrophy.

Conclusions: The development of CD so far from diabetes onset (>15 years) had been never described before to our knowledge and the literature reports a follow up period never longer than 10 years. We conclude that screening for autoimmune disease should be annually performed in T1DM patients possibly lifelong, even in the absence of clinical symptoms, especially in those with a strong family history of autoimmune disease.

PAO-147
A case of congenital hypothyroidism with Hirschsprung’s disease: an unusual association
K D Mod2; Madan Mohan Rao2; Sunil Kumar Kotla
1Medwini Hospitals, Endocrinology, Hyderabad, India; 2HOPE Children’s hospitals, Paediatrics, Hyderabad, India

Background: Hirschsprung’s disease (HD) as well as congenital hypothyroidism can present with functional intestinal obstruction and abdominal dis- tension in neonate. Both the diseases are considered as differential diagnosis, rather than as coexistence. We report one such interesting case with unusual coexistence between these 2 conditions.

Objective and hypotheses: Thyroid hormone is necessary for neuronal migra- tion and lamination during brain development. Although hypothyroidism impairs colonic motility resulting in pseudo-obstruction the effects of hypo- thyroidism on neuronal migration through bowel have not been adequately studied.

Methods: A 21 days baby girl, product of consanguineous marriage presented...
Metabolic syndrome in obese Ukrainian schoolchildren: prevalence and risk factors

Thor Hrytsiuk
Western Ukrainian Specialized Children’s Medical Centre, Paediatrics, Lviv, Ukraine

Background: Obesity in children and adolescents is currently on a rise in Ukraine, posing challenges to personal health and state health care system.

Objectives: To assess prevalence of metabolic syndrome (MS) among obese children and adolescents residing in Lviv, Ukraine, and risk factors leading to its development.

Methods: Obese children and adolescents were selected during annual (2009) medical check-up in 10 city schools. These were referred for further investigations. The major components of MS (abdominal obesity, hypertension, dyslipidemia, and glucose intolerance) were evaluated in a cross-sectional study. Potential risk factors for developing MS (weight at birth, parental obesity, degree of obesity, age, sex) were assessed in a multivariate logistic regression analysis.

Results: The nutritional status of 8523 school students aged 11 to 18 years showed that the prevalence of obesity (BMI ≥ 95%) is 9.1% (n = 776, boys = 381, girls = 395). The prevalence of MS among obese children reaches 14.3% (n = 111, boys = 62, girls = 49). The prevalence of MS tends to increase with increasing of BMI class (3.1% in class I, 6.2% in class II and 14.3% (n = 111, boys = 62, girls = 49). The prevalence of MS tends to increase with increasing of BMI class (3.1% in class I, 6.2% in class II and 14.3% in class III). In a multivariate analysis more advanced age (OR = 4.08, CI = 3.13 - 6.24), BMI (OR = 2.71, CI = 1.34 - V 4.75) and parental obesity (OR = 2.11, CI = 1.07-4.14) were found to be the most significant risk factors for having MS in obese children and adolescents.

Conclusions: Although lower than in neighbouring countries, the prevalence of MS in Ukrainian schoolchildren is growing, which warrants preventive measures. The older the obese child, the higher are chances for MS. The most important preventable risk factors are degree of obesity (BMI) and parental obesity.

Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia and its association with mineral homeostasis and duration of inpatient stay

Musab Elmantaser1; David Young2; Brenda Gibson3; S. Faisal Ahmed4
1Bone and Endocrine Research Group, Department of Child Health, Glasgow, United Kingdom; 2University of Strathclyde, Department of Statistics and Modelling Science, Glasgow, United Kingdom; 3University of Glasgow, Department of Haematology, Royal Hospital for Sick Children, Glasgow, United Kingdom; 4Bone and Endocrine Research Group, Department of Child Health, Royal Hospital for Sick Children, Glasgow, United Kingdom

Background: Reduced activity, older age and abnormal bone mineral status are considered as important determinants of poor bone health in children with acute lymphoblastic leukaemia (ALL).

Aim: To investigate the influence of activity, age and mineral status over the first 12 months of chemotherapy on subsequent SM.

Patients and methods: The medical records of 56 children presenting with ALL between 2003 and 2007 and treated on UKALL 2003 were reviewed for the number of in-patient days over the first 12 months of chemotherapy as a surrogate marker of inactivity and lack of well-being. Data for serum Ca, Alb, Mg and Pho were also collected over this period. SM was defined as any episode of musculoskeletal pain (MSP) or fractures.

Results: The median duration of in-patient days in the first 12 months of treatment in children with no SM was 58 days (IQR = 100) whereas the median number of in-patient days during the first 12 months in those children with any SM, MSP only or fractures only was 83 days (IQR = 131), 81 days (IQR = 119) and 91 days (IQR = 158), respectively (p = 0.003). Children with SM and fractures particularly had lower levels of serum Ca, Mg and Pho compared to those without SM over the first 12 months of chemotherapy. There was a higher risk of SM in those who were diagnosed after the age of 8 years (p = 0.001, OR = 16.95% CI = 3.80). Multiple regression analysis showed that the incidence of SM only had a significant independent association with age at diagnosis (p = 0.001) and the number of in-patient days (p = 0.03) over the first 12 months (r = 23). All children who were diagnosed after the age of 8 years with an inpatient stay of greater than 75 days in the first 12 months of the chemotherapy (n = 14) had some form of SM (OR = 64).

Conclusion: The incidence of SM in children receiving chemotherapy for ALL is associated with a higher likelihood of being older and having longer periods of in-patient stay. The close link between age and changes in bone mineral status may be one explanation for the increased bone morbidity in ALL children.

Trends of body mass index in children with craniopharyngioma from the west of Scotland

Muhammad Jaffar Khan1; Khadija Humayurr; Malcolm Donaldson2; S. Faisal Ahmed3; M. Ghar Shakh4
1University of Glasgow, Human Nutrition, Glasgow, United Kingdom; 2Aga Khan University, Department of Pediatrics and Child Health, Karachi, Pakistan; 3Royal Hospital for Sick Children, Paediatric Endocrinology, Glasgow, United Kingdom

Background: Hypothalamic obesity is one of the major causes of reduced quality of life in survivors of childhood craniopharyngioma, predisposing the patient to a wide variety of complications, including cardiovascular disease.

Objectives and hypothesis: The aim of this study was to examine the trends of change in body mass index (BMI) in childhood onset craniopharyngioma patients over 5 years. The hypothesis being all children with a craniopharyngioma gain weight irrespective of their BMI at presentation.

Methods: This was a retrospective study of 23 children with a diagnosis of craniopharyngioma presenting to the West of Scotland regional endocrine unit over a 5 year period. Data on height, weight, gender and age was collected. BMI SDS for each patient was subsequently calculated and analysed over time. Patients were categorised into 2 groups according to their BMI at presentation, obese BMI >2SDS, non-obese BMI < 1.99SDS. Obesity was defined as patients having a BMI SDS.

Results: At presentation, (M: F 11:12) 47.5% (n = 11) patients were obese, with 52.5% (n = 12) non-obese patients. BMI increased further in 7 of the
obese patients. There was a rise in mean BMI SDS in the first year after di-
agnosis, followed by a fall in BMI over the 5 year period in both groups;
however the obese group at presentation remained obese. In the non-obese
group only 10 had an increase in BMI SDS from presentation, with 8 patients
becoming obese during the 5 years.

Conclusions: Craniosynostosis patients who are obese at presentation con-
tinue to gain weight and remain obese. This probably reflects a greater degree of
hypothalamic damage in these individuals.

PAO-151
Pseudotumor cerebri and diabetes insipidus. Association or coincidence?
Gabriella Pozzobon; Giuseppe Cannally; Chiara Maria Damia;
Gisella Garbetta; Maria Piera Ferrarello; Alessandra Musio;
Berardo di Natale; Giovanna Weber; Giuseppe Chiumello
Vita Salute San Raffaele University, Pediatric Endocrine Unit, Milano, Italy

Background: Pseudotumor cerebri (PTC) is characterized by intracranial
hypertension in the absence of clinical, laboratory or radiological evidence
of space occupying lesion. It can occur in the pediatric population with an
increasing incidence among adolescents, especially in obese females. Idio-
pathic PTC can be associated with anterior pituitary deficiency but there is
no evidence in literature of association with central diabetes insipidus (CDI).

Objective and hypotheses: We report a case of PTC and concomitant CDI.

Methods: 13-yr-old obese female (BMI 2.64 SDS) presented progressive
headache, important visual impairment followed by complete blindness, sixth
cranial nerve palsy, bilateral papilloedema, right hemisymmetry with altera-
tion of the state of consciousness. MRI ruled out the presence of a cerebral
mass as well as pituitary lesions, showing concave superior surface of pitu-
itary gland with normal pituitary stalk; posterior pituitary bright spot was
not described. Furthermore there was no evidence of cerebral venous thrombosis.
High cerebrospinal fluid pressure: 30 mmHg. Autoimmune, vascular, infect-
ive and tumoral aetiologies were excluded (negative tumoral markers at the
beginning and during follow up). Therapy: lumbar puncture+Acetazolamide.
A week after diagnosis she developed polyuria and polydipsia (up to 17 L/
day). Hormonal evaluations demonstrated CDI with normal anterior pituitary
function. The patient started therapy with desmopressin with adequate hydro-
electrolytic balance. Subsequently she was treated with Clobazam for frontal
lobe dysfunction, associated to dysarthria and aimless movements of legs.

Results: During follow up (1 year), the intracranial hypertension gradually
reduced. No more headaches were reported, but visual impairment and diabe-
tes insipidus were still present, even if less severe. Neuroradiological follow-
up remained negative for brain tumors.

Conclusions: We assume that the increased intracranial pressure might have altered
the activity of hypothalamic osmoreceptors and baroreceptors, induc-
ing a lower synthesis of ADH.

PAO-152
Maturity onset diabetes of the young (MODY) - presentation of two cases
Ileana Puiu1; Simona Cosoveanu; Veronica Elena Maria1;
Alexandra Ottea Puiu; Ioana Opritoiu1
1University of Medicine and Pharmacy, Emergency County Hospital,
Craiova, Romania; 2Emergency County Hospital, Emergency County
Hospital, Craiova, Romania

Background: Maturity onset diabetes of the young (MODY) is characterized by
young-onset diabetes that is inherited in an autosomal dominant pattern.

Method: The authors present characteristic features of MODY diabetes in two
sisters.

Results: The family history has shown that the father and paternal relatives
had moderately elevated blood glucose levels, down through successive gen-
erations.

Case 1: second child, gestational age at birth 38 weeks, birth weight 3200g,
breastfed for five months. Case summary: two weeks of polyuria, polydip-
sia, decreased appetite, in the context of an upper respiratory tract infection.
Clinical examination: 8 year-old girl, weight 24 kg, length 120 cm, BMI 17.1
kg/m2. Glucose levels ranged between 95-195 mg %, presence of glycos-
uria, with no ketones, HbA1c level 7.5%, negative anti GAD antibodies and
ICA antibodies. Treatment: diet and a dose of 0.5 IU/kg/day of insulin for 2
months, followed by the diet only, while keeping glucose values between 85-
112 mg% and HbA1c level decreased to 6.5%.

Case 2: the 12 year-old sister was hospitalized after two months without clini-
cal signs of diabetes, but with the ambulatory blood glucose levels between
112-138 mg%, HbA1c level 6%, OGTT with fasting blood glucose 124 mg%
and 2-h postprandial blood glucose 174 mg%, negative anti GAD antibodies
and ICA antibodies. Personal history: first child, with normal evolution of the
pregnancy, gestational age at birth 36 weeks, birth weight 2600g, Apgar score
9, breastfed for four months, psychomotor and weight development according
to child development stages. Clinical examination: weight 35 kg, length 143
cm, BMI 17.5 kg/m2. It was established a diet that maintained a good glyc-
emic control, after 3 months HbA1c was 6.5%.

Conclusions: The main goal of treatment in these cases of MODY diabetes
was to maintain blood glucose levels as close to normal reducing the risk of
complications. An early diagnosis of the disease is very important for family
screening and also for therapy and prognosis.

PAO-153
Long-term (five-year) height outcome in children treated with Norditropin®
Judith Rose1; Peter Lee2; Robert Guit1; John Garson1
1Thomas Jefferson University, DuPont Hospital for Children, Dept. of
Pediatrics, Philadelphia, PA, United States; 2The Milton S Hershey
Medical Center, Penn State College of Medicine, Dept. of Pediatrics,
Hershey, PA, United States; "Novo Nordisk Inc., Dept. of Clinical
Development, Medical and Regulatory Affairs, Princeton, NJ, United
States

Background: The American Norditropin Studies: Web-enabled Research
(ANSWER) Program®, a US-based registry, has collected long term efficacy
and safety information on patients treated with Norditropin® (somatropin
tDNA origin, Novo Nordisk A/S) at the discretion of participating physicians.

Objective and hypotheses: To assess the long-term (5 years) height standard
deviation score (HSDS) and ΔHSDS by age, gender, and pubertal status in
children treated with GH.

Methods: Treatment-naïve pediatric patients with isolated/idiopathic GH
deficiency (GHD; n=4454), multiple pituitary hormone deficiency (MPHD;
n=387), small for gestational age (SGA; n=461), idiopathic short stature (ISS;
n=758), and Turner syndrome (TS; n=435) were analyzed.

Results: Mean baseline ages (yrs) were generally younger in patients with
MPHD (7.4), SGA (8.5), and TS (8.6) than with GHD (10.8) and ISS (11.2).
Lowest peak GH levels were observed in patients with MPHD (3.1 ng/mL)
and GHD (5.3 ng/mL). In the overall population, HSDS increased from -2.2
at baseline to -1.1 at Y3 and -0.9 at Y5, with GHD, MPHD, and SGA showing
better growth response. Boys had significantly greater ΔHSDS than girls after
3 years or longer treatment duration (p<0.001). When stratified by baseline
age, younger patients showed greater ΔHSDS than older patients for both
genders (Table). In addition, children with GHD who remained pre-pubertal
after 5 years of treatment had the greatest ΔHSDS (2.02±1.14) as compared
to patients who were already pubertal at treatment start (1.42±0.69) or who
transitioned into puberty during the study (1.58±0.68).

Conclusions: These results show that boys generally have greater height gain
than girls after long-term treatment. A better growth response is observed in
younger and pre-pubertal children, emphasizing the importance of starting
GH treatment at a young age and pre-pubertal status.

Table. Mean (SD) ΔHSDS over 5 years by Age and Gender.

<table>
<thead>
<tr>
<th>Gender</th>
<th>All N</th>
<th>&lt; 10 yrs</th>
<th>11 yrs</th>
<th>&lt; 10 yrs</th>
<th>11 yrs</th>
<th>&lt; 10 yrs</th>
<th>11 yrs</th>
<th>&lt; 10 yrs</th>
<th>11 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Y1</td>
<td>3632</td>
<td>0.53</td>
<td>0.73</td>
<td>0.39</td>
<td>0.55</td>
<td>0.70</td>
<td>0.39</td>
<td>0.55</td>
<td>0.70</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Y1</td>
<td>2595</td>
<td>0.96</td>
<td>1.16</td>
<td>0.80</td>
<td>0.96</td>
<td>1.12</td>
<td>0.78</td>
<td>0.96</td>
<td>1.12</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Y2</td>
<td>1645</td>
<td>1.27</td>
<td>1.39</td>
<td>1.13</td>
<td>1.20</td>
<td>1.26</td>
<td>1.10</td>
<td>1.20</td>
<td>1.26</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Y3</td>
<td>965</td>
<td>1.47</td>
<td>1.55</td>
<td>1.35</td>
<td>1.34</td>
<td>1.35</td>
<td>1.31</td>
<td>1.34</td>
<td>1.35</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Y5</td>
<td>443</td>
<td>1.65</td>
<td>1.70</td>
<td>1.52</td>
<td>1.94</td>
<td>1.41</td>
<td>1.38</td>
<td>1.94</td>
<td>1.41</td>
</tr>
</tbody>
</table>

50th Annual Meeting of the ESPE

Horm Res 2011;76(suppl 2) 305
PAO-154
Role of prophylactic medical examination for early diagnosis of endocrine disorders
Alexey Resnekov1; Lelia Namazova-Baranova2
1 Scientific Center of Children’s Health, Diagnostic, Moscow, Russian Federation; 2 Scientific Center of Children’s Health, Head, Moscow, Russian Federation

Background: Considerable increasement of endocrine disorders in pediatric population within last years was observed. Routine children and adolescent check up does not include examination by endocrinologist.

Objective and hypotheses: To estimate rate of endocrine disorders in pediatric population we explored 911 Moscow schoolers.

Methods: All children were splitted into groups by sex (sex ratio was 54% boys to 46% girls), age (junior school - from 6 to 11 years, middle school from 11 to 14 years, senior school- from 14 to 17 years). Physical examination, anthropometric measuring, and thyroid ultrasound were performed. On the base of measurements BMI, height velocity and standard deviation score of mesaurments were estimated.

Results: 12% of children had signs of endocrine disorders. Leading position belongs to overweight and obesity (61% of revealed endocrinological disorders). 25% of children with endocrinological disorders had thyroid gland enlargement, 9% had growth abnormalities (7% cases of short stature and 2% cases of high stature), abnormalities of sexual development were revealed in 5%. 9% of children with detected endocrine disorders had two of more diagnosis. Our data shows that overweight and obesity more common for middle and senior school groups and had no significant differences between sexes (sex ratio for overweight and obesity was 51% boys to 49% girls). Thyroid abnormalities predominate at the age of 11-17 years and more common for female population (sex ratio was 13% boys to 87% girls). Most children with growth abnormalities revealed at age 7-14 years, and sex ratio was 82% boys to 18% girls. 5% of boys and 95% of girls with endocrine disorders had sexual development abnormalities with predominance at the age of 11-17 years.

Conclusions: Results of our study show importance of endocrine function asessment in school-age children on a regular basis. This tactics helps to reveal possible endocrine disorders at early stages and form groups of children with high risk of endocrine disorders for prophylactic medical examination.

PAO-155
Rett syndrome associated with thyroid hypoplasia – a synergic association for neurological disturbances: case report
Otilia Marinigean1; Ioan Simedrea2; Tamara Marcovici3; Daniela Chiru1
1 1st Pediatric Clinic University of Medicine and Pharmacy Timisoara, Endocrinology, Timisoara, Romania; 2 1st Pediatric Clinic University of Medicine and Pharmacy Timisoara, Gastroenterology, Timisoara, Romania; 3 1st Pediatric Clinic University of Medicine and Pharmacy Timisoara, Pediatrics, Timisoara, Romania; 4 1st Pediatric Clinic University of Medicine and Pharmacy Timisoara, ICU, Timisoara, Romania

Background: Rett syndrome is a neurodevelopmental disorder that characterized by normal early growth and development followed by a slowing of development, loss of purposeful use of the hands, distinctive hand movements, slowed brain and head growth, problems with walking, seizures, and intellectual disability.

Case presentation: CA 4 years 3 month old girl admitted in our department in September 2010 for developmental regression, loss of purposeful hand movement, hand stereotypes, and seizures. The patients neonatal and perinatal medical history was notable for prolonged jaundice and congenital hypothyroidism when aged 2 months old, secondary to maternal Graves’ disease detected after birth.

Results: PA: Pregnancy monitored. Caesarean at 34 weeks due to premature breakage of membranes, APGAR 9/10. WAB: 2.570 g (P 75-90); LAB: 45 cm (P 50-75). FH: Father healthy, height 170 cm. Mother healthy, height 165 cm. Evolution during neonatal period: Admission at birth due to early asymptomactic hypoglycaemia birth. Metabolopathy screening for low TSH, with TSH of 0.03 mU/L and T4L of 1.84 ng/dl detected. Presents TA 90/43-78/40, FC 157-130 lpm during the first 5 days of life. Irritability and diarrhoea observed. Mother: TSH undetectable, T4L 2.82 ng/dl, antithyroglobulin Ab 45, antiperoxidase Ab 75, TSI Ab 13 (N<10). Follow-up at surgery: 15-day follow-up: Weight: 2.570 kg (P3), Length: 46 cm (P3), macroglossia. TSH 0.02 mU/L, T4L 1.31 ng/dl, T3 1.05 ng/dl, antimicrosomal Ab 71 (N 0-5.6) 2.5 month follow-up: Weight: 4.250 (P3), Length: 53.

Conclusions: In maternal Graves’ disease the transplacental transfer of Ac TSI affects the development of the hypohalamic-pituitary-adrenal axis (HPA). Rarely, exposure to high levels of intrauterine thyroid hormones in Graves’ disease can halt the hypohalamic-pituitary-adrenal axis, leading to a hypothyroidism in the fetus that continues for a variable period of time among newborns.

PAO-157
Congenital chloride diarrhea with congenital hypothyroidism in two siblings: case report
Erdal Adal1; Atilia Erseen2; Hasan Onal3; Sezen Ugan4; Tugba Kontbay4; Ahmet Aydir1
1 Ministry of Health Bakirkoy Maternity and Children Education Hospital, Pediatric Endocrinology, Istanbul, Turkey; 2 Kasimpasa Military Hospital, Pediatrics, Istanbul, Turkey; 3 Ministry of Health Bakirkoy Maternity and Children Education Hospital, Pediatrics, Istanbul, Turkey; 4 Istanbul University, Cerrahpasa Medical Faculty, Division of Metabolic Diseases, Istanbul, Turkey

Background: Congenital chloride diarrhea (CCD) is a rare autosomal recessively inherited disorder causing watery stool and dehydration characterized by impairment of Cl-/HCO3 exchange.

Objective: Infrrequency of CCD makes diagnostics difficult and CCD companying with congenital hypothyroidism has never been reported so far.

Population: A 7-year-old male who was followed with the diagnoses of congenital hypothyroidism, Bartter syndrome and idiopathic chronic diarrhea in different medical centers and treated with L-thyroxine and indomethacin, admitted our unit with electrolyte abnormalities and mental retardation. His medical history was notable for prolonged jaundice and congenital hypothyroidism in neonatal period. L-thyroxine was started but euthyroidism status was hardly supplied with alterations of thyroid hormones. Additionally, dehydration and metabolic alkalosis were recognized in his second months of age with the history of intrauterine polyhydramnios; he was diagnosed as Bartter syndrome and indomethacin treatment was started. But all the medications until now could not heal the problems of watery diarrhea, abdominal distention and electrolyte abnormalities. Additionally, we recognized that this family had a 3-month-old sibling and he was followed-up with the initial diagnoses of congenital hypothyroidism and Bartter syndrome.

Results: We figured out CCD in our investigation of these two siblings that...
Tall stature, gonadal dysgenesis and obesity: unusual phenotype in a female with X chromosomal aberration

Eva Al Talli1; Daniela Zemková2; Drahuse Novotná2
1Charles University, 3rd Faculty of Medicine, Department of Paediatrics, Prague, Czech Republic; 2Charles University, 2nd Faculty of Medicine, Department of Paediatrics, Prague, Czech Republic

Background: Whilst X chromosome structural aberrations in female patients are most frequently characterized by a short stature and Turner’s phenotype, only several patients with strikingly different phenotype have been reported so far.

Objective and hypotheses: To describe clinical and genetic findings in a girl with a rare structural X chromosome rearrangement.

Methods: Physical examination, biochemical analysis, cytogenetic studies, imaging methods, neurological and psychological investigation were performed.

Results: The patient was referred at the age of 13 years because of obesity (BMI 26.3 kg/m², +3.0 SD). She had a tall disproportional stature (183cm, +3.3 SD), only initial pubic hair (Tanner P2), breast enlargement was caused by fatty tissue. No psychomotor delay or mental retardation were mentioned, however she had to attend a special school. Basal gonadotrophin levels were high (FSH 49.5 U/l, LH 7.5 U/l), estradiol was prepubertal (0.05 mmol/l), that was consistent with hypergonadotrophic hypogonadism indicating gonadal dysgenesis. IGF1 levels and thyroid function were normal. Chromosome analysis revealed chromosomal aberration - an isochromosome i(Xp). The result was confirmed by FISH analysis 46, X, i(X)(p10), ish (STS+ , DXZ+, SRY)-. Bone age corresponded to calendar age. Ultrasound visualized a hypoplastic uterus, ovaries were not visible. MRI of central nervous system demonstrated slight cortical atrophy.

Conclusions: We describe a girl with tall stature, obesity, mild mental retardation, gonadal dysgenesis and a rare structural rearrangement of X chromosome. Tall stature can be explained by a triple gene dosage of SHOX (short stature homeobox containing gene) in PAR1 (short arm pseudoautosomal region) together with estrogen deficiency. Oral estrogen replacement therapy was initiated to accelerate puberty and promote epiphyseal fusion, unfortunately the therapeutic effect was diminished due to non-compliance.

PAO-160

The evaluation of body composition and metabolic parameters in girls with central precocious puberty receiving GnRH agonist therapy

Dogus Vural1; Huseyin Demirbilek1; Didem Aydogdu2; Nazli Gonc3; Ayfer Alkaksigolu1; Alev Ozon2; Nurgun Kandemir3
1Hacettepe University, Pediatric Endocrinology, Ankara, Turkey; 2Hacettepe University, Pediatrics, Ankara, Turkey; 3Hacettepe University, Pediatrics, Ankara, Turkey

Background: The changes in body composition and metabolic parameters in girls with central precocious puberty during GnRHa therapy is still under debate. Objective: To evaluate the changes in BMI and metabolic parameters in girls with central precocious puberty during GnRHa therapy.

Population and methods: Thirty-nine girls (mean age 9,13±0,73 years) with central precocious puberty treated with GnRHa were enrolled in the study. BMI:SDS, lipid profile, serum leptin, adiponectin and HbA1c levels were evaluated and standard OGTT was done at the beginning, sixth and twelfth month of therapy.

Results: At diagnosis; mean BMI-SDS was 1,13±0,83. Four girls (10,2%) were obese (BMI>95p). None of the patients had impaired glucose tolerance, 8 girls (20%) had insulin resistance. Dyslipidemia was observed in 35,9% of patients. At the sixth month, 5 cases (12,8%) had insulin resistance, 2 of whom developed impaired glucose tolerance. BMI:SDS did not change significantly in six month period (p=0,96). No changes in frequency of dyslipidemia (35,9%) was observed at sixth month of therapy. No statistically significant difference was found in serum leptin, adiponectin, Hba1c values between baseline and sixth month of therapy. (p values 0,14, 0,433, 0,443 respectively).

Conclusion: At the beginning of therapy one fifth of girls with central precocious puberty had impaired glucose metabolism. However BMI:SDS, lipid and carbohydrate metabolism parameters did not show significant change during six months period. The results of twelfth month evaluation will shed light on the long term changes in patients with central precocious puberty under GnRHa therapy.
Re-evaluation of metabolic parameters of obese children after 5-7 years

Gulay Demirdag1; Sibel Tuglar Kınık2; Ayşe Canan Yazar3
1Baskent University, Pediatrics, Ankara, Turkey; 2Baskent University, Pediatric Endocrinology, Ankara, Turkey; 3Baskent University, Biostatistics, Ankara, Turkey

Background: Obesity beginning in the childhood continues to adulthood and becomes more complicated.

Objective and hypotheses: In this study we aimed to re-evaluate obese children with respect to obesity status and metabolic parameters after 5-7 years from the first admission.

Methods: 100 cases who admitted to our clinic for exogen obesity were called again. 40 of them were male. Their relative BMI was calculated, serum levels of lipids, glucose, insulin, free T4,TSH were studied. There was significant. The cases were divided into 4 group according to metabolic disorders in the follow-up test:

Group 1: only dislipidemia (HDL<40 mg/dL, triglyceride>150 mg/dL, LDL>130 mg/dL)
Group 2: only insulin resistance (HOMA>3)
Group 3: dislipidemia and insulin resistance
Group 4: normal

Results: At the last evaluation, rel BMI decreased significantly in group 1 and 2 compared to first visit (p=0.006 and 0.034 respectively). The percentage of cases whom metabolic parameters improved to normal limits were 56% in group 1,2,4 and 18% in the group 3.

Conclusions: Losing weight is easier in children whom have only dislipidemia or only insulin resistance than children who have both of them. Having that metabolic disorders together makes the metabolic improvement harder. So, prevention of early stages of obesity and metabolic disorders plays important role in adulthood life quality.

Factors to predict the result of GnRH stimulation test in girls with suspicious precocious puberty

Hyo-Kyoung Nam1; Young Jun Rhie; Chang Sung Son; Sang Hee Park; Kee-Hyoung Lee
College of medicine, Korea university, Department of Pediatrics, Seoul, Republic of Korea

Background: In girls with early breast development and bone age advancement, sometimes the clinical findings and the results of gonadotropin-releasing hormone (GnRH) stimulation test are inconsistent.

Objective and hypotheses: The aim of this study was to investigate the factors to predict the positive results of GnRH stimulation test in girls with suspicious central precocious puberty (CPP).

Methods: We reviewed records of 574 girls who visited at Pediatric Endocrinology Clinic of Korea university hospital from March 2005 to May 2010 and underwent GnRH stimulation test under the age of 9 years old. Each of the initial and follow-up tests was divided into two groups based on whether peak LH levels were less or equal to 6 IU/L (negative) or more than (positive).

Results: In the initial GnRH stimulation test, 375 girls were diagnosed as CPP and other 199 girls had negative results. In the follow-up test, 64 girls corresponding to 32% of 199 girls were diagnosed as CPP. Girls with the initial positive results had more accelerated growth, advanced bone age and higher serum basal LH, follicle-stimulating hormone (FSH), estradiol concentration compared to those with the initial negative results. Girls with the follow-up positive results had more accelerated growth and advanced bone age compared to those with the follow-up negative results. In binary logistic regression, the growth velocity ratio was significant predictive factor [initial test, OR 10.7 (95% CI 4.3, 26.7), P = 0.01; follow-up test, OR 6.6, (95% CI 1.5, 28.9), P = 0.011] of positive results.

Conclusions: Considering when the GnRH stimulation test is thought to be helpful for girls with suspicious precocious puberty, rapid growth velocity could be the most useful predictive factor for the positive results.
Results: FISH study confirmed the supernumerary marker chromosome is originated from the 14 or 22 chromosome and includes two copies of the acute p-arms. 47,XX+mar, ish idic(14q22). Array comparative genomic hybridization were performed with arr(1:22) (2853BAC)x2, X(158BAC)x2, Y(27BAC)x0. No pathologic gene dosage variation was detected from array-CGH. PCR and sequence analysis for Hemophilia B and LDL receptor negative control, LDL receptor positive control, and LDL receptor 45,X male with ambiguous genitalia: a case report

Oksana Lazareva; Sheila Perez; Juliana Predescu; Shahid Malik; Svetlana Ten; Amit Bhangoo

State University of New York, Downstate, Pediatric Endocrinology, Brooklyn, NY, United States

Background: Patients with growth hormone insensitivity or Laron syndrome are a heterogeneous group of children with a variety of clinical phenotypes and variable severity of short stature. A relatively high prevalence of IGF-1 deficiency has been reported in ISS patients without classical Laron syndrome features.

Objective and hypotheses: To study the response to rhIGF-1 therapy in short children with Primary IGFD.

Methods: 21 children with short stature, who passed GHRH (1 mg/kg IV) stimulation test (GH peak>15ng/ml) were included in the study. They were treated with Increlex® 0.24 mg/kg/day. Height velocity (HV) and Height (Ht) SDS were measured after 6 months of therapy.

Results: Patient’s characteristics: age 9.84±2.5 SD years, Ht -2.49 ± 0.36 SD (range -2.9 to -1.85 SDS) and IGF-1 levels -2.22 ±0.97 SD (range -3.6 to +0.7SDS). The mean birth weight was 2.86 ±0.41 kg. The average peak of GH after GHRH was 48.9±24.1 SD ng/ml. HV after 6 months of Increlex® therapy was 10.3 ± 3.9 cm/yr. There were only 3 patients in this group whose HV was less than 5 cm/yr onIncrelex® therapy. The mean change in Ht SDS was +0.35±0.33 SD after 6 months of Increlex® therapy.

Conclusions: This pilot data revealed that the rhIGF-1 therapy has good efficacy in less severe Primary IGFD. The average HV after 6 months of therapy is similar to the data on severe Primary IGFD (Ht<-3SDS, IGF-I<-3SDS) patients treated with rhIGF-1.

PAO-168 Hot nodule harboring a papillary microcarcinoma in a girl from an iodine sufficient area

Ana Tanoglu1; Horacio M. Solarz2; Javier Farias3; Horacio Bignon4; Paula Moran5; Patricia Papendieck6

1Sanatorio Güemes, Endocrinología Pediátrica, Buenos Aires, Argentina; 2Sanatorio Güemes, Departamento de Patología, Buenos Aires, Argentina; 3Sanatorio Güemes, Endocrinología, Buenos Aires, Argentina; 4Hospital de Niños Ricardo Gutierrez, Departamento de Cirugía, Buenos Aires, Argentina; 5Sanatorio Güemes, Clínica Pediátrica, Buenos Aires, Argentina; 6Hospital de Niños Ricardo Gutierrez, División de Endocrinología, Buenos Aires, Argentina

Background: Hot nodules on radionuclide imaging of thyroid are generally benign but there are reported some cases of hot nodules associated with thyroid cancer with only a few cases in pediatric age. However a relative high incidence in children’s was reported in iodine deficiency area after introduction of iodine supplementation.

Objective and hypotheses: To report a case of thyroid cancer associated with a hot nodule in a pediatric patient from an iodine sufficient area.

Methods: 3 years old girl consulted for a one week evolution tumor in her neck, her aunt had thyroid cancer. On physical examination an approximately 2 cm firm mobile nodule on thyroid topography was palpated. Thyroid ultrasound showed a cystic nodule of 19 x 14 x 13 mm with heterogeneous pattern and ovaloid shape. No pathologic gene dosage variation was detected from array-CGH. PCR and sequence analysis for Hemophilia B and LDL receptor positive control, and LDL receptor positive control, and LDL receptor

PAO-169 45,X male with ambiguous genitalia: a case report

Senay Savas Erdave1; Bulent Hasicamlioglu1; Merih Berberoglu1; Zeynep Siklar1; Timur Tunca2; Gulnur Gullu3; Sadie Kekin3; Gonul Ocal4

1Ankara University School of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology, Ankara, Turkey; 2Ankara University School of Medicine, Department of Medical Genetics, Ankara, Turkey; 3Ankara University School of Medicine, Department of Pediatric Surgery, Ankara, Turkey

Background: A 45,X karyotype usually result in a female phenotype, with clinical symptoms of Turner syndrome. Rarely, the nonmosaic 45,X chromosomal constitution is associated with maleness. Maleness is usually caused by a reciprocal of the SRY gene on an autosome. These cases generally have
testes and normal male external genitalia with infertility.

Objective and hypotheses: We herein report a male newborn who presented with ambiguous genitalia and had 45,X karyotype.

Methods: A 38-week gestation newborn with 3000 gr birthweight was admitted for evaluation of ambiguous genitalia during the neonatal period. He had predominantly male phenotype with microopenis, chordee, penoscrotal hypoplasia and nonpalpable right gonad. His left gonad was palpable in scrotal region. Ultrasonographic examination showed Mullerian structures and right sided inguinal mass. Laboratory examination revealed no evidence of adrenal disease (eg, Cushing syndrome). Despite this he was treated with glucocorticoid in high doses, followed by treatment cessation soon after the acute episode due to self reported testicular pain. Physical examination showed shrunken statural (151cm), painful palpable mass in left testis, BP- 80-50 mmHg. The sodium level was 127mEq/l, potassium level was 5.6mEq/l. Morning plasma cortisol was decreased with increased ACTH plasma level, testosterone, LH, FSH, AFP and beta hCG levels were in normal range. The ultrasound examination showed normal adrenal glands and three homogeneously hypoechoic masses 1.1/0.9 cm maximum in right testis and two similar masses 3.1/1.8 cm each maximum in left testis.

Conclusions: Presence of testicular tumors in a patient with poor control of CAH is not unusual but in our case the testicular pain associated by mistake with glucocorticoid treatment in high doses administered in acute crisis became a major factor in raising a vicious circle of poor compliance.

PAO-170

The difficulties of investigating and treating an endocrine patient in resource limited countries

Introduction: Adrenal masses (AMs) are often discovered incidentally and are then termed adrenal incidentalomas (AIs). They are often discovered after an imaging procedure is performed that is unrelated to the adrenal gland. Less commonly, AIs are discovered as part of the clinical workup for suspected adrenal disease. Identification of the correct diagnosis is important as follow-up and management may differ significantly between AIs and AMs. It was noted to be common finding in our patient. We report results of further evaluation for a 17-year-old boy history, known with classic 21-hydroxylase deficiency, salt wasting type, diagnosed at birth, referred to our department with a discordant history in the context of the diagnosis of ambiguous genitalia and confirmed by familial testing.

Case presentation: S assertively described his presentation of ambiguous genitalia and had 45,X karyotype. SRY should be detected by PCR, in the patient with FISH negative for Y material, before gonadal genotyping.

Background: Achondroplasia is the most common form of skeletal dysplasia in man, has autosomal dominant inheritance and causes extreme short stature. More than 90% of patients with achondroplasia have a G to A transversion or mutation in man, has autosomal dominant inheritance and causes extreme short stature. More than 90% of patients with achondroplasia have a G to A transversion or mutation in FGFR3 gene. The first patient with achondroplasia was described by Garrod in 1888. Achondroplasia is the most common form of skeletal dysplasia (117/67mmHg). More than 90% of patients with achondroplasia have a G to A transversion or mutation in FGFR3 gene.

Objective: To evaluate the response to growth hormone of Egyptian patient with achondroplasia.

Methods: A prospective follow up study of a girl with achondroplasia. Case presentation: The girl was born on 14.9.2006, is a first infant born to non consanguineous parents. She was born at caesarean section with birth weight 2.000 kgm , height 40 cm, OFC 41cm at full term, the second baby is 3 years and is unaffected. Our patient presented with short stature and large head at birth. Examination on 16.2.2011: The child is active, cheerful with average intelligence. Paternal height 180 cm, maternal height 163 cm, patient height 92.8 cm (+2.5 SD), upper segment 60 cm, span 85 cm, weight 18.9 kgm, OFC 55 cm. Bone age is 5.6 years. Low set ears, skull is large with prominent forehead, flat nasal bridge, small chest compared to the abdomen, medial arm and forearm creases are prominent. Molecular testing: Fibroblast growth factor receptor-3 (FGFR3) mutation: G1138A and G1138C mutations.


Result: One mutation G 1138 A is detected consistent with achondroplasia.

Discussion: On September 2008 he was given growth hormone (GH) 0.09 u/ kg/day, patient height was 78 cm. (+2SD), GH dose increased to 0.12 u/kg/d. On February height is 92.8 cm. +2.5 SD, height velocity 6.048 cm/year.

Conclusion: Patients with achondroplasia with G 1138 A mutation may benefit from GH at a dose range from 0.09kg/d to 0.12a/kg/day to maintain an appropriate height velocity.

PAO-173

A case of transient pseudohypoaldosteronism complicated by cerebral artery infarction

Akiko Seiji; Keisuke Yoshii; Masako Sakauchi; Makiko Osawa

Tokyo women’s medical university hospital, Pediatrics, Tokyo, Japan

Background: Pseudohypoaldosteronism is a rare condition characterized by renal resistance to the action of aldosterone. Transient pseudohypoaldosteronism (TPHA) has been identified in neonates and young infants with obstructive uropathy and urinary tract infection. Objective: To describe a 8-month-old boy with TPHA complicated by cerebral infarction.

Case: The patient was the second child of nonconsanguinous parents and was born at a gestational age of 39 weeks after an uncomplicated pregnancy. Birth weight was 2.4kg and a mild birth asphyxia, current weight is 18kg. On examination the weight was above 97th centile. He had a moon shaped face, striae, trunk obesity, hirsutism, pubarche and was hypertensive. Short stature and large head was noted. Physical examination revealed recurrent hypoglycemia, nausea and vomiting crisis, reported to be refractory to cortisol treatment.

Results: From history we found that he frequently present hypoglycemia, nausea and vomiting crisis treated in emergency department with intravenous glucocorticoid in high doses, followed by treatment cessation soon after the acute episode due to self reported testicular pain. Physical examination showed shrunken stature (151cm), painful palpable mass in left testis, BP-80-50 mmHg. The sodium level was 127mEq/l, potassium level was 5.6mEq/l. Morning plasma cortisol was decreased with increased ACTH plasma level, testosterone, LH, FSH, AFP and beta hCG levels were in normal range. The ultrasound examination showed normal adrenal glands and three homogeneously hypoechoic masses 1.1/0.9 cm maximum in right testis and two similar masses 3.1/1.8 cm each maximum in left testis.

Conclusions: Presence of testicular tumors in a patient with poor control of CAH is not unusual but in our case the testicular pain associated by mistake with glucocorticoid treatment in high doses administered in acute crisis became a major factor in raising a vicious circle of poor compliance.

PAO-172

Achondroplasia in a girl with G 1138 A mutation, response to growth hormone therapy, two and half years follow up

Sameh Tawfiq1; Mona Altea1; Heba Hassan2; Solal Mohamed3

1Maadi, Pediatrics, Cairo, Egypt; 2Cairo University, Pediatrics, Cairo, Egypt; 3Ain Shams, Pediatrics, Cairo, Egypt; 4Ain Shams, Genetics, Cairo, Egypt

Background: Achondroplasia is the most common form of skeletal dysplasia in man, has autosomal dominant inheritance and causes extreme short stature. More than 90% of patients with achondroplasia have a G to A transversion or G1138A mutation in codon 380 of FGFR3 gene.

Objective: To evaluate the response to growth hormone of Egyptian patient with achondroplasia.

Methods: A prospective follow up study of a girl with achondroplasia. Case presentation: The girl was born on 14.9.2006, is a first infant born to non consanguineous parents. She was delivered by caesarean section with birth weight 2.000 kgm, height 40 cm, OFC 41cm at full term, the second baby is 3 years and is unaffected. Our patient presented with short stature and large head at birth. Examination on 16.2.2011: The child is active, cheerful with average intelligence. Paternal height 180 cm, maternal height 163 cm, patient height 92.8 cm (+2.5 SD), upper segment 60 cm, lower segment 32.48 cm, span 85 cm, weight 18.9 kgm, OFC 55 cm. Bone age is 5.6 years. Low set ears, skull is large with prominent forehead, flat nasal bridge, small chest compared to the abdomen, medial arm and forearm creases are prominent. Molecular testing: Fibroblast growth factor receptor-3 (FGFR3) mutation: G1138A and G1138C mutations.


Result: One mutation G 1138 A is detected consistent with achondroplasia.

Discussion: On September 2008 he was given growth hormone (GH) 0.09 u/ kg/day, patient height was 78 cm. (+2SD), GH dose increased to 0.12 u/kg/d. On February height is 92.8 cm. +2.5 SD, height velocity 6.048 cm/year.

Conclusion: Patients with achondroplasia with G 1138 A mutation may benefit from GH at a dose range from 0.09kg/d to 0.12a/kg/day to maintain an appropriate height velocity.
Conclusions: In our study GnRHa treatment did not allow reaching TH but puberty for almost 30 years. However, it is still discussed whether this treatment GNRHa analogues have been used for treatment of precocious PAO-174

G.6.}

Background: GN

Objective and hypotheses: To evaluate the efficacy of GnRH analogues regarding final height and weight of children with central precocious puberty (CPP).

Methods: Total number of 50 patients was evaluated in this retrospective single-centre study. Group 1 included 33 patients (26 females, 7 males). All of them had been treated with triptorelin 100mg/kg/28 days during 3.5 yrs (0.9–7.8 yrs). The median age at the start of treatment was 5.2 (2.0 – 8.0 yrs). This group was subdivided for Group 1A - 19 patients with still open epiphysis and Group 1B - 14 patients who have already reached adult height. Group2 included 17 CPP patients (14 females, 3 males) that have never received any treatment. Predicted adult height (PAH) was calculated according to the Bayley and Pinneau tables. Target Height (TH) was evaluated as midparental height adjusted for sex (+/- 6.5).

Results: GN

Groups Group 1A Group 1B Group 2
PAH (cm) before treatment (1) 151.0 [144.9-152.4] -- --
[150.8-157.0] [0.87-1.28] --
BMI SDS before treatment (3) 1.92 [0.9-2.41] 1.2 -- --
[0.66-1.98] [0.87-2.0] 0.0036 --
BMI SDS after treatment (4) 1.54 [0.87-2.0] 1.13 -- --
[0.87-1.28] [0.87-1.28] 0.0036 --
Target height (TH) (cm) 164.7 [161-169.5] 166.5 [163-167.2] 163.0 [159-160.2]
Adult height (AH) (cm) 156.0 [152.8-164] 146.2 [141-152]
TH-AH) -- 0.003 0.0001

Conclusions: In our study GnRHa treatment did not allow reaching TH but significantly improved AH and did not influence body mass in patients with CPP. Our results correspond to majority of similar studies reported by others.

PAO-175

Physical activity and sedentary behaviours among obese prepubertal children

Sona Galchev1; Violeta Iotova1; Mina Latева1; Yoto Yotov2

1Varna Medical University, Department of Pediatrics, Varna, Bulgaria; 2Varna Medical University, Department of Internal Medicine, Varna, Bulgaria

Background: Physical inactivity is implicated in the development of childhood obesity.

Objective and hypotheses: To investigate the relationships of physical activity (PA) and sedentary behaviours (television (TV) viewing and computer use) with the presence of abdominal obesity in healthy prepubertal children.

Methods: A case-control study of 168 healthy prepubertal children (75 males; mean age 8±1.2 years) was conducted. Body weight, height and waist circumference (WC) were measured; BMI was calculated. Children were divided into three groups according to the WC percentiles for Bulgarian children as a measure of central obesity ("normal-WC", 31.5%; "children at risk", 27.4% and "abnormally obese", 41.1%). A structured parental interview was used to obtain data about children's physical and sedentary behaviours.

Results: No significant difference was found in the frequency and duration of PA among the WC categories in both boys and girls (p>0.05). More than 58% of the parents reported the presence of a seasonal difference in the children’s activity with higher mean PA levels during the spring and summer months. This seasonal behaviour was significantly more frequent among the abdominally obese children compared to the normal-WC group (68.1% vs. 47.1%, p=0.04). Children spent an average of 2.7±1.2 h/d watching TV and 0.9±1.0 h/d in using computers. Although insignificantly, the abdominally obese children spent more hours a day in front of the TV sets and computers compared to their normal-WC counterparts (2.8±1.3 vs. 2.6±1.0 and 0.9±1.0 vs. 0.6±0.9 h, respectively, p>0.05). Boys from all WC-groups used computers more often than girls (1.1±1.0 vs. 0.7±0.9 h/d, p<0.05).

Conclusions: Physical inactivity may be associated with the excess accumulation of abdominal fat mass in prepubertal children, which warrants further investigations.

PAO-176

Retrospective study of 215 patients admitted in a pediatric intensive care unit for diabetic ketoacidosis between 1998 and 2008

Frederique Tixier1; Aline Guevart1; Cecilia Heng Yong1; Jean Claude Berthier1; Philippe Klee1; Frederic Vallerie1; Marc Nicolino1

1Hopital Femme Mère Enfant, Division of Pediatric Endocrinology, Lyon Bron, France; 2Hopital Femme Mère Enfant, Pediatric Intensive Care Unit, Lyon Bron, France

Methods: This retrospective study presents data collected in one center on 215 type 1 diabetic patients admitted in the pediatric intensive care unit (PICU) between 1998 and 2008 for diabetic ketoacidosis (DKA). All patients were treated on the basis of a single standardized protocol.

Results: Among 270 episodes of DKA, 2 populations were distinguished: 1) patients in whom type 1 diabetes was revealed by DKA and 2) known type 1 diabetic patients admitted for decompensation of their pre-existent disease. DKA in new type 1 diabetic patients represented 53% of all episodes of DKA and predominantly concerned young patients (58% below 10 years), males (56%), patients with polyuria and polydipsia with a mean duration of 20 days, and patients with a weight loss of a mean of 12.5%. Secondary DKA in known patients represented 47% of all episodes of DKA and predominantly concerned adolescents (90% above 10 years), females (56%) and patients with psychosocial risk factors (61%). 62% of all patients admitted inadequate self-management. In this group, 11 patients were admitted to the PICU between 3 and 12 times and represented 48% of all episodes of DKA. We did not find any significant difference in DKA severity between both above-mentioned populations. All 4 encountered complications during DKA correction (cardiovascular failure, hypoglycemia, cerebral edema and hypokalemia) had a favorable outcome in our study.

Conclusions: In order to limit the incidence of DKA and its complications, it is necessary to reduce the delay between the onset of type 1 diabetic symptoms and the time of diagnosis by providing better education to health care providers and to the general population.
between females and males. This difference was not statistically significant. No difference was observed.

Results: Both girls showed a CAIS phenotype with normal female external genitalia and absence of Mullerian duct remnants. At the age of 15.8 years the older sister had normal breast development without growth of pubic hair. Hormone profiles showed elevated LH levels and FSH, testosterone, estradiol and SHBG levels within the adult male reference ranges. Gonadal ultrasounds and tumor markers revealed no pathology. The younger girl hadn’t shown any signs of puberty at the age of 12.7 years, but stimulated gonadotropins and testosterone levels were detected with prepubertal estradiol and SHBG levels. Ultrasonic scans displayed unsuspicous testes in the inguinal canals.

Conclusions: The two sisters are undergoing spontaneous puberty, at which they profit from their specific endogenous hormone production. A follow-up protocol has been designed for early diagnosis of malignancy. However further studies are necessary to evaluate the safety of such protocols and establish criteria for intervention.

Conclusions: Survivors of childhood ALL, especially those treated with cranial radiotherapy at young age, are at increased risk for adult short stature. Our results do not appear in accordance with similar studies, but this is probably due to the small number of patients examined. We are collecting further data, also to evaluate the influence of newer treatment regimens on final height.

Results: We hypothesized that adult survivors of childhood ALL would reached shorter adult height compared to mid-parental height. Cranial radiotherapy would be a significant risk factor in all survivor's adult stature of the patients, expressed as HSDS, was not statistically different from their mid-parental height. Patients who received cranial radiotherapy, especially at high doses, reached a shorter final height compared with mid-parental height, whereas those who received only chemotherapy (n=5) reached a taller adult height compared with mid-parental height, but this difference was not statistically significant. No difference was observed between females and males.

Background: In recent publications the prevalence of germ cell tumors in CAIS has been estimated < 1% until puberty. Leaving the gonads in situ will allow endogenous hormone production and spontaneous puberty. However there is no data on the tumor prevalence in CAIS after puberty.

Results: The two sisters with a 46,XY karyotype we identified a M749V mutation in exon 5 of the androgen receptor gene. According to the family’s request the gonads remained in situ. The girls were first seen in our clinics at the age of 13.6 and 11.3 years. Follow-up visits every six months included clinical assessment of growth and puberty, gonadai ultrasound, hormone profiles (LH, FSH, SHBG, testosterone and estradiol) and tumor markers (HCG and AFP).

Conclusions: In two sisters with a 46,XY karyotype we identified a M749V mutation in exon 5 of the androgen receptor gene. According to the family’s request the gonads remained in situ. The girls were first seen in our clinics at the age of 13.6 and 11.3 years. Follow-up visits every six months included clinical assessment of growth and puberty, gonadai ultrasound, hormone profiles (LH, FSH, SHBG, testosterone and estradiol) and tumor markers (HCG and AFP).

Conclusions: The two sisters are undergoing spontaneous puberty, at which they profit from their specific endogenous hormone production. A follow-up protocol has been designed for early diagnosis of malignancy. However further studies are necessary to evaluate the safety of such protocols and establish criteria for intervention.

Conclusions: Survivors of childhood ALL, especially those treated with cranial radiotherapy at young age, are at increased risk for adult short stature. Our results do not appear in accordance with similar studies, but this is probably due to the small number of patients examined. We are collecting further data, also to evaluate the influence of newer treatment regimens on final height.
tuitary adenoma secreting GH, TSH, PRL and α-subunit with sstr 2 and 5 receptors. Pharmacological treatment with somatostatin analogue (octreotide, 30 mg every 28 days i.m.) and bromocriptine (30 mg/d now) was introduced. There was an evident tumour regression with tumour size 40x37x40mm after 4 months of the treatment. Normalisation of GH, IGF-1, TSH and free thyroid hormones and decreasing prolactin level (from 35700 ng/ml to 163 ng/ml) were observed. Due to the successful pharmacological therapy, administered for 16 months now, neurosurgery procedure is planned in a few months.

**Conclusions:** Treatment with somatostatin analogue and bromocriptine is very effective in the therapy of GH, TSH, PRL secreting pituitary adenomas, resulting in not only normalisation of hormones levels but also tumour size regression with better prognosis for the radical surgery.

**Background:** Intracranial germinoma is a rare malignant tumor, only constituting 3-5% of paediatric intracranial tumor. It usually occurs in children and young adults and it’s highly sensitive to radiotherapy and/or chemotherapy. Lymphocytic hypophysitis is an uncommon autoimmune disease in which the pituitary function is usually impaired due to its infiltration by lymphocytes, plasma cells and macrophages. There are just a few cases of coincidence of this two pathologies described in the literature.

**Objective:** We present a patient with coincidence of germinoma and lymphoctic hypophysitis. 9-year-old boy presented polydipsia, polyuria and headache that lasted for 2 years. Neurological and ophthalmological examinations were normal. Wapospressin test confirmed central diabetes insipidus, DDAVP treatment was introduced. TSH, free thyroid hormones, ACTH, cortisol and IGF-1 levels were normal. Tumour markers, α-fetoprotein and βHCG, both in serum and cerebral fluid were negative. Antithyroid and antidiurea antiauto bodies were also negative. Chest X-ray radiograph showed no pulmonary lesion. The first head MRI showed thickened pituitary stalk size 4x6 mm, absent of a posterior pituitary lobe and 5 mm pineal cyst. During 2,5-year observation growth velocity decreased to 3.5 cm/year. Stimulation tests confirmed growth hormone deficiency. The head MRI was repeated every 6 months, after 2,5 years there was increase of tumour mass, now in the region of the pituitary gland, stalk and hypothalamus. Right-side temporal craniano was performed with total re-move of the tumour. Histopathological examination revealed both germinoma and lymphocytic hypophysitis. The patient was referred for further oncological treatment.

**Conclusions:** The diagnosis of central diabetes insipidus with thickened pituitary stalk requires long term follow-up to establish the underlying cause. Lymphocytic hypophysitis in children may be the first sign of a host reaction to an occult germinoma.

**Introduction:** Lipoid congenital adrenal hyperplasia is an autosomal recessive disease due to deficiency of StAR protein that transports cholesterol into the mitochondria for adrenal steroid synthesis. StAR is also essential for gonadal steroidogenesis and is encoded by a gene on chromosome 8p11.2. Case: 6 month female patient was hospitalized for vomiting and lose in weight started at 4th month. She had severe hyponatraemia (Na: 108 mmol/L) and dehydration. She has been referred for persistent hyponatraemia and subsequently developed hyperkalemia. She was born at 33rd gestational week, birth weight was 1750 gr. Parents were second degree related, infant death or sexual development disorder was not described in family history. Physical inspections revealed paleness, vital findings were normal. Dehydration or hyperpigmentation was not present. Height: 58 cm (10-25p), weight: 4 kg (< 3p), external genitalia seemed normal female and systemic examination findings were normal. Na: 130 mEq/l , K: 6.4 mEq/l, Glucose: 82 mg/dl, baseline ACTH was high, DHEA-S was normal. In classical ACTH stimulation test, mineralocorticoid, glucocorticoid and androgen precursors had not been increased. Significant hyperplasia of both adrenal glands observed in magnetic resonance imaging. Carylotype was 46 XY, t(4;9)(p16.6:p13.3) and a paternal translocation was determined.

Laparoscopic investigation showed intra-abdominal located testes, any Mullerian structure was not found. There was no increase in testosterone after three days of stimulation with hCG 1500 U/dose and gonadectomy was performed. She is still receiving hydrocortisone (14mg/m2/day) and fludrocortisone (0.1 mg/day) treatments.

**Result:** StAR protein deficiency is the most severe and rare form of steroid biosynthesis disorders. Mineralocorticoids, glucocorticoids and androgens can not be synthesized and ACTH level is high. Normal DHEA levels helps for differentiating from 3 beta-hydroxysteroid dehydrogenase deficiency. Carylotype analysis and advanced investigations if needed should be performed.

**Conclusion:** Although the adrenal tumours are the most common cause of Cushing syndrome in young children there is a necessity of wide diagnostic procedures in case of hypercortisolaeemia and normal imaging examinations.
PAO-184

Different skeletal maturation patterns in patients with constitutional delay of growth (CDG) and growth hormone deficiency (GHD)

Sandra Barth; Stefan A. Wudy
Justus Liebig University, Division of Paediatric Endocrinology and Diabetology, Center of Child and Adolescent Medicine, Giessen, Germany

Background: The determination of bone age is one of the most important criteria to diagnose and work clinically with short stature.

Objective and hypotheses: The study aimed to identify disparities in the level of phalangeal bone (PH), metacarpal bone (MC) carpal bone (CP) and radius-ulna (RU) - development in patients with CDG or GHD.

Methods: Left hand radiographs of patients with CDG (bone age retardation > 1 yr; no organic diseases; family history of delayed growth and puberty) were compared with those of untreated GHD patients (maximum stimulated GH peak <5μg/l). In each patient, PH, MC, RU, and CP-bone age were calculated by the method of Greulich/Pyle.

Results: In the CDG cohort (13 males, 2 females, mean age 10.2 yr) bone age was retarded on average by 2.0 years. Differences in the developmental stages of PH, MC, CP and RU were identified as shown in table 1. Likewise, the GHD group (13 males, 2 females, mean age 5.71 y) showed delayed bone maturation as revealed in table 1. In GHD patients primarily carpal bone development was delayed, whereas in CDG patients the maturity of metacarpal bones was primarily delayed.

Conclusions: The pattern of bone maturation as assessed by left hand radiographs is different between patients with CDG and GHD. We suggest that the extreme delay in carpal bone maturation could be used as a marker for GHD in the assessment of short stature.

<table>
<thead>
<tr>
<th>Chronological age mean in yr</th>
<th>PH Mean in yr (delay in %)</th>
<th>MC Mean in yr (delay in %)</th>
<th>CP Mean in yr (delay in %)</th>
<th>RU Mean in yr (delay in %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with CDG</td>
<td>10.2</td>
<td>8.1 (21%)</td>
<td>7.4 (27%)</td>
<td>8.2 (20%)</td>
</tr>
<tr>
<td>Patients with GHD</td>
<td>5.7</td>
<td>4.8 (16%)</td>
<td>4.4 (23%)</td>
<td>3.5 (39%)</td>
</tr>
</tbody>
</table>

PAO-185

Abstract withdrawn.

PAO-186

Transsexualism in an African setting; case report

Olumide Jarrett; Olugbenga Esan; Omolola Ayoola

1University College Hospital, Paediatrics, Ibadan, Nigeria; 2University College Hospital, Psychiatry, Ibadan, Nigeria; 3Royal Manchester Children’s Hospital, Endocrine Science Research Group, Manchester, United Kingdom

Background: Transsexualism is the condition in which a person with apparently normal somatic sexual differentiation of one gender is convinced that he or she is actually a member of the opposite gender. It is associated with an irresistible urge to be and live in that gender hormonally, anatomically and psychologically. The patient has persistent discomfort with his or her sex and a sense of inappropriateness in the gender role of that sex. It occurs in all societies and cultures however it is a rare occurrence in Africa.

Objective: We describe a case of Male-to-Female Transsexual who presented at the paediatric endocrine clinic of the University College Hospital.

Case report: EA is a 27 year old male who presented with the desire for sex reassignment surgery. He had already stated wearing female clothes, cosmetics and jewellery. He also changed his name to a female one and moved to another town. Physical examination revealed an individual with Tanner stage I for breast and a well developed normal male external genitalia with a solitary right testis. Hormonal profile revealed normal testosterone (31.2nmol/l, normal values 15 – 40nmol/l) and low estradiol levels (0.1nmol/l). He is awaiting laparoscopy and other investigations which have largely been delayed as a result of lack of funds to pay for them. He is being co-managed with the Psychiatry and Surgical teams.

Conclusions: Transsexualism is a rare condition and it is often marginalized even in developed economy. This report exposes the socio-cultural and religious influences associated with management. The dilemma it causes to the immediate family and relatives which has not been highlighted in previous reports is also described. The financial implication of management in this part of the world could also be frustrating to the individual. To our knowledge, this is the first case reported in Nigeria.

PAO-187

An unusual presentation in an adolescent with parathyroid adenoma: tendinitis

Selim Kurtoku1; Leyla Akpin1; Salih Ozgöcmen1; Mustafa Kendirci1; Nihan Solmaz2; Sema Oner2

1Erciyes University Faculty of Medicine, Pediatric Endocrinology, Kayseri, Turkey; 2Erciyes University Faculty of Medicine, Physical Therapy and Rehabilitation, Kayseri, Turkey

Background: Primary hyperparathyroidism (PHPT) in children and adolescents is a rare condition. PHPT is usually sporadic and caused by parathyroid adenoma. Patients may present with bone pain, proximal myopathy, bony deformities, fractures, renal calculi, neck swelling or acute pancreatitis.

Case: We describe an unusual presentation for PHPT in a 15 years-old male patient. He presented with difficulty in walking due to swelling of the ankles bilaterally. Ultrasonography revealed intratendinous calcific nodules in both achilles tendons. Serum biochemistry showed hypercalcemia and hypophosphatemia. Serum parathormone level was found high (512 pg/ml N:4.5-36). Parathyroaoid scintigam suggested parathyroid adenoma. Parathyroidectomy was performed and the diagnosis of parathyroid adenoma was confirmed histopathologically. The family history was negative for multiple endocrine neoplasim syndrome. The intervention was followed by normalization of phosphocalcic profile and improvement of signs and symptoms of the patient.

Conclusion: We suggest that hyperparathyroidism should be kept in mind in the differential diagnosis of tendonopathies.

PAO-188

Trend in body height distribution and short stature prevalence among children and adolescents aged from 6 to 18 years in two districts of Shanghai

Minxia Zhang1; Feihong Luo; Shuxian Shen; Hong Xia; Yuezhen Tu; Fengxia Guo; Tingting Huang; Dijing Zh1; Zhuhui Zhao1; Rong Ye1; Ruqiang Cheng1; Xiaojing Li1

1Children’s Hospital, Fudan University, Department of Endocrinology and Metabolism, Shanghai, China; 2Public Health Bureau, Minhang District, Shanghai, China; 3Center for Disease Control and Prevention, Minhang District, Shanghai, China

Background: It is unclear how is the trend of height distribution and short stature prevalence change among children and adolescents in Shanghai.

Objective and hypotheses: The aim of this survey was to establish baseline data on the trend in body height distribution and short stature prevalence among children and adolescents in Shanghai.

Methods: We selected two districts in Shanghai in 2003, randomly, one in urban area and the other in suburb area. All students in the primary schools, junior and senior high schools of the two districts were screened in 2003 and 2008. The main variables we studied were the subjects’ height, age and sex. We analysed the body height distribution and the prevalence of short stature.

Results: (1) Body heights were significantly higher in boys than that in girls. (2) Compared with data in 2003, the mean height of 2008 was higher. (3) In the past 5 years, the overall increments were 0.09–4.03cm (Urban male), 0.57–2.55cm (Rural male), 0.42–3.76cm (Urban female) and 0.04–1.81cm (Rural female) for stature. (4) The prevalence of short stature was significantly higher in urban district than in suburb area (2003:X2=139.73, p<0.01; 2008:X2=201.7, p<0.01).
The ovotestis DSD (OMIM # 235600) is characterized by histological presence of testicular and ovarian tissue in the gonads of the same individual. Karyotype is usually 46 XX (60-100%), SRY negative. The most common form of presentation is ambiguous genitalia at birth. Biopsy of gonad around its longitudinal axis is mandatory to avoid misdiagnosis of mixed forms. Frequency of DSD in Africa is high in some series (51% in South Africa vs 8% in Brazil).

Population: We report 3 cases of ovotestis DSD from Mauritania, raised as males. They have different degrees of penile curvature and micropenis, proximal hipoplasias, bifid scrotum and unilateral or bilateral cryptorchidism. In 2 of them a gonad was palpable. No uterus was found. 17OH-progesterone and DHEA-S were in the normal range. Karyotype 46 XX, SRY gene negative. Gonadal biopsy was performed in cases 1 and 3. In case 2, macroscopic diagnosis of bilateral ovotestis was made (Table 1).

Penile curvature correction was performed with penoscutal transposition and testis / ovotestis orchidopexy, with removal of ovary and internal female genitalia (Case 1). Subsequently, two-stage urethroplasty was performed. In Case 2, treatment of micropenis with testosterone ointment 2% was carried out with good response.

Conclusions: The diagnosis of ovotestis DSD should be considered in children of African origin with ambiguous genitalia. The most common presentation is the ovotestis (44-64%). They are usually reassigned male because they have already been raised as males in their origin country.

**PAO-190**

**Disorders of sex development -DSD-(46,XX ovotestis) in 3 children of Africa**

Amaya Rodriguez1; Amaia Vela1; Gema Grau Bolado1; Francisco Oliver2; Jose Luis Blanco3; Luis Cañada3
1Crucero Hospital, Pediatric Endocrinology, Barakaldo, Spain; 2Crucero Hospital, Pediatric Urology, Barakaldo, Spain; 3Hospital de Santiago de Compostela, Spain

Background: The ovotestis DSD (OMIM #235600) is characterized by histological presence of testicular and ovarian tissue in the gonads of the same individual. Karyotype is usually 46 XX (60-100%), SRY negative. The most common form of presentation is ambiguous genitalia at birth. Biopsy of gonad around its longitudinal axis is mandatory to avoid misdiagnosis of mixed forms. Frequency of DSD in Africa is high in some series (51% in South Africa vs 8% in Brazil).

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>2</th>
<th>4</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Height (SD)</td>
<td>-0.4±1.7</td>
<td>-0.3±1.4</td>
<td>0.07±0.7</td>
</tr>
<tr>
<td>Glucocorticoids/m2</td>
<td>14.8±5</td>
<td>14.5±5</td>
<td>14.7±4</td>
</tr>
<tr>
<td>17-OHP Progesterone</td>
<td>20.6±34</td>
<td>21.2±18</td>
<td>22.7±20</td>
</tr>
<tr>
<td>n</td>
<td>12</td>
<td>14</td>
<td>10</td>
</tr>
</tbody>
</table>

Short FH was present in a SW woman (-2.68 SD) with TH 153.8 (-1.6 SD) and a SV man (-2.98 SD) diagnosed at 4 years 3 months with TH 167.2 (-1.6 SD).

Conclusions: No significant loss of height in relation to TH was observed in childhood. Two cases of short FH (-2SD) were associated with late diagnosis (SV forms) and familial (genetic) short stature.
PAO-192

**Generalised arterial calcification of infancy - a novel mutation of the ENPP-1 gene**

**Vishal Mehta**1; Sanjay Gupta2; Rupal Patel1; David Horton1;
Eamonn Sheridan1; Frank Burkart1

1Hull Royal Infirmary, Paediatrics, Hull, United Kingdom; 2St James’ university Hospital, Department of Clinical Genetics, Leeds, United Kingdom; 3Munster University Children’s Hospital, Paediatrics, Munster, Germany

**Background:** Generalised Arterial Calcification of Infancy (GACI) is a severe autosomal recessive disorder characterized by calcification and stenosis of large and medium sized arteries. Although many affected children die in early infancy, approximately 34% of children are expected to survive beyond infancy. Inactivating mutations of the Ectonucleotide Pyrophosphatase/Phosphodiesterase -1 (ENPP-1) gene have been implicated in many cases of GACI and more recently, in causation of hypophosphataemic rickets.

**Case report:** A female baby was born of on-consanguineous Caucasian parents, at 29 weeks of gestation with evidence of GACI on antenatal scans. She died within 24 hours of birth secondary of congestive cardiac failure. Her female sibling was born at 31 weeks of gestation and was diagnosed antenataly to have complex congenital heart disease including hypoplastic left ventricle, double outlet right ventricle, arterio-pulmonary window and iatro-pathic arterial calcification. A postnatal scan confirmed these findings. Due to very poor prognosis of this condition, after extensive discussion with parents and paediatric cardiologist it was decided not to actively treat her cardiac condition. Molecular analysis of the ENPP1 gene showed two novel nonsense mutations on Exon1 (c. DelGC 190/191, p. A64A fsX11) and Exon21 (c. 2230 C/T, Q744X). At two and half years of age she started showing evidence of phosphaturia and hypophosphatemia.

**Discussion:** Within last 20 years, anecdotal GACI cases of survival beyond infancy with spontaneous regression of calcification have been reported. The factors which lead to survival beyond infancy are poorly understood but hypophosphatemia and treatment with bisphosphonates was associated with survival in a large retrospective study. The presence of a novel mutation in our case is unlikely to explain the association with complex CHD but this is the first reported case of such association... In our case, the long term outcome and survival could be affected by pulmonary hypertension, despite bisphosphonate treatment.

---

PAO-193

**Gonadal function in patients with classic galactosemia**

**Milva Orquidea Balcaren**1; Sara Monti; Ilaria Bettocchi; Federico Baronio; Alessandra Cassigni; Alessandro Cicognani

University of Bologna, S. Orsola-Malpighi Hospital, Department of Pediatrics, Bologna, Italy

**Background:** Classic galactosemia is an inherited inborn error of the major galactose assimilation pathway, caused by gactose 1-phosphate uridylytransferase (GALT) deficiency, with an incidence of 1:30,000 newborns. Many GALT mutations have been described, with different clinical consequences. In the neonatal period, after ingestion of milk containing galactose, newborns present a severe clinical situation with jaundice, hepatosplenomegaly and hepatocellular damage, vomiting, hypoglycemia, renal tubular disease and hypotonia. Treatment is represented by a galactose-restricted diet which, unfortunately, does not prevent long-term complications, particularly cognitive and motor abnormalities and primary ovarian failure (POF). The pathogenesis of galactose-induced ovarian toxicity remains unclear but probably involves galactose itself and its metabolites such as galactitol.

**Objective and hypotheses:** The aim of the study is to evaluate pubertal development in classical galactosemia.

**Method:** We report data of our patients (2 couples of brothers) identified by neonatal screening.

**Results:** The table shows our results. 5 patients with classic galactosemia, genotypically characterized, present a cognitive and gonadal behavior in accordance with literature. Indeed, patients 1A and 1B, 2A and 2B show a more severe phenotype although an early diagnosis and therapy and a good dietary compliance; patient 3 has a normal phenotype and is a compound heterozygous for a known mutation linked to a severe phenotype and a mutation not present in literature. Moreover she is carrier of Los Angeles variant, Duarte 1, associated with an increased activity of enzyme GALT.
Effectiveness of gonadotropin-releasing hormone analogue treatment in children with central precocious puberty with respect to bone age acceleration before the therapy
Irena Bobeff1; Diana Bobeff2; Joanna Smyczynska3; Barbara Pniwinska-Slark4; Maciej Hilczer5; Andrzej Lewinski5
1Polish Mother’s Memorial Hospital - Research Institute, Department of Endocrinology and Metabolic Diseases, Lodz, Poland; 2Medical University of Lodz, Medical Faculty, Lodz, Poland; 3Medical University of Lodz, Department of Pediatric Endocrinology, Lodz, Poland

Background: Central precocious puberty (CPP) is defined as the onset of puberty in girls and boys before the age of 8 and 9 respectively. It has a higher incidence in girls. Bone age is almost always advanced. The treatment of choice is long term depot gonadotropin-releasing hormone analogue (GnRHa). The goal of mentioned therapy is to inhibit pubertal development and improve the height prognosis.

Objective and hypotheses: The aim of this research was to evaluate the influence of GnRHa therapy in children with CPP on the height prognosis depending on pretreatment bone age.

Methods: The group of 62 patients with diagnosed CPP was enrolled in the study: 48 girls and 14 boys. Patients were treated with GnRH analogues depot – triptorelin 3.75 mg. For all the patients, the following pre- and post treatment parameters have been calculated and expressed as SDS: height, predicted adult height (PAH), bone age/chronological age (BA/CA) and bone age/height age (BA/HA). Patients were divided in two groups. Group A comprised those children who began their treatment with BA consistent or slightly advanced in relation with CA and HA. Group B gathered those patients whose BA was definitely advanced with respect to CA and HA.

Results: Height prognosis improvement was observed in group B (in children whose BA before treatment was definitely advanced with respect to CA and HA). There was no height prognosis improvement noticed in the group A (which was characterized by consistent or only slightly elevated BA). The results are presented in the Table 1 for BA/CA and in the Table 2 for BA/HA.

<table>
<thead>
<tr>
<th>BA/CA</th>
<th>advanced</th>
<th>normal</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>age before GnRHa [years]</td>
<td>7.4±2.2</td>
<td>9.3±1.7</td>
<td>0.001</td>
</tr>
<tr>
<td>hSDS before GnRHa</td>
<td>1.8±1.14</td>
<td>0.8±1.22</td>
<td>0.007</td>
</tr>
<tr>
<td>PAH SDS before GnRHa</td>
<td>-0.95±0.35</td>
<td>0.14±1.18</td>
<td>0.005</td>
</tr>
<tr>
<td>therapy duration [years]</td>
<td>3.7±2.2</td>
<td>2.8±1.90</td>
<td>0.066</td>
</tr>
<tr>
<td>hSDS after GnRHa</td>
<td>0.10±1.34</td>
<td>0.4±1.21</td>
<td>0.156</td>
</tr>
<tr>
<td>PAH SDS after GnRHa</td>
<td>-0.42±1.15</td>
<td>-0.3±1.23</td>
<td>0.806</td>
</tr>
<tr>
<td>Δ PAH SDS</td>
<td>0.53±0.99</td>
<td>-0.44±0.86</td>
<td>0.001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BA/HA</th>
<th>advanced</th>
<th>normal</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>age before GnRHa [years]</td>
<td>7.8±2.5</td>
<td>8.7±1.6</td>
<td>0.265</td>
</tr>
<tr>
<td>hSDS before GnRHa</td>
<td>0.97±1.15</td>
<td>2.03±1.16</td>
<td>0.001</td>
</tr>
<tr>
<td>PAH SDS before GnRHa</td>
<td>-1.40±0.93</td>
<td>0.60±0.97</td>
<td>0.001</td>
</tr>
<tr>
<td>therapy duration [years]</td>
<td>3.7±2.3</td>
<td>2.8±1.7</td>
<td>0.094</td>
</tr>
<tr>
<td>hSDS after GnRHa</td>
<td>0.32±1.17</td>
<td>1.41±1.23</td>
<td>0.001</td>
</tr>
<tr>
<td>PAH SDS after GnRHa</td>
<td>-0.96±0.93</td>
<td>0.31±1.05</td>
<td>0.001</td>
</tr>
<tr>
<td>Δ PAH SDS</td>
<td>0.42±0.94</td>
<td>-0.28±1.05</td>
<td>0.032</td>
</tr>
</tbody>
</table>

Conclusions: The therapy with GnRHa proved to be effective in improving height prognosis only in children with advanced BA.

A 9 year old prepubertal girl with genital bleeding: premature menarche?
Volker Böttcher1; Patricia G Oppelt2; Katharina Heusinger2; Matthias W Beckmann3; Helmuth G Dörm1
1University of Erlangen-Nürnberg, Pediatric Endocrinology, Erlangen, Germany; 2University of Erlangen-Nürnberg, Gynecology and Obstetrics, Erlangen, Germany

Background: Isolated premature menarche is a rare condition with unknown etiology. There is a predominance of FSH secretion. Before the diagnosis is accepted, all other causes of vaginal bleeding should be excluded.

Case presentation: A 9 year old German girl otherwise healthy was presented with suspected genital bleeding. Vaginal bleeding was at first assumed by the mother 5 months ago when she noted a blood-stained panty of her daughter. Any traumatic injuries or sexual abuse were denied. The girl did not report on abdominal pain, dysuria, incontinence or fever. Physical examination showed a prepubertal girl (height 131 cm, weight 30.3 kg, BMI 17.7 kg/m²; RSA, RR 104/65 mmHg) with fine pubical hairs (Tanner P2), no thelarche and normal, non-estrogenized external genitalia. Basal hormone levels were in the normal range for age (LH < 0.1 mU/ml, FSH 1.3 mU/ml, estradiol < 5.0 pg/ml, FT4 11.7 pg/ml, TSH 0.75 mU/ml, DHEAS 813 ng/ml). After GnRH stimulation, FSH increased more (13.2 mU/ml) than LH (3.4 mU/ml). Pelvic ultrasound showed a normal prepubertal size of uterus and ovaries. Bone age was not accelerated. The girl was presented to the pediatric gynaecologists. By vaginoscopy and urethrectomy a polypous mass was found located at the upper vaginal fornix beginning at the external urethral orifice. At the same time an exploratory excision of the polypous mass was extracted, and histologically confirmed as haemangioma. Currently, it is decided to wait and see in order not to vulnerate the sphincter of the urethra by any therapeutic procedures (e.g. laser- and cryotherapy).

Summary: In our case vaginal bleeding was due to a haemangioma. Thus, the diagnosis of premature menarche could be excluded.

Conclusions: Haemangiomas of the urethra and vagina are extremely rare in childhood. In a large series of 62 girls (< 10 yrs) genital bleeding resulted in 74% from a local lesion of the vagina (vulvovaginitis) > urethral prolapse, trauma > foreign bodies, tumors). Haemangiomas were not reported (Maia et al. Int J Gynecology & Obstetrics 1995).
HYPERLIPEMIA, GHD.

BA: 14ys, Ultrasound: small uterus and ovaries could not be detected, fatty liver, MRI: pituitary mass, decreased pituitary size, echogenic sella, middle cranial fossa hypoplasia, lateral ventricles increased. TPO and Tg antibodies are presented in Table 1. T3, T4, TSH were normal, GH peak of GH stimulating test 1.1 (normal range 2-10), ACTH 5 (normal range 8-35), cortisol 15 (normal range 14-23) and IGF-1 93 (normal range 100-200). Glucose is intrinsic to TS and is at the core of the high risk for DM, excess weight and an abnormal lipid profile, in particular excess triglyceride levels, worsened insulin sensitivity. So to detect and interfere with these disorders earlier are significant for TS patients.

Conclusions: It appears that β-cell dysfunction or insufficiency response to glucose is intrinsic to TS and is at the core of the high risk for DM, excess weight and an abnormal lipid profile, in particular excess triglyceride levels, worsened insulin sensitivity. So to detect and interfere with these disorders earlier are significant for TS patients.

PAO-198

Two cases report of Turner syndrome associated with metabolic syndrome
Ying Zhang; Ruimin Chen; Xiangquan Lin; Xiaohong Yang
Fuzhou Children’s Hospital of Fujian, Department of Endocrinology, Fuzhou, China

Background: Turner syndrome (TS) occurs in approximately one in 2500 female births and is characterized by short stature and sex hormone deficiency. However, it is becoming increasingly evident that patients with TS are also susceptible to a range disorders.

Method: We present two patients with metabolic syndrome (MS).

Results: Case 1, A 13.3ys female patient, karyotype was 45, X/XO, height 127.3cm (<-4.95SD), weight 39.7kg, shield thorax, several pigmented nevi on her face, no puberty signs. Elevation of hepatic enzymes (ALT 60 U/L), TG 5.89 mmol/L, CHOL 6.12 mmol/L, LDL: 1.06 mmol/L, fasting blood glucose, insulin, HBa1C, GH peak of GH stimulating test, LH, FSH, TPO, Tg antibodies are presented in Table 1. T3, T4, TSH were normal, BA: 10y, Ultrasound: small uterus and ovaries were not detected, fatty liver, MRI: pituitary mass, decreased pituitary size, lateral ventricles increased. Elevation of TSH (0.85%). On a second assessment the results were confirmed in 410 cases (recall rate 0.55%). Most of the babies were preterm. Only 52 of them (12.6 %) had birth weight ≥ 2500 g. and 47 (11.5 %) were born after the 36 week of gestation. The diagnosis classic CAH was confirmed in 7 children. Estimated prevalence for the country- 9.4 1:100 000. The treatment was started at average age 15.6 ± 8.3 (days). Three of the children with CAH were preterm (birth weight < 2500 g and gestational age < 36 gestational week).

Conclusions: The first data on CAH (classical forms) prevalence for the Bulgarian population obtained by NS do not differ significantly from the published results. The results show the importance of NS for the early diagnosis and initiation of treatment. Constant improvement of the existing screening logistic is possible during expansion of the screening programs.

PAO-200

Efficacy and safety of adenotonsillectomy in Italian children affected by Prader-Willi syndrome
Benedetta Mariani1; Bruna Cammarata2; Elena Grechi2; Paola Sogno Valin1; Stefania Di Candelier3; Giuseppe Chiumento4; Salvatore Toma5; Francesca Paloantina2; Leone Giordano5
1IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Department of Pediatrics, Endocrine Unit, Milan, Italy; 2IRCSS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, ENT Department, Milan, Italy

Introduction: Children affected by Prader-Willi syndrome (PWS) frequently suffer from sleep-associated breathing disorders, because of muscular hypotonia, obesity, sticky saliva, adenotonsillar hypertrophy and craniofacial dysmorphism. Adenotonsillar hypertrophy is the main cause of nocturnal respiratory pathy with obstructive sleep apneas (OSAS).

If left untreated, it may result in severe complications: excessive daytime sleepiness (EDS), neurocognitive impairment, behavioral problems and pulmonary heart disease. EDS is a common feature in PWS: it begins in childhood and can interfere with school and social activities, providing a significant decline in quality of life. Adenotonsillectomy (A&T) represents the first line of treatment but several studies identified PWS population at high risk for postoperative complications: difficult awakening from anesthesia, hemorrhages, respiratory complications requiring reintubation and/or supplemental oxygen administration.

Material and methods: Eighty-one children underwent a complete otolaryngological examination (anterior rhinoscopy, oral and nasal endoscopy with a flexible fiberscope); nine children underwent surgery because of severe adenotonsillar hypertrophy (grade III or IV). All patients underwent nocturnal polysomnography and Multiple Sleep Latency Test (MSLT) preoperatively; five children underwent a second sleep study three months after surgery.

Results: No postoperative complications were observed in our group of patients. Preoperatively, mean sleep latency (MSL) was 5 minutes (range 3-8). The same study, performed after surgery, showed a significant improvement in daytime sleepiness (MSL 8.4 minutes; range 6-12).

Conclusions: None of the children in our group presented surgical complications, however caution regarding postoperative complications must be taken due to the high-risk profile related to PWS. Furthermore, our data demonstrates that surgery improves quality of life in PWS by contributing to decreasing EDS and increasing mean sleep latency.

PAO-199

First results from the screening for congenital adrenal hyperplasia in Bulgaria
Antonela Kostova1, Iva Stoeva; Radoslava Emilova
University Pediatric Hospital, Screening and functional endocrine diagnosis, Sofia, Bulgaria

Background: Congenital adrenal hyperplasia (CAH) is difficult to diagnose and potentially life-threatening in the neonatal period.

Objective and hypotheses: The objective of the present study is to analyze the first results from the novel Bulgarian neonatal screening (NS) for CAH for the period April 2010 - March 2011.

Methods: The level of 17-OH-Progesterone (17-OHP) in dried blood spot was assessed in all Bulgarian newborns (n=74 133). Until the end of 2010 we used only the cut-off value of 30 nmol/L for full-term infants at age 3-5 days. We began to apply the ISNS referent values since the beginning of 2011.

Results: An increased levels of 17-OHP were found in 637 cases (recall rate 0.85%). On a second assessment the results were confirmed in 410 cases (recall rate 0.55%). Most of the babies were preterm. Only 52 of them (12.6 %) had birth weight ≥ 2500 g. and 47 (11.5 %) were born after the 36 week of gestation. The diagnosis classic CAH was confirmed in 7 children. Estimated prevalence for the country- 9.4 1:100 000. The treatment was started at average age 15.6 ± 8.3 (days). Three of the children with CAH were preterm (birth weight < 2500 g and gestational age < 36 gestational week).

Conclusions: The first data on CAH (classical forms) prevalence for the Bulgarian population obtained by NS do not differ significantly from the published results. The results show the importance of NS for the early diagnosis and initiation of treatment. Constant improvement of the existing screening logistic is possible during expansion of the screening programs.
PAO-201

The medium and short-term effects of sinusoidal and vertical vibratory training on the musculoskeletal and endocrine system in healthy men

Musab Elmantaser1; Martin McMillan1; Sheila Khanina2; Karen Smith3; S. Faisal Ahmed3

1University of Glasgow, Department of Child Health, Royal Hospital for Sick Children, Glasgow, United Kingdom; 2Royal Infirmary, Clinical Biochemistry, Glasgow, United Kingdom

Introduction: The underlying mechanisms that explain the beneficial effect of whole body vibration (WBV) on bone health are unclear.

Aim: To compare the immediate and medium term effects of WBV using the Galileo platform (sinusoidal WBV (sWBV)) and the Juvent1000 platform (vWBV) on muscle function, endocrine status and markers of bone turnover.

Material and method: 10 healthy men (36.0±2.4 yrs) randomized into two groups; the first group stood on the sWBV and the second group stood on vWBV 3times/wk×2months. The measurements were performed at five timepoints (T) over 4 months. T0 (1 month pre-WBV), T1 (the first day of exercise), T2 (1 month post-WBV), T3 (2month WBV) and T4 (1month post-WBV).

Results: There were no significant changes in anthropometry, body composition or muscle function in the two groups at the end of the study period. The change in creatine kinase following exercise was similar in both groups. Both vibration platforms were associated with an immediate decrease (p<0.001) in cortisol following the exercise, but there was no difference in the decrement between the two devices. In the medium term, sWBV was associated with a reduction in median serum cortisol from 333 nmol/l (247-442) to 269 nmol/l (192-322) (p=0.04) whereas there were no significant changes in the vWBV group. Serum CTX, a marker of bone resorption fell significantly after 2months in the sWBV group from a median of 0.42ng/m1 (0.30,87) to 0.29ng/ml (0.20,49) (p=0.03).

Conclusion: WBV is associated with a fall in endogenous cortisol and a reduction in bone resorption particularly in those subjects who were exposed to sinusoidal vibration. Long-term comparative studies are required to further investigate the effect on bone.

PAO-202

An interesting case of delayed puberty associated with neurofibromatosis type 1 and hamartoma

Fiorella Galluzzi; Perla Scalini; Maria Luisa Vetrano; Cristina Manoni; Salvatore Seminara

University of Florence, Department of Sciences for Woman and Child's Health, Florence, Italy

Background: Neurofibromatosis type 1 (NF1) is one of the most common neurogenetic disorder. Complications are quite variable however the most frequent are optic pathway tumors (glioma), short stature and precocious puberty.

Objective and hypotheses: We report the case of a 14 yr old boy that occurred in 30 days from WBC
to HF.

Method: Clinical and laboratory investigations.

Results: Clinical history revealed a previous neurosurgical treatment for a ventricular hydrocephalus caused by a midbrain hamartoma, at the age of 12 yrs. The family history was negative. Upon examination, patient’s height was 176.7 cm (-25th centile), weight was 47.6 kg (-25th centile), height was 154.7 cm (< -25th centile) significantly below his genetic target (186 ± 7 cm) and he exhibited a decrease in growth rate. Tanner stage was G1 PH1, testis 2-3 mL. We observed several café-au-lait spots, of which 5 were recent onset, localized in the thoracic and sub-mandibular areas and on the right ankle, for which we formulated the hypothesis of NF1. Laboratory investigations revealed a peak of LH after GnRH stimulation. Karyotype was normal. Celiac desease, hypothyroidism, growth hormone deficiency were excluded. Bone age was correspondent to chronologic age therefore we excluded constitutional delay of growth and puberty. On suspicion of NF1 we also carried out: dermatological examination, which revealed signs compatible with NF1, ophthalmological exam, which showed one Lisch’s nodule in the anterior segment of right eye. MRI revealed a small midbrain hamartoma, normal morphology and amplitude of ventricles and pericerebral spaces, minimum herniation of the cerebellar tonsils and no areas of pathological impregnation.

Conclusions: This case is interesting for the association of hamartoma and NF1 with delayed puberty, when usually both diseases are associated with precocious puberty.

PAO-203

A novel mutation of abcc8 gene in congenital hyperinsulinism

Nurse1 Muratoglu Sahin1; Sibel Tulgar Kink1; Abdullah Kurt1; Deniz Anuk Ince1; Ayse Ecevit2; Andrew Hattersley3

1Baskent University, Pediatric Endocrinology, Ankara, Turkey; 2Baskent University, Neonatology, Ankara, Turkey; 3Peninsula Medical School, University of Exeter, Institute of Biomedical and Clinical Science, Exeter, United Kingdom

Background: Congenital hyperinsulinism (CHI) is a heterogeneous disease characterized by deregulation of insulin secretion resulting life-threatening hypoglycemia. Mutations of SUR1 gene (ABBC8) are responsible for 50-60% of CHI.

Objective and hypotheses: Herein we reported an infant who diagnosed CHI, due to a novel homozygote mutation (Q392H) in ABBC8 gene. The patient had very severe brain damage, despite early diagnosis and appropriate management.

Patient: A two-day-old baby boy was referred to our center due to resistance seizures. His parents were first degree relatives. At the admission, his hypoglycemia was detected and glucose infusion was started and elevated to 15 mg/kg/min. During hypoglycemia (glucose: 5 mg/dL) blood ketone was normal, ammonia level was normal, insulin: 400 uIU/mL, c-peptide:26.5 ng/mL. Blood glucose levels were elevated more than 30 mg/dl with IV glucon. He was diagnosed as CHI. Diazoxide, somatostatin were started and later nifedipine and uncooked corn starch were added to the therapy. The doses of the diazoxide, somatostatin and nifedipine were increased to maximum doses according to levels of blood glucose. Glucose infusion stopped after total enteral nutrition was tolerated. During follow up, in generally his blood glucose levels were within normal limits. Although hypoglycemia was seldomly detected, his neurological status never improved. The patient was found homozygous for this mutation. The patient died due to respiration failure at 4 months of life.

Conclusions: In CHI patients, genotype-phenotype correlations are unclear. In our case hypoglycemia was detected at the second day of life and severe medical treatment was started in emergence. Although, severe hypoglycemia was seldom, his neurological status did not improve. We hypothesized that, cerebral damage of hyperinsulinemic hypoglycemia might start in utero period due to severely affected phenotype by the novel mutation.

PAO-204

Hypercalciuria and renal function and in children affected by osteogenesis imperfecta

Francesco Dosi1; Elena Monti1; Grazia Morandi1; Evelina Minaes2; Milena Brugnara3; Paolo Cavazzer4; Rossella Gaudino2; Antoniazzi Franco2

1Pediatric Clinic, Department of Life and Reproduction Sciences, Verona, Italy; 2Pediatric Clinic, Department of Life and Reproduction, Verona, Italy

Background: Osteogenesis Imperfecta (OI) is an heterogeneous group of inherited disorders of connective tissue characterized by bone fragility, reduced bone mass, laxity of ligaments, blue sclera and different levels of low stature. Hypercalciuria is a condition characterized by an increased urinary calcium without hypercalcemia. It is characterized by an urinary calcium excretion >4mg/kg/die or urinary Ca/Cr ratio >0.21. The relation between hypercalciuria and OI had been already analyzed in several studies.

Objective: The aim of this study is to observe the incidence of hypercalciuria
We suggested that panhypopituitarism together with stress could result in Myxedema Coma (MC) due to central hypothyroidism together with panhypopituitarism. Patient was administered hormone replacement therapy, followed by oral administration of levothyroxine at a dose corresponding to 80% of the normal range. This was aimed at the replacement of electrolytes and erythrocyte then adrenocortical hormone deficiency. Hormone replacement therapy was administered without any evidence of kidney damage. It is important, in these children, to integrate Calcium and Vitamin D. Hypercalcemia and the treatment with bisphosphonates do not cause any significant kidney alteration. The next studies with DXA are going to make a better evaluation of the influence of hypercalcemia on bones of patients affected by OI.

PAO-205

Myxedematous coma due to secondary hypothyroidism with panhypopituitarism

Leyla Telhan1; Nihal Hatipoglu2; Mehmet Boyraz2; Onder Kilicarslan1; Derya Girgin1
1Sisli Ettil Training and Research Hospital, Pediatric Intensive Care Unit, Istanbul, Turkey; 2Sisli Ettil Training and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey

Introduction: Cranioopharyngiomas (CP) are rare brain tumors in children. The tumor itself or its subsequent surgical treatment causes the most common multiple hormone deficiency and replacement is frequently necessary. Myxedema coma (MC) is a rare, often fatal endocrine emergency. The majority of cases occur in primary hypothyroidism but in central origin is extremely rare. We report the case of a patient with panhypopituitarism due to a craniopharyngioma surgery, who developed myxedema coma due to pituitary hypothyroidism.

Case: A 12-year-old girl with loss of consciousness was admitted to a nearby hospital. She was transferred to our hospital for further hormonal evaluation and treatment. Her medical history was learned that she took multiple hormone replacement for two years because of CP had been operated, but she had no consciousness, hypotensive, bradycardic and hypothermic. Oxygen saturation was 75% without administration of supplemental oxygen. She had peribulbar, periorbital edema. Peripheral blood tests detected decrease in hemoglobin, serum sodium, potassium, calcium levels. All of the pituitary hormone levels was demonstrated as decreased. A thyroid function test reported undetectable levels of both freeT4(<0.67ng/dL), freeT3(<0.67ng/ml), TSH(>0.002 IU/mL). Magnetic resonance imaging of the pituitary gland revealed an empty sella. We initiated replacement of electrolytes and erythrocyte then adrenocortical hormone replacement therapy, followed by oral administration of levothyroxine at an initial dose of 600 mcg. As a result, the patient’s awareness level gradually improved. Following this, dosages were reduced. Our final diagnosis for the patient was PC due to central hypothyroidism together with panhypopituitarism.

Conclusion: We suggested that panhypopituitarism together with stress could rapidly cause MC in children. The reason of this case presentation is that MC is a rare case of secondary hypothyroidism with panhypopituitarism.

PAO-206

Differences in phenotype and genotype: growth in Pompe disease (PD)

Nesrin Karabul; Seyfullah Gökce; Andreas Herzog; Michael Beck
Children’s hospital, Villa Metabolica, Mainz, Germany

Background: Lysosomal storage disorders are very rare diseases that are characterized by a great variability in their clinical presentation. In order to gain experience in this complex field, a center of excellence must be established that covers all aspects of these conditions such as diagnosis, treatment and research. The Villa Metabolica at the Children’s Hospital of the University of Mainz is dedicated to provide diagnosis and multidisciplinary management for all patients affected by any of the about 50 known lysosomal storage disorders. We wanted to show the differences in Phenotype and Genotype in PD. Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body’s cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function.

Results: Actually we have 5 patients with infantile PD, 3 were too small for their gestation age (f. e.: genotype c.1637-2A>G c.1637-2A>G. Also we examined 15 patients with adult PD, one patient is 181 cm, 3 patients are 175 cm, the other are to small for their age (familial predisposition was considered). The growth hormone (GH) insulin-like growth factor (IGF) system is impaired in these cases in PD.

Conclusions: The overall objective of our investigations is to evaluate the long-term growth and development especially of patients with infantile-onset Pompe disease under treatment.

PAO-207

Menstrual cycle in adolescence and its relationship with parameters of metabolic syndrome

Isabel Boyraz1; Claudia Braga1; Lenora Leard1; Maria Cristina Kuschnir1; Daniela Rodeiro1
1UERJ, NESA, Rio de Janeiro, Brazil; 2UERJ, Endocrinol, Rio de Janeiro, Brazil

Background: Clinical evaluation of adolescents should include an assessment of the menstrual cycle (MC), with emphasis on changes in the pattern of the cycle that can represent the first sign of a systemic and evolutive disease as the metabolic syndrome (MS), whose clinical manifestation can occur only in adulthood.

Objective and hypotheses: The evaluation of changes in the pattern of CM may be the opportunity for early diagnosis and initiation of preventive and effective actions. Objective: Evaluate the menstrual cycle in adolescence and its relationship with parameters of MS.

Methods: Observational, comparative and transversal-cut study with 59 female adolescents aged between 12 and 19 and presence of at least one of factors: Overweight/Obesity. All of adolescents underwent a clinical evaluation with anthropometric and laboratorial data, composed of Fasting Glucose, Total Cholesterol, HDL-Cholesterol, Triglycerides, Oral Glucose Tolerance Test (Glucose 120) and Fasting insulin and Insulin post OGTT (insulin 120), Foliccile-Stimulating-Hormone (FSH), Luteinizing Hormone (LH), Total Testosterone (TT), Androstenedione. Two groups were created. G-1 adolescents with irregular cycles, and G-2 with regular cycles.

Results: 59 adolescents evaluated, 36 formed G-1, and 23 formed G-2. In statistical analysis it was observed :G-1 presented: Waist/Height (p=0,009), Waist (p=0,026), Fasting Insulin (p=0,009), Glucose 120 (p=0,002) , insulin 120 (p=0,0001), HOMA-IR (p = 0,0008), Triglycerides (p = 0,013), MS (p=0,0001) and POS (p=0,0001) greater and QUICK (p=0,008), G/I (p=0,002)

Conclusions: We believe that greater knowledge about the correlation between changes in menstrual cycle in adolescents and variables related to metabolic risk in this age group is very useful for an early screening that will enable the prevention of MS and related diseases.
PAO-208
An audit of the use of DDAVP for central DI at a single institution
Esieza Ikaezoboh; Valtza Tziateri; Mehul Dattani
UCL Institute of Child Health, Developmental Endocrinology Research Group, London, United Kingdom

Background: The use of DDAVP in childhood DI is currently non-evidence based.

Objective: We audited the use of DDAVP in patients with central DI diagnosed between January 2000, and December 2010. 32 patients with a history of DI were identified; 4 were excluded: DDAVP had been discontinued in 3, and a diagnosis of central DI was uncertain in one.

Population and methods: Diagnoses of the 28 (11 males) included patients were: Septo-optic dysplasia (SOD)–n=11; Crianiopharyngioma (CP)–n=7; Holoprosencephaly (HPE)–n=3; Langerhans Cells Histiocytosis (LCH)–n=3; Others–n=5. Medical records were retrospectively reviewed.

Results: The median age at diagnosis was 1.38 years (range: 0 – 13.84; N=23), with a mean duration of follow up of 260 (0 – 130) months. 64% were ACTH deficient. The mean daily dose of DDAVP required (N=25) was 226.36 (9.46 – 1019.40) mcg/m². Patients with CP and LCH required higher doses (375.85mcg/m² [mean age=9.6years] and 341.04mcg/m² [7.41years] respectively) whilst patients with SOD and HPE required lower doses (141.2mcg/m² [mean age=5.1years]; 70.78mcg/m² [6.6years] respectively). All patients were on oral preparations except for one who received intranasal DDAVP. Eight patients were on a twice daily dose whilst 20 were on a thrice daily dose at last follow up; 12.5% of children under 7 years were on a thrice daily dose whilst the proportion was higher (55%) in children over seven. 17 patients had relevant tests performed in the last 6 months, and 8 in the last year; data were unavailable in three. Mean plasma Na+ concentration (N=26) was 138.4 (131 – 155) mmol/l. 20 patients had paired urine and plasma osmolalities checked – 155) mmol/l. 20 patients had paired urine and plasma osmolalities checked.

Conclusions: Doses of DDAVP in our population vary according to age and underlying condition. In this high risk cohort, 89% of our patients had relevant tests over the past year and had no adverse events.

PAO-209
Effect of urtica dioica leaves distillate on blood glucose of patients with type 1 diabetes
Maryam Razzaghy-Azar; Hossein Zarei Aghbashahidi
Tehran University of Medical Sciences, H. Aliaashgar Hospital, Tehran, Islamic Republic of Iran

Background: Urtica dioica is an edible plant that is traditionally used for its different effects including lowering of blood glucose.

Objective and hypotheses: The aim of this study was to determine the glucose lowering effect of urtica dioica in patients with type 1 diabetes mellitus (T1DM).

Methods: This phase one study is registered as the number “IRT2010 08174585N1” and has ethical approval. It was done on 24 patients with T1DM aged 12 ± 2 years and duration of diabetes was more than 1 year. They had no chronic complication of diabetes or concomitant disorder. Distillate of urtica dioica leaves was prepared in the laboratory. Patients were divided into 8 groups of 3 subjects and were studied in 6 days. In the first 3 days, they did not receive the solution but in the second 3 days, they drank urtica distillate in the morning as well as while they were on usual insulin therapy. The carbohydrate counting of their foods were equal on these two periods. Their blood glucose was monitored by continuous glucose monitoring system (Medtronichydrate) for 5 minutes in these 6 days. Total daily blood glucose and insulin compared by paired T test on these two periods (SPSS 12). The first group received 30 ml/M2 of the solution and the other groups received 15 ml/M2 more than the previous one up to 150 ml/M2.

Results: Mean blood glucose in the second period and on day 6 were 201 ± 48.6 mg/dl and 194.75 ± 55 respectively that were significantly lower than first period (218 ± 50) (P=0.017, and 0.014 respectively). The total dose of insulin did not change during these periods.

Conclusions: Urtica dioica leaves have a substance with blood glucose lowering effect in T1DM.

PAO-210
Coagulation-factor deficiencies and abnormal bleeding in Noonan’s syndrome
Gabriella Gamba1; Francesca Marabotto; Laura Losa; Gabriele Rufti; Luisa Strocchio2; Arianna Zaroli; Mariangela Cistermíno
1University of Pavia, Department of Internal Medicine - IRCCS Fondazione Policlinico San Matteo, Pavia, Italy; 2University of Pavia, Department of Pediatrics - IRCCS Fondazione Policlinico San Matteo, Pavia, Italy

Background: Noonan syndrome (NS) is a congenital autosomal disorder, characterized by dysmorphic facies, congenital heart defects, short stature and other anomalies including coagulation abnormalities not fully studied so far.

Objective and hypotheses: The aim of this study was to evaluate phenotype typical features, gene mutations and coagulation parameters in a cohort of NS patients.

Method: We studied 19 NS patients (10 M, 9 F), 12 probands and 7 first degree relatives, we found in 7/19 a mutation of PTPN11, in 8 of SOS1 and in 1 case of SOS1/RAF1, the remaining 3 cases were mutation-negative.

Results: A positive history for abnormal bleeding was found in 9 patients (47%), a prolonged PTT in 5 cases (26%), coagulation factors deficiency in 9 patients (47%) and abnormal platelet aggregation in 8 cases (44%); the coagulation abnormalities were found both in patients with a history of abnormal bleeding and in 6 cases (60%) without clinical evidence of bleeding disorders. The coagulation abnormalities were reported both in patients with or without a mutation and were not correlated with a mutation of a specific gene. Important differences in haemostatic status were found between probands and their relatives: the former showed coagulation abnormalities in the majority of the cases while the latter showed a history of bleeding diathesis, but normal laboratory hematological findings. The coagulation abnormalities were more frequent in patients with heart defects; however, a history of bleeding diathesis was detected in patients without cardiopathy.

Conclusions: A high frequency of coagulation abnormalities was found in NS. These abnormalities do not seem to be related with the patients’ genotype. The heart defects should not be the only cause of the haemostatic disorders. The bleeding disorders, as well as the other phenotype NS features, tend to decrease with age. Our advice is to screen patients with NS for bleeding diathesis to avoid bleedings and post-operative complications.

PAO-211
Puberty as precipitating factor of type 2 diabetes. Prospective 5 years clinical and biological study
Corina Paul; Pulu Iluian Veilea; Ionela Tamasan; Oana Alexandra Veilea
1University of Medicine and Pharmacy V.Babes, Clinic II Pediatrics, Timisoara, Romania; 2University of Medicine and Pharmacy V. Babes, Department of Parodontology, Timisoara, Romania

Aim: The relation between puberty and the onset of type 2 diabetes in obese children.

Material and method: Within 2006-2010, we studied 95 children with primary obesity. We monitored: family history of DM, clinical signs of insulin resistance (obesity, anacanthosis nigricans), biologically we assessed the OGTT, lipids metabolism, HbA1c, HOMA index every six months.

Results and discussions: At diagnosis 38 cases presented mild obesity, 32 cases medium obesity while 25 cases were severely obese. Neither one presented clinical symptoms of diabetes. We found positive family history of type 1 and/or type 2 DM in 12 cases. At the first visit, fasting blood glucose was normal in all cases; 18 cases were diagnosed as having impaired glucose tolerance and 1 case type 2 DM (with severe insulinresistance HOMA >5). HbA1c level was normal. In all cases we recommended hypocaloric diet. Af- ter 3 years of follow-up 4 more cases (2 F, 2 M) pubertal age, were diagnosed as type 2 DM. Anti GAD 65 and ICA were negative in the 5 children with type 2 DM. The metabolic desequilibrium was confirmed by the increased level of HbA1c in all 5 cases. 4 of these 5 children had positive family history for DM (3- type 2 and 1- type 1 DM). In 4 cases we initiated therapy with Metformin 2 x 500 mg/ day. After 3 months of therapy HbA1c levels decreased significantly. In the 5th case, with severe insulinresistance HbA1c normalized with diet. At the time of diagnosis 3 of 5 cases with type 2 DM had normal weight (for age,height and sex), puberty being considered the precipitating factor for
Background: Adrenarche may have a positive effect on erythropoiesis at prepubertal age.

Methods: We examined 64 prepubertal children with PA (clinical signs of adrenarche) and serum DHEAS ≥1 µmol/l; 54 girls and 10 boys, and 62 age- and sex matched controls (52 girls, 10 boys) without clinical or biochemical signs of adrenarche. All subjects were clinically examined, and analyzed for serum steroid concentrations and blood count. Mann-Whitney test was used to compare the differences between the study groups along with Univariate linear model. Pearson correlation test was used for analyzing correlations.

Results: Children with PA had higher erythrocyte count than their prepubertal controls [mean 4.7 (95% confidence interval 4.7-4.8) vs. 4.6 (4.5-4.6) E12/l, P=0.01]. The difference in erythrocyte count remained significant after adjustment for age and sex (P=0.04). There was also a small but significant difference in the mean blood hemoglobin concentration between the PA and control children [130 (128-132) vs. 128 (126-130) g/l, P=0.03]. No differences between the groups were found in the mean corpuscular hemoglobin, corpuscular volume or blood leukocyte count. In the entire study population, erythrocyte count was positively correlated with DHEAS, IGF-I and BMI SD score, and hemoglobin concentration with DHEAS, IGF-I and height SD score.

Conclusions: Relative small increases in androgen concentrations due to adrenarche may have a positive effect on erythropoiesis at prepubertal age.

PAO-214
Evaluation of 1218 oral glucose tolerance tests in children and adolescents
Andreas Schuster; Jennifer Krueger; Judith Großé-Sudhues; Annette Richter-Unruh
Endokrinologikum Ruhrt, Pediatric Endocrinology, Bochum, Germany

Background: In our outpatient department we evaluated 1218 oral glucose tolerance tests (oGTT) for impaired glucose tolerance (IGT), impaired fasting glucose (IFG), insulin resistance syndrome (IRS) and Type 2 Diabetes (T2D).

Objective and hypotheses: The indication for oGTT was obesity (n=1052), small for gestational age (SGA) (n=96), SHOX- Gen deficiency/ Ullrich Turner Syndrome (UTS) (n=55) and Prader Willi Syndrome (n=25) before or during growth hormone therapy, as well as IRS at follow up (n=39) and risk factors for disturbance of the glucose homeostasis (n=48).

Methods: All subjects underwent in our ambulance a two hour oGTT (1,75g glucose per kilogram bodyweight, maximum 75g). Following parameters were measured/collected: fasting-, 1- and 2 hour glucose and –insulin, HOMA, HbA1c, weight, body mass index.

Results: The older the children the percentage of impaired fasting glucose and impaired glucose tolerance were rising up from about 12% to 35%. We detected Type 2 Diabetes in children between eight to ten years in one percent, between 10-13 years in three cases and in group older than 13 years of age in 2.1 percent. All patients were obese. The percentage of insulinresistance defined as a fasting insulin greater than 15μU /L and/or a peak insulin greater than 150μU /L (S. Ten, J.Clin. Endocrinol. Metab. 2004;89:2526-2539) was as higher as older the patient evaluated. The HOMA IR >2,5 climbed up from 28% in the younger prepubertal group to 80% in the older subjects. The highest risk factor to develop impaired glucose tolerance, insulin resistance and Type 2 Diabetes was obesity in pubertal children.

Conclusion: In obese children change in lifestyle has to begin before onset of puberty. Performance of OGTT is important to detect insulin resistance as major risk factor to develop Type 2 Diabetes. Insulin und glucose results of non obese children differ from obese children.

PAO-213
Blood count in prepubertal children with premature adrenarche
Pauling Utriainen; Jarmo Jääskeläinen; Raimo Voutilainen
Kuopio University Hospital and University of Eastern Finland, Department of Pediatrics, Kuopio, Finland

Background: Premature adrenarche (PA) refers to earlier than normal increase in adrenocortical androgen production, mainly DHEA and DHEAS, in mid-childhood. Adrenal DHEA and DHEAS are androgen precursors that are converted to more potent androgen receptor agonists in peripheral tissues. Androgens are known to enhance erythropoiesis.

Objective and hypotheses: We hypothesized that PA could affect blood hemoglobin concentration or erythrocyte count at prepubertal age when androgen production in gonads is low.

Methods: We examined 64 prepubertal children with PA (clinical signs of adrenarche and serum DHEAS ≥1 nmol/l; 54 girls and 10 boys), and 62 age- and sex matched controls (52 girls, 10 boys) without clinical or biochemical signs of adrenarche. All subjects were clinically examined, and analyzed for serum steroid concentrations and blood count. Mann-Whitney test was used to compare the differences between the study groups along with Univariate linear model. Pearson correlation test was used for analyzing correlations.

Results: Children with PA had higher erythrocyte count than their prepubertal controls [mean 4.7 (95% confidence interval 4.7-4.8) vs. 4.6 (4.5-4.6) E12/l, P=0.01]. The difference in erythrocyte count remained significant after adjustment for age and sex (P=0.04). There was also a small but significant difference in the mean blood hemoglobin concentration between the PA and control children [130 (128-132) vs. 128 (126-130) g/l, P=0.03]. No differences between the groups were found in the mean corpuscular hemoglobin, corpuscular volume or blood leukocyte count. In the entire study population, erythrocyte count was positively correlated with DHEAS, IGF-I and BMI SD score, and hemoglobin concentration with DHEAS, IGF-I and height SD score.

Conclusions: Relative small increases in androgen concentrations due to adrenarche may have a positive effect on erythropoiesis at prepubertal age.

PAO-215
Treating pediatric obesity using an interdisciplinary supported treatment -Cigotica programme
Snezana Lesovic; Nenad Crcovic
Special Hospital "Cigota", Pediatrics Department, Zlatibor, Serbia

Introduction: The advantage of the ‘Cigotica’ programme is the multidisciplinary approach to treating obese children, which implies specific education, dietetic interventions with the reduction in the total daily calorie intake, physical activity, medical, educational and psychological support, change of behaviour and lifestyle.

Objective: To define obesity complications, metabolic risk factors and treatment effects when it comes to body composition and metabolic parameters in adolescents. Programme:

Methods: 1.030 adolescents were examined (498 girls and 332 boys), aged 12 to 18, average age 15.45, diagnosed with primary obesity, hospitalised
at the Centre for the prevention, treatment and rehabilitation of obesity in children in the period from 27/07/2008 to 03/10/2010. Hospitalisation lasted 21 days.

Results: After the multidisciplinary treatment, the average reduction in body mass (p<0.05) in all adolescents was 5.92 ± 2.71 kg. During the 21-day hospitalisation, the average BMI was reduced by -12.1 ± 0.31 in all examinees, the BMI Z-score was considerably lower in all examinees upon release and it was (p<0.05) -0.26 ± 0.08. % of fat was considerably lower (p<0.05) in all examinees -1.65 ± 0.23, the waist circumference was reduced by -7.85 ± 3.01. Hypertension was observed in 28% of adolescents. Two factors of metabolic syndrome were present in 27.6%, and metabolic syndrome was present in 18.3% of the examinees. The disorder in sugar transport was observed in 8.9% of the examinees.

Conclusions: The effects of the ‘Cigotica’ programme are very encouraging and they show that the multidisciplinary approach directed towards the reduction in energetic intake, education, change of lifestyle and habits related to nutrition and physical activity, leads to a considerable reduction in body mass, improvement in blood pressure, laboratory analyses, aerobic capacities and self-confidence in obese adolescents.


**PAO-216**

**Prevalence of cryptorchism, retractile testis and orchiopexy in children**

Shakhrizza Sultanova  
Endocrinology, Paediatric-endocrinology, Tashkent, Uzbekistan  

**Background:** Cryptorchism represents the most common congenital defect of the male urogenital system. It may be an important cause for male infertility. Very variable figures on the incidence of cryptorchism have been described in different type of studies.

**Objective:** The aim of the present study was to establish the prevalence of the abnormality in Uzbekistan population living in the Tashkent city and Tashkent region.

**Patients/methods:** In total there were surveyed 3417 children and adolescents at the age from 3-14 years. The testis determination was carried out by palpation method.

**Results:** As a whole, the frequency of cryptorchism was 1.2% for boys between 3 years and 14 years. The frequency of pathology was 2.5% for those of between 3 and 6 years, retractile testis was 5.2%, there were no cases of cryptorchism differs significantly from the prevalence reported fifteen years ago. Is it was show prevalence of cryptorchidism, on Uzbek population correlates with those of foreign sources.

**Conclusions:** The effects of the 'Cigotica' programme are very encouraging and they show that the multidisciplinary approach directed towards the reduction in energetic intake, education, change of lifestyle and habits related to nutrition and physical activity, leads to a considerable reduction in body mass, improvement in blood pressure, laboratory analyses, aerobic capacities and self-confidence in obese adolescents.


**PAO-217**

**Cushing syndrome due to adrenocortical carcinoma in an infant**  
Emin Dilek1; Veyssel Oz2; Dideem Bezen3; Mustafa Inan4;  
Fulya Ozyuyan1; Filiz Tutunculer1  
1Trakya University School of Medicine, Pediatric Endocrinology, Edirne, Turkey; 2Trakya University School of Medicine, Department of Pediatric Surgery, Edirne, Turkey; 3Trakya University School of Medicine, Department of Pathology, Edirne, Turkey

**Background:** Adrenocortical tumors are the most common cause of endogenous Cushing syndrome in infancy and early childhood. We present an infant with Cushing syndrome due to adrenocortical carcinoma.

**Case:** A 15 month-old female child was referred to the hospital with a history of progressively increasing weight gain, appetite, terminal hair growth on the back and limbs but arrested growth rate since 4 months. There was no history of oral intake and topical application of steroids. Physical examination revealed weight of 9 kg (25p), length of 69,5 cm (3-10p), blood pressure 80/40 mmHg, cushingoid features with moon face and facial plethora. Rest of the physical examination was unremarkable. She had no cliteromegaly. Serum assays confirmed hypercortisolemia with loss of diurnal variation for cortisol secretion (8 am: 27.05 µg/dl, 03 pm: 21.64 µg/dl, 11 pm: 22.63 µg/dl) and a concomitantly suppressed ACTH level<5pg/ml. DHEA-S<15µg/dl (5-57), androstenedione [0,9µg/ml (0,8-5)], total testosterone [<0,1ng/dl (0,1-1,3)] were normal. Abdominal ultrasound showed 30x40 mm intra-abdominal mass arising from the left adrenal gland. Magnetic resonance imaging also detected a solid mass 40x45 mm in the left adrenal gland. She was operated on left adrenalectomy under perioperative glucocorticoid coverage. Histopathological examination confirmed adrenocortical carcinoma. She was discharged 20 days after surgery on hydrocortisone 4 mg/day. She is doing well on hydrocortisone and has not shown any sign of disease recurrence during follow up.

**Conclusions:** Although Cushing syndrome is rarely seen in infants, the pediatricians should take it into consideration in cases presenting with rapidly weight gain and decreasing growth rate in infancy.


**PAO-218**

**Do children with growth hormone deficiency diagnosed on the strength of one growth hormone stimulation test grow better than patients diagnosed on the strength of two stimulation tests on GH replacement therapy?**

Suneela Nayak; Ali Ng; Swati Upadrastha; Urmil Das;  
Poonam Dharmaraj; Joanne Blair; Mohammed Didi  
Alder Hey Childrens Hospital, Paediatric Endocrinology, Liverpool, United Kingdom

**Background:** A recent consensus statement recommends the use of two growth hormone (GH) stimulation tests for the diagnosis of GH Deficiency (GHD) in childhood. Some clinicians have used a single GH stimulation test because of the high frequency of distress that such tests cause children and the lack of a strong evidence base to the recommendation, while others have followed the recommendation.

**Objective:** To compare the change in height (Ht) Standard deviation score during the first year of GH treatment in subjects diagnosed with Idiopathic Isolated GHD (IGHD) following one GH stimulation test (GHST) to those diagnosed following two GHSTs.

**Methods:** A retrospective case note review of all patients diagnosed with IGHD was undertaken in a single tertiary endocrine centre between 2003 and 2009. Patients were categorised in to those who had 1 test (Group1) and two tests (Group 2). Height at diagnosis, 3-8 months and 9-15 months after starting treatment with GH was identified. Ht SDS at baseline and change in Ht SDS (ΔHt SDS) at each time point during treatment was compared using the Mann Whitney U test.

**Results:** 19 patients were studied. Results are summarised in table 1. Data presented as median(range). Table 1. Ht SDS at diagnosis and ΔHt SDS for patients at the three time points during treatment with GH.

<table>
<thead>
<tr>
<th>Group 1 [n=12]</th>
<th>Group 2 [n=7]</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ht SDS at diagnosis</td>
<td>-2.7 (-0.9 to -4.5)</td>
<td>-2.5 (-1.9 to -3.5)</td>
</tr>
<tr>
<td>ΔHt SDS 3-8 months</td>
<td>0.2 (0.1 to 0.4)</td>
<td>0.5 (0.3 to 0.8)</td>
</tr>
<tr>
<td>ΔHt SDS 9-15 months</td>
<td>0.3 (-0.1 to 0.8)</td>
<td>0.3 (0.1 to 0.8)</td>
</tr>
</tbody>
</table>

**Conclusions:** Patients with IGHD diagnosed on the strength of one and two GHST show no difference in the growth response in the first year when on optimal GH replacement therapy.


**PAO-219**

**Prevalence of metabolic syndrome (IDF 2007 criteria) in obese children and adolescents**

Dideem Bezen1; Emin Dilek1; Filiz Tutunculer1; Necdet Sut1  
1Trakya University School of Medicine, Pediatric Endocrinology, Edirne, Turkey; 2Trakya University School of Medicine, Biostatistics, Edirne, Turkey

**Background:** Metabolic syndrome (MS) frequency is increased in proportion to the increasing prevalence of obesity in children and adolescents.

**Objective and hypotheses:** This retrospective study was performed to de-
termine the prevalence of MS and its risk factors in obese children and adolescents.

**Methods:** A total of 198 (101 males, 97 females) obese children from 10 to 16 years old were involved in the study. International Diabetes Federation (IDF 2007) criteria were used to diagnose the MS classification. Each patient underwent auxological evaluation, blood pressure (BP), blood samples and oral glucose tolerance test (OGTT). Homeostasis model assessment of insulin resistance (HOMA-IR) has been calculated. Patients were divided into two groups according to the presence of MS.

**Results:** The overall prevalence of MS in our study was 38% with no inter-
sex difference. Mean age was 12.7±1.62 years. Eighty nine percent (n=176) of the patients were pubertal and MS was more often in this group. The preva-
\[\text{ldL-C level was significantly lower in MS group when compared to non-MS group. All of the anthropometric measurements and BP levels were found higher in the MS group than those in the non MS group as expected. When we analyzed the cardiovascular risk factors; fasting blood glucose levels, insulin resistance, levels of total cholesterol, prevalence of IGT, hyperinsulinemia were significantly higher but HDL level was significantly lower in MS group when compared to non-MS group. LDL-C levels were found to be similar between two groups.}

**Conclusions:** MS prevalence at diagnosis is high (38%) in obese children. When cardiovascular risk factors are considered, the increase in the MS frequency gets more important for the future of children.

**PAO-220**

**Central precocious puberty unresponsive to LHRH analogue treatment in a patient with chromosomal anomaly and cerebropathia**

Alessandra di Lascio1; Silvia Laura Carla Meroni1; Elena Grechi1; Gianni Russo1; Maria Pia Guarneri2; Stefano D’Amigo3; Giuseppe Chiumento4

1San Raffaele Scientific Institute, Department of Pediatrics, Milan, Italy; 2C. Besta Neurologic Scientific Institute, Department of Neurology, Milan, Italy

**Background:** The treatment of central precocious puberty (CPP) is based on LHRH analogue (LHRH-a) with a good hormonal inhibition.

**Objective and hypotheses:** Our aim is to describe the case of a children with chromosomal alteration, cerebropathia and CPP, who does not respond to the treatment with LHRH-a.

**Population:** The patient, born at 38 gestational weeks, showed hypospadias, microcephaly and some dysmorphic notes. He presented a neuropsychic development delay and seizures, so at the age of 2 years he started antiepileptic treatment. The karyotype was 46XY, the array CGH showed [del(1)(q411)] and [del(7)(q36.1q36.3)]. At 6 months of age he developed pubic hair and then increase in testicolar (5 ml) and penile size. The hormonal investigations (1 year 7 months) showed the activation of hypotalmus-pituitary-gonadal axis (LH peak 18.3 mU/ml, testostosterone 1.94 ng/ml), normal adrenal function and advancement of the bone age, suggestive for CPP. The NMR did not demonstrate anomaly of the brain and the hypotalmic-pituitary region. He started treatment with LHRH-a.

**Results:** The treatment with LHRH-a did not permit an adequate inhibition of the hypotalmus-pituitary-gonadal axis and it also caused an advancement of the pubertal development (basal LH 4.3 mU/ml, testostosterone 6.27 ng/ml), in presence of a good compliance. At 2 years and 2 months the treatment with LHRH-a was stopped and the treatment with luteolozle and cyproterone acetate was started.

**Conclusions:** In our patient the treatment with LHRH-a failed to induce hormonal inhibition. To our knowledge, similar cases are not reported. The possible causes of this failure are unclear: the genetic alteration, the poten-
tial alteration of pharmacokinetic of LHRH-a and the cerebropathia may be involved. Investigations to assess the reliability of these assumptions are in progress.

**PAO-221**

**A 30 year review of congenital adrenal hyperplasia in Northern Ireland**

Jenny Dixon1; Dennis Carson2

1Paediatric Endocrinology, Royal Belfast Hospital for Sick Children, Belfast, United Kingdom

**Background:** Congenital adrenal hyperplasia (CAH) is an autosomal recessive condition with significant consequences if not correctly diagnosed and treated. We have reviewed the patients with CAH presenting in Northern Ire-

**Aims:** To determine the age, sex and clinical features at presentation; treat-
ment modalities including perinatal surgery in childhood; and long-term out-
comes including final height and surgery in adulthood.

**Methods:** The medical notes of patients diagnosed with CAH in this time pe-
riod were reviewed. A literature review was performed and our data compared with that previously published.

**Results:** 37 patients (22 female, 15male) from 30 families presented with CAH over this time period giving an incidence of 1:23,092 live births. 18 (49%) were diagnosed shortly after birth (83% virilised females); 13 (35%) presented in the first few weeks of life with adrenal crises (85% male); and 6 (16%) presented with virilisation in later childhood. 6 (16%) children had diagnosis confirmed on genetic testing. All children required glucocorticoid replacement. 35 (95%) required mineralocorticoid replacement; 3 children were treated with human growth hormone and 2 children required suppression of early puberty. Mean final height was -1.55SD below mean adult height in boys and girls. In the first 16 years reviewed, 8 (80%) girls had perinatal surgery in childhood, compared with 2 (16%) in the second 18 years. 2 (9%) women had adrenalectomy. 11 (58%) of those transferred to adult services have been lost to follow-up. All patients were adequately treated in adolescence.

**Conclusions:** The incidence of CAH is less here than in the rest of the United Kingdom with more females affected than males. The majority present in the first few weeks of life. Mean final height is often impaired. There is a trend towards later surgery in these children. There is a heightened need for effective transition to adult services given the large percentage lost to follow-up in adolescent years.

**PAO-222**

**A rare cause of precocious puberty: β-hCG secreting tumor**

Silvia Laura Carla Meroni1; Alessandra di Lascio1; Matilde Ferrario1; Gianni Russo1; Maura Massimino1; Giuseppe Chiumento1

1San Raffaele Scientific Institute, Department of Pediatrics, Milan, Italy; 2Sant’Anna Hospital, Department of Pediatrics, Como, Italy; 3National Scientific Tumor Institute, Department of Pediatrics, Milan, Italy

**Background:** Beta human chorionic gonadotropin (β-hCG) secreting tu-
mours are a recognized cause of precocious puberty (PP), almost exclusively
in boys. These tumours may occur in gonads, liver, retroperitoneum and me-
diastium or within the central nervous system (CNS).

**Objective and hypotheses:** We present one case of PP due to β-hCG secre-
ting tumor, whose site was difficult to determine.

**Population:** The boy came to our attention at age 6 years. Neurological ex-
amination was normal. Physical examination showed scrotal hair, enlarged penile and testes (4 mL) size and gynecomastia. Hormonal test revealed suppressed levels of gonadotropins at LHRH test (FSH peak 0.6 mIU/mL, LH peak 0.5 mIU/mL), increased testosterone 3.47 ng/mL, normal adrenal function, prolactin and α-fetoprotein and slightly higher β-hCG (6.8 U/L; nv 0-5 U/L).

**Results:** Hormonal picture was compatible with gonadotropin-independent PP due to β-hCG secreting tumour. To determine its site testicular and abdominopelvic ultrasound, thoracic CT, abdominal and CNS NMR were performed. These studies didn’t reveal any suspicious lesion, with the exception of a cyst-
tic-like aspect of pineal gland. A lumbar puncture was performed and revealed slightly higher β-hCG (11.3 U/L).

The abnormal cerebrospinal fluid (CSF)/serum ratio of β-hCG was slightly higher (11.3 U/L). At 6 months of age he developed pubic hair and then increase in testicolar (5 ml) and penile size. The hormonal investigations (1 year 7 months) showed the activation of hypotalmus-pituitary-gonadal axis (LH peak 18.3 mU/ml, testostosterone 1.94 ng/ml), normal adrenal function, prolactin and α-fetoprotein and slightly higher β-hCG (6.8 U/L; nv 0-5 U/L).

**Results:** Hormonal picture was compatible with gonadotropin-independent PP due to β-hCG secreting tumour. To determine its site testicular and abdominopelvic ultrasound, thoracic CT, abdominal and CNS NMR were performed. These studies didn’t reveal any suspicious lesion, with the exception of a cystic-like aspect of pineal gland. A lumbar puncture was performed and revealed slightly higher β-hCG (11.3 U/L).

The abnormal cerebrospinal fluid (CSF)/serum ratio of β-hCG was consistent with a CNS germ cell tumour. Although the tumour was not clearly identified, he underwent four courses of multi-agent chemotherapy (bleomycin, ethopo-
side and cisplatin) and ventricular radiotherapy. β-hCG and testosterone values fell to within the normal range after the first course, indicating significant re-
gression of the tumour. Nowadays the clinical and hormonal picture is stable.
Conclusions: β-hCG secreting tumours are a rare cause of gonadotropin-independent PP. Determining the site of the tumour may be difficult. Detection of both serum and CSF levels of β-hCG may be useful. β-hCG value was also an accurate indicator of the response to therapy.

Background: Neonatal thyrotoxicosis (NT) caused by maternal Graves disease is a rare disorder. In the newborn, characteristic signs and symptoms include tachycardia, irritability, poor weight gain, and prominent eyes. Rarely, infants with NT present with thrombocytopenia, jaundice and hepatosplenomegaly. We report an infant with hemorrhagic diathesis and congenital hyperbilirubinemia, who was diagnosed with NT due to maternal Graves disease.

Case: One month-old male infant was admitted to our hospital for further evaluation of a bleeding after vaccination. He was born vaginally at 38 gestational weeks to a 23 year-old primagravida mother, with a birth weight of 2550g. It was learned that his mother had Graves disease for 2 years and did not take propylthiourasil regularly during pregnancy. Physical examination revealed weight of 3100g (3p), height of 51 cm (3p), head circumference of 34 cm (<3p, -2SD), prominent eyes and 2x2cm hematoma at left inguinal region. The other physical findings were unremarkable. Laboratory studies showed normal hematological and coagulation parameters but mildly elevated transaminases (ALT 74IU/l, AST 55IU/l) and conjugated bilirubin (3.8 mg/dl). Blood and urine culture were negative as were titers for toxoplasmosis, rubella, CMV, herpes, hepatitis B and C. Metabolic screening tests were negative. Thyroid function tests revealed that the infant was suffering from NT (free T4 2.5 mg/dl (0.63-2.3), free T3 4.9 pg/ml (1.8-4.2), TSH 0.17 mIU/ml (0.4-8.6) and TSH-Ab 54U/l (0-9)). We decided to follow up him without treatment, because he had only biochemical thyrotoxicosis but not clinical. After 2 months, his congenital hyperbilirubinemia level resolved as well as thyroid hormone levels returned to the normal range.

Conclusions: We suggest that as infants born from mothers with Graves may develop different clinical signs, they should be followed up carefully and closely after birth.

Conclusions: 95% of Turner syndrome patients are known to have a final adult height 20 cm below the median parental height. It has been proven that these patients respond to rhGH treatment, despite the fact that they are not GH deficient.

Objective and hypotheses: Analysis of the effects of Somatropin therapy on the growth of Turner Syndrome patients and identification of the parameters that influence growth.

Methods: We analyzed a group of 30 patients with Turner syndrome who were treated in our board between 2002 and 2010. We measured and calculated: height, median parental height, growth velocity under treatment, bone age, IGF-I, predicted adult height without treatment, predicted final height when study was carried out.

Results: Mean age was 8.4 yrs (4.5 - 14 yrs); mean initial height was -3.18 SD below normal and 0.12 SD when compared to other girls with Turner syndrome of the same age; the mean period of treatment was 3.26 yrs (1-7 yrs) and the mean dosage was 0.327 mg/kg/week (0.27-0.42); growth velocity per year of treatment averaged at 7.02 cm and growth velocity per year of bone maturation at 5.94 cm. Predicted adult height (PAH) without treatment had an average of 142.6 cm, while the predicted final height, when the study was carried out had an average 150.7 cm. Thus, the mean benefit of the therapy is 8.1 cm.

Conclusions: We analyzed the significant correlations between the height benefit of the therapy and a series of auxometrical parameters. Even if we noted that IGF-I rose to considerably higher levels during the therapy, this phenomenon did not correlate significantly with the gain of centimeters per year of treatment or per year of bone maturation, which leads us to believe we may encounter a certain degree of resistance to the action of IGF-I in some patients. Under treatment the patients recovered an average of 1.98 SD from the growth retardation compared to normal adult females and an average of 1.95 SD from the genetic target height.

Conclusions: Does Letrozole in boys and GnRHα in girls with idiopathic short stature (ISS), constitutional precocious puberty (CPP), or being born small for gestational age (SGA) improve their prospective adult height?

Objective and hypothesis: To investigate the hypothesis that Letrozole in boys and GnRHα (leuprolide acetate) in girls are able to improve the prospective adult height (PAH).

Method: We retrospectively compared growth data of girls with CPP (n= 14, 50th Annual Meeting of the ESPE
median treatment period 2.4 years) and ISS (n=7, median treatment period 1.7 years) as well as data of boys with ISS (n=8, median treatment period 1.8 years) and SGA (n=5, median treatment period 3.0 years) before, during and after treatment. Girls born SGA (n=7, median treatment period 1.9 years) had an additional treatment with growth hormone. Near final height or adult height was reached by n=8 patients.

Results: Girls with CPP (n=4), treated with GnRHα, showed an improvement of their near final height or adult height in median by 6.2 cm. In girls born SGA (n=2), treated with GnRHα and growth hormone, the final height improved by median 8.9 cm. One boy with ISS, treated with letrozole, had an improvement of adult height by only 1.9 cm. However, one boy born SGA, showed an improvement of adult height by 15 cm according to Bayley-Pinneau. A transient decrease of bone density, as measured by the DEXA method, was observed. A patient questionnaire revealed no other relevant side effects due to the treatment with both Letrozole and GnRHα. Fig 1+2 show the reached gain of height.

Conclusions: Both medications seem to be able to improve the PAH. However, a small number of patients failed to improve the prospective adult height. In some patients, the adult height was reached and was higher than calculated before. Therefore, the therapy should be continuously supervised by a pediat- atric endocrinologist. Prospective controlled trials are necessary in future to confirm the results.

PAO-227
The one year catamnnesia in children from mothers after combine treatment of thyroid cancer
Iulia Davydova¹; Tatyana Kurilina²
¹Institution of Pediatrics, Obstetrics & Gynecology, Extragential pathology & perinatal rehabilitation, Kiev, Ukraine; ²Institution of Pediatrics, Obstetrics & Gynecology, Neonatology, Kiev, Ukraine

Background: The frequency of the thyroid cancer in Ukraine is 36:100000 per year and in twice more in women with the tendency to growth.

Objective and hypotheses: The protocol of the combine treatment include different variation of the extended thyroidectomy (in 2nd trimester), radiois- tine therapy, suppressive therapy by thyroid (2,3 mg/kg).

Method: Complex observation in neonatal period and one year follow-up performed in 30 infants from mothers after combine treatment of thyroid cancer.

Results: The most frequent complication of gestation period were threat of abortion, discoordination of the delivery, distress of the fetus, postpartum hemorrhage. Optimal development of the placental complex due to using of gestagens in the treatment complex of threat of abortion decreased morbidity of children during first month of life. In neonatal period 60 % of newborns received treatment of prolonged jaundice, 34 % - severe allergic reactions, 18 % - hypoxic-ischemic encephalopathy. Most every newborns had vegetative disorders (abnormality of microcirculation, regurgitation, breach of cardiac rhythm on the electrocardiogram, heightened disposition to sweating). The data of one year catamnnesis in 3, 6, 9, 12 months show direct close correlation between frequency of neurological pathology, allergic reaction, vegetative dysfunction and exhaustiveness of the postoperative hypothyroidism com- pensation, peculiarities of medication of threat abortion. The physiotherapy of perinatal encephalopathy must have been made out in 36 % of infants 3-6 months of life. Common conditions for all children from mothers after combine treatment of thyroid cancer are high frequency of rachitic, acute respira- tory infections, disorders of feeding and decreasing of frequency & duration of breast-feeding.

Conclusions: All this peculiarities make it possible to include children from mothers after combine treatment of thyroid cancer in high risk group for cre- ation prophylactic-treatment arrangements for them.

PAO-228
New onset type 1 diabetes in the pediatric population of a second level hospital: 12 years' review and evaluation of recent treatment and connection between hospitals
Ana Laura Fitas¹; David Lito²; Patrícia Ferreira²; Rosa Pina³; Florbela Cunha²
¹Hospital de Dona Estefânia, Hospital de Reynaldo dos Santos, Pediatrics, Lisbon, Portugal; ²Hospital de Reynaldo dos Santos, Pediatrics, Vila Franca de Xira, Portugal; ³Hospital de Dona Estefânia, Endocrinology, Lisboa, Portugal

Background: In the pediatric department of a Lisbon area’s second level hos- pital, new onset diabetes is managed in coordination with the tertiary hospi- tal’s endocrinology team.

Objective: To characterize the children with new onset type 1 diabetes (1999- 2011). To describe treatment procedures (2009-10) in order to evaluate the compliance to the 2008-Diabetic Ketoacidosis (DKA) National Protocol. To assess the need for improving the management of new cases without DKA.

Methods: Retrospective study. Clinical files were reviewed.

Results: 41 children were admitted, 3,4 new cases/year, with a modest in- creasing tendency. 61% females, median age 9 years. 90% previously healthy, only one obese child; 15% had type 2 diabetes in non-first degree relatives. All were admitted from the emergency department (44% referred with symp- tomatic hyperglycemia; 1 incidental finding). Classic new onset symptoms were the most common: polydipsia-93%; polyuria-83%; weight loss-68%; polyphagia-37%; lethargy-27%; 44% presented with DKA (severe in 10%). Median hospital stay was 2 days, with subsequent referral to endocrinology (66% to ward; 29% to consultation) and 5% to PICU. Concerning treatment after 2008 (n=13), insulin perfusion was administered to all ketoacidotic pa- tients, with median duration of 6 hours. Insulin perfusion in non-ketoacidotic patients was variable (prescribed to 44%). All but 2 patients started IV iso-
tomic saline with potassium. Saline was replaced by 5-10% dextrose when initiating insulin (91% after at least one hour of IV hydration). One patient required HCO₃ correction before transference to PICU. Intermediate-acting insulin was always started after 24h.

**Conclusions:** These epidemiological and clinical aspects are according to published reports. Overall compliance with DKA guidelines is satisfactory. The lack of uniformity in the management of new cases without DKA highlights the need for implementing uniform procedures and improving the connection pathways between second and tertiary level hospital in the management of new onset diabetes.

**PAO-229**

**Adequacy of implementation of recommendations of dietary intake in children with type I diabetes mellitus**

Lina Kapusta¹; Anzhalka Solntsaeva²

¹Belarusian State Medical University, Medico-psychotherapeutic faculty, Minsk, Belarus; ²Belarusian State Medical University, Department of Children’s Diseases, Minsk, Belarus

**Background:** Nutrition in diabetes mellitus type I in children is an important factor in treating the disease.

**Objective and hypotheses:** The aim of our study was to identify communication and the adequacy of the diet with the peculiarities of the clinical and metabolic status in children with type I diabetes.

**Methods:** An analysis of diet 1 day in 28 children with type I diabetes. Energy expenditure determined by the computational method of WHO at a rate of physical activity. Actual energy consumption calculated on the menu layout. The data obtained was subjected to statistical analysis in Excel, Biostat.

**Results:** Table 1: Actual feeding of children

<table>
<thead>
<tr>
<th>Indicators</th>
<th>Girls prepubertal period (15,7%)</th>
<th>Girls pubertal period (83,3%)</th>
<th>Boys prepubertal period (30%)</th>
<th>Boys pubertal period (70%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy value (%)</td>
<td>66,7 33,3</td>
<td>33,3 66,7</td>
<td>66,7 14,3</td>
<td>85,7 33,3</td>
</tr>
<tr>
<td>Proteins (%)</td>
<td>100 0</td>
<td>46,7 53,3</td>
<td>66,7 33,3</td>
<td>0 100</td>
</tr>
<tr>
<td>Fat (%)</td>
<td>33,3 66,7</td>
<td>20 80</td>
<td>66,7 33,3</td>
<td>28,6 71,4</td>
</tr>
<tr>
<td>Carbohydrates (%)</td>
<td>66,7 33,3</td>
<td>20 80</td>
<td>0 100</td>
<td>14,3 85,7</td>
</tr>
<tr>
<td>Calcium (%)</td>
<td>0 100</td>
<td>0 100</td>
<td>0 100</td>
<td>6,7 93,3</td>
</tr>
<tr>
<td>Magnesium (%)</td>
<td>100 0</td>
<td>73,3 26,7</td>
<td>100 0</td>
<td>42,9 57,1</td>
</tr>
</tbody>
</table>

**Conclusions:** In children prepubertal period dominated by an increase in energy value, at puberty - a decline. Excessive intake of protein, including animals, in children prepubertal period. Carbohydrate intake increased in girls prepubertal period. Fat intake increased in boys prepubertal period. Girls prepubertal period, an increase calories by excess consumption of protein and carbohydrates, the boys - protein and fat. At puberty there is an increase calories from fat and carbohydrates. Girls and boys prepubertal period body mass index as normal 33.3% and 66.7%, and at puberty there is a tendency to increase 53.3% and 57.1%. Excessive food intake in boys and girls to dominate the dinner 83.3% and 100% respectively.

**PAO-230**

**Trends in type I diabetes mellitus**

Majid Aminzadeh¹; Najmeh Navidi²

¹Diabetes Research Center, Ahzaz Jundishapur University of Medical Sciences, Pediatrics, Ahvaz, Islamic Republic of Iran; ²Ahvaz Jundishapur University of Medical Sciences, Pediatrics, Ahvaz, Islamic Republic of Iran

**Background:** Type 1 diabetes mellitus (T1DM) is the most common endocrine problem in childhood, with increasing worldwide incidence. The risk of developing diabetic ketoacidosis (DKA) is higher in children because of non-specific and non-classical signs and symptoms.

**Objective and hypotheses:** This study was designed to review trends in presentation and incidence of childhood diabetes in the last 10 years in southwestern Iran.

**Methods:** During a detailed review of compiled records of Abuzar Children’s Hospital from Jan 2000 to Dec 2009, the following clinical information relevant to diabetes were extracted and analyzed: admissions for diabetes, all data regarding demographics, clinical status, laboratory findings, hospital course, morbidity, and mortality.

**Results:** Excluding 129 repeated admissions, 297 cases were enrolled for analysis: 223 new and 74 known cases. Among the new cases, 67.3% presented with DKA, without any gender bias. Among the DKA subjects, 45% had some degree of unconsciousness, and the mortality rate was 4%. The mortality risk was significantly higher in the <2-year group and in girls (boy:girl=1:7; p=0.039). Despite the increase in the number of medical centres that manage diabetic children, there is a regular increase (nearly 50.5% rises over 5 years-Figure) in the disease incidence.

**Conclusions:** Most of the new cases of T1DM presented with DKA, and this is similar to the trend seen in other developing countries. With an increasing incidence of DM, more attention to education of families and periodic retraining of health staff is essential to enable earlier diagnosis and management of new subjects, and to reduce morbidity and mortality rates associated with the disease.

We aimed to investigate the relation between skinfold thickness and serum leptin, ghrelin, adiponectin and resistin levels in infants of diabetic mothers.

**PAO-231**

**The relation between skinfold thickness and leptin, ghrelin, adiponectin and resistin levels in infants of diabetic mothers**

Mustafa Kara¹; Zerrin Orbak²; Hakan Doneray³; Behzat Ozkan²; Fatih Akcay²

¹Ataturk University, Department of Pediatrics, Erzurum, Turkey; ²Ataturk University, Department of Pediatric Endocrinology, Erzurum, Turkey; ³Ataturk University, Department of Biochemistry, Erzurum, Turkey

**Objective and hypotheses:** This study was designed to review trends in presentation and incidence of childhood diabetes in the last 10 years in southwestern Iran.

**Methods:** During a detailed review of compiled records of Abuzar Children’s Hospital from Jan 2000 to Dec 2009, the following clinical information relevant to diabetes were extracted and analyzed: admissions for diabetes, all data regarding demographics, clinical status, laboratory findings, hospital course, morbidity, and mortality.

**Results:** Excluding 129 repeated admissions, 297 cases were enrolled for analysis: 223 new and 74 known cases. Among the new cases, 67.3% presented with DKA, without any gender bias. Among the DKA subjects, 45% had some degree of unconsciousness, and the mortality rate was 4%. The mortality risk was significantly higher in the <2-year group and in girls (boy:girl=1:7; p=0.039). Despite the increase in the number of medical centres that manage diabetic children, there is a regular increase (nearly 50.5% rises over 5 years-Figure) in the disease incidence.

**Conclusions:** Most of the new cases of T1DM presented with DKA, and this is similar to the trend seen in other developing countries. With an increasing incidence of DM, more attention to education of families and periodic retraining of health staff is essential to enable earlier diagnosis and management of new subjects, and to reduce morbidity and mortality rates associated with the disease.

We aimed to investigate the relation between skinfold thickness and serum leptin, ghrelin, adiponectin and resistin levels in infants of diabetic mothers. The mother two were diagnosed as having gestational diabetes by an Oral Glucose Tolerance Test (OGTT) performed between 24-28 gestational weeks, and their babies were included into this study. Mean HbA1C level between diabetic and control mothers were not significantly different. Mean Body Mass Index (BMI), abdominal circumference, upper extremity circumference, and biceps skinfold thickness were also not significantly different between infants of diabetic and control mothers. Our results indicate that early diagnosis of gestational diabetes and control by appropriate diet or insulin treatment may be effective in protection of fetuses of diabetic mother from the negative effects of gestational diabetes.
Correlation of childhood obesity with obesity at late adolescence and young adulthood

Elias Vlachopapadopoulos; Fotini-Eleni Karachalios; Pelagia Soutoulou; Stefanos Michalakos
Children’s Hospital P&A. Kyriakou, Growth and Development, Athens, Greece

Aim: The aim of this study is to answer the question whether an obese child becomes an obese adolescent and/or obese young adult.

Methods: It’s a follow-up study of obese children followed in our department for the time period 1997-2006. We contacted 234 (109 M) of them during the last trimester of 2010, and they were asked to answer a semi-structured questionnaire. The questionnaire included questions regarding sociodemographic data of the family, current height and body weight of the index case, factors that in their opinion affect weight control. At present 141 cases were contacted, from them 43 were not available because of address change, 3 refused to participate and 22 were excluded because of young age (< 16 yrs old). The response rate is 96.6%. To analyze the data we used descriptive statistics.

Results: The two sexes were equally represented in both the childhood sample (46.5% M and 53.4% F) and the follow-up sample (46.7% M, 53.3% F). Of this cohort of obese children, at follow-up, 24.7% were obese, 32.6% were overweight and 42.7% were of normal weight. More than half, 52.8%, were overweight and obese at follow-up. Examining the sexes separately, 7.9% of the women were obese and 22.5% were overweight whereas 16.9% of men were obese and 10.1% were overweight.

Conclusions: These data, based on this particular sample of obese children, that they were investigated and received dietetic counseling in a tertiary center, suggest that more than half of this cohort have body mass index higher than normal, at young adulthood. Furthermore we conclude that obesity is more prevalent in men, whereas overweight is more prevalent in women. The limitations of the present study is the relative small sample size (the study is ongoing) and the absence of control group in order to assess whether early intervention has a positive effect on long term weight control.

Pseudohypoparathyroidism: monogenic obesity and tall stature

Filiz Mine Cizmecioglu; Elif Oztur; Gul Yesiltepe Mutlu; Sukru Hatun
Kocaesi University School of Medicine, Pediatric Endocrinology and Diabetes, Kocaeli, Turkey

Background and aim: Obesity is a common feature in patients with type 1a pseudohypoparathyroidism (PHP) and affected patients typically also have short stature. We describe a infant with PHP who developed morbid obesity with tall stature in early infancy.

Methods: 6 months female infant with history of abnormal weight gain and increased appetite was referred for endocrinological evaluation. She was born 38 week gestation with birth weight 4500 gram and rapid weight gain at 1 month. She was only breastfed from birth. Frequently nursed due to crying 3kg/last 1 month. Prenatal history unremarkable. No vitamin D taken by mother during pregnancy or child after birth. On physical examination at 6 months of age length was 76cm (1.4SD) weight was 13 kg (4.8SD) and head circumference was 48(>2SD). She had no dysmorphic feature but she had a hard subcutaneous nodule in her lumbar area and umbilical hernia. Laboratory investigation showed the following values: serum calcium: 6.8 mg/dl (8.6-10mg/dl), phosphorous: 7.6mg/dl (4.2-7mg/dl), magnesium: 3.7 mg/dl (1.6-2.6mg/dl), alkaline phosphatase:333 U/L(145-420U/L), parathyroid hormone:400 pg/ml (9-69pg/ml), albumin: 3.7 mg/dl (4-5mg/dl), 25(OH)D: 55 ng/ml (15-80ng/mL), thyrotropin: 6.87 mIU/ml (0.5-5.2mIU/mL), free thyroxin: 0.69 ng/dl (0.8-1.8ng/dl), cortisol: 2.65 ug/dl (4-27ug/dl), corticoterone: 12.9 pg/ml (10-60), leptin: 23 ng/mL. Excessive weight gain, mild hypothyroidism and increased parathyroidism and decreased serum calcium suggested a diagnosis of Pseudohypoparathyroidism type 1a.

Conclusion: Hypothalamic G-protein coupled melanocortin receptor may mediate the central effects of leptin. GNAS mutation result in undetectability of MCR4 It explains the obese, hyperphagic and tall stature phenotype and suggest that the genetic mutations which underlie PHP may be a more common cause of severe obesity.

Clinical evaluation of short children referred by school screening: an analysis of 2589 children according to the WHO norms of 2007

Ibrahim Louati1; Feriel Limami2; Ines Kamoun3; Bouzid Chiraz3; Zinef Turki4; Sihem Saad Allahi4; Fatma Baalouch4; Claude Ben Slama4; Olfa Larbech4; Chhib Ben Rayane4
1Hôpital Grombalia, Pédiatrie, Nabeul, Tunisia; 2Grombalia Hospital, Pediatric, Nabeul, Tunisia; 3National Institute of Nutrition, Endocrinology, Tunis, Tunisia; 4National Institute of Nutrition, Biology, Tunis, Tunisia

Background: An isolated delay in growth can reveal a treatable pathology. A school inquiry was launched. A prospective study was made during the school year 2008/2009 in the north of Tunisia.

Objective and hypotheses: To determine the prevalence of stunting growth and the etiologies.

Methods: All school children 5 to 8 years old: 2589 children have benefitted from a school screening. Infants with short stature (heights< -2DS) have been identified for exploration. Exploration included: a detailed medical history, nutritional inquiry, physical examination and successive tests, according to primary results, of blood count, bone age, thyroid function, celiac serology, chromosome tests, and growth hormone screening. We use the new tables of the WHO published in 2007.

Results: 1.4%(36) infants have a pathological short stature: thyroid dysfunction (2 children), growth hormone deficiency (9 children ), intra-womb short stature (8 children), Turner syndrome (1 child), bone constitutional disease (2 children), congenital hepatic disease (1 child) and 14 children with constitutional delay.

Conclusions: The majority of short stature in our region is due to either constitutional delay or endocrine causes. The screening for stunting growth in 5 to 8 year old children would allow treatment resulting in a more effective, and improved height development.
PAO-236
Graves' disease management with antithyroid drug (ATD) therapy - retrospective analysis of 35 children
Paweł Matusik; Martyna Lopatacka; Anna Gronma; Agnieszka Bargielaska; Aleksandra Januszek-Tyczowska; Ewa Malecka-Tendera
*Medical University of Silesia, Department of Paediatrics, Endocrinology and Diabetes, Katowice, Poland; *Medical University of Silesia, Scientific Society of Students, Katowice, Poland

Background: Graves’ disease is the most common cause of thyrotoxicosis in children, which can have many negative effects on both physical and psychological development. Antithyroid drug (ATD) therapy is recommended as the initial treatment but still exist many controversies concerning optimal duration of ATD therapy.

Objective and hypotheses: The aim of our study was the retrospective evaluation of ATD therapy in children with Graves’ disease.

Methods: The medical history of 35 children (29 girls) in mean age of GD diagnosis 12.1 years was analyzed. Total duration of treatment, time to initial remission, number of relapses, way of ATD therapy discontinuation and block and replace treatment were taken into consideration.

Results: Mean time of observation was 2.5 yrs (max. 5.83 yrs.). The initial hormonal remission was achieved in 30 (85.7%) children.

Mean ATD therapy duration for hormonal remission was 4 months. Only in 14 (34.3%) discontinuation of ATD was possible and mean time free from ATD was 6 months.

Mean number of relapses 2.42 was observed. In 34.3% of children ATD dose reduction was fast (by 50% during a weeks), 34.3% of children had prolong ATD low dose therapy (form 1.25 to 2.5 mg/d for several months), in 54.3% of children combination of L-thyroxine with ATD was used.

No differences concerning time of initial remission, time and number of relapses depending on way of ATD dosage was found. 5 children from that group were qualified to radioiodine therapy.

Conclusions: ATD therapy in children is effective way to achieve initial clinical and hormonal remission in GD thyrotoxicosis but longer permanent remission (after ATD discontinuation) than 6 months is unusual. The late outcome of ATD therapy seems to have no relationship to way and duration of dosage.

PAO-238
Final height in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Suey Keiko Kohara; Tatadzwa Masaya; Paul Dimitri; Neil Wright; Jerry Wales
*UNIVILLE, Pediatrics, Joinville, Brazil; *Sheffield Children’s Hospital, Endocrinology, Sheffield, United Kingdom

Background: Achievement of optimal growth is one of the major problems in the management of children affected by congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD). The current literature reports that patients with classic CAH often do not achieve their target height (TH) and that they are obese. Glucocorticoid replacement is vital for preventing adrenal crisis and reducing androgen excess, but results in growth inhibition when administered in larger doses. If the androgens are not suppressed, there is advancement of bone age with premature fusion of the epiphyses and ultimate short stature.

Aim: The aim of this study was to evaluate final height (FH) of patients with the classic form of 21-OHD and compare to TH.

Methods: We reviewed the growth charts of patients with CAH who had attained FH.

Results: We evaluated 14 patients who had attained FH. 7 salt-wasting (SW) and 7 simple virilizing (SV). Five patients were male. Mean age at onset of treatment was 2.6y. Target height was available in twelve patients and mean TH-SDS was -0.15±1.1. Mean FH-SDS was -0.58±1.24. Corrected FH (FH-SDS– TH-SDS) was -0.66. All the patients were treated with hydrocortisone. Patients were overweight at FH. The last bone age done at a mean chronological age of 13 years were advanced more than 1 year in 6 patients.

Conclusions: We concluded that mean FH of our CAH patients was within normal range, but in 8 patients was below the genetic target, as reported in the literature. Only one patient was obese.

PAO-239
Response of C-peptide/insulin during a mixed meal test in combination with repaglinide to identify the diabetes type and the option for oral treatment
Diemut Simm; Henk-Jan Veeze; Henk-Jan Aanstoot
Diabetes, National Center of Diabetes in Children and Young Adults, Diabetology, Rotterdam, Netherlands

Background: The aetiology and type of diabetes is not always clear in young diabetes patients. While clinical features, autoimmune antibodies (IC, GAD, IA2 and insulin) as well as molecular diagnostics for Mody 1 – 6 help to distinguish diabetes forms, a subgroup remains without a certain diagnosis.

Objective and hypotheses: For such cases we aimed to develop a method to evaluate β-cell function and subsequent options of treatment by repaglinide, a short acting insulin secretagogue (maximum plasma concentration within 0.5 – 1h, half life 1h) which also stimulates early insulin secretion and is thus suitable to be combined with a β-cell provocation. A mixed meal test combined with incremental dosages of repaglinide was previously applied by Lawrence S. Coma et al. to show the effectiveness of the medication in type 2 diabetes.

Methods: Seven patients with unclear aetiology of diabetes and 1 healthy control person underwent after an overnight fasting period a MMTT with Susatcal 6 ml/kg (max.: 360 ml) ingested in combination with repaglinide 1 mg directly before the meal intake. Glucose, insulin and c-peptide were determined after fasting and 30, 60, 90, 120, 150 minutes after test start, i.e. repaglinide medication and start meal intake.

Results: In this pilot study we identified five patients who responded with sufficient insulin release to change medication from insulin to repaglinide.

Conclusions: We conclude that this test identifies individuals with repa-
glide responsive diabetes in whom traditional tests couldn’t clarify the autoimmunity and thereby were placed on insulin therapy. Using this test we can offer an oral treatment option despite in some of the cases the molecular diagnosis is not yet clear.

### PAO-240

**Incidence and clinical characteristics of the new cases of type 1 diabetes in Galicia, Spain**

Claudia Heredia1; Jesús Barreiro1; Aurora Pavor1; Pablo Lázaro2; José Luis Chamorro3; Pablo Fanghua4; María Mercedes Rodrígico4; Alicia Cepeodan5; Maravilla Santos6; Ciro Quintela7; Cordo Loursel8; Paloma Cabanas9; María José Pita10; Marian Rodríguez11

1Hospital de Santiago de Compostela, Universidad de Santiago de Compostela, Unidad de Endocrinología Pediátrica, Creiomento y Adolescencia, Santiago de Compostela, Spain; 2Hospital Provincial de Pontevedra, Pediatría, Pontevedra, Spain; 3Hospital Infantil Teresa Herrera, Pediatría, A Coruña, Spain; 4Hospital Xeral-Cies, Pediatría, Vigo, Spain; 5Hospital Cristal Piñor, Pediatría, Ourense, Spain; 6Hospital Da Costa, Pediatría, Burela, Spain; 7Hospital Xeral Calde, Pediatría, Lugo, Spain; 8Hospital Arquitecto Marcide, Pediatría, Ferrol, Spain; 9Hospital Virxe da Xunqueira, Pediatría, Cee, Spain; 10Hospital Comarcal Montforte, Pediatría, Montforte, Spain; 11Hospital del Barbanza, Pediatría, Riveira, Spain

**Objective:** Studying the epidemiology of childhood-onset type 1 diabetes (DM1) less than 15 years of age in hospitals of Galicia (Spain) during the period 2001-2010.

**Methods:** We identify new cases with DM1 criteria diagnosed by a paediatrician in Galicia Autonomous Community from January 2001 to December 2010 and conducted a data collection protocol to hospitalization include age, prior to the debut diabetic symptoms, duration, associated autoimmune disease, family history and biochemical parameters at diagnosis.

**Results:** We identified 559 subjects with childhood-onset DM1 during 2001-2010 and distributed by sex: 44.3% females and 55.6% males. The annual incidence rate was 17.2/100,000/year (range: 15.0-19.4); younger than 5 years were 151 children (21.7% from 8 months to 4.9 years); 179 (32%) were 5-9.9 years; 201 (35%) were 10-14.9 years and between 10-14.9 years were 224 patients (40.8%). Nineteen patients (3.3%) had celiac disease, 15 patients (2.68%) autoimmune thyroiditis (6 subjects hypothyroidism) and 72.7% of patients tested positive for at least one autoantibody (insulin autoantibody, GAD antibody or insulinoma-associated protein 2 (IA2). In relation to family history: 31 children have a first degree relative with DM1 and 16 with DM2. The debut diabetic symptoms are shown in table 1.

<table>
<thead>
<tr>
<th>0-4.9 years</th>
<th>5-9.9 years</th>
<th>10-14.9 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average time onset (days)(range)</td>
<td>14.7 (1-24)</td>
<td>24.6 (2-68)</td>
</tr>
<tr>
<td>Polyuria (%)</td>
<td>97.6</td>
<td>96.4</td>
</tr>
<tr>
<td>Polydipsia (%)</td>
<td>97.6</td>
<td>94.9</td>
</tr>
<tr>
<td>Enuresis (%)</td>
<td>75.4</td>
<td>59</td>
</tr>
<tr>
<td>Weight loss (%)</td>
<td>68.5</td>
<td>76</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>92.5</td>
<td>55</td>
</tr>
<tr>
<td>Average glycemia (mg/dL)</td>
<td>475</td>
<td>386.3</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>8.9</td>
<td>10.9</td>
</tr>
<tr>
<td>Diabetic ketoacidosis (DKA) (%)</td>
<td>34.4</td>
<td>29.6</td>
</tr>
</tbody>
</table>

**Conclusions:** The incidence peak was found in the 10 to 14 years age-group and a third of the children was diagnosed with DKA. The 0-4.9 years group was diagnosed in less time and with lower values of HbA1c. The most common symptoms were polydipsia, polyuria and weight loss. The incidence remained stable over the 10 years.

### PAO-241

**Use of 70/30 premixed insulin in DM1 pediatric patients with a basal bolus regimen with multiple snacks**

Marta Ferrer-Lozano1; Mercedes Rodriguez-Riquel1; Gracia M. Lou-Françès2; Maria D. Cañas-Redondo3; Jose L. Perales-Martínez4; Sofia Congost-Marin5

Children’s University Miguel Servet Hospital, Paediatric Diabetes and Endocrinology, Zaragoza, Spain

**Background:** Metabolic control is related with the number of short-acting analogs bolus administered, as we reported in a previous study [3 bolus (n:33) HbA1c: 8.54+/-0.8; And 24 bolus (n:73) HbA1c: 7.52+/-0.8; p<0.001]. In our country, children have 4-5 meals/d, with midmorning and midafternoon snacks. Some of them, especially adolescents, refuse to receive more bolus/d, and have snacks without insulin. In these patients a premixed 70/30 insulin at breakfast and/or lunch could better satisfy insulin requirements, improving glycemic profile and HbA1c.

**Objective and hypotheses:** To analyze the characteristics of a regimen using a premixed insulin 70/(aspartic)30(NPH), related to insulin requirements (U/kg/d), time of the injection and its effect on metabolic control.

**Methods:** 28 DM1 patients with a basal-bolus regimen, 3 short-acting analogs/d and poor metabolic control were proposed to change to 70/30 premixed insulin at breakfast and/or lunch. 21 patients were included. Mean age +/- DS: 15.14+/- 2.49 years (range 9-17). Diabetes evolution: 7.52+/- 4.19 years (1-16). 11 males (52.4%), 10 females (47.6%), 2 prepubertal (9.5%), 19 pubertal (90.5%).

**Results:**

<table>
<thead>
<tr>
<th>Insulin requirements (U/Kg/d)</th>
<th>Before change</th>
<th>After change</th>
<th>Mean of differences</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c (%)</td>
<td>Before change</td>
<td>After change</td>
<td>Mean of differences</td>
<td>p</td>
</tr>
<tr>
<td>8.48 ± 0.85</td>
<td>7.8 ± 0.87</td>
<td>-0.68 ± 1.65</td>
<td>0.002</td>
<td>0.000</td>
</tr>
</tbody>
</table>

Premixed insulin administered at breakfast in 33% of the patients, at lunch in 42.9%, and at breakfast and lunch in 23.8%.

**Conclusions:** In DM1 patients having multiple snacks who refuse to receive more than 3 bolus, the change to a regimen with 70/30 premixed insulin at breakfast and/or lunch improve significantly their metabolic control, reducing HbA1c. The change from a short-acting analog to 70/30 premixed insulin does not vary total insulin dose significantly.

### PAO-242

**Disorder of sex development in southern Nigeria: a report of four cases and constraints in management**

Tamunopriye Jaja1; Iforo Yarhere2; Ifeoma Anochie3

University of Port Harcourt Teaching Hospital, Paediatrics, Port Harcourt, Nigeria

**Background:** Disorder of sex development (DSD) is a congenital condition in which development of chromosomal, gonadal, or anatomical sex is atypical. The prevalence of DSD is about 1% among live births and about 0.1-0.2% present with marked genital ambiguity. In most developing countries, the exact incidence is not known. This is because some cases are missed at delivery, which is mainly by traditional birth attendants and amongst clinicians, poor awareness is a major challenge.

**Objective and hypotheses:** To report four cases of DSD seen in a tertiary hospital in Southern Nigeria and highlight management constraints.

**Methods:** Case notes of patients with ambiguous genitalia seen at the Paediatric endocrine unit between January 2008 and December 2010 were reviewed. Literature was reviewed for comparison with current trend in investigations and management. Parents were interviewed using a structured questionnaire and results analysed.
PAO-243

The TRH test identifies hypothalamic defects of the thyroid axis in children with euthyroid state

Ana de la Puente Arévalo1; Julio Guerrero-Fernández1; R Mora1; Jose María Iturzaeta2; R. Gómez2; Antonio Buñó2; Maria Antonia Molina2; Isabel González Casado2; Ricardo Gracia Bouthelier2; Jose Carlos Moreno2

1La Paz University Hospital, Pediatric Endocrinology, Madrid, Spain; 2La Paz University Hospital, Biochemistry and Clinical Analysis, Madrid, Spain; 3La Paz University Hospital, Molecular Thyroid Laboratory, ING EMM-Institute for Medical and Molecular Genetics, Madrid, Spain

Background: Congenital Central Hypothyroidism (CCH) has a prevalence of 1:16,000 neonates. 40% of cases are isolated pituitary or hypothalamic deficiencies. CCH is not screened for in Europe where TSH is mainly used as screening. Besides, it is not routine to discriminate between secondary or tertiary CCH using the TRH test. Pituitary CH is due to TSHB and TRHR genes mutations, while hypothalamic CH remains genetically “orphan”.

Objective and hypotheses: To test the discriminative capacity of the TRH test in the etiology of CCH.

Methods: After 7 μg/kg TRH, TSH and PRL were determined at -15, 0, 15, 30, 60, 120 and 180 min. and Free T4 and TotalT3 at 0 and 180 min. We analyzed TSH peak, its return to basal levels and dynamics of TSH increase (ratios 15’/0’ and 30’/0’) and fall (ratios 30’/60’ and 180’/0’) upon Van Tijn. The test was performed in: 1. A 20 month old girl with postnatal progressive and severe growth retardation (~3.7 SD weight and height), hyperfagia and reduced TSH related to her FT4 (TSH 1.2 mU/L, FT4 0.92 ng/dL). 2. A 12 year old boy with hypothyromiademia (TSH 5.4-8 mU/L) and 3. An 11 year old boy with hypothyromiademia (TSH 9.82 mU/L) and hyperglycemia (109 mg/dL) (TRH defect suspicion).

Results: Patients 1 and 2 had type 3 TSH response (hypothalamic defect) with 15’/0’ ratios of 23.8 and 9.1 (N=6-5) respectively, without return to basal TSH after 3 h. (180’/0’ ratios of 2.87 and 1.7). Patient 3 had type 0 response (thyroidal defect) with 15’/0’ and 180’/0’ ratios of 4.6 and 0.8, respectively.

Conclusions: The 180 min. TRH test identifies hypothalamic defects of the thyroid axis even in the biochemically euthyroid state. Tertiary hypothyroidism can present as mild TSH elevation or as TSH decreases (even within normal values) relative to FT4 levels.

PAO-244

Type 1 diabetes mellitus in schools - monitoring of current practice

Cristina Matei1; Nadeem Abdullah2

1Norfolk and Norwich Hospital, Paediatrics, Newmarket, United Kingdom; 2Addenbrooke’s hospital, Paediatrics, Cambridge, United Kingdom

Background: It has been shown that by improving diabetes control, the rate of complications later in life is reduced. In the recent years, there is more interest in multiple injection therapy and continuous subcutaneous infusions compared to the conventional twice daily regimens.

Objective: We wanted to establish the level of support in school for children and young people with diabetes in our area.

Methods: We prospectively collected questionnaires, anonymised from parents or patients attending paediatric diabetes outpatient clinics over 2 months period, (July-September 2010). Our questionnaires included: who does blood glucose testing?, what insulin regimes children are on ?, who does the insulin injection in school? and the patient’s views about different aspects of education and understanding of school staff of diabetes.

Results: We had a total of 78 questionnaires completed and returned. Most children had insulin given in school (44 out of total 78) In the overall sample, most injections were done by the children or young people with supervision from school staff. Who does blood glucose test? school staff 7 you/ school staff 2 you/ your child 3 your child 62 your child/ school staff 3 Total 77 However, when we analysed the data by ages it appeared that in the young children (less than 8 years), all (7) had the insulin given by school staff(4) or parents (2).

Conclusions: We concluded that even in some schools there continues to be fear of managing diabetes. The main problem continues to be the administration of insulin in the young age group, who are most vulnerable group. However, insulin is only a part of the complex assistance children with diabetes need in school. We believe that our efforts should concentrate in improving schools’ understanding of diabetes and education in management of this condition.

PAO-245

Variation of the heart rhythm in children with type 1 diabetes mellitus-preliminary report

Aleksander Basiaik1; Julia Nocen-Bohusz1; Beata Wikiera1; Anna Noczynska2

1University of Medicine in Wroclaw, Endocrinology and Diabetology for Children and Adolescents, Wroclaw, Poland

Background: In very early stage of diabetes type 1, we may observed symptoms of autonomic neuropathy, which unfavorably effect on course of diabetes type 1. Especially sense have complications which are connected with heart-vascular system. In adults the complications may increase risk of death because of cardiac complications.

Aim: Early detection neuropathy in diabetes type 1 with different time of going the IDDM.

Methods: In both groups were done 24 Holter electrocardiography examination. Mean value of diabetes type 1 was 7,1±3,7 y and level of the HbA1C was 9,2%±/-. We analyzed patients with good and bad compensation of diabetes type 1. We observed children 19 with diabetes type 1 (11 girl and 8 boys)-mean age 14,12±4,32 y. Control group was consist of 11 girls and 8 boys mean age 14,02±2,8 y.

Results: Mean value of all parameters of variation of the heart rhythm were lower than in healthy group and it was correlate with duration of diabetes type 1.

Conclusions: 1. Indirect symptoms of diabetic autonomic neuropathy, which disturb adaptation of the heart rhythm, may observed in very early stage of diabetes type 1. 2. Preliminary results indicate, that is necessary to do 24h electrocardiography examination in patients with diabetes type 1.
PAO-246
A case of short stature due to phosphatediabetes
Ekaterine Kvaratskeli1; Maia Rekhviashvili2; David Metreveli2; Medea Tsanava2; Rolf Peter Willig4
1Center for Endocrinology, Metabolism, Nutrition, Pediatric Endocrinology, Tbilisi, Georgia; 2Center for Endocrinology, Metabolism, Nutrition, Endocrinology, Tbilisi, Georgia; 3Tbilisi State Medical University, Pediatric Nephrology, Tbilisi, Georgia; 4Endokrinologikum Hamburg, Pediatric Endocrinology, Hamburg, Germany

Background: Primary hypophosphatemic rickets is rare disorder caused by inborn defect of renal tubular reabsorption and usually manifested in childhood and infancy with stunted growth and deformities of lower limbs.

Objective and hypotheses: The female patient from healthy parents, born without complications at term, normal weight and length. Psychomotor development until the age of 2 years was normal. Since the age of 2 years deformation of legs and difficulties with walking have been observed.

Methods: The patient was consulted by Pediatric Orthopedist, Nephrologist and Endocrinologist. The blood biochemical findings revealed normal pH, normal calcium (CA)-, potassium (K)-, sodium (Na)-concentrations, very low phosphate (P)- with markedly elevated alkaline phosphatase (AP)- and slightly elevated parathyroid hormone (PTH)-concentration; urine test indicated impaired tubular function: mild glucosuria, proteinuria, erythrocyturia and markedly increased phosphaturia. Phosphate tubular reabsorption (PTR) was 52%, phosphate clearance/creatinine clearance 0,52, renal threshold phosphate concentration (TmP/GFR) 0,25mmol/l. Genetic tests results not available yet.

Results: The diagnosis of phosphate diabetes made on the basis of clinical-laboratory data. The therapy with Inorganic phosphate (100mg/kg/d) and 1,25(OH)2VitD 50-60ng/kg/d had been started. Child’s walking abilities improved with treatment, the deformation of legs decreased, but O-legs and other skeletal deformations are still remarkable. Auxological parameters are not satisfactory. Physical growth is below the normal range (height SDS -3, 84); the patient’s predicted height less than target height. Biochemical monitoring performed regularly under the treatment, serum phosphate remains below normal, serum AP is still elevated.

Conclusion: This case is in line with other publications and indicates the difficulty to achieve normal phosphate levels and normal growth without an additional treatment with growth hormone.

PAO-247
Particularities of diabetes mellitus type 1 according to gender, date of birth, onset of disease and complications
Vira Yakovenko1; Galina Solovyova2
1Crimean State Medical University, Periatric Department, Simferopol, Ukraine; 2Ukrainian Children Specialized Hospital “OHMARDIT”, Endocrinology, Kyiv, Ukraine

Background: Diabetes Mellitus (DM) is one of the hardest diseases and is not only a medical, but social problem. DM takes the third place on mobility and mortality in developed countries. Children and adolescent make 8 to 10% out of all patients with diabetes. One out of 500 children or one out of 200 adolescent has diabetes.

Objective and hypotheses: The aim of the study was to investigate particularities of DM1 according to gender, date of birth, onset of disease and complications.

Methods: 397 children from 0 to 18 years of age with diagnose DM1 were discovered according to standard medical protocols for this pathology.

Results:

<table>
<thead>
<tr>
<th>Complication</th>
<th>Total %</th>
<th>Boys %</th>
<th>Girls %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic retinopathy</td>
<td>31.8</td>
<td>50.8</td>
<td>49.2</td>
</tr>
<tr>
<td>Diabetic nephropathy</td>
<td>34.6</td>
<td>46.7</td>
<td>53.3</td>
</tr>
<tr>
<td>Diabetic angiopathy of the lower extremities</td>
<td>14.4</td>
<td>49.1</td>
<td>50.9</td>
</tr>
<tr>
<td>Peripheral nephropathy</td>
<td>27.0</td>
<td>51.4</td>
<td>48.6</td>
</tr>
<tr>
<td>Central nephropathy</td>
<td>2.0</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Choroidopathy</td>
<td>5.6</td>
<td>54.5</td>
<td>45.5</td>
</tr>
<tr>
<td>Mauriac syndrome</td>
<td>0.5</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

Conclusions: There is practically the same prevalence of onset of DM in all age groups among boys, with an increase in number of cases at 8 and 12 years of age in girls, and decrease at the age of 15 to 17 years. Children born in spring and summer months have higher risk of developing DM1. The onset of the DM1 usually occurs in autumn and winter months. Most commonly children develop nephropathy, retinopathy, and peripheral nephropathy, 1/3 of all patient would have these complications. Gender is not a risk factor for chronic complications’development in DM1. Though girls seem to develop diabetic nephropathy more frequently than boys, but have lower risk of choroidopathy and Mauriac syndrome.
tremors, and fluctuating mental status. Her thyroid function studies revealed a Free T3 of 747 pg/dl, Free T4 of 4.8 ng/dl, and TSH of <0.01 uu/ml. She was started on Methimazole, Propranolol, and Potassium Iodide for thyroid storm. Antibody testing revealed anti-TPO of 1355.5 iu/ml, anti-thyroglobulin of 291.8 iu/ml, and TSI of 335% baseline. She was diagnosed with Grave’s disease and continued treatment with Methimazole and Propranolol.

Conclusions: Graves’ disease accounts for 10-15% of all childhood thyroid disorders, with incidence ranging from 0.1-3.0 in 100,000 children. Approximately 1-2% of patients with hyperthyroidism progress to thyroid storm when physiologically stressed. To our knowledge cases of asymptomatic Grave’s disease with initial presentation of thyroid storm in pediatric patients are not commonly reported.

PAO-249
Complication of subcutaneous fat necrosis of the newborn
Nazanin Hazhir; Robabeh Ghergherehchi
Tabriz University of Medical Sciences, Students’ Research Committee, Tabriz, Islamic Republic of Iran

Background: Subcutaneous Fat Necrosis(SCFN) of the newborn is uncommon, self-limited disorder that occurs in full term infant who experienced a perinatal distress in the first weeks of life. It can be complicated by life threatening hypercalcemia and other rare complication such as hypoglycemia, thrombocytopenia, hypertriglyceridemia, anemia and fever. SCFN with hypercalcemia frequently has been reported.

Objectives: To describe a case of subcutaneous fat necrosis with all of the above complications.

Methods: We recorded risk factors concerning the mother, pregnancy and delivery, clinical aspects of SCFN and early and late outcomes.

Results: The child was born at term. Lesions appeared on the 22th day of life. Delivery was complicated by meconium aspiration. Complications were hypoglycemia, hypercalcemia, nephrocalcinosis, dyslipidemia, thrombocytopenia and fever.

Conclusions: Physicians caring for infants with subcutaneous fat necrosis of the newborn should be aware of the above associations in order to provide prompt and appropriate treatment to prevent associated, undesirable sequelae.

Figure 1: The erythematous subcutaneous nodular plaque on the middle of the back and arm.

PAO-250
Nutritional status in PKU patients in Mazandaran province: is it acceptable or not?
Peiman Esraghi1; Ali Abbaskhanian2; Sahar Taghavi3
1Mashhad University of Medicine, Pediatric Endocrinology, Mashhad, Islamic Republic of Iran; 2Sari University of Medicine, Pediatric Neurology, Sari, Islamic Republic of Iran; 3University of Pharmacy, Biotechnology, Mashhad, Islamic Republic of Iran

Background: Phenylketonuria is one of the most frequent metabolic diseases which is transmitted as autosomal recessive pattern. Appropriate diet with restricted phenylalanine is the base of treatment, so special formulas and diet replace phenylalanine containing foods. Limited native studies exist about the results of such treatment means protein limitation and replacing an expensive and unavailable foods. This study was designed to evaluate nutritional status the calorie, protein, carbohydrate and fat of patients’ diet and iron storage and iron deficiency anemia in PKU patients.

Objective and hypothesis: This is a cross sectional study which evaluated all of the PKU patients in Mazandaran province during 2009-2010 in metabolic clinics in Babol and Sari. Nutritional status was evaluated according to 72 hours diet recall sheet which is the method for recording nutrients eaten within 3 days. Nutritional and demographic information was studied according to questionnaire and blood sampling results and iron deficiency anemia.

Results: Twenty one PKU patients were studied which 7 ones (33.3%) were female and 14 ones (66.7%) were male with mean age of 7.26±6.64 years. Iron deficiency and iron deficiency anemia was present in respectively in 10 (47.1%) and 6 patients (28.6%). Five patients (23.8%) were underweight and 4 patients (19%) were short stature.

Conclusion: Energy, protein, carbohydrate, fat and iron deficiency was significant in patients; According to the price of special foods in our country, families cannot prepare enough foods. So, attention to nutritional demands in PKU patients to reduce malnutrition and iron deficiency is critical.